<SEC-DOCUMENT>0001628280-22-021068.txt : 20220804
<SEC-HEADER>0001628280-22-021068.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804161004
ACCESSION NUMBER:		0001628280-22-021068
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		221136616

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arwr-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:368d367d-beb3-477f-87b6-b6cfd3b1dc77,g:0bc56581-7549-4bc1-a0c5-dd60a0bc219c,d:f686a6c4f85140f4912306552c96c723--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:arwr="http://www.arrowheadresearch.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl8yLTEtMS0xLTIyNQ_0ee567be-5f68-42a8-8dc5-42f35fbd2440">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl8zLTEtMS0xLTIyNQ_ff887b4b-0013-4007-9e7c-91d215397f81">09-30</ix:nonNumeric><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl80LTEtMS0xLTI5NjI_af5967b4-d245-4987-8fcd-fc4d627bb5d0">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl80LTEtMS0xLTIyNQ_f02045fd-aaf2-41be-b08f-13baf4354088">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl81LTEtMS0xLTIyNQ_2e317707-14d8-4f36-bcbf-376671657606">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb90c33d05c47c88c1c6aaef59590bb_I20220728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib685fad7e1394c24a0d385826599cb7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id07622b31e124512bd809dd85be92060_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb451dbc614647eeae7a8d0e4c8c7be7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6efb1ddfc5453da4e77a64f7bc884a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id27f4b394fa046b1992266b861dbe1a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66bad26c2a34d24ad5ca9c5e4eef6da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff04c31da3124bb8b79f993576b1d6c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc87ab7199fb4b3894709d1fad320fa4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8144dd9083c8420182eb7611a33d74e6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986c27fd3f64481193e82610f25e702e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd3e354c4fb4c46a320a7f30a707610_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4268a9aa4a4ceda2df7e5e808d365e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i360a277f7b40494f87b23039e4db0bbb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548093d511844b36a5a27eaae0e82e44_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ded07ed27245818bf9aef5e7ba2a7e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d32639f7f104939ab0a9725e78b69b4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4651ee9cf1f14481bedc0b2c11215a6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f6234a3685486ca994214a4764e7bb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b5dd0c8a3394f31908e92a5913fb593_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7312b8ac99bc4e898fb36582961f90c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90eb9a8e9b544abd9ab19dcd6a62b233_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fedd5fe7074d0ca9d9238d4393208b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie837290bad674840a22e8de24d43f73c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a078090d8343278240c419c75f7557_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd2cca928df4e10961ee81cc592602f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd117bd825d749678065575557ebea36_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4508cff922436192b0b439cebf0c7c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4816eaf78464899a0da70c9cb57dd1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e00d55cfe1d49e8949d5d504a8eb36d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ba2ab14d6444fc96945d0ba6cf971a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c60489a1c8647218a6a815fd8643604_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibce805be2cf34d7588c5ad783725855d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf1d96581774db2a2a88ed7dc4eb1c2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad6d36250af4ca0b2a87fa8a8832424_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d1f89e869e4a68b93c3ebcad9d0749_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de2006bd97d4d02bf198bf6b206a3f0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84cbcad7ba9d4502ad0c6277ddf1e420_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2764942d41741bfa09cf6591e60e421_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2cf5b805bdc476da8693441f1133ab1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic62dce18edcc450bb26c92091fc67be4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30bc05a0d514445b8ab051db8e7aa4dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75d457b5e22f453999509e78b6199c10_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if399881c34fd417fbed0c60ffc0323c5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd56a7531d2463f9a5c4f9801bbc96c_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4717e9d5d29411bb00be37c6e0d8988_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578cd120a7ab48f790437217bbc8556b_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9768d66c104f1aa87e005d6db6e1d7_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="acre"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:context id="ic75e9e025dbd4b38aa62c9741d197da1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="id75ca493ec1f402f850e52443619f642_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1022cf2430e6451eb267b84ac9a5d1c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd085594814a45419028bebfd289cf4e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4cf8a5af7f4d69aa755310016c82ad_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3a720bc2944c47a2dbc3160113d536_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d04990863c4ffebb18aa567f52c795_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i8557188d4af54eb08dc810e89d94a2af_D20160928-20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-28</xbrli:startDate><xbrli:endDate>2016-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85c5ae5131b4cf5aee60543418e6dc7_D20160928-20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseCollaborationAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-28</xbrli:startDate><xbrli:endDate>2016-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d7c8f61f044b1ca180ce2a40fa4c78_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a4c6243f314042b988b3644714d5ae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i642afe5a3db1459fb006b42ac0e0fda2_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdbfdc5869124c39b1b3bb71ecfc7d8a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15de6290b08748d4860a17dafd0dc478_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia535e3b54c9f4258ab014490ba47a9cb_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56acccdf27c144ef8f241ed180cb1e68_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd831e272413430f8e8bd86d511a426d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a529c59ccab48439e6e1f6656cfb54b_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433c47b3f8c8462580eaf03f04ea786f_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1a46243860468ebedfd52732a1d64a_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058a0e84238747de838a9ae350816175_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7a8bafb0694de299c426ee0b32a895_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c2ff8f563d4797bb710b4c5bf60938_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:context id="ib12fd50d833f43e7ab0c3963c67d8c7c_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683a96e617044dc7a7cfc73242c01f94_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33863eeccc354ec290037c1feffc9fcd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ecd1a82934c4324b5fdce6ab2812055_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59f147408ce4825a0772a7efc899c0a_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4395de79fe9145328658914e46b9ac3b_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7d1814c3ee4dc8b62b5e12fbdc725a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45013fbe4c444400b19d92afe847608f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25fe0bc8a244e299ac437cbe6dd0756_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d15264a4c8a455daaa0f41c6d369f33_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e11bca521447a3a3b4efbe502f791a_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee335bd52ba2451a8a52d753c51da9f0_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f168d9bf5d04ce3988dc7c810cc2a80_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecd2c5ebb7545b1afca8e3a81415b21_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib729c3113dd941d48caf68aba7dcd82b_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0e106a6904ed442d9339a7236c68726c_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e4e7286efe4e7e9875b4571c089f8c_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb6f8d22f8d4f1f9241a3072aac7249_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if94556e4a361454299073a451c9f3184_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:context id="i067c1e4b9a0247c7a50ae4cdf3371c7c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b4742bad8448c69d778802996dd6bf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7012433fc1464bb4b1ce9ec8d2e4ea99_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc281b2b25f4c18bb40e5a85d4aa480_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic97a79c8293c4fe0bbd8c8743f172820_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9359ec9011884267a96788ac6a2ad3c9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2d0e8036de47a38214f8da27a75c2b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5da86e52d344df6bdd898bbe4acfef7_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd0fff411780433c8b41924a087c4995_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f76d63dd964a6a80d47beca9e8f6af_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib336907d2752401e850feece66ae0251_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac4cb40a788432a8608233b693cb386_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if864eef3f413411faa9649ecf780d795_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244740bda57c4515a402b65ce9115249_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd0e90e113d47a59150ec0852ccdc57_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceda2f32a68d4891ba199eab359ecbd6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf3b5392cc94e35b5172697c4a4b526_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610703f0575242bebd037f61c55a72f3_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeba9082710947699803c66c72381300_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b8212c8479404199b23c9c498f31a9_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic540fad5d90642a2b2dda2b6047c73c0_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63bff98126fe415385b5f094684f04c1_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1956315e881a45299f1a80ddb4410e27_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c2718553fd46d69ad19a4d0391e677_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d593f14b6cb41c990078718ee591af5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56e80163bfa40bc908f0611a5ea88cc_D20220425-20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-25</xbrli:startDate><xbrli:endDate>2022-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77fd51ba125e419fbba6f8c78ee5dccb_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d571372f7da4510a63fa25715f88db4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesDueWithinNinetyDaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbbdb15dc3e40fe8077c9625e204afe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1f86d220804f7184099925062e5674_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70569a67857b45de8cf63d09a492b8b0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CertificateOfDepositDueWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d441b649884843a5fd944aaba32e08_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a7391425e04e84be5220dd1fbd8895_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12572392d85c4114bacfb1a517b43c1e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48a971a1200644508883665152308229_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CertificateOfDepositDueWithinOneThroughTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ac20dc1b6c4e8089f4f3a352305d67_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7dab9325362475c8d7c98474f501710_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35243ae1496c4b5397e5376a54a5213e_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea210cb7e064575b12fb0ca788bb100_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9c3675bb1c483490de44cfa494ff0d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c06ed8ba612412c9c704fef2aa0558c_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505d3506ef1048dfa8e34da8a51f5a14_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33ee3925344148cf9ff3b0be626dbb9a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84bb462914da49deab71348a6efb6c40_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cab2225d77f4ca6a233208a8d4c59f5_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a16451ca658448c8cea645ec09ff1d2_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ba847cf8c8e49c5bddc809e4dc8d3f7_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0867bc01dd94d139541c0b51a1ab546_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376ce739b9c345478ec0d64a72a9dd1e_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644bf2a958784d90a68f8b4c4f576ef5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64b93b7539a474baa3e0eb46dbbd950_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf66a768eba4ecb8fe84a26654807ed_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6885dc858b074038a02f3117afb66394_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i692059f5d1fe4e29a4e0274f8340c5e5_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>arwr:Option</xbrli:measure></xbrli:unit><xbrli:context id="i162842da9c754c31a54c9669b0abb806_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5cf456b9e5a4cfcb2e90173f201d53f_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae3244d52008465399c8cf8280559727_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i773403c141e742faaafdffe0102289bb_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia255aa9db9e44c3abb416601214d870b_D20201101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied64e4423da840bc99bd1ce7b1418f51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8783fb2c40044c1b857062a070f80527_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id660743071414df3aeca314c0c062149_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa41fe62302434990f633a5d20b8810_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cd815b480347a286bc4f71cff5bbcb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ce38c05a5f42e5aef4eab075945c1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379e60ba18ab41bebaf6384f97789684_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3aae72041c247afb7d654e771941178_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7882ec681e8845bdafe4d93a1da25ae0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4351ec20fd374ac591919ea36aeda735_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3423502b6f4eff862ece7e6ce5ab9f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia900dec5d8af437f8940adc4f0279a04_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10471b52c2b6469eadb29efc00dc46d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c1075e233c4c4285d6a3aadd4db3ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c13269bb6524b0cb33ce18d229e84d4_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb156c620804981b8a0721dfa56e51a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259144688fe44f518dbdd195d182b514_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id47421dd3b3e45a88df5bdc71cefa55c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e9d9c8bcbb4fcaabd247d4fbea501a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4414d1709ac14596b6a26d0204f04e45_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7214723d69d141009860a51209e72550_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7cc07f5f5684808976783384030924f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7c4db4499354a50be2f2351fc8b9349_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i224620efc59044b19ba131a63fb0f173_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffbe6a0a54524c628256db91d4b3fe22_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if686a6c4f85140f4912306552c96c723_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjYz_d1d32c20-d7f6-467c-8ad2-218cbb858f99">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.796%"><tr><td style="width:1.0%"></td><td style="width:3.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6NmQ0YTRmZTA3ZDdiNGZmZThlZmI5ZjRkMzM5ODc1YzYvdGFibGVyYW5nZTo2ZDRhNGZlMDdkN2I0ZmZlOGVmYjlmNGQzMzk4NzVjNl8wLTAtMS0xLTIyNQ_9bd0e20b-1671-4978-9336-569cfc314d45">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN181NDk3NTU4MTYyMDI_6a3d0f19-1b06-4859-a63b-5dd00aaec584">June 30, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6N2VlZGU2M2NkNDZiNDNkNGE4YTM0ODE5ZTM5OTJlMDgvdGFibGVyYW5nZTo3ZWVkZTYzY2Q0NmI0M2Q0YThhMzQ4MTllMzk5MmUwOF8wLTAtMS0xLTIyNQ_65058c8d-f9ea-4933-9cd8-03b0abd0b9c5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjY4_0ea36c2c-d6d9-470b-bcc7-bdb8aa65aee5">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjY1_e0682a35-c8f7-4b0f-af15-03382d89a04f">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6MDAzODk2YzA4ZDZmNDZhZTlkNzAyMzZjMjE3OGUxMTgvdGFibGVyYW5nZTowMDM4OTZjMDhkNmY0NmFlOWQ3MDIzNmMyMTc4ZTExOF8wLTAtMS0xLTIyNQ_052f127e-a356-40c7-8c90-74cc0cfbc559">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6MDAzODk2YzA4ZDZmNDZhZTlkNzAyMzZjMjE3OGUxMTgvdGFibGVyYW5nZTowMDM4OTZjMDhkNmY0NmFlOWQ3MDIzNmMyMTc4ZTExOF8wLTItMS0xLTIyNQ_d1cbd591-6673-4dc7-a90d-6c09767ca5d7">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180Nzc_ba7defbd-2254-449a-aab8-f159e44cba5c">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180ODE_06b5110a-1782-49bc-aa96-f6760aac68cf">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180ODQ_96f66a4b-f08e-490d-a366-a07bf5596b18">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180ODg_936f04ce-3c55-4037-848e-af8187dd2fc3">California</ix:nonNumeric> <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180OTE_115fa39c-c23e-4e04-941b-3a890939983f">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180OTU_27f366f0-8fbe-40cc-b38d-5504e57857d2">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180OTk_67f989dd-5aa5-48e5-8af5-45574649293d">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Former name, former address, and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:37.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6YTkyMWQ4ODlhNTUzNGJmN2IzOWJjZjViOWJhNjkwMjUvdGFibGVyYW5nZTphOTIxZDg4OWE1NTM0YmY3YjM5YmNmNWI5YmE2OTAyNV8xLTAtMS0xLTIyNQ_4495d374-1de0-4692-acf7-0e5e24c80b6a">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.38pt;padding-right:1.38pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6YTkyMWQ4ODlhNTUzNGJmN2IzOWJjZjViOWJhNjkwMjUvdGFibGVyYW5nZTphOTIxZDg4OWE1NTM0YmY3YjM5YmNmNWI5YmE2OTAyNV8xLTItMS0xLTIyNS90ZXh0cmVnaW9uOjg0ZmViNzMwZWUwYTQ2YWI4ZmIyYTc3NGJmZTZmNWE5XzQ_fb309160-e540-4c5a-bf6e-0819e77f1ab2">ARWR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6YTkyMWQ4ODlhNTUzNGJmN2IzOWJjZjViOWJhNjkwMjUvdGFibGVyYW5nZTphOTIxZDg4OWE1NTM0YmY3YjM5YmNmNWI5YmE2OTAyNV8xLTQtMS0xLTIyNQ_0e8ee536-c348-41a5-82e0-7e1cf19c37db">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjU5_ae7badca-c5f5-4418-b829-42cf9386b5a3">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjY2_dfcba5ee-5898-4227-a38b-86dcc0c5bbce">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6Yzc1NDNiZDJjMTQxNDIxYTg2N2NiMDdmNGYxYTkyNjMvdGFibGVyYW5nZTpjNzU0M2JkMmMxNDE0MjFhODY3Y2IwN2Y0ZjFhOTI2M18wLTAtMS0xLTIyNS90ZXh0cmVnaW9uOjBiODAzMjZiMjAyNzRhZWY5MzkwY2Y0NDBmMDU5YTQxXzQ_0445aa17-6cf3-4793-8802-1502c6697da2">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6Yzc1NDNiZDJjMTQxNDIxYTg2N2NiMDdmNGYxYTkyNjMvdGFibGVyYW5nZTpjNzU0M2JkMmMxNDE0MjFhODY3Y2IwN2Y0ZjFhOTI2M18yLTMtMS0xLTIyNQ_eded1000-a882-4c0d-9fcd-012431157f90">o</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6Yzc1NDNiZDJjMTQxNDIxYTg2N2NiMDdmNGYxYTkyNjMvdGFibGVyYW5nZTpjNzU0M2JkMmMxNDE0MjFhODY3Y2IwN2Y0ZjFhOTI2M180LTEtMS0xLTIyNQ_2ec3edb8-2884-406c-bb73-86422ecfd79d">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjYx_3eff7b80-b6a1-4e54-81b6-f87d7916a08b">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding as of July&#160;28, 2022 was <ix:nonFraction unitRef="shares" contextRef="i0eb90c33d05c47c88c1c6aaef59590bb_I20220728" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMTk5MDIzMjU3OTUz_69c75aa7-bb02-4b9b-9223-4a5e93233357">105,848,963</ix:nonFraction>. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:88.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Page(s)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_10">PART I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_13">ITEM 1. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_16">Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_19">Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_19">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_22">Consolidated Statements of Stockholders&#8217; Equity and Noncontrolling Interest</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_22">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_25">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_25">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_28">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_28">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_67">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_67">19</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_88">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_88">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_91">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_91">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_94">PART II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_94">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_97">ITEM 1. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_97">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_100">ITEM 1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_100">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_103">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_103">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_106">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_106">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_109">ITEM 4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_109">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_112">ITEM 5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_112">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_115">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_115">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if686a6c4f85140f4912306552c96c723_118">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if686a6c4f85140f4912306552c96c723_118">34</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION </span></div><div id="if686a6c4f85140f4912306552c96c723_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span></div><div id="if686a6c4f85140f4912306552c96c723_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(unaudited) June&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CURRENT ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMy0xLTEtMS0yMjU_20446129-27cf-4ab9-a718-8398b20fc271">139,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMy0zLTEtMS0yMjU_127207e1-4284-4bd7-9434-0a0ec1dba9ef">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNC0xLTEtMS0yMjU_9dcb1297-c637-4728-95e0-738189a7a81a">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNC0zLTEtMS0yMjU_450a63aa-886a-412b-b13f-ceba321e1a9a">10,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNS0xLTEtMS0yMjU_4647e5e9-df8a-48d1-b7b7-6c71eda33040">6,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNS0zLTEtMS0yMjU_a9b4cca1-1c67-494c-86ec-18882f6babad">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNi0xLTEtMS0yMjU_457a20b6-d94f-4ae0-8666-60cc5a82435f">8,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNi0zLTEtMS0yMjU_f7e3b736-7ea8-420d-a4af-e318a6723a83">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNy0xLTEtMS0yMjU_1194abbd-b145-4509-8055-ed8adb07e325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNy0zLTEtMS0yMjU_81727d85-c844-4c31-951c-e81a3878dd78">126,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOC0xLTEtMS0yMjU_9ba4bb89-36e0-4c63-93f5-2b30b129423c">277,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOC0zLTEtMS0yMjU_9fbef565-1059-48e4-8cdf-136187393629">56,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL CURRENT ASSETS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOS0xLTEtMS0yMjU_f1639adc-3f5f-48f9-be4a-38478de92a09">432,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOS0zLTEtMS0yMjU_7a318fe8-6083-4704-a636-6f47180d96e5">384,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTAtMS0xLTEtMjI1_27c5a3af-0c4c-4230-b82c-b132717aa4ff">71,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTAtMy0xLTEtMjI1_6803e639-50c3-4472-822f-43e81a1f3ee5">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTEtMS0xLTEtMjI1_6a085d09-e3ef-4b14-9325-6a1a835dacd2">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTEtMy0xLTEtMjI1_ff58bcdc-f9ef-466f-a14b-ee0daf79ff4b">13,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTItMS0xLTEtMjI1_cd02148a-306d-47af-bc73-4c945c6f29a2">165,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTItMy0xLTEtMjI1_f8801a81-2320-442a-98ef-90af0b1b1fec">245,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTMtMS0xLTEtMjI1_11d86e7c-204b-4b6e-8f70-0eb0bb0f82da">68,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTMtMy0xLTEtMjI1_65a76b4f-1e29-4e9a-bab8-c152c824982f">17,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTQtMS0xLTEtMjI1_15877e4f-1d49-45f5-936b-042b67ca3c92">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTQtMy0xLTEtMjI1_889504cc-565e-4867-bb8d-3a7a680979d5">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTUtMS0xLTEtMjI1_83d03fec-dae4-4678-9249-96665f939f99">751,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTUtMy0xLTEtMjI1_9ce54122-6771-4ebb-9847-0916d352038a">710,148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTgtMS0xLTEtMjI1_95e6084c-d2c7-4d2c-a96e-5ba449899b8a">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTgtMy0xLTEtMjI1_6d956b66-e562-4fe0-acf0-a76a190eafa8">9,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTktMS0xLTEtMjI1_5609593b-b402-481e-a811-699c4c393ba2">32,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTktMy0xLTEtMjI1_7c3010d3-b18e-4649-b01c-536ebec6e142">14,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjAtMS0xLTEtMjI1_00bbe890-94e5-43e0-a237-f4b51ef5dc27">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjAtMy0xLTEtMjI1_6aaad85f-ad6d-4588-9370-39c84a4b54b5">9,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjEtMS0xLTEtMjI1_09be5ca0-91c1-4ffb-9951-14e399188f54">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjEtMy0xLTEtMjI1_054b2bbf-fd2c-4696-84b6-2d3accc6b5da">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjItMS0xLTEtMjI1_9f3223b5-f24d-407a-af5e-609fea7e9667">84,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjItMy0xLTEtMjI1_b3ad6243-3dba-4387-a32d-67665326ae5d">111,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL CURRENT LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjMtMS0xLTEtMjI1_0fa5c83c-45ad-4be1-b6a6-24c52ab3b3b4">128,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjMtMy0xLTEtMjI1_07359fdd-8a28-4463-baf1-e70abe8ee4fa">146,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">LONG-TERM LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjUtMS0xLTEtMjI1_bea85cb5-5909-4891-bb78-0708a73ba8cf">78,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjUtMy0xLTEtMjI1_bbe7d507-ba7e-4123-a6a9-097a94770334">23,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjYtMS0xLTEtMjI1_f8655530-cf7d-4fc7-b9df-a283b023673c">71,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjYtMy0xLTEtMjI1_d71ce60f-8207-43bd-9d0a-9c10a8f1105f">131,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL LONG-TERM LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjctMS0xLTEtMjI1_474ede3d-94e2-4b77-9bc4-48f789ebab21">149,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjctMy0xLTEtMjI1_0710e99c-57c4-4fe2-9455-3b02179f514d">154,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjgtMS0xLTEtMjI1_2debe0ef-39fe-47e8-8329-3beb5e23672f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjgtMy0xLTEtMjI1_c38f95dc-4626-4077-84ce-d29bc12f5854"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMTg_4527fa5a-2726-45ca-aa0c-9aaf5b54fbf6"><ix:nonFraction unitRef="usdPerShare" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMTg_a6491fb4-7c79-4136-9080-ca56ced7a7c3">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMzI_d186e1c3-6718-4e02-b8a4-4833ee7f4d9e"><ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMzI_fe3f6d7e-afbf-404b-bb10-8f0ebb5f4d4e">145,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNTQ_35390206-f7eb-47b7-bae5-1d3dbb072bac"><ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNTQ_b04a506e-38f1-4d1f-a3aa-47189786cacc">105,795</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNjE_8127097f-6660-4cd3-b90b-b817ba5e7364"><ix:nonFraction unitRef="shares" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNjE_f5a41eb5-be0b-49da-a3f5-dcd385b1b6be">104,327</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2022 and September&#160;30, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMS0xLTEtMjI1_d49b316c-e9cd-4dda-aa9f-5d022c365a20">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMy0xLTEtMjI1_dac28f79-9a45-413b-8957-1013be216554">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzItMS0xLTEtMjI1_a0a1819a-d255-4d68-8592-26d403a7ffe3">1,189,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzItMy0xLTEtMjI1_dad98d50-e600-472a-89ac-bcf0e11298b0">1,053,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzMtMS0xLTEtMjI1_60c273d7-aa68-4667-bde5-bac24e084856">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzMtMy0xLTEtMjI1_a07cf1ff-a46d-449e-a20f-4f4db9a637a3">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMS0xLTEtNTQ3NA_9094dd1b-d939-4bec-8a18-8dbc8511687c">735,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMy0xLTEtNTQ3NA_88ca647c-adb5-4967-8b2c-9abadb1ffce1">644,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL ARROWHEAD PHARMACEUTICALS INC. STOCKHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMS0xLTEtNzA3NQ_be4700a3-c0f5-4e16-9cac-ce05858c7874">453,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMy0xLTEtNzA3NQ_8894e6ec-18ee-46cc-91d0-88dbf6a96899">408,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncontrolling Interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMS0xLTEtMjI1_c4cc5b6b-a38f-40a4-ae81-52035d86d838">20,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMy0xLTEtMjI1_20c88a86-f43d-42a1-a597-a2cc85529917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMS0xLTEtMjI1_25b5252f-af05-4fa1-bdbd-f8089fb608b3">474,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMy0xLTEtMjI1_cc4cc334-4cd9-4eca-a998-3fb03021f2db">408,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TOTAL LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzYtMS0xLTEtMjI1_cda1d37d-d31c-4923-9c1f-2f8778909569">751,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzYtMy0xLTEtMjI1_3b71008c-af33-40c8-8d32-97599ee1a77f">710,148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">REVENUE</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi0xLTEtMS0yMjU_4ff87c1c-f73f-4a2a-b891-d67071c76c7b">32,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi0zLTEtMS0yMjU_ac97b1fc-d8d3-4cb0-b161-a8ebdce6e364">45,891</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi01LTEtMS0yMjU_3a6e8325-ec3d-4ac9-a6ed-926e6dfcf270">211,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi03LTEtMS0yMjU_f0de4194-708e-49e9-b35f-f4ac4d2a6cd9">100,004</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">OPERATING EXPENSES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC0xLTEtMS0yMjU_4f54ea1c-1e38-49fa-825c-d26b714861c5">72,180</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC0zLTEtMS0yMjU_7c6d0d03-2bce-4e80-ba53-6db43b37e73e">59,325</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC01LTEtMS0yMjU_d8111596-0e73-41fa-b594-ef3d37f7403c">213,930</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC03LTEtMS0yMjU_d61fab63-3c37-4f25-b14f-da9eca8fd7dc">140,576</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS0xLTEtMS0yMjU_36d888a4-46f5-4bb5-8f52-d8e12768dc7b">33,141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS0zLTEtMS0yMjU_4dbf50c1-fa1a-44aa-b409-62dcfbbe52f1">18,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS01LTEtMS0yMjU_bf72ed4c-e0c4-4703-aeb4-9857428a4c18">92,403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS03LTEtMS0yMjU_446d6b29-9d44-414c-af82-5530858f6c2d">43,581</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL OPERATING EXPENSES</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi0xLTEtMS0yMjU_64a80447-9d61-4e61-b143-a3ff47259206">105,321</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi0zLTEtMS0yMjU_ae450bd2-0301-474e-9ceb-4135956bc178">77,759</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi01LTEtMS0yMjU_ddf38e7b-7eed-42cc-8e7a-f5a181ffd67b">306,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi03LTEtMS0yMjU_0c16766d-4c27-494f-be54-8794b78a5b18">184,157</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OPERATING INCOME (LOSS)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy0xLTEtMS0yMjU_911dc241-1834-4168-b54f-0d152fb2f0ab">72,909</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy0zLTEtMS0yMjU_b4511077-ae55-470e-9da2-82bb564cdc68">31,868</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy01LTEtMS0yMjU_4426d91b-459b-42e5-ab25-be6b1cbeed39">94,677</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy03LTEtMS0yMjU_60563785-4864-4cbc-b991-289ed46cb059">84,153</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">OTHER INCOME</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS0xLTEtMS0yMjU_bd62d596-1ba3-40d3-ba56-68adbb02f0af">1,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS0zLTEtMS0yMjU_38ba2e27-27ca-4ee5-abe4-9b0e27b898ca">1,280</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS01LTEtMS0yMjU_a0320a54-73ab-4d04-90d3-fcbacfad3e48">3,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS03LTEtMS0yMjU_16244bae-9be5-4be5-8a0e-6d31a041776c">4,972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense)</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtMS0xLTEtMjI1_ead78237-669f-4235-ad56-dadfba771459">377</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtMy0xLTEtMjI1_ee9ba2de-1cba-4309-a05a-ac1da1bcd835">664</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtNS0xLTEtMjI1_82afbdcf-5fe3-49e8-b3eb-29c7d5ec1825">675</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtNy0xLTEtMjI1_1b807f57-c1aa-4cdd-87ac-7c6c3d673d6a">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL OTHER INCOME</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtMS0xLTEtMjI1_acbfaef2-4c1b-4e97-91f2-45231a161873">863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtMy0xLTEtMjI1_192e1021-8465-4567-a839-69dc00473fb1">1,944</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtNS0xLTEtMjI1_55ee762f-fa3b-4b8a-9270-f297d2817d29">4,125</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtNy0xLTEtMjI1_5fe3f444-4cf0-4fc9-b0ed-8ed50c016b4d">6,679</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INCOME (LOSS) BEFORE INCOME TAXES</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItMS0xLTEtMjI1_045e2348-85f4-49bf-af8c-1aca1e68e424">72,046</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItMy0xLTEtMjI1_7f0da18b-3b0a-46e8-bc64-a01c97bc7258">29,924</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItNS0xLTEtMjI1_0928f40e-15e5-4817-a84b-d193fe3f17b3">90,552</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItNy0xLTEtMjI1_15f85c6d-24ee-42c8-b491-93c0c3c11720">77,474</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision for income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtMS0xLTEtMjI1_a1b761ea-b7fb-46ae-957a-4c2e95188589">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtMy0xLTEtMjI1_3b105bbb-21d2-49bf-b10b-83279a88ed0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtNS0xLTEtMjI1_b3bfe7c5-12bd-4c4b-b2e3-9bde1f5df755">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtNy0xLTEtMjI1_cfb7b07d-33cc-4c4f-b3ea-3226748be149">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET INCOME (LOSS)</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtMS0xLTEtMjI1_b035d0ad-0a30-4039-849e-4c5b73d2114d">72,046</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtMy0xLTEtMjI1_0f882455-e6a2-40ce-ba4a-8ad5d4f85dc0">29,924</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtNS0xLTEtMjI1_521df68a-2f75-49fd-81fb-35192cea43cd">90,552</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtNy0xLTEtMjI1_a8106991-38b3-45c7-bd98-a8273bd40c3c">77,474</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET INCOME (LOSS) PER SHARE - BASIC</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtMS0xLTEtMjI1_744d917e-eedc-4ad8-8e9c-d06d18bc5b53">0.68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtMy0xLTEtMjI1_b7bc2abf-e81d-4329-a2cb-c1ccd42b4e02">0.29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtNS0xLTEtMjI1_42a88be2-695d-4544-bd55-a45d9e08748c">0.86</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtNy0xLTEtMjI1_8b97687a-852f-4aad-9ee3-f41e5e7b5cc2">0.75</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET INCOME (LOSS) PER SHARE - DILUTED</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtMS0xLTEtMjI1_f282c6e4-83bb-4487-8e06-78aadf050632">0.68</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtMy0xLTEtMjI1_3db488ea-fe10-4ebd-a0a0-b297e3ddfc92">0.29</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtNS0xLTEtMjI1_7e26b059-a3ca-4be9-9e49-0187f1b79a67">0.86</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtNy0xLTEtMjI1_063b471c-a89b-4251-9788-e4234e6c3b8a">0.75</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctMS0xLTEtMjI1_15671269-a5ca-4aef-9383-0ad031c635b0">105,753</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctMy0xLTEtMjI1_c1eb8c16-cc20-40fb-b2f5-9548708a2062">104,099</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctNS0xLTEtMjI1_38de0f6b-6d5f-4a8b-8984-f1a0d32ed794">105,273</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctNy0xLTEtMjI1_7b35a2d7-596e-4039-8e7c-da8a4c9021ff">103,569</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtMS0xLTEtMjI1_f0af838e-92ea-411c-bd71-69291c72a335">105,753</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtMy0xLTEtMjI1_f033b684-ebb8-490e-a009-c7361a608423">104,099</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtNS0xLTEtMjI1_7de91ff2-241b-4285-a081-0d9088e81248">105,273</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtNy0xLTEtMjI1_b2bf66f7-6461-413e-ba3c-ea72261a5d16">103,569</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtMS0xLTEtMjI1_099070c9-96af-4729-9ebe-7f2308d72906">33</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtMy0xLTEtMjI1_87aff911-3537-4bbe-9924-ee03c215e34d">40</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtNS0xLTEtMjI1_25fa3908-e88c-4286-86f4-3eecce372bde">71</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtNy0xLTEtMjI1_a6c56a2f-e0ef-45ff-9cbd-ee3aaac70d9e">44</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">COMPREHENSIVE INCOME (LOSS)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtMS0xLTEtMjI1_d5ad7c7c-c426-4a61-910e-499650284b5f">72,079</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtMy0xLTEtMjI1_8677e62f-8e13-4afa-99ac-600bfe8d2394">29,964</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtNS0xLTEtMjI1_6926f006-ce78-4f48-afb9-f9677b3c7f47">90,623</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtNy0xLTEtMjI1_cf76cc72-8972-4dd1-8f14-2c314aea0277">77,430</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity and Noncontrolling Interest </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:37.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated Other</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Noncontrollling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="icb451dbc614647eeae7a8d0e4c8c7be7_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0xLTEtMS0yMjU_4501c6ce-af87-4226-88bc-b2907277a74e">104,020</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icb451dbc614647eeae7a8d0e4c8c7be7_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0zLTEtMS0yMjU_a451330d-c7a9-4de6-9b7f-1d3b888c49b8">196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1e6efb1ddfc5453da4e77a64f7bc884a_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS01LTEtMS0yMjU_de44c02b-e0e8-4091-bf7a-a016e52c6293">996,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id27f4b394fa046b1992266b861dbe1a0_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS03LTEtMS0yMjU_7b341ab8-055e-4919-be4d-64a8bf7dd9d2">102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia66bad26c2a34d24ad5ca9c5e4eef6da_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS05LTEtMS0yMjU_9cacc995-01b2-4f55-a530-d2acd5e23d5e">551,394</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iff04c31da3124bb8b79f993576b1d6c8_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0xMS0xLTEtNDU3Ng_1a888223-f500-4ddd-a01f-b9de529b4fd2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icc87ab7199fb4b3894709d1fad320fa4_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0xMS0xLTEtMjI1_4bbd5b66-6863-4642-bd32-8bd086491e91">445,549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8144dd9083c8420182eb7611a33d74e6_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMi01LTEtMS0yMjU_dbb20bbd-5417-4b56-8521-80857ec536e0">18,549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMi0xMS0xLTEtMjI1_67a03888-7df5-4ae5-b887-7e43f27093aa">18,549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy0xLTEtMS0yMjU_4d5c2297-b554-4450-9fe0-74dfd05dc5f5">161</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy0zLTEtMS0yMjU_1f6ef0de-5642-4e97-9176-181893af346d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8144dd9083c8420182eb7611a33d74e6_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy01LTEtMS0yMjU_bb3c21a1-9f1c-4f7e-bded-a5bba8197f90">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy0xMS0xLTEtMjI1_843fc0cd-4b19-446c-8279-8bb628c937f5">2,756</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNC0xLTEtMS0yMjU_263654fe-03be-47fe-8fac-c749b3ec471a">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i986c27fd3f64481193e82610f25e702e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNS03LTEtMS0yMjU_28b73b0f-40a8-452c-bed5-dd53693b3dcf">40</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNS0xMS0xLTEtMjI1_e2f99992-465c-4803-8126-8e1be2ac4c37">40</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income (loss) for the three months ended June&#160;30, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iefd3e354c4fb4c46a320a7f30a707610_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNi05LTEtMS0yMjU_93e4ef1f-e777-414f-b5a3-e73b33b3e91a">29,924</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNi0xMS0xLTEtMjI1_8af8c125-87b8-478a-aac0-4d74f05039c0">29,924</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0xLTEtMS0yMjU_fd26cea0-b1da-45b1-96a0-a17559b130d0">104,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0zLTEtMS0yMjU_179197d2-4231-4741-8e42-3a86b4dae4f2">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f4268a9aa4a4ceda2df7e5e808d365e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy01LTEtMS0yMjU_c2ff586f-b88d-40b8-967e-e5e52861030f">1,017,949</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i360a277f7b40494f87b23039e4db0bbb_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy03LTEtMS0yMjU_a916867b-ac0a-4c62-866f-27476de94b3c">62</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i548093d511844b36a5a27eaae0e82e44_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy05LTEtMS0yMjU_41c6d085-90fd-4cb4-8531-ad1a78df7b20">581,318</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib6ded07ed27245818bf9aef5e7ba2a7e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0xMS0xLTEtNDU3Ng_adae2bbb-5f17-4ce5-abee-ded803e244ff">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d32639f7f104939ab0a9725e78b69b4_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0xMS0xLTEtMjI1_00c0d97a-7717-4651-9248-3273fe02d43e">436,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:37.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated Other</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Noncontrollling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4651ee9cf1f14481bedc0b2c11215a6b_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0xLTEtMS0yMjU_0ac8b00f-048f-4650-a844-080d7f2f5d98">105,702</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4651ee9cf1f14481bedc0b2c11215a6b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0zLTEtMS0yMjU_d09cdc6c-a31f-4e41-af89-09c427404681">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4f6234a3685486ca994214a4764e7bb_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS01LTEtMS0yMjU_9e712b57-5507-48b1-a61a-d5321bfedee6">1,115,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4b5dd0c8a3394f31908e92a5913fb593_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS03LTEtMS0yMjU_2537eaa9-77e6-4cc1-95a2-ac955574eca5">107</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7312b8ac99bc4e898fb36582961f90c2_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS05LTEtMS0yMjU_f14de943-893a-44cd-998f-e23a2362988c">663,198</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i90eb9a8e9b544abd9ab19dcd6a62b233_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0xMS0xLTEtNDYxMQ_ca024a8f-326a-42b4-8cf3-fdb246258e73">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i89fedd5fe7074d0ca9d9238d4393208b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0xMS0xLTEtMjI1_339c62b1-47c2-4340-8ed5-8efecffbb19f">452,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMi01LTEtMS0yMjU_c4a39206-6114-4660-8a60-34091274f2a8">33,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMi0xMS0xLTEtMjI1_62649527-1ce1-49f7-b07c-f81faef18b41">33,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ie837290bad674840a22e8de24d43f73c_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMy0xLTEtMS0yMjU_502b5bf9-a125-4601-8424-a639b8b958d3">53</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMy01LTEtMS0yMjU_027de726-d0a7-4418-b92d-27c813fe263b">599</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMy0xMS0xLTEtMjI1_606b4d87-bba1-493e-bb3c-fd3ed6cb2d11">599</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ie837290bad674840a22e8de24d43f73c_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNC0xLTEtMS0yMjU_a4d39797-b682-4b1d-a16f-15558c7f7714">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNC0xMS0xLTEtMjI1_e9e4cc5e-8fac-42ba-9e8b-c1c9d707491c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic4a078090d8343278240c419c75f7557_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNS03LTEtMS0yMjU_f57374ac-cc96-4186-ad7a-e11d5725b87f">33</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNS0xMS0xLTEtMjI1_77a04ce2-340a-4338-a38c-1b1eb89d29f8">33</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Interest in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi01LTEtMS01OTU5_917b657a-7ee1-4975-93a1-b3ebb6779902">39,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="iefd2cca928df4e10961ee81cc592602f_D20220401-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi0xMS0xLTEtNTk1OQ_8a88160a-9dca-497f-bb70-510a4e8346da">20,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi0xMy0xLTEtNTk1OQ_d10688c3-bb2c-44db-8236-58d756b11dc2">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income (loss) for the three months ended June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ifd117bd825d749678065575557ebea36_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi05LTEtMS0yMjU_a73bb06d-8efa-4b7a-b48b-2301f29d053a">72,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi0xMS0xLTEtMjI1_c6442e18-5a29-45f5-a7c9-720e14b09268">72,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0xLTEtMS0yMjU_9f95c4ad-236b-4055-9fa7-d69d7bd32d0d">105,795</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0zLTEtMS0yMjU_7d731aed-16a7-453d-be49-2018009b9aa6">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4816eaf78464899a0da70c9cb57dd1a_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy01LTEtMS0yMjU_f00c0f9e-8bdc-495a-9cba-36a9e9cada8e">1,189,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3e00d55cfe1d49e8949d5d504a8eb36d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy03LTEtMS0yMjU_f3dba0d7-56d0-43da-8ef0-7d820ee6bf6a">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i44ba2ab14d6444fc96945d0ba6cf971a_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy05LTEtMS0yMjU_f9df3a19-10ea-479c-9fb9-bccd6fe91c3c">735,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5c60489a1c8647218a6a815fd8643604_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0xMS0xLTEtNDYxMQ_22e2d6db-b19e-4fb6-8610-a6388b3e1a55">20,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0xMS0xLTEtMjI1_e4e58976-4889-4dad-ba19-76cfbed3d3a5">474,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:37.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated Other</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Noncontrollling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ibce805be2cf34d7588c5ad783725855d_I20200930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0xLTEtMS0yMjU_b6a2bb6e-c916-46e9-9e5e-66691b1c6c66">102,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ibce805be2cf34d7588c5ad783725855d_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0zLTEtMS0yMjU_39b2048c-4860-4f1f-a016-af302d3cb9aa">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iabf1d96581774db2a2a88ed7dc4eb1c2_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS01LTEtMS0yMjU_c4d865c2-c9ba-4962-b6e3-91677da0e632">965,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2ad6d36250af4ca0b2a87fa8a8832424_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS03LTEtMS0yMjU_e8adc1f2-9253-437a-8d62-827698c0c325">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i40d1f89e869e4a68b93c3ebcad9d0749_I20200930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS05LTEtMS0yMjU_4ff4839f-2838-437e-b42a-a3aab18ab669">503,844</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4de2006bd97d4d02bf198bf6b206a3f0_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0xMS0xLTEtNDYyMQ_5f7a507b-4e94-4545-8d9a-37289aae9cec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0xMS0xLTEtMjI1_f6c1014d-a277-403e-9a8c-b44f57617502">461,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMi01LTEtMS0yMjU_5530e6a6-b3e8-45a3-a9c0-69b4a568a38e">42,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMi0xMS0xLTEtMjI1_7b121b78-dfdf-4e63-8ae2-2304f96403b4">42,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy0xLTEtMS0yMjU_f28580b0-bb8f-43f1-a3cb-c8fb05a4b302">981</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy0zLTEtMS0yMjU_d3e10415-1f45-4498-8d08-ec83817869d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy01LTEtMS0yMjU_245b754d-a80b-4c81-ad32-750ea36d5a3d">10,489</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy0xMS0xLTEtMjI1_fd4641f0-a201-4b98-a07a-d490850861a5">10,490</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC0xLTEtMS0yMjU_f37cae06-e3be-486f-8abb-f19cdebeef92">852</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC0zLTEtMS0yMjU_19b5bd43-ede2-4dd0-8527-73be0c05a2ca">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC01LTEtMS0yMjU_d8930e5a-1bc7-47fd-b589-f72c57e0d886">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC0xMS0xLTEtMjI1_237a6b32-eb17-4ebc-910b-74866293ca01">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i84cbcad7ba9d4502ad0c6277ddf1e420_D20201001-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNi03LTEtMS0yMjU_089e9ae5-81e5-444e-a494-af82c77f42eb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNi0xMS0xLTEtMjI1_e9d8c828-2a10-4a97-a178-dba5c18d4dfc">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income (loss) for the nine months ended June 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id2764942d41741bfa09cf6591e60e421_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNy05LTEtMS0yMjU_968aeca9-e27f-405c-8c99-c8443ec7560d">77,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNy0xMS0xLTEtMjI1_3f6d3654-5129-44b5-b0dc-d14cd3d6480c">77,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0xLTEtMS0yMjU_6e806a8f-fb7e-4758-9689-ab9d32e1f878">104,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0zLTEtMS0yMjU_ce99495e-0567-4854-acc3-855b441540b0">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f4268a9aa4a4ceda2df7e5e808d365e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC01LTEtMS0yMjU_0f932d92-ce6e-48d6-ab2f-ab0390721277">1,017,949</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i360a277f7b40494f87b23039e4db0bbb_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC03LTEtMS0yMjU_e9fddd14-014d-4099-8912-f21c0ba91bfd">62</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i548093d511844b36a5a27eaae0e82e44_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC05LTEtMS0yMjU_b12a92d6-9c66-4753-8537-83180a18a51b">581,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib6ded07ed27245818bf9aef5e7ba2a7e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0xMS0xLTEtNDYyMQ_8a177277-b77c-49be-aec4-de25aeb68d62">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d32639f7f104939ab0a9725e78b69b4_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0xMS0xLTEtMjI1_394c4ab8-24f6-4b1b-a017-41bb960cfe51">436,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:37.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated Other</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Noncontrollling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia2cf5b805bdc476da8693441f1133ab1_I20210930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0xLTEtMS0yMjU_c7094f76-0a6e-43e3-b3a7-9365d16b0081">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia2cf5b805bdc476da8693441f1133ab1_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0zLTEtMS0yMjU_78b7e742-3878-4277-a888-b80478b10272">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic62dce18edcc450bb26c92091fc67be4_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS01LTEtMS0yMjU_335201fc-9abd-4a0a-8236-3f07292b2e0d">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i30bc05a0d514445b8ab051db8e7aa4dc_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS03LTEtMS0yMjU_5298b10f-4a78-4ede-b977-1e58cf98931f">69</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i75d457b5e22f453999509e78b6199c10_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS05LTEtMS0yMjU_bef8a58a-2759-4662-8f2f-670774e1d172">644,692</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if399881c34fd417fbed0c60ffc0323c5_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0xMS0xLTEtNDYzMA_820762b8-eb15-4294-b005-be2393a0cc84">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0xMS0xLTEtMjI1_a55a6df4-3eb6-4d69-bc21-d73d0c4a7e82">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMi01LTEtMS0yMjU_0ff58dac-b650-4527-841c-8fa4c05136a9">91,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMi0xMS0xLTEtMjI1_440ab4c2-1365-413c-9654-3b9428f5a1b9">91,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMy0xLTEtMS0yMjU_3928c876-f7ba-4dd9-9263-ae1cfa12037e">497</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMy01LTEtMS0yMjU_e5aac727-f84f-4be5-8bd2-ef2cf362ac19">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMy0xMS0xLTEtMjI1_002ccac7-5d97-452c-a7cd-3932da68a62a">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC0xLTEtMS0yMjU_68996ccc-6672-4546-8164-fffdd4019559">971</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC0zLTEtMS0yMjU_e6d5ee38-5638-42a6-95b7-a15898e9a7f0">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC01LTEtMS0yMjU_7377c1c1-25ff-4bd5-b206-71d1f8833931">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC0xMS0xLTEtMjI1_c72502ca-e6fd-4228-b5d5-9166fbcd2f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icdd56a7531d2463f9a5c4f9801bbc96c_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNS03LTEtMS0yMjU_2b547628-bfe9-45c3-b6d3-aaf6b6b68744">71</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNS0xMS0xLTEtMjI1_16d97d20-af11-4ec6-8f2d-ce37670adfb8">71</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Interest in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi01LTEtMS01OTcw_1036ae15-b8c2-4785-9d91-31919f56e0fa">39,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="ia4717e9d5d29411bb00be37c6e0d8988_D20211001-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi0xMS0xLTEtNTk3MA_6361f4c6-accc-4204-a530-81c8c7a6270a">20,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi0xMy0xLTEtNTk3MA_b12d6142-549e-4a17-817a-9cb1c3078334">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income (loss) for the nine months ended June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i578cd120a7ab48f790437217bbc8556b_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi05LTEtMS0yMjU_378ba4a9-4097-4a4c-b606-5eafd9387b1c">90,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi0xMS0xLTEtMjI1_1ee0924c-7c81-4493-9283-5a99a72ca889">90,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0xLTEtMS0yMjU_ac5f2c5d-9504-42ee-8a9e-6cd5b15bbce0">105,795</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0zLTEtMS0yMjU_7e386eef-bc60-4294-a739-4ad4112a1392">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4816eaf78464899a0da70c9cb57dd1a_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy01LTEtMS0yMjU_039ec94d-1174-430b-b6c1-ea03a7840a4f">1,189,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3e00d55cfe1d49e8949d5d504a8eb36d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy03LTEtMS0yMjU_7ff15845-8573-458a-b79e-dba01fbdf304">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i44ba2ab14d6444fc96945d0ba6cf971a_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy05LTEtMS0yMjU_0ef9e742-b99a-46aa-9e32-1d1a8ba74c70">735,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5c60489a1c8647218a6a815fd8643604_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0xMS0xLTEtNDYzMA_0d46b5fe-fd64-4818-a5ab-9f64cef7f253">20,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0xMS0xLTEtMjI1_f6b603bc-da9c-4e08-bbc6-a03f50089970">474,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMy0xLTEtMS0yMjU_3cdce52f-0f03-49d8-819c-35ed384fc07d">90,552</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMy0zLTEtMS0yMjU_56b91241-f509-49a6-b716-056214ad6423">77,474</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNC0xLTEtMS0yMjU_e9393d77-87b7-47fe-b93f-b2d5310eeb2d">91,697</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNC0zLTEtMS0yMjU_02d014b0-b72f-4eb7-a606-10c8076eb034">42,051</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNS0xLTEtMS0yMjU_33fbcd0f-06da-423c-af95-9b71d2253eb6">7,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNS0zLTEtMS0yMjU_d1b3d1ba-f0e7-431d-837b-db5c16572d99">5,763</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized (gains) losses on marketable securities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNi0xLTEtMS0yMjU_054a293d-e084-410a-8acd-3ff0f70869ad">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNi0zLTEtMS0yMjU_91563402-5311-43ac-b196-6d159c5fc33d">1,387</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization/(accretion) of note premiums/discounts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNy0xLTEtMS0yMjU_67725ea6-4d18-49b3-b3c1-a2e5923fd60c">2,013</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNy0zLTEtMS0yMjU_2b121916-f56f-4957-8f12-6b163e5a7797">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfOS0xLTEtMS0yMjU_23b35063-a4e3-4204-9d78-5bf99c879a10">10,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfOS0zLTEtMS0yMjU_eeaa8437-5c5e-4a0d-876f-2820a0138b89">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTAtMS0xLTEtMjI1_b399a76f-5027-4526-ae8c-ea7ba6e8fd48">8,876</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTAtMy0xLTEtMjI1_c0d9775a-7b6d-4c20-8432-2a8f8fa13b51">2,895</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTEtMS0xLTEtMjI1_cd9b1545-9728-4488-b060-f1f62a5d40fd">87,100</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTEtMy0xLTEtMjI1_c4d0df23-faa5-41c9-b711-5c17714780ce">211,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTItMS0xLTEtMjI1_87028446-d059-4237-81e7-4aa9ad2129e6">3,563</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTItMy0xLTEtMjI1_8fd82025-e875-40c4-b63c-591d558f446d">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTMtMS0xLTEtMjI1_e4df4dbb-2621-4189-8301-7e0807408f86">1,713</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTMtMy0xLTEtMjI1_793618fc-7f40-4a43-bb67-41db12e896b9">13,682</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTQtMS0xLTEtMjI1_ed1a18f5-d245-49cb-a441-c2d3863c303d">3,672</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTQtMy0xLTEtMjI1_bc4df4ba-4fca-4646-9c62-fde2cb5b8037">685</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTUtMS0xLTEtMjI1_670339e8-3075-424c-a187-a7d40436bff4">67,464</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTUtMy0xLTEtMjI1_36959fa0-5cc1-47e0-9f3e-581e9d43ccef">195,341</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTctMS0xLTEtMjI1_53dd497c-82ba-4dab-9243-f1ad7463d9fd">20,066</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTctMy0xLTEtMjI1_7e9c979c-938c-4330-83e6-8ddf58c16a98">15,368</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Purchases of investments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTgtMS0xLTEtMjI1_5a44361b-ea9e-4966-902a-cd18560b424b">223,391</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTgtMy0xLTEtMjI1_e11db30b-9739-4cae-a809-fbdc1d9eaba8">95,195</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from sale of investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTktMS0xLTEtMjI1_a8be1784-ab50-4799-8dea-3c68d6fdd61f">201,595</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTktMy0xLTEtMjI1_8b6ee0de-9330-4515-8f04-f1a1e2123567">87,130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjAtMS0xLTEtMjI1_cde698ad-11d4-46d3-9bfb-af3f02e5584a">41,862</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjAtMy0xLTEtMjI1_49cdbfd8-621b-45c4-ba05-79621d1a844e">23,433</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjItMS0xLTEtMjI1_e6df9b15-9e6c-41e9-91f4-c6a15e420029">4,331</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjItMy0xLTEtMjI1_81d4d0c1-8107-41a6-bf64-3628e9a740dd">10,490</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from investment in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMS0xLTEtNTY0MA_526e43d8-f1ab-46a4-b3c3-223e4ec88489">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMy0xLTEtNTY0MA_0920472d-322d-414a-bb88-27f85a423941">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET CASH PROVIDED BY FINANCING ACTIVITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMS0xLTEtMjI1_4f533e29-5d02-4b49-94aa-c89befeff812">64,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMy0xLTEtMjI1_d3224d52-77e6-4bb4-b132-39d14430207f">10,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NET INCREASE (DECREASE) IN CASH</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjQtMS0xLTEtMjI1_bff4ec38-ee70-4011-a658-41025ba87fe2">44,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjQtMy0xLTEtMjI1_c797c40e-cfde-4c22-a530-2c4cdbc01988">182,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjUtMS0xLTEtMjI1_3b7c6b30-ff39-4639-9f05-03ce8dd62cd9">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjUtMy0xLTEtMjI1_84d67f04-1eab-4fcb-8e66-431f84fc3662">143,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CASH AND CASH EQUIVALENTS AT END OF PERIOD</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjYtMS0xLTEtMjI1_68d3ff2f-efb4-48d0-929b-a3cc3d521751">139,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d32639f7f104939ab0a9725e78b69b4_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjYtMy0xLTEtMjI1_1ca32518-f7d2-4db0-9791-308bdb6d548e">325,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise noted, (1) the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2) the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3) the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), Visirna Therapeutics Inc. ("Visirna"), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4) the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, par value $0.001 per share, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock, par value $0.001 per share, and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead&#8217;s Common Stock. </span></div><div id="if686a6c4f85140f4912306552c96c723_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfODE1OQ_e3568006-4290-44cc-a8d9-794f77357516" continuedAt="i3ecb1a4f872d4359ad01bf22c88cbffa" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i3ecb1a4f872d4359ad01bf22c88cbffa" continuedAt="i99c410029e934a0586c3df2d5cbcbf50"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Business and Recent Developments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#8217;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC2 for cystic fibrosis, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens, ARO-C3 for complement mediated diseases, ARO-RAGE and ARO-MUC5AC for various muco-obstructive or inflammatory pulmonary conditions and ARO-MMP7 for idiopathic pulmonary fibrosis. ARO-HSD for liver disease was out-licensed to Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;) in November 2021. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;). JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. JNJ-3989 (formerly referred to as ARO-HBV) for chronic hepatitis B virus was out-licensed to Janssen in October 2018. Olpasiran (formerly referred to as AMG 890 or ARO-LPA) for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016. While the Company believes that initial ARO-HIF2 Phase 1 clinical data provides proof of concept for the ability to deliver siRNA to RCC tumors, the Company has decided not to pursue further clinical development of ARO-HIF2 based on a number of factors including the evolving competitive landscape for HIF2 inhibitors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three quarters of fiscal 2022, the Company continued to develop and advance its pipeline and partnered candidates and expanded its facilities to support the Company&#8217;s growing pipeline. Several key recent developments include: </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.9pt">dosed the first patients in its PALISADE study, a phase 3 clinical study to evaluate the safety and efficacy of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.13pt">entered into an exclusive license agreement with GSK for ARO-HSD; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.36pt">Janssen presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989 (JNJ-3989), formerly called ARO-HBV, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB);</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.9pt">filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 and subsequently dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s </span><span style="background-color:#f3f3f3;color:#676767;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nvestigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">presented additional interim clinical data from AROHSD1001, AROAAT2002, and AROAPOC31001; </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i99c410029e934a0586c3df2d5cbcbf50" continuedAt="i90cb8413d3864272960d1716d82403c3"><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">completed the purchase of <ix:nonFraction unitRef="acre" contextRef="i5c9768d66c104f1aa87e005d6db6e1d7_D20211001-20220630" decimals="INF" name="arwr:NumberOfAcresOfLandPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMzc0MQ_c5622f1a-583b-4c86-936e-2740dc07c008">13</ix:nonFraction> acres of land in the Verona Technology Park in Verona, Wisconsin and held a groundbreaking ceremony on the site. The site is being developed into an approximately <ix:nonFraction unitRef="sqft" contextRef="ic75e9e025dbd4b38aa62c9741d197da1_I20220630" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1NTI1NQ_439964a0-795f-4e96-b728-104456d877a4">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="id75ca493ec1f402f850e52443619f642_I20220630" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1NTI1OQ_308528a2-e298-40f3-a69e-b8c454209c62">140,000</ix:nonFraction> square foot laboratory and office facility which will support the Company's process development and analytical activities. The Company also announced that it received awards for up to $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-6" name="arwr:TaxIncrementFinancingAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTM5NTY_9ab23105-4aa9-4e28-af2f-eade0be5b2e6">16</ix:nonFraction>&#160;million in tax increment financing from the city of Verona, and up to $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTM5NjA_2891ea1f-1234-4251-a745-67bf5931d881">2.5</ix:nonFraction>&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.  Additionally, The Company entered into a lease agreement for a new <ix:nonFraction unitRef="sqft" contextRef="i1022cf2430e6451eb267b84ac9a5d1c2_I20220630" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNDAxNw_b0fdb20a-12ab-45e5-825f-690540854b65">144,000</ix:nonFraction> square foot laboratory and office facility in San Diego, California to support discovery activities;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.13pt">completed enrollment in Phase 2b ARCHES-2 study of investigational ARO-ANG3 for patients with mixed dyslipidemia;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">viii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-RAGE for treatment of Asthma;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-MUC5AC for treatment of muco-obstructive lung disease;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">initiated and dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholersterolemia;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">xi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">entered into definitive agreements to form a joint venture, Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;) with Vivo Capital (&#8220;Vivo&#8221;) through which the Company and Vivo intend to expand the reach of innovative medicines in Greater China;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">xii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:22.13pt">hosted a pulmonary research &amp; development (R&amp;D) Day to discuss the Company&#8217;s emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) platform, including an announcement of its previously undisclosed candidate designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF); and</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xiii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt">in conjunction with Takeda, announced results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), and was recently published in the New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress&#8482; 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the three and nine months ended June&#160;30, 2022 were not significantly impacted by COVID-19. Operationally, the Company has experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#8217;s preclinical programs. Additionally, the Company has experienced delays in enrollment in its clinical trials. The Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees and the length and severity of the COVID-19 pandemic. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), which contemplate the continuation of the Company as a going concern. Historically, the Company&#8217;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials, as well as with the Company&#8217;s plans to increase its internal manufacturing capabilities, and expand its footprint in Verona, Wisconsin and San Diego, California. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i90cb8413d3864272960d1716d82403c3"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzU3Ng_72fc57ec-73a2-4aa9-b732-f6dade9fb463">139.4</ix:nonFraction> million in cash and cash equivalents (including $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMjE5OTAyMzI2NzQwNQ_9a1443fa-8717-42a9-9459-dba38820be57">7.4</ix:nonFraction> million in restricted cash), $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzU4NA_b5f8d857-5668-485a-a259-af7ddd3298d6">277.1</ix:nonFraction> million in short-term investments, $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzU5Mg_13ffc8a0-702e-4686-8d32-d6f195c8971c">0</ix:nonFraction> in marketable securities and $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzYwMA_7b3ed07d-06ac-48bb-8702-eb4045492395">165.9</ix:nonFraction> million in long-term investments to fund operations. $<ix:nonFraction unitRef="usd" contextRef="idd085594814a45419028bebfd289cf4e_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNTQ5NzU1ODM0MzU2_4a620ac1-8bd2-425e-9cef-efb100dc8441">60</ix:nonFraction>&#160;million of our cash balance resulted from the formation of our joint venture, Viserna. During the nine months ended June&#160;30, 2022, the Company&#8217;s cash and investments balance decreased by $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" sign="-" name="arwr:IncreaseDecreaseInCashAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMjE5OTAyMzI2NzQyNw_9c288ff6-1214-4786-9e86-6913461a4bae">31.0</ix:nonFraction> million, which was primarily due to cash being used to fund the Company&#8217;s operations, partially offset by the $<ix:nonFraction unitRef="usd" contextRef="i3f4cf8a5af7f4d69aa755310016c82ad_D20211001-20220630" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNzQzMQ_ba1e7fcf-4723-462f-9edb-9f9b26eac80b">120.0</ix:nonFraction> million upfront payment received from GSK, and $<ix:nonFraction unitRef="usd" contextRef="idd085594814a45419028bebfd289cf4e_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNTQ5NzU1ODM0MzY5_12de1424-e7a5-4dbb-9328-7db3a4d4f52c">60</ix:nonFraction>&#160;million cash infusion to Viserna. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company remains eligible for $<ix:nonFraction unitRef="usd" contextRef="i8d3a720bc2944c47a2dbc3160113d536_I20220630" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNzUxMw_3b49c2b2-04d4-473c-90e8-05e9c6b75e7e">4.9</ix:nonFraction> billion in developmental, regulatory and sales milestones and various royalties on net sales from its licensing and collaboration agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2 below. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfODE1OA_7da720f2-0c8a-454c-820c-483fda7d9d7a" continuedAt="idf632043db6541bdb57b7ff5127c43cd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf632043db6541bdb57b7ff5127c43cd">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K.</ix:continuation><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNTQ5NzU1ODM4NDI1_a7a6ef9c-a539-4401-a4ab-67c6f76046c2" continuedAt="i475b7676f0ec416492640bacb326c952" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-indent:40.8pt"><span><br/></span></div><ix:continuation id="i475b7676f0ec416492640bacb326c952"><div style="text-indent:40.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In our opinion, the unaudited consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending September 30, 2022 or any other period.</span></div><div style="text-indent:40.8pt"><span><br/></span></div><div style="text-indent:40.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited consolidated financial statements include the accounts of our wholly owned subsidiaries, as well as the accounts of Visirna, a variable interest entity for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our unaudited consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC.</span></div></ix:continuation></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgxOTA_8361ce8a-3185-4d5d-ac6d-06b8ed4f25f3" continuedAt="idb5a890cf653439dabcb995bdfb419f3" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="idb5a890cf653439dabcb995bdfb419f3" continuedAt="i69bb47644b58428fbb3c7dd7f9e9b762"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;28, 2016, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="if5d04990863c4ffebb18aa567f52c795_I20160928" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTM_3ff4c268-c583-438d-8e8d-c29f91b7a6c6">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement with Amgen. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="usd" contextRef="i8557188d4af54eb08dc810e89d94a2af_D20160928-20160928" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTAzNg_449dfdbc-c756-481b-ad59-febc03ac6d51">35.0</ix:nonFraction> million in upfront payments, $<ix:nonFraction unitRef="usd" contextRef="id85c5ae5131b4cf5aee60543418e6dc7_D20160928-20160928" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTA2MA_aee5cd4c-3bcf-4a26-a8c9-f91ea5527861">21.5</ix:nonFraction> million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $<ix:nonFraction unitRef="usd" contextRef="i16d7c8f61f044b1ca180ce2a40fa4c78_I20160928" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE0Mw_70914a06-1c6c-469b-880f-52d9aaff53df">30.0</ix:nonFraction> million in milestone payments, and may receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="if6a4c6243f314042b988b3644714d5ae_I20220630" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTIwNQ_075b3325-dc28-4a53-bc32-d7fde692b6ec">400.0</ix:nonFraction> million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i69bb47644b58428fbb3c7dd7f9e9b762" continuedAt="i4c7778ae8b184890b4a41fb84727c130"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ARO-AMG1 Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i642afe5a3db1459fb006b42ac0e0fda2_I20200731" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjA4MQ_65e50155-6885-4ba2-86e4-00415843ad55">20.0</ix:nonFraction> million milestone payment to the Company. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibdbfdc5869124c39b1b3bb71ecfc7d8a_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE3OQ_0312a6b5-ab47-47e1-b4bc-8bbdc3b752b9"><ix:nonFraction unitRef="usd" contextRef="i15de6290b08748d4860a17dafd0dc478_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE3OQ_ccf9593b-1854-4456-8421-6b1145ae1a3d">0</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia535e3b54c9f4258ab014490ba47a9cb_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE4Ng_893adb70-c25c-4b21-b268-24eaf6e13b31"><ix:nonFraction unitRef="usd" contextRef="i56acccdf27c144ef8f241ed180cb1e68_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE4Ng_c0571178-9a15-4630-882a-b7f5f9f3840e">0</ix:nonFraction></ix:nonFraction> of revenue associated with its agreement with Amgen, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="icd831e272413430f8e8bd86d511a426d_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjI3Nw_b1e6ca02-3e04-46a3-a62d-f99eb1779dea">0</ix:nonFraction> in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="icd831e272413430f8e8bd86d511a426d_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjMzNQ_37cfd1a1-89f9-4ff2-8924-dd540ac2950d">0</ix:nonFraction> contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;3, 2018, the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;) with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company also entered into a stock purchase agreement with JJDC (&#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which Arrowhead would develop clinical candidates. These candidates were subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="usd" contextRef="i9a529c59ccab48439e6e1f6656cfb54b_D20181003-20181003" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDIyNA_a5d95de5-3dd5-4470-a422-5a6f98bec02e">175.0</ix:nonFraction> million as an upfront payment, $<ix:nonFraction unitRef="usd" contextRef="i433c47b3f8c8462580eaf03f04ea786f_D20181003-20181003" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDI1MA_7ba8a6dd-ddfb-47ea-b3b0-a479bf061d6b">75.0</ix:nonFraction> million in the form of an equity investment by JJDC in Arrowhead Common Stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $<ix:nonFraction unitRef="usd" contextRef="i4e1a46243860468ebedfd52732a1d64a_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDQwNw_b1ff7490-c02e-4ad1-a21f-c46b9c40b0ec">73.0</ix:nonFraction> million, and the Company may receive up to $<ix:nonFraction unitRef="usd" contextRef="i058a0e84238747de838a9ae350816175_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDQ0NQ_80ffea3b-1ee4-4277-828a-d7693b82a971">1.6</ix:nonFraction> billion in development and sales milestones payments for the Janssen License Agreement, and up to $<ix:nonFraction unitRef="usd" contextRef="iea7a8bafb0694de299c426ee0b32a895_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDUzOA_0a712a1f-e11b-4f55-8119-536acb35fbe0">0.6</ix:nonFraction> billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During the three months ended June&#160;30, 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. At the inception of these agreements, the Company identified <ix:nonFraction unitRef="obligation" contextRef="i44c2ff8f563d4797bb710b4c5bf60938_D20181003-20181003" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTI0Ng_2ab34bc8-649f-43be-b60d-37e72b029c28">one</ix:nonFraction> distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ib12fd50d833f43e7ab0c3963c67d8c7c_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjI0OA_3fd54729-eb2d-4281-883b-1213062cacaa">252.7</ix:nonFraction> million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $<ix:nonFraction unitRef="usd" contextRef="i683a96e617044dc7a7cfc73242c01f94_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjM1OQ_cc520f60-2678-4fa6-ba57-f6350923d74d">25.0</ix:nonFraction> million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="ib12fd50d833f43e7ab0c3963c67d8c7c_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjUyNg_29e4d673-7a4f-484d-9131-eed2add38083">252.7</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the three months ended June&#160;30, 2022 and 2021, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i33863eeccc354ec290037c1feffc9fcd_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjk5Ng_ce196b7d-a937-4c2f-906c-dbe0e4d43bf4">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4ecd1a82934c4324b5fdce6ab2812055_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzAwMw_a8ccfafe-a86b-4963-8d69-29186f96e310">0</ix:nonFraction> of revenue associated with this performance obligation, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ic59f147408ce4825a0772a7efc899c0a_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzE1MQ_e572b45b-6088-413b-ab35-7101f94ab081">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4395de79fe9145328658914e46b9ac3b_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzE1OA_a6f21c53-af31-44b6-a081-c4d3df917d51">20.2</ix:nonFraction> million of revenue associated with this performance obligation, respectively. As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="ife7d1814c3ee4dc8b62b5e12fbdc725a_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzI1Mg_24dc2368-133e-4b32-84fc-30b8b97d1709">0</ix:nonFraction> in contract </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4c7778ae8b184890b4a41fb84727c130" continuedAt="i58497a60e80d43d3abcd4fadad24d50c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets recorded as accounts receivable, and $<ix:nonFraction unitRef="usd" contextRef="ife7d1814c3ee4dc8b62b5e12fbdc725a_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzMxMQ_6e456463-5e78-4468-8495-346d6fea4af1">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. During the three months ended June&#160;30, 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement as reported in the second quarter of 2022. During the three months ended June&#160;30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i45013fbe4c444400b19d92afe847608f_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzkzNg_81fee451-1ea7-4ef7-a19a-327575683b89">0.0&#160;million</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if25fe0bc8a244e299ac437cbe6dd0756_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzk0Mw_74f59184-9e78-4bb2-a55e-f9fd99ae5d4c">0.2</ix:nonFraction> million of revenue associated with these efforts, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2d15264a4c8a455daaa0f41c6d369f33_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODA2Mw_e12e6f48-3b75-41c0-b697-3c711c796f1f">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia5e11bca521447a3a3b4efbe502f791a_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODA3MA_5e7a388a-bf9c-464c-9240-b6c7d512264a">0.5</ix:nonFraction> million of revenue associated with these efforts, respectively. In May 2021, Janssen exercised its option right for ARO-JNJ1, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="iee335bd52ba2451a8a52d753c51da9f0_I20210531" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTQ5NzU1ODg1MTAw_a6c102cc-85a6-4bfb-b019-3b1b315cd2c5">10.0</ix:nonFraction>&#160;million milestone payment to the Company. This $<ix:nonFraction unitRef="usd" contextRef="i6f168d9bf5d04ce3988dc7c810cc2a80_I20210630" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTQ5NzU1ODg1MTE1_dbad744c-8fba-401f-a14d-828f9ccd9dcc">10</ix:nonFraction>&#160;million milestone payment was recognized entirely during the three months ended June 30, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="idecd2c5ebb7545b1afca8e3a81415b21_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODE1MA_5a0b3e57-76a8-4703-8d8b-ee181d13fa86">0</ix:nonFraction> of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="idecd2c5ebb7545b1afca8e3a81415b21_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODIwOA_9ab5f476-6ca8-4154-b4ae-7c07543770e9">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, the Company entered into an Exclusive License and Co-funding agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda. Under the Takeda License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="ib729c3113dd941d48caf68aba7dcd82b_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTA3Nw_15516732-9e3d-4aaa-8759-3c178fdc49a2">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i0e106a6904ed442d9339a7236c68726c_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTA4Mw_2ba7c5a8-0ae3-45ae-91a0-76d5dcb7b668">25</ix:nonFraction>% on net sales. In January 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="ic1e4e7286efe4e7e9875b4571c089f8c_I20210131" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTEyOA_70a825b4-415c-494e-bb52-ed220cdefe8c">300.0</ix:nonFraction> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iecb6f8d22f8d4f1f9241a3072aac7249_I20210131" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTI0OQ_6a4ec9cb-22a6-4358-b68f-5dcee3260ce5">740.0</ix:nonFraction> million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTQ5NA_893db1e3-5a87-4cfd-9680-cbd6e6c0aa92">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTAwNzA_a84dacf0-de7f-4624-957a-05b1bc4c88ff">one</ix:nonFraction> distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTA4OTk_c3619794-fe91-42a6-9311-fabf15a511bd">300.0</ix:nonFraction> million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTEwNzI_5721a85f-85b8-4087-812b-e8849b59397b">300.0</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services. Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i067c1e4b9a0247c7a50ae4cdf3371c7c_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE0NjQ_59883535-666a-4d20-ae8b-a875ca65364a">25.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i28b4742bad8448c69d778802996dd6bf_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE0NzE_d3a9dde3-9b90-4b3d-8613-b38f6c9596bc">35.7</ix:nonFraction> million, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i7012433fc1464bb4b1ce9ec8d2e4ea99_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE1MzU_bf60bcd9-6878-4992-991d-e35cdc9ff68d">67.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6fc281b2b25f4c18bb40e5a85d4aa480_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE1NDI_807c94df-8a39-4413-a580-0489aa511c86">69.3</ix:nonFraction> million, respectively. As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="ic97a79c8293c4fe0bbd8c8743f172820_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE1ODE_1a3327e3-0605-4561-b5ff-ed09f59f71f9">0</ix:nonFraction> in contract assets recorded as accounts receivable, $<ix:nonFraction unitRef="usd" contextRef="i9359ec9011884267a96788ac6a2ad3c9_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE2MzY_1ca1029f-16a2-4a29-b903-53a5ce54c9cb">71.0</ix:nonFraction> million in contract liabilities recorded as deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="i9359ec9011884267a96788ac6a2ad3c9_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE2OTY_935ffca3-ee0b-4914-9156-78a69d393b76">71.2</ix:nonFraction> million in contract liabilities recorded as deferred revenue, net of the current portion, and $<ix:nonFraction unitRef="usd" contextRef="ifb2d0e8036de47a38214f8da27a75c2b_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE3ODU_26604eea-b11e-456f-8413-569c24939d38">7.8</ix:nonFraction> million in contract liabilities recorded as accrued expenses. The $<ix:nonFraction unitRef="usd" contextRef="ifb2d0e8036de47a38214f8da27a75c2b_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE4NDY_5d7a2bdf-213d-4434-9fdc-70d87316804f">7.8</ix:nonFraction> million in accrued expenses was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Horizon Therapeutics Ireland DAC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, the Company entered into the Horizon License Agreement with Horizon. Under the Horizon </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i58497a60e80d43d3abcd4fadad24d50c" continuedAt="ia06ab37e5ace418dba01e4f8c67c4021"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of ARO-XDH, and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="ic5da86e52d344df6bdd898bbe4acfef7_I20210731" decimals="-6" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTI1NDA_3857120b-a9a2-4f6e-9478-983135e8a37f">40</ix:nonFraction> million as an upfront payment and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ifd0fff411780433c8b41924a087c4995_I20210731" decimals="-6" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTI1OTg_6f7f5497-c7ae-4150-a43f-87605bb61026">660</ix:nonFraction> million in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="i70f76d63dd964a6a80d47beca9e8f6af_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM0NzE_a259373b-bc26-4fe6-8374-ca33ae2964c7">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="i70f76d63dd964a6a80d47beca9e8f6af_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM1MDE_9a34d4ee-b81b-445a-b292-3e39e59b9f67">one</ix:nonFraction> performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="ib336907d2752401e850feece66ae0251_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM3NzE_28c8dbe4-6253-428b-b2f3-69b29a36e831">40.0</ix:nonFraction> million, including the upfront payment. The Company has excluded any future estimated milestones or royalties, from this transaction price to date. The Company will allocate the total $<ix:nonFraction unitRef="usd" contextRef="ib336907d2752401e850feece66ae0251_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM5NTA_ecd02fa8-d034-433f-b880-9b422742e612">40.0</ix:nonFraction> million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="ib336907d2752401e850feece66ae0251_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM5ODY_cae3146e-6bc4-4de9-b614-fd966b35d2e3">one</ix:nonFraction> distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;D Services. Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ifac4cb40a788432a8608233b693cb386_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ0MjI_aa7bbfd8-911f-43a7-b41d-65cbae8352fe">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if864eef3f413411faa9649ecf780d795_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ0Mjk_4c3cc7d0-9cd5-469a-adae-0af73e8a013c">0</ix:nonFraction>, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i244740bda57c4515a402b65ce9115249_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ0OTM_272e006d-1d6c-4f1e-8318-328add2f2a86">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibfd0e90e113d47a59150ec0852ccdc57_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ1MDA_d1da98d1-2cea-4e9f-b4b4-0dfb9f9e403a">0</ix:nonFraction>, respectively. As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="iceda2f32a68d4891ba199eab359ecbd6_I20220630" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ1Mzk_f0477b56-b744-45b7-9aa9-bafdc57449d9">0 million</ix:nonFraction> in contract assets recorded as accounts receivable, $<ix:nonFraction unitRef="usd" contextRef="iceda2f32a68d4891ba199eab359ecbd6_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ1OTQ_2b8593c0-651b-4497-9c44-d7774d804dd6">13.3</ix:nonFraction> million in contract liabilities recorded as deferred revenue. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has manufactured ARO-XDH material for Horizon in furtherance of the research plan entered into pursuant to the Horizon License Agreement, for which the Company has been reimbursed for its costs. During the nine months ended June 30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibaf3b5392cc94e35b5172697c4a4b526_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ5MjA_dd921b88-3676-4438-9c1b-ad06b7752c70">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i610703f0575242bebd037f61c55a72f3_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ5Mjc_fb30cedf-46f6-43cd-81d9-d643b620d1e2">0</ix:nonFraction> with these efforts, respectively. As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="ibeba9082710947699803c66c72381300_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ5ODU_c48054c2-7046-4465-9f72-42dbfbc98ec4">0.0 million</ix:nonFraction> of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="ibeba9082710947699803c66c72381300_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTUwNDM_de0834fb-c8cf-443b-bef4-5ec4d0686f7a">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;) with GSK. Under the GSK License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK has received an exclusive license for ARO-HSD, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the Company&#8217;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">itory. Under the terms of the agreement, the Company has received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122" decimals="-6" name="arwr:MilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTYwMTQ_2d539b51-a3fc-4cf2-a1e0-753dcbb97b4c">120</ix:nonFraction> million and is eligible for additional payments of $<ix:nonFraction unitRef="usd" contextRef="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122" decimals="-6" name="arwr:MilestonePaymentReceivableAtStartOfPhaseTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTYwNjg_210389ea-4842-4e09-ba0d-971f6fbd9b21">30</ix:nonFraction> million at the start of Phase 2 and $<ix:nonFraction unitRef="usd" contextRef="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122" decimals="-6" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTYxMDc_0da342bf-26d6-4f04-964c-4c5b0c9adc43">100</ix:nonFraction> million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="ia4b8212c8479404199b23c9c498f31a9_I20211122" decimals="-6" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTY0Mjk_5a26c4b7-d491-4c52-8147-84b1e220284b">190</ix:nonFraction> million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="ia4b8212c8479404199b23c9c498f31a9_I20211122" decimals="-6" name="arwr:SalesRelatedMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTY0Njg_3676cdc5-a8b1-421f-80a9-a75d4f9d4565">590</ix:nonFraction> million in sales-related milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the GSK License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the GSK License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTY3NTM_7d70a35e-b641-48bf-a161-442a654c3b15">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study, (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of these GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTcxNTc_5dab0b02-a319-4337-8113-67e9f9baaaa8">one</ix:nonFraction> distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia06ab37e5ace418dba01e4f8c67c4021"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc0NTY_48942d3c-7cff-416e-84e8-7929326850b0">120.0</ix:nonFraction> million, including the upfront payment. The $<ix:nonFraction unitRef="usd" contextRef="ic540fad5d90642a2b2dda2b6047c73c0_D20220101-20220131" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc0OTU_ae39a3d3-5485-4ac5-8ce5-fc37faa29550">120.0</ix:nonFraction> million upfront payment was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODI0NjMzNzIyNjUyOQ_464092ee-94fe-4557-8202-2bb084d2808d">120.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i63bff98126fe415385b5f094684f04c1_D20211001-20220630" decimals="-5" name="arwr:PerformanceObligationRelatedToAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc5Mjk_b619bc53-f838-4b10-8fc7-623b1b916554"><ix:nonFraction unitRef="usd" contextRef="i1956315e881a45299f1a80ddb4410e27_D20220401-20220630" decimals="-5" name="arwr:PerformanceObligationRelatedToAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc5Mjk_dba72b20-2907-4215-8a86-5c7951ea468a">120.0</ix:nonFraction></ix:nonFraction> million will be fully recognized as of the three and nine months ended June&#160;30, 2022. Revenue for the nine months ended June 30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i63bff98126fe415385b5f094684f04c1_D20211001-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgwMzM_f6ccab50-7abe-4cdb-bc28-40e54cce0cb9">120.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i97c2718553fd46d69ad19a4d0391e677_D20201001-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgwNDA_430ea673-33a7-48b8-9042-2c22e4bbcfed">0</ix:nonFraction>, respectively. As of June&#160;30, 2022, there were $<ix:nonFraction unitRef="usd" contextRef="i9d593f14b6cb41c990078718ee591af5_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgwNzk_7a3ea3a6-57fa-4bdd-91fb-e446c5106570">0</ix:nonFraction> in contract assets recorded as accounts receivable, $<ix:nonFraction unitRef="usd" contextRef="i9d593f14b6cb41c990078718ee591af5_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgxMzQ_85aefe4d-d1ea-455d-a1b3-38288a7dd56e">0</ix:nonFraction> in contract liabilities recorded as deferred revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2022, the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;) with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of Arrowhead&#8217;s RNAi-based investigational cardiobolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Visirna SPA, entities affiliated with Vivo Capital (&#8220;Vivo&#8221;) also acquired a minority stake in Visirna in exchange for $<ix:nonFraction unitRef="usd" contextRef="if56e80163bfa40bc908f0611a5ea88cc_D20220425-20220425" decimals="-6" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTQ5NzU1ODM1Mzkw_15840624-95fd-4f09-af8b-d5ee90d9a439">60</ix:nonFraction>&#160;million in upfront capital to support the operations of Visirna.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has determined that Visirna is a variable interest entity upon its formation and as of June 30, 2022, and it has been determined that Arrowhead is the primary beneficiary; accordingly, Arrowhead consolidates the financial statements of Visirna.</span></div></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfNTQy_20064ad5-73df-4289-8d07-f813906d8dac" continuedAt="ied9aa0ed68fc4809b8efdf8d1ded00bf" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="ied9aa0ed68fc4809b8efdf8d1ded00bf" continuedAt="i8a2952a2d6c24e5b9ecd94827730c897"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfNTQz_5be3a51e-f862-4a49-8387-85b9ff9a92ed" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMi0xLTEtMS0yMjU_fec55f91-a74f-4f3d-94f1-8aa208bf5be3">2,210</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMi0zLTEtMS0yMjU_08169f85-bf28-4071-b7d0-4d5c9827f2c5">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMy0xLTEtMS0yMjU_785f6753-a67f-4599-b0a6-b5b3988d4cf0">31,678</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMy0zLTEtMS0yMjU_23f35696-fbde-46f7-997c-650b21c306b4">27,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNC0xLTEtMS0yMjU_e00fe314-2958-4804-94c4-80b8ce6295be">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNC0zLTEtMS0yMjU_7b502d37-5ecd-4726-8ab7-c2f9841f8cc5">41,524</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in Progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNS0xLTEtMS0yMjU_9c8b6636-d501-4108-b82f-faeb34c5d0e4">22,338</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNS0zLTEtMS0yMjU_b5b63ac3-7a7d-4261-a1a0-b71894c5ed3d">345</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNi0xLTEtMS0yMjU_48a313ae-2a5c-4c60-b2f9-cd140ab6253b">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:Land" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNi0zLTEtMS0yMjU_3bd66a68-ed63-4519-bf69-4075a944c3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total gross fixed assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNy0xLTEtMS0yMjU_fbd8e53e-dc7b-411e-b532-b0ce25310748">101,239</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNy0zLTEtMS0yMjU_90620d06-46bf-4fe9-aa17-2cbaa0ae8798">71,539</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOC0xLTEtMS0yMjU_6a5c21bb-1ea5-4abb-8b52-f3c6ab283c9d">29,335</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOC0zLTEtMS0yMjU_156955d2-4220-4d38-8e62-e2fedf7baa79">22,864</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOS0xLTEtMS0yMjU_080f3127-089c-4e78-a92d-062e60d66e47">71,904</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOS0zLTEtMS0yMjU_3a3776c4-a6be-4914-947e-259448a93758">48,675</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a2952a2d6c24e5b9ecd94827730c897">Depreciation and amortization expense for property and equipment for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMjMx_af1c8cf7-a310-4ef7-a01b-3e7839b2fc16">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMjM4_24b71162-6fee-4be2-8ebf-1332f3a21f9b">1.6</ix:nonFraction> million, respectively. Depreciation and amortization expense for property and equipment for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMzU5_3a59ddef-4f8d-479d-8249-eb5f571d8dec">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMzY2_43e5e8cc-7966-4810-aac3-7afdbec6fffc">4.5</ix:nonFraction> million, respectively. Construction in Progress relates to the Company&#8217;s Verona and San Diego research facilities. Land relates to the Company&#8217;s Verona, Wisconsin research facility.</ix:continuation> </span></div><div id="if686a6c4f85140f4912306552c96c723_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RleHRyZWdpb246ZTgxMWVmZTk0MjgwNGJhOGE2NTYwMjU2MmY0NGQwYjdfMTYxNw_37405903-92f6-4740-8779-f19d84a3ddb1" continuedAt="i18701d02ee8d44d1b42d1808d7325721" escape="true">INVESTMENTS</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i18701d02ee8d44d1b42d1808d7325721"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Investments at June&#160;30, 2022 primarily consisted of commercial paper and corporate bonds that have maturities of less than 36 months and a certificate of deposit. Cash and cash equivalents consist of cash on hand and commercial paper purchased with 90-days or less remaining to maturity.  The Company&#8217;s corporate bonds consist of both short-term and long-term bonds and are classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheets. The Company&#8217;s certificate of deposit matures in less than 12 months and is classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheet,&#8217;. The Company&#8217;s marketable equity securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, corporate bonds and other asset-backed debt securities. Dividends from these funds were automatically re-invested. In April 2022, all marketable securities were sold for  $<ix:nonFraction unitRef="usd" contextRef="i77fd51ba125e419fbba6f8c78ee5dccb_D20220401-20220430" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RleHRyZWdpb246ZTgxMWVmZTk0MjgwNGJhOGE2NTYwMjU2MmY0NGQwYjdfNTQ5NzU1ODIyOTc0_356dc724-9557-4958-8983-d03d4595e23c">122.3</ix:nonFraction>&#160;million. The Company may also invest excess cash balances in money market accounts, and these securities would be classified as cash and cash equivalents on the Company&#8217;s Consolidated Balance Sheet. The Company accounts for its &#8220;held-to-maturity&#8221; investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#8211; Equity Securities. We did not record any impairment charges related to our marketable debt securities during the three and nine months ended June&#160;30, 2022.</span></div><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RleHRyZWdpb246ZTgxMWVmZTk0MjgwNGJhOGE2NTYwMjU2MmY0NGQwYjdfMTYxOQ_b94d170c-562e-40f5-9094-239b43c7138f" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s short-term and long-term investments and marketable securities as of June&#160;30, 2022 and September&#160;30, 2021 by measurement category: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Cash Equivalents</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within ninety days)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC0xLTEtMS0yMjU_b829ddf8-8cde-4089-8a6b-516a51fbd6f9">25,325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630" decimals="-3" name="arwr:CashEquivalentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC0zLTEtMS0yMjU_a010ca97-e3d5-45b9-84a7-82b76bc91369">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630" decimals="-3" name="arwr:CashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC01LTEtMS0yMjU_6c2feb52-14e5-413c-8d2f-4726a95ac864">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC03LTEtMS0yMjU_35dc31e2-21f3-4ee8-b893-3d1f64e2f39c">25,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi0xLTEtMS0yMjU_7e14aedf-16e8-444a-aa79-22586bb7bed0">227,057</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi0zLTEtMS0yMjU_74f33d97-7922-413d-9257-cf8dc7377236">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi01LTEtMS0yMjU_6c17ba81-8ee7-4d60-86a5-067a9b372435">1,588</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi03LTEtMS0yMjU_f4cc8169-e968-4749-9b9e-0a5f0207cdfc">225,490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial notes (due within one through three years)</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b1f86d220804f7184099925062e5674_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy0xLTEtMS0yMjU_17eecd03-ffd8-4e10-b8dd-515895e85be9">165,920</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b1f86d220804f7184099925062e5674_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy0zLTEtMS0yMjU_6f48d16b-ae3c-4b6a-b06f-5ffb97c076be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b1f86d220804f7184099925062e5674_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy01LTEtMS0yMjU_3a1a6079-7cc6-406f-8bb0-566650368420">6,380</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b1f86d220804f7184099925062e5674_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy03LTEtMS0yMjU_4b6cf064-fdea-4d92-aeae-a040c7188617">159,540</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposit (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC0xLTEtMS0yMjU_3554ce4d-e83c-4879-9144-ad6527c90089">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC0zLTEtMS0yMjU_0dd6286c-4a50-4495-bfa5-f2df82545314">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC01LTEtMS0yMjU_4920c1d4-c7f1-41d0-99d2-837bc6a3fa32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC03LTEtMS0yMjU_d7a0be98-cafd-4aac-a135-a38d6a161560">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i01d441b649884843a5fd944aaba32e08_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtMS0xLTEtMjI1_503f7eee-e5a5-4f19-b3b8-e349b67f7a1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i01d441b649884843a5fd944aaba32e08_I20220630" decimals="-3" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtMy0xLTEtMjI1_6ad5ae4b-8a99-4471-b164-568729c0a2f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i01d441b649884843a5fd944aaba32e08_I20220630" decimals="-3" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtNS0xLTEtMjI1_0b13a84d-59ef-4f99-8095-489aa0d87b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i01d441b649884843a5fd944aaba32e08_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtNy0xLTEtMjI1_94b3d304-d82d-4600-a42d-f1188a9104a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtMS0xLTEtMjI1_0ee6bb03-0bcd-4da2-bfdd-b2f6ff020fab">468,302</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtMy0xLTEtMjI1_155bea63-0b45-47c4-b176-b6ea8a0ed25c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtNS0xLTEtMjI1_6984e230-66bd-4d23-b891-830e8f576d80">7,968</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtNy0xLTEtMjI1_f82a6e7d-9e27-4f76-bb1d-771c8473a643">460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September&#160;30, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctMS0xLTEtMjI1_cd3577a1-c3f4-434a-8c97-e637f5f3ef98">56,627</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctMy0xLTEtMjI1_d650487a-415f-4735-9896-55d48914248a">803</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctNS0xLTEtMjI1_50a92b95-d682-4313-b351-5a87dca765ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctNy0xLTEtMjI1_48325303-cf38-494f-8afc-4e18fe78d89b">57,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial notes (due within one through three years)</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtMS0xLTEtMjI1_3213941a-9d4c-468c-ae95-7acd04ebdb5f">195,595</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtMy0xLTEtMjI1_0a0d6072-640f-44a1-bddd-230382adf03b">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtNS0xLTEtMjI1_63737211-d02e-4cca-bc05-7f2c5e64a6b7">103</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtNy0xLTEtMjI1_a5fc8efb-0ab6-4dae-8872-617fca381740">196,643</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit (due within one through two years)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i48a971a1200644508883665152308229_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktMS0xLTEtMjI1_8cc2be63-f387-45e8-95f3-8f4f423c9f30">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i48a971a1200644508883665152308229_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktMy0xLTEtMjI1_7023ecf1-d707-422c-bb0a-fff0062ad1e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i48a971a1200644508883665152308229_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktNS0xLTEtMjI1_2e1a53db-b302-4241-b45a-bd6afdf80eea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i48a971a1200644508883665152308229_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktNy0xLTEtMjI1_4fd7dc02-aca0-4407-80b8-a7cf3b4f7e89">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtMS0xLTEtMjI1_9b68eb77-d5fa-408d-9eab-aeb2213b259a">127,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930" decimals="-3" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtMy0xLTEtMjI1_5a0603b5-2023-45d5-9b98-a20bbf013f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930" decimals="-3" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtNS0xLTEtMjI1_33c5cef7-abc5-478b-bcdf-139085eab225">753</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtNy0xLTEtMjI1_fba9a974-5367-49d0-89bc-419ba58d6887">126,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItMS0xLTEtMjI1_fde05d23-b1ea-48aa-88d1-e59e96c8c340">429,703</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItMy0xLTEtMjI1_30cc184c-db9e-488a-acbc-f3629ec29da1">1,954</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItNS0xLTEtMjI1_520247d5-7883-4bd2-b253-4ce6a696980b">856</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItNy0xLTEtMjI1_6aa67dac-7bfa-498f-a4ee-9be732439b81">430,801</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTAxOA_7295d091-ee8d-44c4-a150-e7c3b3925fc3" continuedAt="ib4ed6134c7444411aedbce2ad996eb5c" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib4ed6134c7444411aedbce2ad996eb5c" continuedAt="i876cef9f59f341a483f039df7c8a9a38">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was <ix:nonNumeric contextRef="i70ac20dc1b6c4e8089f4f3a352305d67_D20211001-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMzUy_27ad1956-cda4-4a4b-9d15-d09c8ce7c29e">21</ix:nonNumeric> years, and the accumulated amortization of the asset is $<ix:nonFraction unitRef="usd" contextRef="id7dab9325362475c8d7c98474f501710_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjY5Ng_0a4bab9c-6d30-4793-82ec-6f8c22bb17ed">1.1</ix:nonFraction> million. The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was <ix:nonNumeric contextRef="i35243ae1496c4b5397e5376a54a5213e_D20211001-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfNTY1_c582f75f-40ad-4117-8515-718bed641965">14</ix:nonNumeric> years, and the accumulated </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i876cef9f59f341a483f039df7c8a9a38"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortization of the assets is $<ix:nonFraction unitRef="usd" contextRef="i3ea210cb7e064575b12fb0ca788bb100_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjY4Nw_971eac0b-c2b7-4a43-9e8e-386beb95f053">11.4</ix:nonFraction> million. Amortization expense for the three months ended June 30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjgyMQ_9d2957b0-f77e-43f8-8d78-ddd944d29927">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjgxNA_4771c0b7-9c6e-4e27-a811-0d0ad10b9bad">0.4</ix:nonFraction>&#160;million, respectively. Amortization expense for the nine months ended June 30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0Mjc5NQ_3a916449-22ff-4215-9167-d6aad3665741">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjgwNg_59a9a312-8e29-4e5f-bb05-ac3289a38825">1.3</ix:nonFraction>&#160;million, respectively. Amortization expense is expected to be $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0Mjc4Ng_ebb68a9e-8371-42c8-99df-d7a1738a10d1">0.4</ix:nonFraction> million for the remainder of fiscal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfODcw_b03f357a-3421-4f22-90dc-7691119a24f1">1.7</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfODgy_a8df05e2-62af-42bb-8256-c8919c28d6da">1.7</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfODk0_5c75f804-0049-4cef-a00b-a597754c6328">1.7</ix:nonFraction> million in 2025, $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfOTA2_a5a55f9a-7ddd-4c63-9de1-b61ced337fae">1.7</ix:nonFraction> million in 2026 and $<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-5" name="arwr:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfOTIx_863ead87-754f-49b5-90b3-5a5f3f139517">5.2</ix:nonFraction> million thereafter.</span></div><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTAxOQ_ace99f1f-3c6c-4a96-aa49-6ddb394407be" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details on the Company&#8217;s intangible asset balances: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible<br/>Assets<br/>Subject to<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfMi0xLTEtMS0yMjU_ad3e3af3-f188-4d9c-b2d8-82f73fad1924">13,663</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfMy0xLTEtMS0yMjU_550e4e0e-ffc3-4b37-9fa9-e3d0ce9c8768">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfNC0xLTEtMS0yMjU_a7125727-1f47-422d-8a31-2d4a99df23b5">1,276</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfNS0xLTEtMS0yMjU_0fcb22bd-cec1-406e-87eb-aea15e9c2f09">12,387</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTM3NA_8553ded5-7617-4024-9ab7-3855abe34d90" continuedAt="i54605efe5dc04abe81e39635e1a39dd4" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i54605efe5dc04abe81e39635e1a39dd4"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company had a total of <ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:CapitalUnitsAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfNjg_9073d62d-91ab-4a94-945c-2f7a3d66105b">150,000,000</ix:nonFraction> shares of capital stock authorized for issuance, consisting of <ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTM0_1b8580af-d1d4-464b-ac86-29cc0200958a">145,000,000</ix:nonFraction> shares of Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTcx_2eff5d6a-bd2c-40cd-9cff-d50a6197c407">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTg5_3977253b-916a-4b4e-addd-bc1647fce604">5,000,000</ix:nonFraction> shares of Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMjI5_b99ba519-ea5e-4cb9-8d81-041a0c449ce2">0.001</ix:nonFraction> per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMjUx_e52f3797-0c12-442e-a342-f5e8208463b6">105,795,456</ix:nonFraction> shares of Common Stock were outstanding. At June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i7c9c3675bb1c483490de44cfa494ff0d_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMzAy_5aa8473e-d2ee-4695-8463-c0a48505cc72">13,942,716</ix:nonFraction> shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i5c06ed8ba612412c9c704fef2aa0558c_I20200831" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfNzk4_9fa912ef-185e-444b-95d8-bdc589fbe02d">250,000,000</ix:nonFraction> in shares of the Company&#8217;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="i505d3506ef1048dfa8e34da8a51f5a14_D20200801-20200831" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTA2Mw_37d815e3-7809-48ca-a925-160e140896ea">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i33ee3925344148cf9ff3b0be626dbb9a_I20220630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTMyNg_807fcf87-3bc4-49bc-b4f0-fd7ceb2c35a7">no</ix:nonFraction> shares have been sold under the ATM Agreement.</span></div></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjMzNA_446ca3e5-da48-4617-9602-3eb0c2451dd0" continuedAt="ic5b385e3dbe649cdb784f908a8f20301" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ic5b385e3dbe649cdb784f908a8f20301" continuedAt="i7f52d56a037349caab45f4670ed67ce7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMzky_186195d7-3625-4d5f-af04-ae150d8941b0">no</ix:nonFraction> contingent liabilities recorded as of June&#160;30, 2022. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2021, the Company completed a purchase of <ix:nonFraction unitRef="acre" contextRef="i84bb462914da49deab71348a6efb6c40_D20211220-20211220" decimals="INF" name="arwr:NumberOfAcresOfLandPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfNDkz_f31607af-e135-48d1-879f-8584bae7e774">13</ix:nonFraction> acres of land in the Verona Technology Park in Verona, Wisconsin, which is planned to be the site of an approximately <ix:nonFraction unitRef="sqft" contextRef="i9cab2225d77f4ca6a233208a8d4c59f5_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfNjA3_b41bff40-1a6e-4360-a316-55deb14c647e">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="i4a16451ca658448c8cea645ec09ff1d2_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfNjcx_09dea1a8-c789-462f-bbd5-9948ec3e4e9d">140,000</ix:nonFraction> square foot laboratory and office facility to support process development and analytical activities. Arrowhead intends to invest between $<ix:nonFraction unitRef="usd" contextRef="i4ba847cf8c8e49c5bddc809e4dc8d3f7_I20211220" decimals="-6" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfODEx_3648c059-a702-4533-af83-0f94dc9d6f6b">200</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if0867bc01dd94d139541c0b51a1ab546_I20211220" decimals="-6" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfODE4_fe70e7fe-2fe5-4238-89ea-a4472aa75ca6">250</ix:nonFraction> million into the buildout of the facilities. As part of this acquisition, the Company also entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the TIF district, and will be reimbursed by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay as reimbursements under the TIF program for these improvements is not guaranteed and will depend on future tax revenues generated from the developed property.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i7f52d56a037349caab45f4670ed67ce7" continuedAt="i63905facdb7b4344a809e719fab42d04">Technology License Commitments</ix:continuation></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63905facdb7b4344a809e719fab42d04">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon a new drug application and upon certain sales level milestones. These milestone payments could amount to the mid to upper double-digit millions of dollars. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company did <ix:nonFraction unitRef="usd" contextRef="i376ce739b9c345478ec0d64a72a9dd1e_D20201001-20210630" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_3eea0e5e-7057-42b7-a861-4ddfb3739711"><ix:nonFraction unitRef="usd" contextRef="i644bf2a958784d90a68f8b4c4f576ef5_D20210401-20210630" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_a7985c55-c9b2-40ee-a6b6-251065140974"><ix:nonFraction unitRef="usd" contextRef="if64b93b7539a474baa3e0eb46dbbd950_D20220401-20220630" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_b5e7b575-4dfa-49f6-b929-a7f977aaba25"><ix:nonFraction unitRef="usd" contextRef="ifdf66a768eba4ecb8fe84a26654807ed_D20211001-20220630" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_f0f1f404-2060-4a80-b238-1b96feaedfa8">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> reach any milestones. Under certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of sales of the relevant products.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div id="if686a6c4f85140f4912306552c96c723_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0Mw_db92695d-00ea-4813-9b8b-f2913146467a" continuedAt="i6f62e1edaf2d494b9d4f80c5068910ca" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i6f62e1edaf2d494b9d4f80c5068910ca" continuedAt="i070dc3d7ded847328cf48e1f5d589956"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California. The <ix:nonNumeric contextRef="i6885dc858b074038a02f3117afb66394_I20190430" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTI3_3826b52c-b590-4f42-ba6a-f3e64ad94a5d">91</ix:nonNumeric> month office building lease between the Company and 177 Colorado Owner, LLC is for approximately <ix:nonFraction unitRef="sqft" contextRef="i6885dc858b074038a02f3117afb66394_I20190430" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjI3_06015124-d6f8-425e-8145-7ec6d48baa0a">24,000</ix:nonFraction> square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. The increased capacity of this new office space compared to the Company&#8217;s prior corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves closer to market. Lease payments began on September&#160;30, 2019 and are estimated to total approximately $<ix:nonFraction unitRef="usd" contextRef="i6885dc858b074038a02f3117afb66394_I20190430" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNjAy_e30f400f-8d44-4a35-939a-0710552d11ff">8.7</ix:nonFraction> million over the term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease expires on April&#160;30, 2027. The Company has paid approximately $<ix:nonFraction unitRef="usd" contextRef="i692059f5d1fe4e29a4e0274f8340c5e5_D20190401-20190430" decimals="-5" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNjgx_9694e7c1-a1f5-4e99-a52c-1d5a911574d3">3.5</ix:nonFraction> million for leasehold improvements, net of tenant improvement allowances. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="i6885dc858b074038a02f3117afb66394_I20190430" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNzky_800e683a-e85e-4eb0-99f0-eadf8ceaf514">one</ix:nonFraction> term of <ix:nonNumeric contextRef="i6885dc858b074038a02f3117afb66394_I20190430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfODAz_3b64576b-27f6-43ff-a837-9f5609b1e432">five years</ix:nonNumeric>. The exercise of this option was not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at June&#160;30, 2022. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately <ix:nonFraction unitRef="sqft" contextRef="i162842da9c754c31a54c9669b0abb806_I20201023" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTA2Mg_31b120e0-df75-467f-9faa-7ee983078d5a">24,000</ix:nonFraction> square feet of office space at the same location for its corporate headquarters. Lease payments for the expansion began in July 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the lease for the expansion expires in April 2027. The lease payments for the expansion are expected to total $<ix:nonFraction unitRef="usd" contextRef="i162842da9c754c31a54c9669b0abb806_I20201023" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTI5Nw_87d6c57f-1def-4a77-88f6-76cc846c1068">6.9</ix:nonFraction> million. The Company has paid approximately $<ix:nonFraction unitRef="usd" contextRef="ie5cf456b9e5a4cfcb2e90173f201d53f_D20201023-20201023" decimals="-5" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTMzNg_45e0b461-9ce4-4a89-9b76-c9ad9f5906d9">4.0</ix:nonFraction> million of leasehold improvements, net of tenant improvement allowances, for the lease expansion. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin. The lease was for approximately <ix:nonFraction unitRef="sqft" contextRef="iae3244d52008465399c8cf8280559727_I20160131" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTgwMg_db7aa983-a194-43ca-a5d2-2bf72d407d52">60,000</ix:nonFraction> square feet of office and laboratory space and had an expiration date of September&#160;30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional <ix:nonFraction unitRef="sqft" contextRef="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531" decimals="INF" name="arwr:AdditionalLandSubjectToLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTk3OQ_b72c9f99-f38c-413d-b99b-2cc524c7fbd0">40,000</ix:nonFraction> square feet and to extend the lease expiration date to September&#160;30, 2031. Lease payments are estimated to total approximately $<ix:nonFraction unitRef="usd" contextRef="i773403c141e742faaafdffe0102289bb_I20200531" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjA5Mw_f8654e78-25da-4d19-a627-fc6e85cc1eb4">26.2</ix:nonFraction> million for the term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531" decimals="-5" name="arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjE0NQ_db0356e5-2b1d-430d-bda1-a5b5d364e06a">11.0</ix:nonFraction> million of leasehold improvements for the additional <ix:nonFraction unitRef="sqft" contextRef="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531" decimals="INF" name="arwr:AdditionalLandSubjectToLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjE5OTAyMzI2MjAyMg_b72c9f99-f38c-413d-b99b-2cc524c7fbd0">40,000</ix:nonFraction> square feet, net of tenant improvement allowances. The lease contains <ix:nonFraction unitRef="option" contextRef="iae3244d52008465399c8cf8280559727_I20160131" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjI3MA_d1334bd9-a889-4385-a4f6-c5b1e2e5ade3">two</ix:nonFraction> options to renew for two terms of <ix:nonNumeric contextRef="iae3244d52008465399c8cf8280559727_I20160131" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjMwNw_24d063fa-1f83-468c-b566-474d4233db1f">five years</ix:nonNumeric>. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at June&#160;30, 2022. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional <ix:nonFraction unitRef="sqft" contextRef="ia255aa9db9e44c3abb416601214d870b_D20201101-20201231" decimals="INF" name="arwr:AdditionalLandSubjectToLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjU5OA_7af466b5-c328-47a2-a658-17c895a0c341">10,743</ix:nonFraction> square feet and these amendments added a total of approximately $<ix:nonFraction unitRef="usd" contextRef="ied64e4423da840bc99bd1ce7b1418f51_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjY2NQ_bb349ab5-9266-440f-bd29-f88e183d63da">1.2</ix:nonFraction> million of lease payments for the remainder of the term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a sublease agreement for additional research and development facility space in San Diego, California. The Sublease provides additional space needed to accommodate the recent growth of the Company&#8217;s personnel and discovery efforts. The Sublease is for approximately <ix:nonFraction unitRef="sqft" contextRef="i8783fb2c40044c1b857062a070f80527_I20200331" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzAxNA_fd562ad9-e49f-43e7-bf16-7e4854dfb263">21,000</ix:nonFraction> rentable square feet. The term of the Sublease commenced on April&#160;1, 2020 and will end on January&#160;14, 2023. Sublease payments are estimated to total approximately $<ix:nonFraction unitRef="usd" contextRef="i8783fb2c40044c1b857062a070f80527_I20200331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzE1NQ_68c8aadb-a354-419f-b56f-c54eaeb0c15c">2.0</ix:nonFraction> million over the term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a new lease for a San Diego, California research facility. The <ix:nonNumeric contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0NA_7831165b-b8c7-4a3a-a8a8-7c1eff2870ed">15-year</ix:nonNumeric> lease is for approximately <ix:nonFraction unitRef="sqft" contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzMwMw_a2b51c99-0450-4f0f-b9db-eb04d1220b6e">144,000</ix:nonFraction> square feet of office and research and development laboratory space to be constructed in San Diego, California. This lease will replace the Company&#8217;s current research facility sublease for property located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for the Company&#8217;s expanding pipeline of current and future drug candidates. The estimated rent commencement date for the lease is in March 2023, after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $<ix:nonFraction unitRef="usd" contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzk3Mw_9c4eb206-1376-493f-ae38-272f23dbff64">119.0</ix:nonFraction> million over the initial <ix:nonNumeric contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5NTU3_59e3f9d4-263b-4b2e-88cc-f8eadf4615e9">15-year</ix:nonNumeric> term. The Company also estimates payments for operating expenses to be approximately $<ix:nonFraction unitRef="usd" contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" decimals="-5" name="arwr:EstimatedPaymentsForOperatingExpensesYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDA4Ng_bc41b418-194c-40ef-8725-ead1540aa0df">3.0</ix:nonFraction> million for the first year of the lease, and these payments will continue throughout the initial <ix:nonNumeric contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5NTU4_9df21d12-c4fe-493b-b5e0-c31177ac2675">15-year</ix:nonNumeric> term. The Company expects to pay approximately $<ix:nonFraction unitRef="usd" contextRef="id660743071414df3aeca314c0c062149_D20211119-20211119" decimals="-5" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDIzMw_e0c8392e-4fb6-4774-a622-4c2a9b5ae5c4">31.0</ix:nonFraction> million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5NTU5_7ca50ae2-ce2e-4cae-a02e-738dec050582">15-year</ix:nonNumeric> term, the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i070dc3d7ded847328cf48e1f5d589956"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="i5fa41fe62302434990f633a5d20b8810_I20211119" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDQ1MA_da1a5ad3-4811-44ba-8f7a-c499aca56e6f">one</ix:nonFraction> additional <ix:nonNumeric contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0MQ_14b6eeac-2317-47d5-b716-a5a098e5c356">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. .</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost during the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDY4OQ_b16b2b56-39da-42f4-bb25-c7a9450dc35c">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDY5Ng_2ab86a88-c1fd-4b7f-a3e4-a30d2dcc9b9a">1.6</ix:nonFraction> million, respectively. Operating lease cost during the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDc3Ng_f7c23786-0df3-4099-8be0-9602785bada9">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDc4Mw_297e3f5c-f70e-4184-ac03-b13948fefe7f">3.6</ix:nonFraction> million, respectively. Variable lease costs for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDg2Mw_cb36ecf4-35b0-4366-a7f8-eb9bc2dfb811">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDg3MA_199a7655-0b17-4979-87dd-b248bc8a670c">0.1</ix:nonFraction> million, respectively. Variable lease costs for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk0Nw_4554bc32-b627-41d3-a6a8-cf7da2c7ba3c">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk1NA_04f676de-096b-4c47-ac3b-c9a2a1616ab5">0.6</ix:nonFraction> million, respectively. There was <ix:nonFraction unitRef="usd" contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_446fe3f9-f185-48f0-86a7-41fe19096ac1"><ix:nonFraction unitRef="usd" contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_9148194f-ee73-46e0-a578-c3b475f43741"><ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_c0e701e6-da9c-4d63-9117-e2bb541c37b4"><ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_c23d5431-685b-4c2d-806b-dfeaeff9092d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> short-term lease cost during the three and nine months ended June&#160;30, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0Mg_1565e87b-ae33-45d8-b698-e02de8b3ce85" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 (remainder of fiscal year)</span></div></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfMS0xLTEtMS0yMjU_40f7f87e-f776-46a6-800f-e7eedd2bc26f">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfMi0xLTEtMS0yMjU_e6872276-2702-4546-87ef-bf054363f882">5,802</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfMy0xLTEtMS0yMjU_cd89258d-e6b0-4ce4-ae3a-a6ae410f24e8">8,094</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNC0xLTEtMS0yMjU_aa2f8da9-bca3-4174-babc-bee8bd636cc8">11,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNS0xLTEtMS0yMjU_cdb2f434-3775-4655-a90e-04646631d650">12,313</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNi0xLTEtMS0yMjU_53293171-9c35-45b1-8c95-6f5c02435c92">114,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNy0xLTEtMS0yMjU_e7753204-2d2d-4564-8e5d-ea97d385c1ee">153,427</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfOC0xLTEtMS0yMjU_a19d3357-17b9-47b1-9824-af764ef321ad">72,313</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfOS0xLTEtMS0yMjU_08a4d170-bd35-4514-a63c-3f519dc15c33">81,114</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#8217;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#8217;s Consolidated Statements of Cash Flows for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ4OA_34c46053-d953-45aa-89a3-a21f320f037c">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NQ_104dafad-a8b2-46e5-959e-73a22e8d607a">2.2</ix:nonFraction> million, respectively. The weighted-average remaining lease term and weighted-average discount rate for all leases as of June&#160;30, 2022 was <ix:nonNumeric contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5ODIz_eaead4a4-0126-4876-8be9-2c2ef501bef7">7.3</ix:nonNumeric> years and <ix:nonFraction unitRef="number" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTYyNQ_a38177dc-bdf3-4337-9227-41d9594d0d84">8.5</ix:nonFraction>%, respectively.</span></div></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTI0MA_6a2a79e6-f3b6-4b1b-b467-29a490d4cd60" continuedAt="i83e8a1966d574288959e34bcf51fca46" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i83e8a1966d574288959e34bcf51fca46" continuedAt="i18103d342e974379b07ac4a46d68e32d">Arrowhead has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, as of June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i05cd815b480347a286bc4f71cff5bbcb_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTg0_2fa4bd7a-f380-4cd3-84ee-ac9874b7c66a">216,607</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i65ce38c05a5f42e5aef4eab075945c1a_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTkx_24a1d0ae-68eb-4439-b5f5-6127b33b1655">4,114,999</ix:nonFraction> shares, respectively, of Arrowhead&#8217;s Common Stock are reserved for the grant of stock options, stock appreciation rights, and restricted stock unit awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan. As of June&#160;30, 2022, there were options granted and outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i379e60ba18ab41bebaf6384f97789684_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIw_4e41dba9-addc-4cc6-b6f0-9611663dcec8">216,607</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if3aae72041c247afb7d654e771941178_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTI3_68da07c9-b9db-4a58-9462-32a1e06071b7">1,806,987</ix:nonFraction> shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were <ix:nonFraction unitRef="shares" contextRef="i7882ec681e8845bdafe4d93a1da25ae0_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNjQ4_b074c95c-48cc-43fa-8fb0-ad75a82694f1">2,308,012</ix:nonFraction> restricted stock units granted and outstanding under the 2013 Incentive Plan. As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i4351ec20fd374ac591919ea36aeda735_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNzUw_3a8d9fe5-ba8c-480a-9bac-55b5cb2beb5b">816,248</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="shares" contextRef="i9a3423502b6f4eff862ece7e6ce5ab9f_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNzg1_97f664f5-e71f-4eb5-8548-dc32708a0ac2">682,500</ix:nonFraction> shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ia900dec5d8af437f8940adc4f0279a04_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfOTM1_99624040-59d4-4e78-8404-4f8a5e2500e9">3,000</ix:nonFraction> shares of Common Stock reserved for options and <ix:nonFraction unitRef="shares" contextRef="i10471b52c2b6469eadb29efc00dc46d7_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfOTg2_53817e84-3395-4e2c-981a-31ba55f1db0c">1,507,267</ix:nonFraction> shares of Common Stock reserved for restricted stock units granted and outstanding under the 2021 Incentive Plan. As of June&#160;30, 2022, the total number of shares available under the 2021 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="ib4c1075e233c4c4285d6a3aadd4db3ea_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTE4NA_5f15aa51-7ffe-4cf9-a67b-4472b7645dad">6,627,845</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="i4c13269bb6524b0cb33ce18d229e84d4_D20211001-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTIxMA_02a47e4a-e738-47a6-8028-1de2ea1c8c36">119,612</ix:nonFraction> shares that were forfeited under the 2013 Incentive Plan.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i18103d342e974379b07ac4a46d68e32d" continuedAt="i73194087d0b24015ae7400a144df88dc"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTI0MQ_bc245659-0c78-4876-b558-f5bd74a6e7be" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMS0xLTEtMS0yMjU_38901d1c-b04a-4f2a-b094-96ce8624169b">3,456,239</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMS0zLTEtMS0yMjU_c942710e-211c-4908-ac7d-8ab5115f5e3a">19.60</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMi0xLTEtMS0yMjU_eb75b7b5-14f1-4079-ade0-e72c213ea89f">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMi0zLTEtMS0yMjU_5a749439-4718-41f1-9a8b-ea434476ffc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMy0xLTEtMS0yMjU_47d19cfa-d822-459b-abf9-9c8f70807d2c">106,801</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMy0zLTEtMS0yMjU_fe6e8079-a844-4b1a-aa29-14423897c696">43.68</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNC0xLTEtMS0yMjU_5b7e7573-0596-40e1-b7ef-74b0c7320d32">506,596</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNC0zLTEtMS0yMjU_34d38d62-5cd8-48a7-bc68-0e49a5a5267d">8.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS0xLTEtMS0yMjU_bab7d6d4-8ca9-47c2-a8fd-09a1c725ffd8">2,842,842</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS0zLTEtMS0yMjU_fe59dc11-5804-4234-933d-6c0d711fceaa">20.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS01LTEtMS0yMjU_08fd8be5-2dfd-4d31-9092-913717495237">5.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS03LTEtMS0yMjU_b64eb440-8815-434c-b2ed-bc6d766bc964">55,434,252</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable at June&#160;30, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi0xLTEtMS0yMjU_cc6e61fd-32e4-495f-9a50-2a8dc61a67e4">2,370,089</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi0zLTEtMS0yMjU_f641ed51-1f2e-4dc7-ba1f-03df4d3e24ad">16.14</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi01LTEtMS0yMjU_6546d593-2a12-481a-9fcb-63fcd0853a44">4.6</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi03LTEtMS0yMjU_4511ecdc-cafe-4df1-a0cd-78b79bc778ba">52,941,990</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTQ1MA_5cd99336-0fd4-4de9-905d-2605e996bf1d">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTQ1Nw_42f30ada-4166-425b-9585-96e89b019a81">3.2</ix:nonFraction> million, respectively. Stock-based compensation expense related to stock options for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTU3MQ_b2cf6d91-b66c-4685-82db-0fc736f4b3c3">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTU3OA_49a2510c-c106-4073-957f-d32eb1acb615">9.6</ix:nonFraction> million, respectively. For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the options granted by the Company for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630" decimals="-5" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTg2MQ_b2f84a0d-5ebf-4689-88f9-c37bbd7577b3">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630" decimals="-5" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTg2OA_2ea3f03b-f748-4149-b70b-21810b2c4131">0.9</ix:nonFraction> million, respectively. The grant date fair value of the options granted by the Company for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630" decimals="-5" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTk4OA_7e8e4435-c023-46d7-9146-59b6b9275518">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630" decimals="-5" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTk5NQ_6d9180dc-3e3a-4def-bd35-56564bdf9d98">9.0</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of the options exercised during the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjEwMw_5f39e3ff-6a38-4e3b-af7a-889d573dd038">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjExMA_3e8c6a18-141d-4591-930f-e74546b3b62d">10.2</ix:nonFraction> million, respectively. The intrinsic value of the options exercised during the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjIyOA_3fcbc27b-8deb-4c5c-ae08-9bc431535356">24.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjIzNQ_d1d155cd-79f7-4497-b1d1-ae3a653a93c7">63.0</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="usd" contextRef="i3bb156c620804981b8a0721dfa56e51a_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjM1Nw_cea942d6-cfd1-48c0-a07e-bb0101bf966f">14.9</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjQ1Mg_77c6e450-a1ad-47bc-98a2-02909ed8a122">1.7</ix:nonNumeric> years. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIzOA_845b75be-6f3e-426e-a1a5-91c585f28ddf" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to value stock options are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfMi0zLTEtMS0yMjU_35bce74a-1978-44ac-9664-931051125daf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfMy0zLTEtMS0yMjUvdGV4dHJlZ2lvbjpiNmQ2NTkyMzVhMjI0ZTQ4ODI1N2FlOWI0ZTQxMTAyNF8yMTk5MDIzMjU1NTY5_0ac6d5d7-0185-4aed-bd85-a1ebb22be82d">0.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfMy0zLTEtMS0yMjUvdGV4dHJlZ2lvbjpiNmQ2NTkyMzVhMjI0ZTQ4ODI1N2FlOWI0ZTQxMTAyNF8yMTk5MDIzMjU1NTgw_84c9bb0f-e9a9-4809-bbba-8932ad338eaf">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNC0zLTEtMS0yMjUvdGV4dHJlZ2lvbjplNzNlNDRhMGU4NWQ0NTNiYTE3NzI4M2E3MzhmMDlhM18yMTk5MDIzMjU1NTcy_edec214b-c53e-4b47-b4a7-70400285109f">86</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNC0zLTEtMS0yMjUvdGV4dHJlZ2lvbjplNzNlNDRhMGU4NWQ0NTNiYTE3NzI4M2E3MzhmMDlhM18yMTk5MDIzMjU1NTg1_96143cd1-9f7e-45ab-a75c-8d87aa730f23">90.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNS0zLTEtMS0yMjU_bfe0d769-3824-44ee-937f-3acbec9bbdc6">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNi0zLTEtMS0yMjU_db3d82cd-57c4-4a7e-9c2a-0151c8568c6a">48.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is <ix:nonFraction unitRef="number" contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMzQxOQ_a333a29d-7c79-4944-bb23-7aca56cdf7ae">zero</ix:nonFraction> as the Company currently does not pay a dividend. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on that of the U.S. Treasury bond. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i73194087d0b24015ae7400a144df88dc" continuedAt="i7338aaa5296042bcb421de6105ceaf38"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including time-based, market condition-based, and performance condition-based awards, have been granted under the Company&#8217;s 2013 Incentive Plan, 2021 Incentive Plan, and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIzOQ_8bba572e-b3cc-4fa8-b817-ecb77345e4db" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested at September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i259144688fe44f518dbdd195d182b514_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMS0xLTEtMS0yMjU_868eb9bd-40bc-4814-a23c-825a4a32d2fe">3,831,850</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i259144688fe44f518dbdd195d182b514_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMS0zLTEtMS0yMjU_f7847e90-e677-430a-a7a8-1a462b0574b1">61.24</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMi0xLTEtMS0yMjU_184b4764-43a5-4916-bccb-4f947264cf2a">1,691,367</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMi0zLTEtMS0yMjU_845cf8df-df6e-4de4-be59-a713489dfffc">56.73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMy0xLTEtMS0yMjU_2e02f6ed-9af9-4153-bd22-2cee003b105e">962,188</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMy0zLTEtMS0yMjU_bb0ff0d9-efc2-489c-8cfd-8d28811a151d">49.10</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNC0xLTEtMS0yMjU_2c0dbec7-c7d0-4e78-a92e-fa577d1dd637">95,625</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNC0zLTEtMS0yMjU_05d8a92c-a943-4f62-805a-6fe2848d121e">69.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id47421dd3b3e45a88df5bdc71cefa55c_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNS0xLTEtMS0yMjU_c3193888-fae8-4b85-b306-dce7eae2a4fa">4,465,404</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="id47421dd3b3e45a88df5bdc71cefa55c_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNS0zLTEtMS0yMjU_4059f196-cd64-4f0c-8106-d811c84b8ca1">61.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDEzNA_3f626865-7135-4848-8730-f04c585fd210">33.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i88e9d9c8bcbb4fcaabd247d4fbea501a_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDE0MQ_89265620-720a-4b46-85b2-42fbc82ee397">15.4</ix:nonFraction> million of expense related to RSUs, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDI0NQ_26a8e63b-fd5e-4be6-b866-78f7b5a0b1d6">83.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4414d1709ac14596b6a26d0204f04e45_D20201001-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDI1Mg_f0359171-95ec-4d28-a3fe-042bfe066d52">32.5</ix:nonFraction> million of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For RSUs, the grant date fair value of the award is based on the Company&#8217;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. The grant date fair value of the RSUs granted by the Company for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630" decimals="-5" name="arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDkwOQ_2eaa488f-189e-45ed-9587-4030fc005fff">42.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i88e9d9c8bcbb4fcaabd247d4fbea501a_D20210401-20210630" decimals="-5" name="arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDkxNg_4cead625-1423-47c9-9acc-599630f81945">3.1</ix:nonFraction> million, respectively. The grant date fair value of the RSUs granted by the Company for the nine months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630" decimals="-5" name="arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTAzMw_aee6e93f-6c55-4276-a34c-50a9a0474da5">95.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4414d1709ac14596b6a26d0204f04e45_D20201001-20210630" decimals="-5" name="arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTA0MA_30d1ea1e-9988-4067-96a0-f120adc2d0a7">112.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7338aaa5296042bcb421de6105ceaf38">As of June&#160;30, 2022, the pre-tax compensation expense for all unvested RSUs in the amount of $<ix:nonFraction unitRef="usd" contextRef="id47421dd3b3e45a88df5bdc71cefa55c_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTE0MA_e829a408-cde1-440b-b6fd-d41f28191db6">190.3</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIzNQ_70987eb0-32bb-4ace-8cd2-3bf2c647f9c8">2.7</ix:nonNumeric> years.</ix:continuation> </span></div><div id="if686a6c4f85140f4912306552c96c723_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RleHRyZWdpb246NmVmOWQ5MWI1MjI2NDJjZmFlZjlmOTBmYThlN2JiOWJfMTY0OQ_faa32bfc-f995-47a1-a291-5ea3ad34f9e0" continuedAt="icf1efb13c00f49f8aed354f6f912fcf3" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="icf1efb13c00f49f8aed354f6f912fcf3" continuedAt="if4c7e146982849a9ab1631d1515ca817"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if4c7e146982849a9ab1631d1515ca817"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RleHRyZWdpb246NmVmOWQ5MWI1MjI2NDJjZmFlZjlmOTBmYThlN2JiOWJfMTY1MA_6a39c43d-c60b-4dcf-be6b-3157dcc6dd05" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair value measurements at June&#160;30, 2022 and September&#160;30, 2021 for assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Cash and cash equivalents</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial Notes</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7214723d69d141009860a51209e72550_I20220630" decimals="-3" name="arwr:CommercialNotes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy0xLTEtMS0yMjU_985ad0bd-c568-4f18-b490-445f3fd05ac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7cc07f5f5684808976783384030924f_I20220630" decimals="-3" name="arwr:CommercialNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy0zLTEtMS0yMjU_c6baeb63-40b9-458e-b42d-cdf404a2bfcc">25,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630" decimals="-3" name="arwr:CommercialNotes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy01LTEtMS0yMjU_5a3ad241-cfdd-4bab-95d0-91baf678d67a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630" decimals="-3" name="arwr:CommercialNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy03LTEtMS0yMjU_705e1298-1546-4921-a370-a85666d0d2f0">25,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7214723d69d141009860a51209e72550_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS0xLTEtMS0yMjU_d911b7b3-ccf4-442c-91d3-0b4c57f6d44b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7cc07f5f5684808976783384030924f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS0zLTEtMS0yMjU_2ac298b1-8864-479c-8b44-4bdfd713ee3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS01LTEtMS0yMjU_13396b41-5aeb-4ca9-b501-b39598f2d071">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS03LTEtMS0yMjU_0e4c47ad-2835-4175-b21f-40946f0ac4fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7214723d69d141009860a51209e72550_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy0xLTEtMS0yMjU_bdcdafad-7bb6-4b6e-9c2e-b27ae4dbebfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7cc07f5f5684808976783384030924f_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy0zLTEtMS0yMjU_b82aad49-b17d-4d66-9e81-ff3e3d5eecc5">225,490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy01LTEtMS0yMjU_1de5bf43-a1f2-4f5c-9bf4-05af0aaacb2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy03LTEtMS0yMjU_1a6c7641-d1df-4292-95e2-95a3e31a1598">225,490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term investments</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7214723d69d141009860a51209e72550_I20220630" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC0xLTEtMS0yMjU_55cabc80-c54e-4699-a930-7fae33fbe3d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7cc07f5f5684808976783384030924f_I20220630" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC0zLTEtMS0yMjU_c40f8df2-62b2-4926-8f42-8e62f4f87ab2">159,540</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC01LTEtMS0yMjU_cab67ed2-8599-43a7-b457-ffeae4031524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC03LTEtMS0yMjU_4394bd93-ac9c-4786-8886-7fc21316b341">159,540</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposits</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7214723d69d141009860a51209e72550_I20220630" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS0xLTEtMS0yMjU_4eae3ad6-3e97-4f4d-8e89-5df8ccb55de6">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7cc07f5f5684808976783384030924f_I20220630" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS0zLTEtMS0yMjU_e9a41ea3-6ec5-4f47-aa70-e576521808a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS01LTEtMS0yMjU_ce344730-3cc5-4aec-baa7-7145af2d0e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS03LTEtMS0yMjU_c3029687-0ee6-4c10-9067-c18a0954d4fd">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Contingent Consideration</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7214723d69d141009860a51209e72550_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtMS0xLTEtMjI1_2b4f8fb1-e965-42e3-9847-ef8adaa8d702">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if7cc07f5f5684808976783384030924f_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtMy0xLTEtMjI1_e3f9edd6-9abc-43ba-ad4c-94c07bf55e42">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtNS0xLTEtMjI1_61b69a33-48ef-407e-a2f2-12db7163396a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtNy0xLTEtMjI1_2f82a9c9-40c0-4212-9356-4a26e87f08bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy0xLTEtMS0yMjU_aa9f5ba4-950f-4eaa-b3d6-4771190821cc">126,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i224620efc59044b19ba131a63fb0f173_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy0zLTEtMS0yMjU_0e71801b-dec2-4f32-99ea-1096819742d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy01LTEtMS0yMjU_f2059a9a-f935-495b-bd90-e126fbbca50f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy03LTEtMS0yMjU_615eff32-7f55-4209-a864-d10167030197">126,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS0xLTEtMS0yMjU_ed5a6542-1751-4f0d-bc44-f47a91e7b6cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i224620efc59044b19ba131a63fb0f173_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS0zLTEtMS0yMjU_7760a33b-ddb8-444f-8d4d-6c9e1bd046de">57,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS01LTEtMS0yMjU_cec8a69c-200f-489d-b27f-02dbe2e2441d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS03LTEtMS0yMjU_0168d38d-d67c-491b-94f8-1c9d5afcf682">57,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term investments</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi0xLTEtMS0yMjU_8d0a1609-34e6-4fc1-a3d7-0128fadf7400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i224620efc59044b19ba131a63fb0f173_I20210930" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi0zLTEtMS0yMjU_90743d87-90bd-43f3-b17d-2f9cbe188d2a">196,643</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi01LTEtMS0yMjU_dccc3c86-589e-4a08-893f-e45bde229ce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930" decimals="-3" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi03LTEtMS0yMjU_570b8fa8-b2da-4c8a-bfdf-61cca47d90eb">196,643</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy0xLTEtMS0yMjU_c91312a4-091c-46bc-95e4-22893d9e7346">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i224620efc59044b19ba131a63fb0f173_I20210930" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy0zLTEtMS0yMjU_189eee30-00d2-40e0-9711-fea7218a91f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy01LTEtMS0yMjU_cedbea6a-b84e-42b0-925c-47e9d2691fa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930" decimals="-3" name="arwr:CertificateOfDeposits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy03LTEtMS0yMjU_5df4eceb-b3fe-4c3d-929f-ddcf170f4477">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Contingent Consideration</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS0xLTEtMS0yMjU_206d63c0-6ca6-4bab-8df8-c15af5495f87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i224620efc59044b19ba131a63fb0f173_I20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS0zLTEtMS0yMjU_ce52393f-d108-4389-9880-de9afb0e4dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS01LTEtMS0yMjU_48df7cb3-8ef2-4652-aa26-d2626d035f21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS03LTEtMS0yMjU_d0c495b0-ea4a-49fe-b09a-da396c83f78f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if686a6c4f85140f4912306552c96c723_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182NC9mcmFnOmZjNGQwMjI4YmJiYjQyZGE5MmFlN2ZmZThlOWE3ODIwL3RleHRyZWdpb246ZmM0ZDAyMjhiYmJiNDJkYTkyYWU3ZmZlOGU5YTc4MjBfNzc0_5f2fe5a1-b9fe-4396-bc8c-062b3cf4686d" continuedAt="i7a09b3afdf2c476aab04008847248c16" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a09b3afdf2c476aab04008847248c16">None.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. In addition, many of these risks and uncertainties may be exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. As such, our actual results may differ materially from those expressed in any forward-looking statements. Readers should carefully review the factors identified in our most recent Annual Report on Form 10-K under the caption &#8220;Risk Factors&#8221; as well as the additional risks and uncertainties described in other documents we file from time to time with the Securities and Exchange Commission (&#8220;SEC&#8221;), including this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div id="if686a6c4f85140f4912306552c96c723_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise noted, (1) the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2) the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3) the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), Visirna Therapeutics Inc. ("Visirna"), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4) the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, par value $0.001 per share, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock, par value $0.001 per share, and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead&#8217;s Common Stock.</span></div><div id="if686a6c4f85140f4912306552c96c723_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#8217;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC2 for cystic fibrosis, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens, ARO-C3 for complement mediated diseases, ARO-RAGE and ARO-MUC5AC for various muco-obstructive or inflammatory pulmonary conditions and ARO-MMP7 for idiopathic pulmonary fibrosis. ARO-HSD for liver disease was out-licensed to Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;) in November 2021. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;). JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. JNJ-3989 (formerly referred to as ARO-HBV) for chronic hepatitis B virus was out-licensed to Janssen in October 2018. Olpasiran (formerly referred to as AMG 890 or ARO-LPA) for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016. While the Company believes that initial ARO-HIF2 Phase 1 clinical data provides proof of concept for the ability to deliver siRNA to RCC tumors, the Company has decided not to pursue further clinical development of ARO-HIF2 based on a number of factors including the evolving competitive landscape for HIF2 inhibitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three quarters of fiscal 2022, the Company continued to develop and advance its pipeline and partnered candidates and expanded its facilities to support the Company&#8217;s growing pipeline. Several key recent developments include: </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.9pt">dosed the first patients in its PALISADE study, a phase 3 clinical study to evaluate the safety and efficacy of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.13pt">entered into an exclusive license agreement with GSK for ARO-HSD; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.36pt">Janssen presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989 (JNJ-3989), formerly called ARO-HBV, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB);</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.9pt">filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 and subsequently dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s </span><span style="background-color:#f3f3f3;color:#676767;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nvestigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">presented additional interim clinical data from AROHSD1001, AROAAT2002, and AROAPOC31001; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">completed the purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin and held a groundbreaking ceremony on the site. The site is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company's process development and analytical activities. The Company also announced that it received awards for up to $16&#160;million in tax increment financing from the city of Verona, and up to $2.5&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.  Additionally, The Company entered into a lease agreement for a new 144,000 square foot laboratory and office facility in San Diego, California to support discovery activities;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.13pt">completed enrollment in Phase 2b ARCHES-2 study of investigational ARO-ANG3 for patients with mixed dyslipidemia;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">viii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-RAGE for treatment of Asthma;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-MUC5AC for treatment of muco-obstructive lung disease;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">initiated and dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholersterolemia;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">xi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">entered into definitive agreements to form a joint venture, Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;) with Vivo Capital (&#8220;Vivo&#8221;) through which the Company and Vivo intend to expand the reach of innovative medicines in Greater China;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">xii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:22.13pt">hosted a pulmonary research &amp; development (R&amp;D) Day to discuss the Company&#8217;s emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) platform, including an announcement of its previously undisclosed candidate designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF); and</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xiii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt">in conjunction with Takeda, announced results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), and was recently published in the New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress&#8482; 2022 - </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Meeting of the European Association for the Study of the Liver (EASL).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the three and nine months ended June&#160;30, 2022 were not significantly impacted by COVID-19. Operationally, the Company has experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#8217;s preclinical programs. Additionally, the Company has experienced delays in enrollment in its clinical trials. The Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees and the length and severity of the COVID-19 pandemic. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net losses were $72.0 million for the three months ended June 30, 2022 as compared to net losses of $29.9 million for the three months ended June 30, 2021. Net losses were $90.6 million for the nine months ended June 30, 2022 as compared to net losses of $77.5 million for the nine months ended June 30, 2021. Net losses per share-diluted were $0.68 for the three months ended June 30, 2022 as compared to net losses per share-diluted of $0.29 for the three months ended June 30, 2022. Net losses per share-diluted were $0.86 for the nine months ended June 30, 2022 as compared to net losses per share-diluted of $0.75 for the nine months ended June 30, 2021. The increase in net losses for the three months ended June 30, 2022 was due to an increase in research and development and general and administrative expenses as the Company&#8217;s pipeline of candidates has expanded and progressed through clinical trial phases, partially offset by an increase in revenue from the Company&#8217;s license and collaboration agreements, primarily from the Takeda License Agreement (as defined below) and the Horizon License Agreement (as defined below). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has strengthened its liquidity and financial position through upfront and milestone payments received under its collaboration agreements, as well as equity financings. Under the terms of the Company&#8217;s agreements with Janssen, taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock, and four milestone payments totaling $70.0 million. Under the terms of the Company&#8217;s agreements with Amgen, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock and $30.0 million in milestone payments. The Takeda License Agreement resulted in a $300.0 million upfront payment, and the Horizon License Agreement resulted in a $40.0 million upfront payment. Finally, the GSK License Agreement resulted in an upfront payment of $120.0 million, which was received in January 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $139.4 million of cash and cash equivalents, $277.1 million in short-term investments, $165.9 million of long term investments and $751.8 million of total assets as of June&#160;30, 2022, as compared to $184.4 million of cash and cash equivalents, $126.7 million of marketable securities, $56.6 million in short-term investments, $245.6 million of long term investments and $710.1 million  of total assets as of September&#160;30, 2021. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div><div id="if686a6c4f85140f4912306552c96c723_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes our results of operations for the following periods indicated: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands, except per share</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(29,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income (loss) per share-diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands, except per share</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">211,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(84,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(90,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(77,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income (loss) per share-diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue for the nine months ended June 30, 2022 compared to the nine months ended June 30, 2021 was driven by the revenue recognized from the GSK, Takeda and Horizon License Agreements.</span></div><div id="if686a6c4f85140f4912306552c96c723_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the three months ended June&#160;30, 2022 and 2021 was $32.4 million and $45.9 million, respectively. Total revenue for the nine months ended June&#160;30, 2022 and 2021 was $211.7 million and $100.0 million, respectively. Revenue for the nine months ended June 30, 2022 is primarily related to the recognition of the $120.0 million of revenue associated with the upfront payment received from GSK under the GSK License Agreement in the second quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;28, 2016, the Company entered into two collaboration and license agreements and a common stock purchase agreement with Amgen. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0 million milestone payment to the Company. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company recognized $0 and $0 of revenue associated with its agreement with Amgen, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;3, 2018, the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;) with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company also entered into a stock purchase agreement with JJDC (&#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. Under the Janssen </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement, Janssen was able to select three new targets against which Arrowhead would develop clinical candidates. These candidates were subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0 million, and the Company may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $0.6 billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During the three months ended June&#160;30, 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. At the inception of these agreements, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the three months ended June&#160;30, 2022 and 2021, the Company recognized approximately $0 and $0 of revenue associated with this performance obligation, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized approximately $0 and $20.2 million of revenue associated with this performance obligation, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. During the three months ended June&#160;30, 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement as reported in the second quarter of 2022. During the three months ended June&#160;30, 2022 and 2021, the Company recognized $0.0&#160;million and $0.2 million of revenue associated with these efforts, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized $0.1 million and $0.5 million of revenue associated with these efforts, respectively. In May 2021, Janssen exercised its option right for ARO-JNJ1, which resulted in a $10.0&#160;million milestone payment to the Company. This $10&#160;million milestone payment was recognized entirely during the three months ended June 30, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there were $0 of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, the Company entered into an Exclusive License and Co-funding agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda. Under the Takeda License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. In January 2021, the Company received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $300.0 million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services. Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the three months ended June&#160;30, 2022 and 2021 was $25.5 million and $35.7 million, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $67.1 million and $69.3 million, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, $71.0 million in contract liabilities recorded as deferred revenue and $71.2 million in contract liabilities recorded as deferred revenue, net of the current portion, and $7.8 million in contract liabilities recorded as accrued expenses. The $7.8 million in accrued expenses was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Horizon Therapeutics Ireland DAC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, the Company entered into the Horizon License Agreement with Horizon. Under the Horizon License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of ARO-XDH, and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $40 million as an upfront payment and is eligible to receive up to $660 million in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties, from this transaction price to date. The Company will allocate the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the associated Horizon R&amp;D Services. Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the three months ended June&#160;30, 2022 and 2021 was $6.7 million and $0, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $20.0 million and $0, respectively. As of June&#160;30, 2022, there were $0 million in contract assets recorded as accounts receivable, $13.3 million in contract liabilities recorded as deferred revenue. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has manufactured ARO-XDH material for Horizon in furtherance of the research plan entered into pursuant to the Horizon License Agreement, for which the Company has been reimbursed for its costs. During the nine months ended June 30, 2022 and 2021, the Company recognized $1.3 million and $0 with these efforts, respectively. As of June&#160;30, 2022, there were $0.0 million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;) with GSK. Under the GSK License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK has received an exclusive license for ARO-HSD, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the Company&#8217;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">itory. Under the terms of the agreement, the Company has received an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the GSK License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study, (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of these GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0 million, including the upfront payment. The $120.0 million upfront payment was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million will be fully recognized as of the three and nine months ended June&#160;30, 2022. Revenue for the nine months ended June 30, 2022 and 2021 was $120.0 million and $0, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, $0 in contract liabilities recorded as deferred revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2022, the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;) with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of Arrowhead&#8217;s RNAi-based investigational cardiobolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Visirna SPA, entities affiliated with Vivo Capital (&#8220;Vivo&#8221;) also acquired a minority stake in Visirna in exchange for $60&#160;million in upfront capital to support the operations of Visirna.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has determined that Visirna is a variable interest entity upon its formation and as of June 30, 2022, and it has been determined that Arrowhead is the primary beneficiary; accordingly, Arrowhead consolidates the financial statements of Visirna.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> </span></div><div id="if686a6c4f85140f4912306552c96c723_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. Certain reclassifications have been made to prior-period operating expense categories to conform to the current period presentation. For purposes of comparison, the amounts for the three and nine months ended June&#160;30, 2022 and 2021 are shown in the tables below. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are related to the Company&#8217;s research and development efforts and related program costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to operations at our research facilities in Madison, Wisconsin and San Diego, California, including facility costs and laboratory-related expenses. Salaries and stock compensation expense consist of salary, bonuses, payroll taxes and related benefits and stock compensation for our R&amp;D personnel. Depreciation and amortization expense consist of depreciation on lab equipment and leasehold improvements at our research facilities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separately track R&amp;D expenses by individual research and development projects, including by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses for research and development activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses for the periods indicated:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(table below in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">61,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation/amortization</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">72,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">59,325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Candidate costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">183,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">117,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">66,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation/amortization</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">213,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">140,576</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">73,354</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased by $2,725,000 from $8,518,000 during the three months ended June 30, 2021 to $11,243,000 during the current period. Salaries expense increased by $8,266,000 from $25,375,000 during the nine months ended June 30, 2021 to $33,641,000 during the current period. This increase is primarily due to an increase in R&amp;D headcount that has occurred as the Company has expanded its pipeline of candidates. We anticipate this expense to continue to increase as we continue to expand our pipeline of candidates and increase headcount to support our discovery efforts to identify new drug candidates, in addition to inflationary pressures in the labor market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities expense increased by $2,521,000 from $1,306,000 during the three months ended June 30, 2021 to $3,827,000 during the current period. Facilities expense increased by $3,188,000 from $4,456,000 during the nine months ended June 30, 2021 to $7,644,000 during the current period. This category includes rental costs for our research and development facilities in Madison, Wisconsin and San Diego, California. We expect this expense to continue to increase as we continue to build out our manufacturing capabilities to support our discovery efforts to identify new drug candidates. The increase in facilities expense is due to the recognition of rent expense from the San Diego research facility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs increased by $264,000 from $31,468,000 during the three months ended June 30, 2021 to $31,732,000 during the current period. Candidate costs increased by $34,637,000 from $67,152,000 during the nine months ended June 30, 2021 to $101,789,000 during the current period. This increase is primarily due to the progression of our pipeline of candidates into and through clinical trials, which results in higher outsourced clinical trial, toxicity study and manufacturing costs. For example, our cardiometabolic candidates, ARO-ANG3 and ARO-APOC3, have advanced into phase 2 and phase 3 clinical trials. We anticipate these expenses to continue to increase as our pipeline of candidates grows and progresses to later phase clinical trials, in addition to unforeseen inflationary pressure on goods and services. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased by $4,999,000 from $10,082,000 during the three months ended June 30, 2021 to $15,081,000 in the current period. R&amp;D discovery costs increased by $20,052,000 from $20,295,000 during the nine months ended June 30, 2021 to $40,347,000 in the current period. This increase is primarily due to the growth of our discovery efforts, including the addition of our research facility in San Diego. We anticipate this expense to continue to increase as we increase headcount to support our discovery efforts to identify new drug candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, increased by $1,568,000 from $6,530,000 during the three months ended June 30, 2021 to $8,098,000 during the current period. Stock compensation expense, a non-cash expense, increased by $5,537,000 from $18,421,000 during the nine months ended June 30, 2021 to $23,958,000 during the current period. Stock compensation expense is based upon the valuation of stock options and restricted stock units granted to employees, directors and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. The increase in the expense in the current period is primarily due to the increased headcount discussed above. We generally expect future stock compensation expense to continue to increase as our headcount continues to increase to support our clinical pipeline. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a non-cash expense, increased by $779,000 from $1,421,000 during the three months ended June 30, 2021 to $2,200,000 during the current period. Depreciation and amortization expense, a non-cash expense, increased by $1,674,000 from $4,877,000 during the nine months ended June 30, 2021 to $6,551,000 during the current period. The majority of depreciation and amortization expense relates to depreciation on lab equipment and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leasehold improvements at our Madison and San Diego research facilities. The increase in depreciation and amortization expense is due to an increase in laboratory equipment and leasehold improvements. We expect this amount to increase in the future as we continue to purchase additional lab equipment and increase our footprint expansions to support our growing pipeline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of our general and administrative expenses for the periods indicated: </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(table below in thousands) </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr style="height:19pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional/outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other G&amp;A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total general &amp; administrative expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr style="height:19pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional/outside services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other G&amp;A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">595&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,739&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,631&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,108&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total general &amp; administrative expense</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">92,403</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">43,581</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">48,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased by $605,000 from $2,570,000 during the three months ended June 30, 2021 to $3,175,000 during the current period. Salaries expense increased by $1,954,000 from $8,411,000 during the nine months ended June 30, 2021 to $10,365,000 during the current period. This increase is primarily due to an increase in G&amp;A headcount that has occurred as the Company has grown. We expect salaries expense to continue to increase as our headcount continues to increase to support our expanding clinical pipeline, in addition to inflationary pressures in the labor market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional/outside services include legal, accounting, consulting, patent expenses, business insurance expenses and other outside services retained by the Company. Professional/outside services expense increased by 1,197,000 from $379,000 during the three months ended June 30, 2021 to $1,576,000 during the current period. Professional/outside services expense increased by $1,884,000 from $4,199,000 during the nine months ended June 30, 2021 to $6,083,000 during the current period. We expect future professional/outside services expense to increase as we continue to increase discovery efforts. The increase in professional/outside services expense is due to intellectual property and general legal fees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense increased by $93,000 from $610,000 during the three months ended June 30, 2021 to $703,000 during the current period. Facilities-related expense decreased by $42,000 from $2,127,000 during the nine months ended June 30, 2021 to $2,085,000 during the current period. This category primarily includes rental costs for our corporate headquarters in Pasadena, California. The increase in facilities related expenses is due to an increase in building maintenance and repair costs. We expect future facilities related expenses to increase as we continue to increase our headcount and footprint to support our discovery efforts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other G&amp;A expense decreased by $286,000 from $2,278,000 during the three months ended June 30, 2021 to $1,992,000 during the current period. Other G&amp;A expense increased by $595,000 from $4,326,000 during the nine months ended June 30, 2021 to $4,921,000 during the current period. This category consists primarily of travel, communication and technology, office expenses, and franchise and property tax expenses. The decrease during the three months ended June 30, 2022 and 2021 is due to a decrease in consulting expenses from the prior year. The increase during the nine months ended June 30, 2022 and 2021 is due to software and software implementation costs..</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, increased by $13,272,000 from $12,020,000 during the three months ended June 30, 2021 to $25,292,000 during the current period. Stock compensation expense, a non-cash expense, increased by $44,108,000 from $23,631,000 during the nine months ended June 30, 2021 to $67,739,000 during the current period. Stock compensation expense is based upon the valuation of stock options and restricted stock units granted to employees, directors and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. The increase in the current period is due to a performance award that was achieved earlier than anticipated, as well as a modification of certain performance awards to include market conditions. The fair value of market condition-based awards is expensed ratably over the service period and is not adjusted for actual achievement. We generally expect future stock compensation expense to continue to increase as our headcount continues to increase to support our clinical pipeline. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a noncash expense, decreased by $174,000 from $577,000 during the three months ended June 30, 2021 to $403,000 during the current period. Depreciation and amortization expense, a noncash expense, increased by $323,000 from $887,000 during the nine months ended June 30, 2021 to $1,210,000 during the current period. The decrease in depreciation expense in the current quarter is due to reclassification of certain depreciation from general and administrative to research and development. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income decreased by $1,080,000 from $1,944,000 during the three months ended June 30, 2021 to $863,000 during the current period. Other income decreased by $2,554,000 from $6,679,000 during the nine months ended June 30, 2021 compared to $4,125,000 during the current period. Other income is primarily related to interest income and realized and unrealized gain/loss on our marketable securities. The decrease in other income is due to lower yields on more recently purchased bonds and increase in realized loss on the sale of marketable securities offset by a property tax credit the company received during the current period. </span></div><div id="if686a6c4f85140f4912306552c96c723_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead has historically financed its operations through the sale of its equity securities and revenue from its collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company plans to expand its facilities with its purchase of land in Verona, Wisconsin, and its entry into a new lease in San Diego, California. Each of these expansions is designed to increase the Company&#8217;s internal manufacturing and discovery capabilities, and each will require significant capital investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company's cash and cash equivalents totalled approximately $139.4 million as compared to $184.4 million at September&#160;30, 2021. Cash invested in short-term fixed income securities and marketable securities was $277.1 million at June&#160;30, 2022, compared to $183.4 million at September&#160;30, 2021. Cash invested in long-term fixed income securities was $165.9 million at June&#160;30, 2022, compared to $245.6 million at September&#160;30, 2021. The Company also entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;) in August 2020, pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s Common Stock through Jefferies LLC. As of June&#160;30, 2022, no shares have been sold under the ATM Agreement. The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of cash flows for the nine months ended June 30, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(67,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">195,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(44,995)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">182,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">184,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended June 30, 2022, cash flow used by operating activities was $67.5 million, which was primarily due to the receipt of the $120.0 million upfront payment from GSK, offset by the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities was $41.9 million, which was primarily related to the purchase of property and equipment of $20.1 million and net sales of investments of $21.8 million. Cash provided by financing activities of $64.3 million was primarily related to the formation of our joint venture, Viserna, as well as cash received from stock option exercises. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended June 30, 2021, cash flow provided by operating activities was $195.3 million, which was primarily due to the $300 million payment received under the Takeda License Agreement, partially offset by ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities was $23.4 million, which was primarily related to the purchase of property and equipment of $15.4 million, partially offset by the net sales of investments of $8.1 million. Cash provided by financing activities of $10.5 million was related to cash received from stock option exercises.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is planned to be the site of an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support process development and analytical activities. Arrowhead intends to invest between $200 million and $250 million into the buildout of the facilities. As part of this acquisition, the Company also entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the TIF district, and will be reimbursed by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay as reimbursements under the TIF program for these improvements is not guaranteed and will depend on future tax revenues generated from the developed property.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources and Material Cash Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our capital resources and material cash requirements is presented in Item 7 of our Annual Report on Form 10-K for our fiscal year ended September 30, 2021. Other than as described above, there were no material changes to our capital resources and material cash requirements during the three months ended June 30, 2022.</span></div><div id="if686a6c4f85140f4912306552c96c723_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in our exposure to market risk from that described in Item 7A of our Annual Report on Form 10-K for the year ended September 30, 2021.</span></div><div id="if686a6c4f85140f4912306552c96c723_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Financial Officer, after evaluating our &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of the end of the period covered by this Quarterly Report on Form 10-Q (the &#8220;Evaluation Date&#8221;), have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reported within the time periods specified in Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer where appropriate, to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in the Company&#8217;s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) occurred during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="if686a6c4f85140f4912306552c96c723_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of legal proceedings, particularly complex legal proceedings, cannot be predicted with any certainty. There have been no material developments in the legal proceedings that we disclosed in Part I, Item 3 of our Annual Report on Form 10-K for the year ended September 30, 2021.</span></div><div id="if686a6c4f85140f4912306552c96c723_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended September 30, 2021 as updated by our Quarterly Report on Form 10-Q for the period ended March 31, 2022. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended September 30, 2021 and in Part II, &#8220;Item 1A. Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.</span></div><div id="if686a6c4f85140f4912306552c96c723_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if686a6c4f85140f4912306552c96c723_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="if686a6c4f85140f4912306552c96c723_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div id="if686a6c4f85140f4912306552c96c723_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Document Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20220630xexx311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20220630xexx312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20220630xexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20220630xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">Furnished herewith.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="if686a6c4f85140f4912306552c96c723_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: August&#160;4, 2022</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kenneth A. Myszkowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kenneth A. Myszkowski<br/>Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>arwr-20220630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5ec26377cd2e4b02bb103fc485a7335f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;4, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; CHRISTOPHER ANZALONE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>arwr-20220630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i72a714dc41fd48138d067e846a5c07c9_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;4, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth A. Myszkowski,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>arwr-20220630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i466f40c067a4415982153b9b04327f02_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June&#160;30, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;4, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">NZALONE</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>arwr-20220630xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i443fdc6e5fba4cf084475db1c58b05a1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June&#160;30, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;4, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>arwr-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:368d367d-beb3-477f-87b6-b6cfd3b1dc77,g:0bc56581-7549-4bc1-a0c5-dd60a0bc219c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest">
        <link:definition>1004005 - Statement - Consolidated Statements of Stockholders&#8217; Equity and Noncontrolling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>2104102 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
        <link:definition>2406403 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
        <link:definition>2407404 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail">
        <link:definition>2408405 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail">
        <link:definition>2409406 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails">
        <link:definition>2410407 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment">
        <link:definition>2111103 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables">
        <link:definition>2312301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetail" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail">
        <link:definition>2413408 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail">
        <link:definition>2414409 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>2115104 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>2316302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail">
        <link:definition>2417410 - Disclosure - Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1">
        <link:definition>2417410 - Disclosure - Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>2118105 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>2319303 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail">
        <link:definition>2420411 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetail" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail">
        <link:definition>2421412 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>2122106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2423413 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>2124107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2425414 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>2126108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>2327304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2428415 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail">
        <link:definition>2429416 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1">
        <link:definition>2429416 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>2130109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>2331305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizeInformationaboutStockOptionsDetail" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail">
        <link:definition>2434419 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUsActivityDetail" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail">
        <link:definition>2435420 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>2136110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>2337306 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2438421 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents">
        <link:definition>2139111 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" abstract="false" name="CashReceivedAsDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" abstract="false" name="PerformanceObligationRelatedToAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" abstract="false" name="MilestonePaymentReceivableAtStartOfPhaseTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" abstract="false" name="ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredRevenueMember" abstract="true" name="DeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TechnologyLicenseCommitmentsMember" abstract="true" name="TechnologyLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommercialNotesDueWithinNinetyDaysMember" abstract="true" name="CommercialNotesDueWithinNinetyDaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" abstract="true" name="TwoThousandsFourEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_CashEquivalentsGrossUnrealizedLosses" abstract="false" name="CashEquivalentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_UpfrontMilestonePaymentReceived" abstract="false" name="UpfrontMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VeronaTechnologyParkMember" abstract="true" name="VeronaTechnologyParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AROXDHSupplyAgreementMember" abstract="true" name="AROXDHSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EstimatedPaymentsForOperatingExpensesYearOne" abstract="false" name="EstimatedPaymentsForOperatingExpensesYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" abstract="false" name="HeldToMaturitySecuritiesFairValueNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROHSDAgreementMember" abstract="true" name="AROHSDAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" abstract="true" name="LicenseCollaborationAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" abstract="false" name="GrantDateFairValueOfOptionsGrantedDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JNJ3989AROHBVAgreementMember" abstract="true" name="JNJ3989AROHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_CertificateOfDeposits" abstract="false" name="CertificateOfDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashEquivalentsGrossUnrealizedGains" abstract="false" name="CashEquivalentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialNotes" abstract="false" name="CommercialNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" abstract="false" name="GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HalozymeIncMember" abstract="true" name="HalozymeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" abstract="false" name="CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" abstract="false" name="ComputersSoftwareOfficeEquipmentAndFurnitureGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" abstract="false" name="CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" abstract="true" name="CertificateOfDepositDueWithinOneThroughTwoYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialNoteDueWithinOneYearMember" abstract="true" name="CommercialNoteDueWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_OutsideOfEquityCompensationPlansMember" abstract="true" name="OutsideOfEquityCompensationPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JNJ75220795AROJNJ1Member" abstract="true" name="JNJ75220795AROJNJ1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TaxIncrementFinancingAward" abstract="false" name="TaxIncrementFinancingAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmountIntendsToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendsToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" abstract="false" name="CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OlpasiranAndAROAMG1AgreementMember" abstract="true" name="OlpasiranAndAROAMG1AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" abstract="false" name="PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_NumberOfAcresOfLandPurchased" abstract="false" name="NumberOfAcresOfLandPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AROXDHAgreementMember" abstract="true" name="AROXDHAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchEquipmentGross" abstract="false" name="ResearchEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_SubleaseAgreementMember" abstract="true" name="SubleaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CertificateOfDepositDueWithinOneYearMember" abstract="true" name="CertificateOfDepositDueWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AdditionalLandSubjectToLease" abstract="false" name="AdditionalLandSubjectToLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" abstract="true" name="CommercialNoteDueWithinOneThroughThreeYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" abstract="false" name="CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>arwr-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:368d367d-beb3-477f-87b6-b6cfd3b1dc77,g:0bc56581-7549-4bc1-a0c5-dd60a0bc219c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9312eff3-d96b-48e4-a725-05ea9cfa96ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2b9f5a32-8fcc-4427-a4ce-c30b3ca555fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9312eff3-d96b-48e4-a725-05ea9cfa96ec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2b9f5a32-8fcc-4427-a4ce-c30b3ca555fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d23670c0-4ac5-41b5-9b14-7fc8fdaa9211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9312eff3-d96b-48e4-a725-05ea9cfa96ec" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d23670c0-4ac5-41b5-9b14-7fc8fdaa9211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_482fc797-9bf2-4823-9d61-c6bb0f6fcd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9312eff3-d96b-48e4-a725-05ea9cfa96ec" xlink:to="loc_us-gaap_CommonStockValue_482fc797-9bf2-4823-9d61-c6bb0f6fcd2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a266dadb-be7e-4fe5-a886-034159f618f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9312eff3-d96b-48e4-a725-05ea9cfa96ec" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a266dadb-be7e-4fe5-a886-034159f618f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebf831ce-712a-4e1d-870f-6810f642795b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_777da0a9-c319-49e0-96b3-439ba5d52eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebf831ce-712a-4e1d-870f-6810f642795b" xlink:to="loc_us-gaap_StockholdersEquity_777da0a9-c319-49e0-96b3-439ba5d52eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7ae5640b-f545-41a1-8bba-6b2dc4bdbef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebf831ce-712a-4e1d-870f-6810f642795b" xlink:to="loc_us-gaap_MinorityInterest_7ae5640b-f545-41a1-8bba-6b2dc4bdbef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_806525f0-8cfa-4ad7-a7f9-a5e1c66b027a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c3fed359-936a-4ca8-a892-86ac032ef1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_806525f0-8cfa-4ad7-a7f9-a5e1c66b027a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c3fed359-936a-4ca8-a892-86ac032ef1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf9152cd-4bfe-4404-b05b-03ada432e4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_806525f0-8cfa-4ad7-a7f9-a5e1c66b027a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf9152cd-4bfe-4404-b05b-03ada432e4e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_09e6d0aa-cef3-441d-ab05-001e769fc955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a44061eb-243d-4e8b-92c6-f75e495d5d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09e6d0aa-cef3-441d-ab05-001e769fc955" xlink:to="loc_us-gaap_LiabilitiesCurrent_a44061eb-243d-4e8b-92c6-f75e495d5d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_19f57d34-ea26-4c96-b7bc-b7dbc73bcdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09e6d0aa-cef3-441d-ab05-001e769fc955" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_19f57d34-ea26-4c96-b7bc-b7dbc73bcdd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cd5939f2-3eaf-443c-8e75-e9eaa570e0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09e6d0aa-cef3-441d-ab05-001e769fc955" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cd5939f2-3eaf-443c-8e75-e9eaa570e0fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2c009377-cbf4-4892-a5ea-85f25f8ffd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09e6d0aa-cef3-441d-ab05-001e769fc955" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2c009377-cbf4-4892-a5ea-85f25f8ffd50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dd8b0349-6d0c-4736-86cc-fdec1e9dc196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:to="loc_us-gaap_AssetsCurrent_dd8b0349-6d0c-4736-86cc-fdec1e9dc196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c8e7537-e99d-4d4b-aa65-86ed40e617ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c8e7537-e99d-4d4b-aa65-86ed40e617ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_85a3d09e-3931-43a8-a7c0-ffd901f0b00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_85a3d09e-3931-43a8-a7c0-ffd901f0b00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1b1774d4-39e4-4967-87fa-2378bc9c4ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1b1774d4-39e4-4967-87fa-2378bc9c4ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ebbbd585-f5ea-488e-9cef-8362023d4ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ebbbd585-f5ea-488e-9cef-8362023d4ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_66ee9e55-5412-4b30-b736-b38a5bd89e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb387ce9-9e3f-4d7a-a200-477240c3747f" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_66ee9e55-5412-4b30-b736-b38a5bd89e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b292658-85b6-44ed-8ade-dda16dc60a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b292658-85b6-44ed-8ade-dda16dc60a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_146f862a-b2f6-472f-9d7f-fe14ca861582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_146f862a-b2f6-472f-9d7f-fe14ca861582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5e6f0198-9e03-4356-97fa-fb3d713bd0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5e6f0198-9e03-4356-97fa-fb3d713bd0cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2f5f03a4-4e64-4a46-b95e-68039110df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:to="loc_us-gaap_OtherAssetsCurrent_2f5f03a4-4e64-4a46-b95e-68039110df0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f126e61f-322f-4191-8c36-85a6bfbf025c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f126e61f-322f-4191-8c36-85a6bfbf025c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9c846b76-b32c-450b-ad75-6260abad0647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bc23205f-4cae-4035-bc76-21272b8d5cc9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9c846b76-b32c-450b-ad75-6260abad0647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_76b18e38-50d0-4e68-ab39-5ebabd5b6131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_92226221-3a0d-4efe-a640-7a20bbcd0612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76b18e38-50d0-4e68-ab39-5ebabd5b6131" xlink:to="loc_us-gaap_AccountsPayableCurrent_92226221-3a0d-4efe-a640-7a20bbcd0612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dfffff87-14ea-4bee-92e0-ead05226656f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76b18e38-50d0-4e68-ab39-5ebabd5b6131" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dfffff87-14ea-4bee-92e0-ead05226656f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dfd4a36c-fdcd-4889-84a0-4f1bd9dea951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76b18e38-50d0-4e68-ab39-5ebabd5b6131" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dfd4a36c-fdcd-4889-84a0-4f1bd9dea951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7bc6fcb3-bb7a-4abf-a239-429df3510507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76b18e38-50d0-4e68-ab39-5ebabd5b6131" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7bc6fcb3-bb7a-4abf-a239-429df3510507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a482a76-fcbf-4f0b-bd61-76373133d574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76b18e38-50d0-4e68-ab39-5ebabd5b6131" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a482a76-fcbf-4f0b-bd61-76373133d574" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_731f0d60-3e17-4478-a805-74466d35e734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b0953366-5741-45ed-855a-b3ffee897106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_731f0d60-3e17-4478-a805-74466d35e734" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b0953366-5741-45ed-855a-b3ffee897106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4583e055-7066-4226-a0db-2549ddddf210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_731f0d60-3e17-4478-a805-74466d35e734" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4583e055-7066-4226-a0db-2549ddddf210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aed3dc3e-73d0-4fc7-af43-6c2b38c6da2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2288d7d5-4421-4792-ba2d-b486da92b9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_aed3dc3e-73d0-4fc7-af43-6c2b38c6da2c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2288d7d5-4421-4792-ba2d-b486da92b9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d4cf8cab-87da-4940-8a4a-a03efee774e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_aed3dc3e-73d0-4fc7-af43-6c2b38c6da2c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d4cf8cab-87da-4940-8a4a-a03efee774e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3c2c1429-92b4-43ba-82f7-61bd73f960b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de519323-07d3-4688-8677-b0f472c3e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3c2c1429-92b4-43ba-82f7-61bd73f960b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de519323-07d3-4688-8677-b0f472c3e78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_49ecfe31-12a0-40c8-9fd0-d479f342b8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3c2c1429-92b4-43ba-82f7-61bd73f960b9" xlink:to="loc_us-gaap_OperatingExpenses_49ecfe31-12a0-40c8-9fd0-d479f342b8b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b94f0087-d708-4f5a-8290-6c191d9596c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_882852f2-852f-416d-a677-1aee0130bbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b94f0087-d708-4f5a-8290-6c191d9596c2" xlink:to="loc_us-gaap_NetIncomeLoss_882852f2-852f-416d-a677-1aee0130bbff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c6d76bad-e83d-4e4a-a9e9-a91144a06217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b94f0087-d708-4f5a-8290-6c191d9596c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c6d76bad-e83d-4e4a-a9e9-a91144a06217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cfb15eb9-a987-4f40-b551-2161be1079a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2978e928-132f-4bb7-ba7c-15ecad0b9364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cfb15eb9-a987-4f40-b551-2161be1079a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2978e928-132f-4bb7-ba7c-15ecad0b9364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2fd4bf6b-ff36-4507-8251-fc0e124c4e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cfb15eb9-a987-4f40-b551-2161be1079a6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2fd4bf6b-ff36-4507-8251-fc0e124c4e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b0dd2759-9688-4f7e-8da5-63d873a14a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_68090b62-4838-4eec-af00-cf1d2eb331e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b0dd2759-9688-4f7e-8da5-63d873a14a11" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_68090b62-4838-4eec-af00-cf1d2eb331e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7b4fad33-aa80-4e23-b365-9b3901f25b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b0dd2759-9688-4f7e-8da5-63d873a14a11" xlink:to="loc_us-gaap_OperatingIncomeLoss_7b4fad33-aa80-4e23-b365-9b3901f25b1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9f17b165-2087-4cad-841a-f6188598e31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_ShareBasedCompensation_9f17b165-2087-4cad-841a-f6188598e31c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_46e6a136-314e-469e-bf2b-01b9451802ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_DepreciationAndAmortization_46e6a136-314e-469e-bf2b-01b9451802ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_05396a45-9fab-424f-bcbf-6b4492e0f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_05396a45-9fab-424f-bcbf-6b4492e0f11e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ecec1565-683a-403e-9415-106eee0284ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ecec1565-683a-403e-9415-106eee0284ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_831365a8-5bd4-485b-b03a-b199fcfb3e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_831365a8-5bd4-485b-b03a-b199fcfb3e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2e4f0143-5347-41b1-8bc2-fe8e5e3db7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2e4f0143-5347-41b1-8bc2-fe8e5e3db7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b643797b-a9f2-457f-8b17-dedf6812c0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b643797b-a9f2-457f-8b17-dedf6812c0ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7adc1a19-314f-44c1-a79d-0a999d1d67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7adc1a19-314f-44c1-a79d-0a999d1d67d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ece70d70-f789-41cb-8f07-5497062d6a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ece70d70-f789-41cb-8f07-5497062d6a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_58125dda-10d3-42da-a866-6be8b6820775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_58125dda-10d3-42da-a866-6be8b6820775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f9146d3-2113-4ee1-bd6b-6aabd3fcf728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09774ad-8c4a-45f5-a974-a847e6e7630b" xlink:to="loc_us-gaap_NetIncomeLoss_6f9146d3-2113-4ee1-bd6b-6aabd3fcf728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a62dfc5e-81ac-4cb5-978f-59594c9a978b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_650eb492-b0aa-41df-8507-8eabb9e0221c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a62dfc5e-81ac-4cb5-978f-59594c9a978b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_650eb492-b0aa-41df-8507-8eabb9e0221c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b2681e8a-2d59-4493-9fc3-fc10ce417a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a62dfc5e-81ac-4cb5-978f-59594c9a978b" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b2681e8a-2d59-4493-9fc3-fc10ce417a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b51d85ca-d673-423c-9a8e-cd7b4889b8da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a62dfc5e-81ac-4cb5-978f-59594c9a978b" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b51d85ca-d673-423c-9a8e-cd7b4889b8da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e57ab8bd-5764-4102-a401-3af2001a914c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_85e778a8-1739-4396-9ce2-0544f04a1993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e57ab8bd-5764-4102-a401-3af2001a914c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_85e778a8-1739-4396-9ce2-0544f04a1993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63ad9480-947c-4862-beb2-58fe12a8cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e57ab8bd-5764-4102-a401-3af2001a914c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63ad9480-947c-4862-beb2-58fe12a8cfda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25e2d9b8-ef1f-473c-a6f9-c01da52e907f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e57ab8bd-5764-4102-a401-3af2001a914c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25e2d9b8-ef1f-473c-a6f9-c01da52e907f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f9123a7-0a6e-4bb8-9012-f03404486bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3d5f3d96-19b3-4869-9b4b-e0c772077179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f9123a7-0a6e-4bb8-9012-f03404486bd7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3d5f3d96-19b3-4869-9b4b-e0c772077179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_74f8745f-7836-4c43-949c-259b3a203e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f9123a7-0a6e-4bb8-9012-f03404486bd7" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_74f8745f-7836-4c43-949c-259b3a203e26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3cbe8470-d9a4-4802-b55f-1d7c5ea79394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_5f8797db-9695-43d0-9da2-0ffd09cb05f7" xlink:href="arwr-20220630.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_3cbe8470-d9a4-4802-b55f-1d7c5ea79394" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_5f8797db-9695-43d0-9da2-0ffd09cb05f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_ca34052d-f92a-4b1b-9f6c-f70503ebfd07" xlink:href="arwr-20220630.xsd#arwr_ResearchEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_3cbe8470-d9a4-4802-b55f-1d7c5ea79394" xlink:to="loc_arwr_ResearchEquipmentGross_ca34052d-f92a-4b1b-9f6c-f70503ebfd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_0987f362-b554-4e83-9f9b-642acd555e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_3cbe8470-d9a4-4802-b55f-1d7c5ea79394" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_0987f362-b554-4e83-9f9b-642acd555e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_b12264b9-2458-4655-85eb-08d7bb1279c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_3cbe8470-d9a4-4802-b55f-1d7c5ea79394" xlink:to="loc_us-gaap_ConstructionInProgressGross_b12264b9-2458-4655-85eb-08d7bb1279c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_211a393a-da5f-49d6-8f72-bff700f339dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_3cbe8470-d9a4-4802-b55f-1d7c5ea79394" xlink:to="loc_us-gaap_Land_211a393a-da5f-49d6-8f72-bff700f339dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de49b9e1-34fe-40ac-963e-731961b1e0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_53ef427e-c531-4162-83ba-507ef03d14cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_de49b9e1-34fe-40ac-963e-731961b1e0e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_53ef427e-c531-4162-83ba-507ef03d14cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ce73129e-2fa8-4c20-9474-f9b5cc4628f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_de49b9e1-34fe-40ac-963e-731961b1e0e7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ce73129e-2fa8-4c20-9474-f9b5cc4628f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c13c1411-3330-4142-89d0-307796ebb4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedGains_d1a2b8b0-36da-45e6-a266-960740acd866" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_c13c1411-3330-4142-89d0-307796ebb4e8" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedGains_d1a2b8b0-36da-45e6-a266-960740acd866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedLosses_e4d70409-2956-418e-8f17-49c4c2332f21" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_c13c1411-3330-4142-89d0-307796ebb4e8" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedLosses_e4d70409-2956-418e-8f17-49c4c2332f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1d53c62a-f524-489c-93fc-294cb04658d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_c13c1411-3330-4142-89d0-307796ebb4e8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1d53c62a-f524-489c-93fc-294cb04658d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_53ebdd1a-0cc3-4e93-ae42-e2917384712f" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2ba84ef4-4249-4278-b358-9e1d64962bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_53ebdd1a-0cc3-4e93-ae42-e2917384712f" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2ba84ef4-4249-4278-b358-9e1d64962bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_6b12d040-7f27-45a5-a64a-d84d47b90b22" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_53ebdd1a-0cc3-4e93-ae42-e2917384712f" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_6b12d040-7f27-45a5-a64a-d84d47b90b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedLosses_f2c17263-7c96-48a4-be7a-8fd2a7de3374" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_53ebdd1a-0cc3-4e93-ae42-e2917384712f" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedLosses_f2c17263-7c96-48a4-be7a-8fd2a7de3374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_71fca665-ee19-404a-8bea-13910635b27d" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aaa2b6da-47f2-477d-9204-8bf013e2e374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_71fca665-ee19-404a-8bea-13910635b27d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aaa2b6da-47f2-477d-9204-8bf013e2e374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_61afecdc-7d6b-4157-bd59-4d8d1d41c816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_71fca665-ee19-404a-8bea-13910635b27d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_61afecdc-7d6b-4157-bd59-4d8d1d41c816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1569a15e-b3d2-47b7-beb6-5cd888e6619a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_71fca665-ee19-404a-8bea-13910635b27d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1569a15e-b3d2-47b7-beb6-5cd888e6619a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cc199a03-4c98-482c-9a61-8e3398077bf7" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_417f6c5e-aca5-4b05-8f29-abed91a70566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cc199a03-4c98-482c-9a61-8e3398077bf7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_417f6c5e-aca5-4b05-8f29-abed91a70566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_2bc929fc-2636-4789-b9ed-795ea31158ab" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cc199a03-4c98-482c-9a61-8e3398077bf7" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_2bc929fc-2636-4789-b9ed-795ea31158ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedGains_2f1d52c3-8664-4b99-badc-412dbad5bda1" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedGains"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cc199a03-4c98-482c-9a61-8e3398077bf7" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedGains_2f1d52c3-8664-4b99-badc-412dbad5bda1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_2fef1b82-6fad-49d3-bce4-e8864e56c468" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_858ce47d-fdbd-4510-b0ca-78d9ab8702ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_2fef1b82-6fad-49d3-bce4-e8864e56c468" xlink:to="loc_us-gaap_HeldToMaturitySecurities_858ce47d-fdbd-4510-b0ca-78d9ab8702ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_1a82e333-5cf4-440f-b092-b9c7b01e0828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_2fef1b82-6fad-49d3-bce4-e8864e56c468" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_1a82e333-5cf4-440f-b092-b9c7b01e0828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c3f1e767-fee4-48e9-8e9d-98f796a1a311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_2fef1b82-6fad-49d3-bce4-e8864e56c468" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c3f1e767-fee4-48e9-8e9d-98f796a1a311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_61a76844-04eb-4031-ba5f-319bed36b6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_8d5bf0fb-6f24-4f85-9b1b-04e7a741e989" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_61a76844-04eb-4031-ba5f-319bed36b6cd" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_8d5bf0fb-6f24-4f85-9b1b-04e7a741e989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b3c35b29-df7e-43c1-8156-0aa611cb8061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_61a76844-04eb-4031-ba5f-319bed36b6cd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b3c35b29-df7e-43c1-8156-0aa611cb8061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_36da3f9d-c4aa-44f9-a70a-128d941bb6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_35c79d9d-2b84-4b56-a98f-c9655d535034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_36da3f9d-c4aa-44f9-a70a-128d941bb6f6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_35c79d9d-2b84-4b56-a98f-c9655d535034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_d9384e27-4879-4aa4-b962-cf47feef6373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_36da3f9d-c4aa-44f9-a70a-128d941bb6f6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_d9384e27-4879-4aa4-b962-cf47feef6373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_faa0db76-8f17-4329-91dc-e1b6f4f23d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_36da3f9d-c4aa-44f9-a70a-128d941bb6f6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_faa0db76-8f17-4329-91dc-e1b6f4f23d58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1" xlink:type="simple" xlink:href="arwr-20220630.xsd#InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_65b8116b-a87c-4bb7-bf10-a30a284e6716" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_7b62496b-14b1-4bf8-bc76-c0c3a38f9099" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_65b8116b-a87c-4bb7-bf10-a30a284e6716" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_7b62496b-14b1-4bf8-bc76-c0c3a38f9099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_d02f7002-71d5-4d42-bbd1-337a623e18a6" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_65b8116b-a87c-4bb7-bf10-a30a284e6716" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_d02f7002-71d5-4d42-bbd1-337a623e18a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_8ea02144-7e59-442a-ad67-10fa0e7c41b4" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_65b8116b-a87c-4bb7-bf10-a30a284e6716" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_8ea02144-7e59-442a-ad67-10fa0e7c41b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9dbe8c98-8682-4c45-9ce8-0eb641143aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9dbe8c98-8682-4c45-9ce8-0eb641143aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c360603-6299-4a46-bfcc-07fd1b0a79d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c360603-6299-4a46-bfcc-07fd1b0a79d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2239825b-c3c5-4cf1-9c7e-bd554ca3d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2239825b-c3c5-4cf1-9c7e-bd554ca3d64a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd71d8d4-953a-483a-8509-93b4a5c285e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd71d8d4-953a-483a-8509-93b4a5c285e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc8a27f1-42ea-40f3-96c9-98479b85c5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc8a27f1-42ea-40f3-96c9-98479b85c5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_80098bcd-aaf9-4019-8668-19993ce99f0f" xlink:href="arwr-20220630.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9cc1e57-22a5-42cf-b844-9cb24ad3267e" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_80098bcd-aaf9-4019-8668-19993ce99f0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_992bc674-4e56-41b4-9e0a-7f59248989c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_89fecc06-b14a-44d2-a235-f5c5bc17ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_992bc674-4e56-41b4-9e0a-7f59248989c3" xlink:to="loc_us-gaap_OperatingLeaseLiability_89fecc06-b14a-44d2-a235-f5c5bc17ff48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_afc2dba4-89dd-4cee-983d-df9144f56a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_992bc674-4e56-41b4-9e0a-7f59248989c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_afc2dba4-89dd-4cee-983d-df9144f56a8c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>arwr-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:368d367d-beb3-477f-87b6-b6cfd3b1dc77,g:0bc56581-7549-4bc1-a0c5-dd60a0bc219c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest" xlink:type="extended" id="if50fa5c1c14f4ca1823e4c78db336237_ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d87046b-4cfd-4aec-b1bf-4a33e016e766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d87046b-4cfd-4aec-b1bf-4a33e016e766" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49852c58-c53c-463f-8464-2a0268660568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49852c58-c53c-463f-8464-2a0268660568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_688a86fd-2dff-4c57-8283-e989d7528bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_SharesOutstanding_688a86fd-2dff-4c57-8283-e989d7528bb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a22e9ac-bd5c-41ed-8912-04896b6385ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a22e9ac-bd5c-41ed-8912-04896b6385ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0bc3421e-a2bf-4832-89fb-4bd9013de783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0bc3421e-a2bf-4832-89fb-4bd9013de783" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2d84c45-1030-4f3b-a181-c6d5bf846252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2d84c45-1030-4f3b-a181-c6d5bf846252" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9d8a7b7c-e23b-401e-94d3-19e5d5d5107b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9d8a7b7c-e23b-401e-94d3-19e5d5d5107b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e2d292c9-88ed-47f4-b959-ea5d20e5fb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e2d292c9-88ed-47f4-b959-ea5d20e5fb74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e8f8350-69cb-4f19-8b68-29cddeaca8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e8f8350-69cb-4f19-8b68-29cddeaca8e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2b433364-aca2-41ee-a093-fadb25097616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2b433364-aca2-41ee-a093-fadb25097616" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2af58dc-92cd-4b5c-8f7f-5ab756e0a02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_NetIncomeLoss_a2af58dc-92cd-4b5c-8f7f-5ab756e0a02d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e04d6e0-4a1c-4522-8ad4-336638e36e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_65a11dd2-d0ef-4995-8391-661aa844b895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7d87046b-4cfd-4aec-b1bf-4a33e016e766" xlink:to="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0973a06d-f49b-4d23-b700-741d78e5913a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:to="loc_us-gaap_EquityComponentDomain_0973a06d-f49b-4d23-b700-741d78e5913a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:to="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_001f8de1-204c-418f-a597-76ab5d371371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_CommonStockMember_001f8de1-204c-418f-a597-76ab5d371371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cf17cc9e-b050-497b-91c8-1ed5cf6cc341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cf17cc9e-b050-497b-91c8-1ed5cf6cc341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_537a8e56-9c18-44cb-b462-78c044244c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_537a8e56-9c18-44cb-b462-78c044244c6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac09d773-8bda-45ae-8a11-0e1754830130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_RetainedEarningsMember_ac09d773-8bda-45ae-8a11-0e1754830130" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_38b224ee-7956-4af3-8f73-38664a25a6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_NoncontrollingInterestMember_38b224ee-7956-4af3-8f73-38664a25a6cd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i6dfed10261b2481085938d938204c20f_OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:href="arwr-20220630.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_ffcd6087-c28e-4d22-a8fe-7f5b0fa290df" xlink:href="arwr-20220630.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_ffcd6087-c28e-4d22-a8fe-7f5b0fa290df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_050f3c9d-dc23-4f20-90b7-bd57cee64647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_AreaOfLand_050f3c9d-dc23-4f20-90b7-bd57cee64647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_06e4190d-0bee-45ff-ab2f-751c7dad5d65" xlink:href="arwr-20220630.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_TaxIncrementFinancingAward_06e4190d-0bee-45ff-ab2f-751c7dad5d65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7edd9d19-9045-4137-a932-68da0f04c2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7edd9d19-9045-4137-a932-68da0f04c2a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_ec9eff69-43e9-452a-a961-a2b539c69734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_ec9eff69-43e9-452a-a961-a2b539c69734" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61e8b8fc-8ada-4ed3-a36b-085d35b8a179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61e8b8fc-8ada-4ed3-a36b-085d35b8a179" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_48d44b9f-3731-4dca-89eb-7a21ea9a95a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_48d44b9f-3731-4dca-89eb-7a21ea9a95a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ec1f78e-6b08-4326-a056-7d1f220439ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ec1f78e-6b08-4326-a056-7d1f220439ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_893bb336-18f2-477c-9029-fc4c35628e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_893bb336-18f2-477c-9029-fc4c35628e5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_d25e5689-c5df-4b84-be74-d6b429e65b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_d25e5689-c5df-4b84-be74-d6b429e65b4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_0256a3b2-4e18-4fa1-8643-5a85682dea02" xlink:href="arwr-20220630.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_0256a3b2-4e18-4fa1-8643-5a85682dea02" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_77f28f08-e096-43d4-9872-ce00a1b75d62" xlink:href="arwr-20220630.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_77f28f08-e096-43d4-9872-ce00a1b75d62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_04c22525-a2f2-4971-beba-a9a085e8010a" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_04c22525-a2f2-4971-beba-a9a085e8010a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:href="arwr-20220630.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_30a7a1cd-3125-4ba2-b945-314283c25e57_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:to="loc_srt_SegmentGeographicalDomain_30a7a1cd-3125-4ba2-b945-314283c25e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:to="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_6d999041-4bc6-40fd-aa3c-b20bdf7a5869" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:to="loc_stpr_WI_6d999041-4bc6-40fd-aa3c-b20bdf7a5869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_85846856-4b32-43cb-a4e2-61523ca8cb81" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:to="loc_stpr_CA_85846856-4b32-43cb-a4e2-61523ca8cb81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61b4fbba-3e94-45f8-8359-8a6a6039adfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61b4fbba-3e94-45f8-8359-8a6a6039adfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_2d220798-5e25-4232-8170-273acc0c180c" xlink:href="arwr-20220630.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_VeronaTechnologyParkMember_2d220798-5e25-4232-8170-273acc0c180c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_1a6fb2c7-96a7-479b-b8e2-f5f8d065f2b9" xlink:href="arwr-20220630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_DrugManufacturingFacilityMember_1a6fb2c7-96a7-479b-b8e2-f5f8d065f2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_46f7a508-4f72-4070-9fef-864844b4b589" xlink:href="arwr-20220630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_46f7a508-4f72-4070-9fef-864844b4b589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_57db959d-dbaa-4bc7-88a5-50990692e40c" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_57db959d-dbaa-4bc7-88a5-50990692e40c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_07697952-1dbc-417a-aacc-c341a255a3be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_07697952-1dbc-417a-aacc-c341a255a3be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_22c29f26-a545-4acd-b17e-11e51ee9725e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_07697952-1dbc-417a-aacc-c341a255a3be" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_22c29f26-a545-4acd-b17e-11e51ee9725e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e759d66-7a19-4849-97ef-53488aea7ff3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e759d66-7a19-4849-97ef-53488aea7ff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0906a952-ece3-48d1-aff7-ff8c3fa0dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0906a952-ece3-48d1-aff7-ff8c3fa0dd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_8244a88e-0a04-42d4-8089-c3b024e5789a" xlink:href="arwr-20220630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0906a952-ece3-48d1-aff7-ff8c3fa0dd7d" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_8244a88e-0a04-42d4-8089-c3b024e5789a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_86210364-aa9c-4223-b2f4-6acda6c97c8a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:to="loc_dei_EntityDomain_86210364-aa9c-4223-b2f4-6acda6c97c8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:to="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_4cd70a6c-d961-4e02-97b7-6210d0b684db" xlink:href="arwr-20220630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_4cd70a6c-d961-4e02-97b7-6210d0b684db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_fefb506b-6f6d-4cb9-9524-5b169267eb44" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_fefb506b-6f6d-4cb9-9524-5b169267eb44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="extended" id="ibd0a4d1f0f764e83bf836330c06f83bb_CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_23e0b417-bf64-4e9e-8f01-d933b65b5b59" xlink:href="arwr-20220630.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_NumberOfAgreements_23e0b417-bf64-4e9e-8f01-d933b65b5b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0f1c5ed5-de7d-4e0b-8d99-80df9b6e41ad" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0f1c5ed5-de7d-4e0b-8d99-80df9b6e41ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30809b22-4348-455f-8140-1e74169d7bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30809b22-4348-455f-8140-1e74169d7bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_10377ebf-40cb-4452-9788-5f040d7bdf0c" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_MilestonePaymentReceived_10377ebf-40cb-4452-9788-5f040d7bdf0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_319e939c-57c7-4d18-90d5-adff493547ad" xlink:href="arwr-20220630.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_319e939c-57c7-4d18-90d5-adff493547ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5ad92ba-9d78-47e3-9f38-afeaab2d7342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5ad92ba-9d78-47e3-9f38-afeaab2d7342" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e04414c-4729-4145-bcdb-a877e9fb3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e04414c-4729-4145-bcdb-a877e9fb3e51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1b5ed001-686f-44f7-baa9-f0844e301101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1b5ed001-686f-44f7-baa9-f0844e301101" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e5a4d2f-561d-42c0-bb77-38960d1f139f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e5a4d2f-561d-42c0-bb77-38960d1f139f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_60f703f6-b4a7-446d-8b6f-120cef0218a5" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_60f703f6-b4a7-446d-8b6f-120cef0218a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_a613dc50-145b-41aa-9535-c96ccc06511c" xlink:href="arwr-20220630.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_a613dc50-145b-41aa-9535-c96ccc06511c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_dac6034e-df01-4e5b-8e13-58c246f05488" xlink:href="arwr-20220630.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_dac6034e-df01-4e5b-8e13-58c246f05488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_86daf284-45eb-445e-9cdb-ec9bb4c1b640" xlink:href="arwr-20220630.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_OlpasiranAgreementMember_86daf284-45eb-445e-9cdb-ec9bb4c1b640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2ff8039c-fe64-411d-93aa-adac8741b87e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:to="loc_dei_EntityDomain_2ff8039c-fe64-411d-93aa-adac8741b87e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_063910cb-9ac5-4f24-8a3c-5df163d3df2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:to="loc_dei_EntityDomain_063910cb-9ac5-4f24-8a3c-5df163d3df2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_ce2372dc-fc55-498c-9c1f-0e43b872ab23" xlink:href="arwr-20220630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_063910cb-9ac5-4f24-8a3c-5df163d3df2e" xlink:to="loc_arwr_AmgenIncorporatedMember_ce2372dc-fc55-498c-9c1f-0e43b872ab23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e953841-2bcd-4861-8810-478d8ba6158c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:to="loc_srt_RangeMember_1e953841-2bcd-4861-8810-478d8ba6158c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1caa31b8-9012-4ecb-b2bb-30d5e2030f47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:to="loc_srt_RangeMember_1caa31b8-9012-4ecb-b2bb-30d5e2030f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae7b3e91-cb3d-44f2-8c00-d027dce6a21d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1caa31b8-9012-4ecb-b2bb-30d5e2030f47" xlink:to="loc_srt_MaximumMember_ae7b3e91-cb3d-44f2-8c00-d027dce6a21d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="extended" id="i5ba51b73779542b984bc1ffa9bbde298_CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_9dfe72f3-8aad-4ff3-ad66-2ea3740ca113" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_9dfe72f3-8aad-4ff3-ad66-2ea3740ca113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_035b8d8f-d7f7-43f3-adc5-65eb92d006f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_035b8d8f-d7f7-43f3-adc5-65eb92d006f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_1e48dd5e-cecf-4263-b539-21a268da396d" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_MilestonePaymentEarned_1e48dd5e-cecf-4263-b539-21a268da396d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_6061b7cc-f784-4ff4-8cca-29c30cab15b3" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_6061b7cc-f784-4ff4-8cca-29c30cab15b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_45810978-d348-4ad2-a9d9-019510f8a4fd" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_45810978-d348-4ad2-a9d9-019510f8a4fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_614b5a68-33f2-4186-a489-42486172e23d" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_InitialTransactionPrice_614b5a68-33f2-4186-a489-42486172e23d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fbfda6f-d4cb-4e8f-ac42-c01575a5fcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fbfda6f-d4cb-4e8f-ac42-c01575a5fcea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9f29d84c-15fc-4b73-b398-5e7172d846eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9f29d84c-15fc-4b73-b398-5e7172d846eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11e05f00-7f51-4ba7-9389-0b90f6bf33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11e05f00-7f51-4ba7-9389-0b90f6bf33ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_16545aaf-a4e1-44a5-ba17-d47512b31e9c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:to="loc_dei_EntityDomain_16545aaf-a4e1-44a5-ba17-d47512b31e9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:to="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_78b2e6d1-40d5-4de6-a4c9-5b4c19fdf7a6" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_78b2e6d1-40d5-4de6-a4c9-5b4c19fdf7a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_824c3dd9-ff47-443e-8bf4-eae5d59ae708" xlink:href="arwr-20220630.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_824c3dd9-ff47-443e-8bf4-eae5d59ae708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_ad200eca-f40c-4582-b432-d5ea778be9fa" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_ad200eca-f40c-4582-b432-d5ea778be9fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_5185df26-b7ae-4fca-acb7-acb232aa5432" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d76defdf-877e-472c-a0bf-3dd50943820b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d76defdf-877e-472c-a0bf-3dd50943820b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_c40e0e67-6679-4cd5-afaa-a71f5bc7a3b1" xlink:href="arwr-20220630.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_LicenseAgreementMember_c40e0e67-6679-4cd5-afaa-a71f5bc7a3b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_cdd103cb-553d-429a-aef0-abb4e1379cf6" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_cdd103cb-553d-429a-aef0-abb4e1379cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember_bd18ddc9-ad20-49ba-bc24-456a9dafa2d5" xlink:href="arwr-20220630.xsd#arwr_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_CollaborationAgreementMember_bd18ddc9-ad20-49ba-bc24-456a9dafa2d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_8f019598-5469-4388-af72-4605f72464a1" xlink:href="arwr-20220630.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_8f019598-5469-4388-af72-4605f72464a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_d78b1e18-21f0-4065-9881-08a69ec8cafa" xlink:href="arwr-20220630.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_d78b1e18-21f0-4065-9881-08a69ec8cafa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a025ef6e-17dd-4f78-845b-c6d0672e2f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a025ef6e-17dd-4f78-845b-c6d0672e2f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_07a44608-d75b-4b4a-9950-68a09e69e315" xlink:href="arwr-20220630.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a025ef6e-17dd-4f78-845b-c6d0672e2f5f" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_07a44608-d75b-4b4a-9950-68a09e69e315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d957c2e4-6afd-450b-85a5-60df24f84435_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:to="loc_srt_RangeMember_d957c2e4-6afd-450b-85a5-60df24f84435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:to="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_007082bd-8bde-4f8d-84e4-3a1381af80e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:to="loc_srt_MaximumMember_007082bd-8bde-4f8d-84e4-3a1381af80e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b8873b9-7003-4425-88b8-392ff8b721c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:to="loc_srt_MinimumMember_3b8873b9-7003-4425-88b8-392ff8b721c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="extended" id="ibfc1f11090ba40ef904b18c3ab243fa9_CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_e0e7f316-285d-4f91-9456-10fd5b32dd5b" xlink:href="arwr-20220630.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_e0e7f316-285d-4f91-9456-10fd5b32dd5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_06f56824-a2b1-444a-80d1-c6da712d0152" xlink:href="arwr-20220630.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_06f56824-a2b1-444a-80d1-c6da712d0152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_7cbee8db-876c-4e61-8ba2-e0fb36af5a66" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_7cbee8db-876c-4e61-8ba2-e0fb36af5a66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_b7245ec2-f65d-47ec-9609-d3f4ac8aa934" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_b7245ec2-f65d-47ec-9609-d3f4ac8aa934" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_8e220364-a246-4b6a-8202-23581fcf27e1" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_NumberOfDistinctBundle_8e220364-a246-4b6a-8202-23581fcf27e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_cbf53270-a23f-4b6b-9980-a995892104fc" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_InitialTransactionPrice_cbf53270-a23f-4b6b-9980-a995892104fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acd1e026-3b03-403e-a547-9b2de94eb091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acd1e026-3b03-403e-a547-9b2de94eb091" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c4638865-b40f-4117-a1eb-1417c569a33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c4638865-b40f-4117-a1eb-1417c569a33e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb0cdd5c-630c-4b34-b9c3-14c03ebcb7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb0cdd5c-630c-4b34-b9c3-14c03ebcb7f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d9035381-7a2b-41a4-a632-37bac11337dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d9035381-7a2b-41a4-a632-37bac11337dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c5c3926d-a118-45a5-b187-162801a598dc_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:to="loc_dei_EntityDomain_c5c3926d-a118-45a5-b187-162801a598dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c199179-47e4-491d-989a-4800e332377d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:to="loc_dei_EntityDomain_7c199179-47e4-491d-989a-4800e332377d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ec199726-1c45-4e51-ab3f-636e8074a630" xlink:href="arwr-20220630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7c199179-47e4-491d-989a-4800e332377d" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ec199726-1c45-4e51-ab3f-636e8074a630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e31de04-0fe2-426e-a49a-611dcf653543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e31de04-0fe2-426e-a49a-611dcf653543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_43f2003b-8d56-4bd6-8fae-da88e9d2b34c" xlink:href="arwr-20220630.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e31de04-0fe2-426e-a49a-611dcf653543" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_43f2003b-8d56-4bd6-8fae-da88e9d2b34c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f46596c-5ddc-438c-aeff-e2d2882b4dde_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:to="loc_srt_RangeMember_8f46596c-5ddc-438c-aeff-e2d2882b4dde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:to="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04a3a9be-6155-46e0-b87c-cb6c82436a34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:to="loc_srt_MinimumMember_04a3a9be-6155-46e0-b87c-cb6c82436a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_791f7652-014a-40bb-8930-9ac5ed1c61a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:to="loc_srt_MaximumMember_791f7652-014a-40bb-8930-9ac5ed1c61a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c9c72133-f7e1-4714-ab85-5e180b31b49b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c9c72133-f7e1-4714-ab85-5e180b31b49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_de12a286-eb9b-45b4-9cbd-3451d87b9afa" xlink:href="arwr-20220630.xsd#arwr_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:to="loc_arwr_DeferredRevenueMember_de12a286-eb9b-45b4-9cbd-3451d87b9afa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2ecf3d9b-11f6-4e24-adb9-ad656ce11611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2ecf3d9b-11f6-4e24-adb9-ad656ce11611" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:type="extended" id="i71f3e218b2d740aa8aa14e6a3fe48287_CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e594ade8-df86-442e-b97f-c02d7b97f077" xlink:href="arwr-20220630.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e594ade8-df86-442e-b97f-c02d7b97f077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_e31b1e22-6d2b-465e-ac66-772708c6d58a" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_e31b1e22-6d2b-465e-ac66-772708c6d58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_e7b907d8-2cf2-4734-943e-2225622793cb" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_NumberOfDistinctBundle_e7b907d8-2cf2-4734-943e-2225622793cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_689a2603-5480-4353-9875-cdc2388c976f" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_689a2603-5480-4353-9875-cdc2388c976f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_1015653f-e695-444f-bb65-2e001909bec1" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_InitialTransactionPrice_1015653f-e695-444f-bb65-2e001909bec1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_181a9590-5acc-492b-8ddd-c125e1c17cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_181a9590-5acc-492b-8ddd-c125e1c17cc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_31ceab32-e331-40f7-8bff-b2b51be8d2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_31ceab32-e331-40f7-8bff-b2b51be8d2cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4caed521-d220-4ef8-8a0e-e0f05be51dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4caed521-d220-4ef8-8a0e-e0f05be51dde" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ff72ede7-df51-4708-bc20-2a29f6afc937_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:to="loc_dei_EntityDomain_ff72ede7-df51-4708-bc20-2a29f6afc937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e7c3fb24-c3b5-44bb-9d4a-0d958e54f6cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:to="loc_dei_EntityDomain_e7c3fb24-c3b5-44bb-9d4a-0d958e54f6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_d2c27a6f-032a-4fb4-a4a3-ae995427f989" xlink:href="arwr-20220630.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e7c3fb24-c3b5-44bb-9d4a-0d958e54f6cc" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_d2c27a6f-032a-4fb4-a4a3-ae995427f989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f324927-352b-4be0-b977-1a4e33f6fb43_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:to="loc_srt_RangeMember_2f324927-352b-4be0-b977-1a4e33f6fb43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9030304-9605-4844-8737-042e4ef49524" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:to="loc_srt_RangeMember_c9030304-9605-4844-8737-042e4ef49524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_77f97aaf-a58b-4516-91a6-db750e170744" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c9030304-9605-4844-8737-042e4ef49524" xlink:to="loc_srt_MaximumMember_77f97aaf-a58b-4516-91a6-db750e170744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_0112135d-786d-41ff-b093-5c0b58f44a53" xlink:href="arwr-20220630.xsd#arwr_AROXDHAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:to="loc_arwr_AROXDHAgreementMember_0112135d-786d-41ff-b093-5c0b58f44a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_e32dd1fb-7d4c-437f-ac15-a2cf0293d158" xlink:href="arwr-20220630.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:to="loc_arwr_LicenseAgreementMember_e32dd1fb-7d4c-437f-ac15-a2cf0293d158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHSupplyAgreementMember_fe4efc26-858f-41cc-9a48-7bbd7f6cf211" xlink:href="arwr-20220630.xsd#arwr_AROXDHSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:to="loc_arwr_AROXDHSupplyAgreementMember_fe4efc26-858f-41cc-9a48-7bbd7f6cf211" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail" xlink:type="extended" id="i33f6053bcb014687b021f9373f5b6a1e_CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_69bd73a9-0354-42f5-a109-1396a5b1844a" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_MilestonePaymentEarned_69bd73a9-0354-42f5-a109-1396a5b1844a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_d53c007d-0f64-4e08-af44-e4523393df9b" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_d53c007d-0f64-4e08-af44-e4523393df9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_c0052e34-122e-43f7-8aa5-cd458c8beeda" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_c0052e34-122e-43f7-8aa5-cd458c8beeda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_5e58d0df-d7dc-4555-a9b7-61ad310a29aa" xlink:href="arwr-20220630.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_5e58d0df-d7dc-4555-a9b7-61ad310a29aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_b0443e92-b153-4277-a873-5d0667e342f9" xlink:href="arwr-20220630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_SalesRelatedMilestonePayments_b0443e92-b153-4277-a873-5d0667e342f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_23bc2679-de2f-4281-b533-7a7b66ada325" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_23bc2679-de2f-4281-b533-7a7b66ada325" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_e0a1a040-77b8-4166-9cd7-d880442285d1" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_NumberOfDistinctBundle_e0a1a040-77b8-4166-9cd7-d880442285d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_f27952cf-91f3-420c-b086-edd3c46737c0" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_InitialTransactionPrice_f27952cf-91f3-420c-b086-edd3c46737c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_73d8f381-81f6-4488-a906-3b73a44eb4b0" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_73d8f381-81f6-4488-a906-3b73a44eb4b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_1c1d513c-44c6-4544-9bf3-b45a24e75139" xlink:href="arwr-20220630.xsd#arwr_PerformanceObligationRelatedToAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_1c1d513c-44c6-4544-9bf3-b45a24e75139" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_26ee633a-7bbe-4baf-9153-baa82d773111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_26ee633a-7bbe-4baf-9153-baa82d773111" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3c74c9a0-bf78-4fe3-8438-291051c78dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3c74c9a0-bf78-4fe3-8438-291051c78dd9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a230438d-4945-49af-a62c-376a22eb1b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a230438d-4945-49af-a62c-376a22eb1b01" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:to="loc_dei_EntityDomain_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a5194e4b-fa97-4192-8d7b-7e8940e24d3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:to="loc_dei_EntityDomain_a5194e4b-fa97-4192-8d7b-7e8940e24d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_582f138e-9f72-4f2c-bc01-a27c370f7562" xlink:href="arwr-20220630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a5194e4b-fa97-4192-8d7b-7e8940e24d3b" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_582f138e-9f72-4f2c-bc01-a27c370f7562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_146ebd7e-dba6-4427-b4b8-157f29a1785f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_146ebd7e-dba6-4427-b4b8-157f29a1785f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_91859e32-b0dd-4abf-a970-7334bf89d6a2" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_91859e32-b0dd-4abf-a970-7334bf89d6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember_4c0335d3-b3c0-428d-a251-8910437ff379" xlink:href="arwr-20220630.xsd#arwr_AROHSDAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:to="loc_arwr_AROHSDAgreementMember_4c0335d3-b3c0-428d-a251-8910437ff379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53c179f4-f254-456b-b78c-91472bec043c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:to="loc_srt_RangeMember_53c179f4-f254-456b-b78c-91472bec043c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a19b0c7-e56f-42f7-adf4-e65aae3b983f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:to="loc_srt_RangeMember_5a19b0c7-e56f-42f7-adf4-e65aae3b983f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c680b8f0-778b-439f-8b78-c0713ef1122f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a19b0c7-e56f-42f7-adf4-e65aae3b983f" xlink:to="loc_srt_MaximumMember_c680b8f0-778b-439f-8b78-c0713ef1122f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails" xlink:type="extended" id="id3f021ee3ae444ecadae435f5b1e3f75_CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f645b33-d8ac-4863-959c-bee23108683f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_03335322-0e71-4aa1-90c6-c2c0c1d67c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f645b33-d8ac-4863-959c-bee23108683f" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_03335322-0e71-4aa1-90c6-c2c0c1d67c47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f645b33-d8ac-4863-959c-bee23108683f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fda3b7f0-9f84-477e-99cf-9995724100b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fda3b7f0-9f84-477e-99cf-9995724100b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93051647-5cc3-4972-9dc0-31a2551dfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93051647-5cc3-4972-9dc0-31a2551dfb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_7c94151f-7056-46ff-b6de-a4ba15562eab" xlink:href="arwr-20220630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93051647-5cc3-4972-9dc0-31a2551dfb13" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_7c94151f-7056-46ff-b6de-a4ba15562eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:to="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_814960fb-2b60-4744-a773-45dcb24b38cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_814960fb-2b60-4744-a773-45dcb24b38cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_230c9b0a-5ae9-497c-b72a-ac432d2e4663" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_230c9b0a-5ae9-497c-b72a-ac432d2e4663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_20712ad2-430c-4339-8a8b-6a5b1c951b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_230c9b0a-5ae9-497c-b72a-ac432d2e4663" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_20712ad2-430c-4339-8a8b-6a5b1c951b5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" xlink:type="extended" id="i1501ce78c8dd4e17b737ef7c00894493_InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:href="arwr-20220630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_49eab448-0c92-4a39-b77a-759181136de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_49eab448-0c92-4a39-b77a-759181136de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7fedc2fb-9c44-400f-b3d1-9539dbf266f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7fedc2fb-9c44-400f-b3d1-9539dbf266f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedGains_4c600628-8b14-46e5-811e-0808cc5a4024" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedGains_4c600628-8b14-46e5-811e-0808cc5a4024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedLosses_2cffee57-45ec-470b-9f1b-3091dea7aa1d" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedLosses_2cffee57-45ec-470b-9f1b-3091dea7aa1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0be80e20-666c-49e2-9bdc-f06d681a24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0be80e20-666c-49e2-9bdc-f06d681a24fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d3247f50-0710-4a72-a7e1-2ee1231c3155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecurities_d3247f50-0710-4a72-a7e1-2ee1231c3155" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_57a0ec74-d88a-43c8-b4bf-c3e0af6215fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_57a0ec74-d88a-43c8-b4bf-c3e0af6215fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8da3d180-323b-4cce-b223-aa742d36a611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8da3d180-323b-4cce-b223-aa742d36a611" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_20a57fea-34a6-4a5f-941b-7893947aeb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_20a57fea-34a6-4a5f-941b-7893947aeb42" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_6dc3e9ec-4901-48e2-807b-f0dff52db79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_6dc3e9ec-4901-48e2-807b-f0dff52db79b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_cb2ea378-0239-4dcb-bee7-15b5e18a3e9c" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_cb2ea378-0239-4dcb-bee7-15b5e18a3e9c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_b5364f95-7fd4-49db-ac79-a48050ef5c08" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_b5364f95-7fd4-49db-ac79-a48050ef5c08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8cc2dd54-8cde-45e6-8e70-b76506d99359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8cc2dd54-8cde-45e6-8e70-b76506d99359" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_e41a687a-aaef-46c3-ad74-b75dbb276c0c" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_e41a687a-aaef-46c3-ad74-b75dbb276c0c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cfd8f444-753e-4ba1-bfa7-5960ebfe7dc8" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cfd8f444-753e-4ba1-bfa7-5960ebfe7dc8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_ff084a7c-1893-48f3-b2da-30eb1622cf8a" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_ff084a7c-1893-48f3-b2da-30eb1622cf8a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_ef8eb01c-ef14-4e44-bb43-7e0543acb5c2" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_ef8eb01c-ef14-4e44-bb43-7e0543acb5c2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:href="arwr-20220630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_263da7a1-3b08-4efe-88a5-52dde3ce27c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_263da7a1-3b08-4efe-88a5-52dde3ce27c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_984363a1-2463-46de-be61-862b150bf75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_984363a1-2463-46de-be61-862b150bf75d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesDueWithinNinetyDaysMember_bd6bd1e8-c01e-4e1c-a58d-7ec7d4ceba27" xlink:href="arwr-20220630.xsd#arwr_CommercialNotesDueWithinNinetyDaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_984363a1-2463-46de-be61-862b150bf75d" xlink:to="loc_arwr_CommercialNotesDueWithinNinetyDaysMember_bd6bd1e8-c01e-4e1c-a58d-7ec7d4ceba27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:to="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35777f64-1945-4f05-8e2b-294ec55b1625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35777f64-1945-4f05-8e2b-294ec55b1625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNoteDueWithinOneYearMember_a3b21d27-74df-4b31-982d-b648459e8fda" xlink:href="arwr-20220630.xsd#arwr_CommercialNoteDueWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CommercialNoteDueWithinOneYearMember_a3b21d27-74df-4b31-982d-b648459e8fda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_908ab3bf-3603-4b8a-a829-74607400c2a8" xlink:href="arwr-20220630.xsd#arwr_CommercialNoteDueWithinOneThroughThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_908ab3bf-3603-4b8a-a829-74607400c2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_470bf9b3-a40d-466a-bbf4-ef5bee7ba82b" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_470bf9b3-a40d-466a-bbf4-ef5bee7ba82b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDepositDueWithinOneYearMember_19246647-6a8c-4a9f-b9a7-f785ebbae64e" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDepositDueWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CertificateOfDepositDueWithinOneYearMember_19246647-6a8c-4a9f-b9a7-f785ebbae64e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MarketableSecuritiesMember_bbbc789c-a997-461a-8521-51ef27f57c9f" xlink:href="arwr-20220630.xsd#arwr_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_MarketableSecuritiesMember_bbbc789c-a997-461a-8521-51ef27f57c9f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#IntangibleAssetsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended" id="i540a815b2bc244688d51016129769a9e_IntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2da40820-9ae6-40e9-9d4a-b8ada9a82289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2da40820-9ae6-40e9-9d4a-b8ada9a82289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_816c2244-2195-4ecc-b335-f526ed19bcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_816c2244-2195-4ecc-b335-f526ed19bcd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6f51e813-4a31-46dc-aae3-31ee1466e806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6f51e813-4a31-46dc-aae3-31ee1466e806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5114baed-36f4-4f7f-85d1-8d46e94eb854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5114baed-36f4-4f7f-85d1-8d46e94eb854" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4fd18ae1-e0ba-4525-b88d-4af577b0be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4fd18ae1-e0ba-4525-b88d-4af577b0be2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_806ee7ce-c319-4b4a-912c-f88a74c74764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_806ee7ce-c319-4b4a-912c-f88a74c74764" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_187cd2e4-e169-4788-a710-900242f77c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_187cd2e4-e169-4788-a710-900242f77c08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6cb1abe5-610e-499b-b6a5-d9777c140651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6cb1abe5-610e-499b-b6a5-d9777c140651" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_c9124a9a-15f0-45f2-b29e-e22df419e771" xlink:href="arwr-20220630.xsd#arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_c9124a9a-15f0-45f2-b29e-e22df419e771" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:to="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_95bb351e-cb23-49bc-89c8-285992ed0566_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:to="loc_us-gaap_AssetAcquisitionDomain_95bb351e-cb23-49bc-89c8-285992ed0566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_a63efd70-e76a-4bcd-9f1a-9b13adf5fbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:to="loc_us-gaap_AssetAcquisitionDomain_a63efd70-e76a-4bcd-9f1a-9b13adf5fbdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_28427133-b245-4bd7-abf6-33c24286210f" xlink:href="arwr-20220630.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_a63efd70-e76a-4bcd-9f1a-9b13adf5fbdb" xlink:to="loc_arwr_NovartisMember_28427133-b245-4bd7-abf6-33c24286210f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0140623a-fdaa-426e-8d6b-f8b0696521b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0140623a-fdaa-426e-8d6b-f8b0696521b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_dd676efd-d9c4-4954-8930-d1d13cc71c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:to="loc_us-gaap_LicensingAgreementsMember_dd676efd-d9c4-4954-8930-d1d13cc71c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_4e62cd4b-1f66-42ef-ae8f-c79efaada85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:to="loc_us-gaap_PatentsMember_4e62cd4b-1f66-42ef-ae8f-c79efaada85b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" id="i0f9548dbecd74e00b7b50f514ed7146c_StockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitsAuthorized_fce8ca7f-3c42-4d05-8bb6-8546d69be294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CapitalUnitsAuthorized_fce8ca7f-3c42-4d05-8bb6-8546d69be294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4e256cfb-20b9-4e46-a0cf-105401537526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4e256cfb-20b9-4e46-a0cf-105401537526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_54c5b329-56a4-4ea7-bb2a-089fab7cb1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_54c5b329-56a4-4ea7-bb2a-089fab7cb1e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3f56c0ef-52ce-4f6c-a4e0-c93acfee8e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3f56c0ef-52ce-4f6c-a4e0-c93acfee8e28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fc821fbe-b479-44d0-a86a-5a35b804b6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fc821fbe-b479-44d0-a86a-5a35b804b6f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_40f49d25-aa0a-430c-86c1-6a27ce41670a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_40f49d25-aa0a-430c-86c1-6a27ce41670a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3e85f86-3299-44cf-82a5-454b9409d7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3e85f86-3299-44cf-82a5-454b9409d7eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_64fbd09e-674b-4bf8-975c-d6ba2307957e" xlink:href="arwr-20220630.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_64fbd09e-674b-4bf8-975c-d6ba2307957e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_16198ace-142e-4fb5-aea7-352e65395d95" xlink:href="arwr-20220630.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_16198ace-142e-4fb5-aea7-352e65395d95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f22d6854-fa1d-416c-9d18-1914ec3bc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_SharesIssued_f22d6854-fa1d-416c-9d18-1914ec3bc72e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6cbc469e-df63-445f-adb1-b3b3be9e693e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:to="loc_us-gaap_PlanNameDomain_6cbc469e-df63-445f-adb1-b3b3be9e693e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_178fda08-a417-42cf-bea1-de0f891a871d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:to="loc_us-gaap_PlanNameDomain_178fda08-a417-42cf-bea1-de0f891a871d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_4af2386c-7e6c-42fb-aa53-0531a840db90" xlink:href="arwr-20220630.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_178fda08-a417-42cf-bea1-de0f891a871d" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_4af2386c-7e6c-42fb-aa53-0531a840db90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e64ff073-b604-42cc-aa2d-e49afd0812a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e64ff073-b604-42cc-aa2d-e49afd0812a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_352786b4-1522-4244-90f9-2fc8406a19ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_352786b4-1522-4244-90f9-2fc8406a19ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_65e80c2d-b8fc-406d-b91c-0d90d184e849" xlink:href="arwr-20220630.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_352786b4-1522-4244-90f9-2fc8406a19ae" xlink:to="loc_arwr_AtTheMarketAgreementMember_65e80c2d-b8fc-406d-b91c-0d90d184e849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_551dcc9d-7515-4766-a377-6c8fbb72570c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:to="loc_srt_RangeMember_551dcc9d-7515-4766-a377-6c8fbb72570c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_692b0684-4383-4f79-b0e8-73719110f55c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:to="loc_srt_RangeMember_692b0684-4383-4f79-b0e8-73719110f55c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10418e42-8f77-4072-be4b-d85e4803f706" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_692b0684-4383-4f79-b0e8-73719110f55c" xlink:to="loc_srt_MaximumMember_10418e42-8f77-4072-be4b-d85e4803f706" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i11d8638496724e5496d7cc6667320d50_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_c6e65586-16b1-4ede-9129-f8d555e56db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_c6e65586-16b1-4ede-9129-f8d555e56db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_2ac3f0cc-ba18-4140-9753-709227dfdbed" xlink:href="arwr-20220630.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_2ac3f0cc-ba18-4140-9753-709227dfdbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_3aec2188-bca6-4918-b86a-ab5eecc45fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_us-gaap_AreaOfLand_3aec2188-bca6-4918-b86a-ab5eecc45fe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_ad2b1c7e-da4d-430e-bab9-c06f9641ad1c" xlink:href="arwr-20220630.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_ad2b1c7e-da4d-430e-bab9-c06f9641ad1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_5b8ced0b-03bb-42bc-8574-292915e7f12e" xlink:href="arwr-20220630.xsd#arwr_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_arwr_MilestonePayments_5b8ced0b-03bb-42bc-8574-292915e7f12e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2744d164-e238-4d3f-9e13-6432c36a220e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2744d164-e238-4d3f-9e13-6432c36a220e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_ea6ba52e-e54b-4c33-85b0-f590518844f7" xlink:href="arwr-20220630.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_VeronaTechnologyParkMember_ea6ba52e-e54b-4c33-85b0-f590518844f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_09293b28-9b71-4a3d-96ca-c53e9da0559d" xlink:href="arwr-20220630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_DrugManufacturingFacilityMember_09293b28-9b71-4a3d-96ca-c53e9da0559d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_2db4d50b-d56d-4349-93e5-b33d56d7c864" xlink:href="arwr-20220630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_2db4d50b-d56d-4349-93e5-b33d56d7c864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_dcf47d58-6b34-48e5-8cbc-80036b077357" xlink:href="arwr-20220630.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_FacilitiesMember_dcf47d58-6b34-48e5-8cbc-80036b077357" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_027c5abb-240e-4b57-a0e3-876c3236c29f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:to="loc_srt_RangeMember_027c5abb-240e-4b57-a0e3-876c3236c29f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:to="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1313a158-00d5-47fd-ac06-95792df736ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:to="loc_srt_MinimumMember_1313a158-00d5-47fd-ac06-95792df736ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6fe5bfad-5285-4eca-b282-95db78600e43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:to="loc_srt_MaximumMember_6fe5bfad-5285-4eca-b282-95db78600e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f22169ed-7bb1-45ef-85e8-4227ebc0b215_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:to="loc_srt_SegmentGeographicalDomain_f22169ed-7bb1-45ef-85e8-4227ebc0b215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e258375-2a09-4676-ba42-021cc48aa8d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:to="loc_srt_SegmentGeographicalDomain_9e258375-2a09-4676-ba42-021cc48aa8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_b2bd3ac3-b270-4f76-b925-1d867ab8f21c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e258375-2a09-4676-ba42-021cc48aa8d3" xlink:to="loc_stpr_WI_b2bd3ac3-b270-4f76-b925-1d867ab8f21c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_61bcd3cc-656f-4693-8017-388fb962b617_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:to="loc_us-gaap_OtherCommitmentsDomain_61bcd3cc-656f-4693-8017-388fb962b617_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_0f2fa07b-cf48-4a53-826e-51e8ff15420b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:to="loc_us-gaap_OtherCommitmentsDomain_0f2fa07b-cf48-4a53-826e-51e8ff15420b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_55ed6bea-12b8-4fa4-bebc-f7ce0ccd074f" xlink:href="arwr-20220630.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f2fa07b-cf48-4a53-826e-51e8ff15420b" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_55ed6bea-12b8-4fa4-bebc-f7ce0ccd074f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="i0cc71cbc57914eee8a1509764cd5d0d0_LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_454f7d7b-9672-47a8-b1e4-05e6d5a10023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_454f7d7b-9672-47a8-b1e4-05e6d5a10023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_046a7d08-7726-40e3-b617-610669812294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_046a7d08-7726-40e3-b617-610669812294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e74c70f-3695-45c1-b3f4-59b25271e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e74c70f-3695-45c1-b3f4-59b25271e81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_06050efe-8d4a-4e47-86ea-53843315acc0" xlink:href="arwr-20220630.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_06050efe-8d4a-4e47-86ea-53843315acc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_e057f029-ff1a-420b-9fde-9e647e0034e7" xlink:href="arwr-20220630.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_NumberOfOptionsToRenew_e057f029-ff1a-420b-9fde-9e647e0034e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4cc32493-cdba-4369-aee2-bdb6c20cdd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4cc32493-cdba-4369-aee2-bdb6c20cdd14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalLandSubjectToLease_3df64b68-e6b5-4416-bd2b-718f080d843d" xlink:href="arwr-20220630.xsd#arwr_AdditionalLandSubjectToLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_AdditionalLandSubjectToLease_3df64b68-e6b5-4416-bd2b-718f080d843d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_84a15e70-b332-49d6-897c-e7667b35ebe0" xlink:href="arwr-20220630.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_84a15e70-b332-49d6-897c-e7667b35ebe0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_fa01eaf1-b456-4c08-b3f4-8b0bed25e731" xlink:href="arwr-20220630.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_fa01eaf1-b456-4c08-b3f4-8b0bed25e731" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3319d39d-acf1-4bfb-b490-2cb1c26568c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeaseCost_3319d39d-acf1-4bfb-b490-2cb1c26568c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_03003fb1-b8c4-4c9b-bfe0-3a1befe5dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_VariableLeaseCost_03003fb1-b8c4-4c9b-bfe0-3a1befe5dc93" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3feb944c-fd53-4a03-a98b-a82473eaced5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_ShortTermLeaseCost_3feb944c-fd53-4a03-a98b-a82473eaced5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7e5dcfcc-d682-4d4a-a4c8-79c6d79fb408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeasePayments_7e5dcfcc-d682-4d4a-a4c8-79c6d79fb408" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64311836-66a2-4619-9b0b-243fbfdb9d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64311836-66a2-4619-9b0b-243fbfdb9d15" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4319d5d-a839-402b-9708-2fe5013e1096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4319d5d-a839-402b-9708-2fe5013e1096" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_e428e31f-01d5-428d-9f8c-cac0f9b44199" xlink:href="arwr-20220630.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_e428e31f-01d5-428d-9f8c-cac0f9b44199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_d4f96151-1601-422c-acb8-4e34e6256ff0" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_d4f96151-1601-422c-acb8-4e34e6256ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_528ff223-40a8-4180-bf6d-217a4d05f75a" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_528ff223-40a8-4180-bf6d-217a4d05f75a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cdb2ad2c-34e4-450d-86f1-c60db13a28aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cdb2ad2c-34e4-450d-86f1-c60db13a28aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_61370f42-b1aa-4c19-991b-84aba6f61ba1" xlink:href="arwr-20220630.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:to="loc_arwr_ColoradoOwnerLLCMember_61370f42-b1aa-4c19-991b-84aba6f61ba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HalozymeIncMember_7704bc1b-d62a-4c21-8aec-5bde97101abb" xlink:href="arwr-20220630.xsd#arwr_HalozymeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:to="loc_arwr_HalozymeIncMember_7704bc1b-d62a-4c21-8aec-5bde97101abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:to="loc_srt_SegmentGeographicalDomain_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:to="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_36af62be-77d1-4029-b887-e1ab42a4112f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:to="loc_stpr_CA_36af62be-77d1-4029-b887-e1ab42a4112f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_f57d2d4a-8e53-4349-948c-bf5a62627b17" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:to="loc_stpr_WI_f57d2d4a-8e53-4349-948c-bf5a62627b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6962db4b-b11a-42cc-8ffe-4cb025a076f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6962db4b-b11a-42cc-8ffe-4cb025a076f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6c498d7-d841-4441-99d6-438a3894308f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6c498d7-d841-4441-99d6-438a3894308f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SubleaseAgreementMember_c94bda6d-ea68-4020-9d05-b87040e8b4b3" xlink:href="arwr-20220630.xsd#arwr_SubleaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6c498d7-d841-4441-99d6-438a3894308f" xlink:to="loc_arwr_SubleaseAgreementMember_c94bda6d-ea68-4020-9d05-b87040e8b4b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:to="loc_srt_RangeMember_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ce76e49-fe26-49da-b6ff-6ddeb81c67a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:to="loc_srt_RangeMember_3ce76e49-fe26-49da-b6ff-6ddeb81c67a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_389de7f4-febf-46c7-9586-1c90f2661191" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ce76e49-fe26-49da-b6ff-6ddeb81c67a6" xlink:to="loc_srt_MaximumMember_389de7f4-febf-46c7-9586-1c90f2661191" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="iba1e979eba874588b4ea3f614d1690cf_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_949b6afb-2c93-44d7-91b9-9477267fc92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_949b6afb-2c93-44d7-91b9-9477267fc92a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3194832c-52e3-4575-b522-1640f39341e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3194832c-52e3-4575-b522-1640f39341e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e0e2964f-9f37-4a61-8576-478c7e5cfbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e0e2964f-9f37-4a61-8576-478c7e5cfbd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_932170ba-8015-41a7-976c-db354396493a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_932170ba-8015-41a7-976c-db354396493a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44af3ca3-2d4f-421f-bcc2-697b76c78017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44af3ca3-2d4f-421f-bcc2-697b76c78017" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_54ff31e5-59ed-4aac-9edf-8fdb46262ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_54ff31e5-59ed-4aac-9edf-8fdb46262ce9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_a54863a6-ccfb-4101-93be-bf0064c67ec4" xlink:href="arwr-20220630.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_a54863a6-ccfb-4101-93be-bf0064c67ec4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35b96e41-99bb-4903-9e67-bc3cf93f2f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35b96e41-99bb-4903-9e67-bc3cf93f2f34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0434c210-ba40-4eb1-b3d3-2998779f0710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0434c210-ba40-4eb1-b3d3-2998779f0710" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d1641d1-fbd8-4208-8ee4-706c652fa10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d1641d1-fbd8-4208-8ee4-706c652fa10d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b91f1f3-a8bd-46f0-b910-8dfef185dcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b91f1f3-a8bd-46f0-b910-8dfef185dcac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_b6cd7f47-54a3-41c4-95d8-0b5163b4141a" xlink:href="arwr-20220630.xsd#arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_b6cd7f47-54a3-41c4-95d8-0b5163b4141a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_df0c7a30-f8b8-46a6-8c6d-09e5a810e110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_df0c7a30-f8b8-46a6-8c6d-09e5a810e110" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:to="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bf5b31bf-cabc-446d-8db0-62ea8cde5ced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:to="loc_us-gaap_PlanNameDomain_bf5b31bf-cabc-446d-8db0-62ea8cde5ced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:to="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_6c68ec47-c2b6-424a-bf96-2ffa888a198b" xlink:href="arwr-20220630.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_6c68ec47-c2b6-424a-bf96-2ffa888a198b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_f9172ca0-3410-459b-b5a8-5c4506d67b66" xlink:href="arwr-20220630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_f9172ca0-3410-459b-b5a8-5c4506d67b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember_34c8df79-efad-430d-bfa1-7091619fd7c4" xlink:href="arwr-20220630.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_OutsideOfEquityCompensationPlansMember_34c8df79-efad-430d-bfa1-7091619fd7c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_01e2a287-6d28-498d-a894-f373df22d5fd" xlink:href="arwr-20220630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_01e2a287-6d28-498d-a894-f373df22d5fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:to="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf66f674-575e-4918-bf46-d4c316602382_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf66f674-575e-4918-bf46-d4c316602382_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f28928f6-913b-4b95-91d6-381df6fede38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f28928f6-913b-4b95-91d6-381df6fede38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fdbf76d0-6137-4525-b1ef-34debcf066e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fdbf76d0-6137-4525-b1ef-34debcf066e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationSummaryofRSUsActivityDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail" xlink:type="extended" id="i95231dc5a7b54e53b5eb9e338c188a1b_StockBasedCompensationSummaryofRSUsActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67078415-46ec-48cb-bd7c-93b80e3e9f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67078415-46ec-48cb-bd7c-93b80e3e9f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61d13184-c3b3-4dfd-8b18-8d8d61badf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61d13184-c3b3-4dfd-8b18-8d8d61badf79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f562fcc-44d5-4ff6-819b-43929e0bfa80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f562fcc-44d5-4ff6-819b-43929e0bfa80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5823f338-ffa8-4c04-a007-c59b41ca678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5823f338-ffa8-4c04-a007-c59b41ca678d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_818bc719-f4d2-424d-bd55-bb387ffa1b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc2b9f36-a3bf-4ee0-b686-7b307a0ba109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc2b9f36-a3bf-4ee0-b686-7b307a0ba109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fa1b806-b031-4dfc-8272-33b7edb4ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fa1b806-b031-4dfc-8272-33b7edb4ab6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfeb4f37-fb2d-45a7-b004-7d12080e8bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfeb4f37-fb2d-45a7-b004-7d12080e8bb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8b2d7886-1482-4194-9d81-7650ee9d97c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8b2d7886-1482-4194-9d81-7650ee9d97c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e1e25b3-1235-4b62-be84-a612698788ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:to="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ad2ae2-a0b9-4cac-a72c-99114a809087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ad2ae2-a0b9-4cac-a72c-99114a809087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a641240-db36-42c4-b179-6ec5c4c157ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a641240-db36-42c4-b179-6ec5c4c157ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_96507221-f3ba-4ab6-bdce-4cc12d0db943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a641240-db36-42c4-b179-6ec5c4c157ba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_96507221-f3ba-4ab6-bdce-4cc12d0db943" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="i07a9613db1f048478e7d8521b7a4bbd1_FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotes_15dc4556-dcbe-433d-8ea8-a0945c5f2305" xlink:href="arwr-20220630.xsd#arwr_CommercialNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_arwr_CommercialNotes_15dc4556-dcbe-433d-8ea8-a0945c5f2305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d56d2318-c480-4db5-af31-3e527996e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d56d2318-c480-4db5-af31-3e527996e2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_7a8a2f68-3979-403c-be9a-de96c60264de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_7a8a2f68-3979-403c-be9a-de96c60264de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_600eb199-1ecf-4918-99b6-986fc4856894" xlink:href="arwr-20220630.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_600eb199-1ecf-4918-99b6-986fc4856894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDeposits_c5f6927f-4e18-4e19-a312-9282386666c5" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_arwr_CertificateOfDeposits_c5f6927f-4e18-4e19-a312-9282386666c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b4bf37dd-21ce-43ac-bfa4-002398b25900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b4bf37dd-21ce-43ac-bfa4-002398b25900" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_282035b8-7d6d-4463-90ab-908cd4422a1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_282035b8-7d6d-4463-90ab-908cd4422a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48b483ec-7ab8-4b52-aadd-3c2eb01ba91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48b483ec-7ab8-4b52-aadd-3c2eb01ba91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a91ce80a-ef15-4c17-8dbf-a3e6eaba6ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_48b483ec-7ab8-4b52-aadd-3c2eb01ba91b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a91ce80a-ef15-4c17-8dbf-a3e6eaba6ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_320ca8e2-7f72-4f91-af3e-a963a387a3f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_320ca8e2-7f72-4f91-af3e-a963a387a3f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73082eff-7808-4e17-9aa6-14c2df14cee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_73082eff-7808-4e17-9aa6-14c2df14cee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4fb1a803-923b-44a2-af34-2ac18f0a1a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4fb1a803-923b-44a2-af34-2ac18f0a1a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_690dcd18-4aa4-4587-91c5-ca5337879337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_690dcd18-4aa4-4587-91c5-ca5337879337" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>arwr-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:368d367d-beb3-477f-87b6-b6cfd3b1dc77,g:0bc56581-7549-4bc1-a0c5-dd60a0bc219c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b09b152-ab67-479a-985e-48413463290e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acf19bf-d38a-4302-b9e4-3424210172d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a80342a1-4620-4de3-a62a-b0919290934d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_943cb49d-5a78-425a-8518-330aa423abbd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_40dfdf4e-9c25-47aa-81f6-f496a52ab5ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_235d1940-9a00-4d3e-97a9-06436578fce3_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to Maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e2ffb0f9-c8a0-4443-b9ff-a91e6f8f5c46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_f1708e71-0e18-49fe-bf3b-1762c26d834a_terseLabel_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_label_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments [Member]</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology license commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:href="arwr-20220630.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:to="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_fcb64e07-2ff3-4d0a-90a9-9e70474244c4_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable At Start Of Phase Two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:to="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_34e32ac8-8686-424b-8d58-02214c7aece3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_83b78c4e-9146-441d-919d-57092a86f2d7_terseLabel_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax increment financing award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_label_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_documentation_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward" xlink:href="arwr-20220630.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxIncrementFinancingAward" xlink:to="lab_arwr_TaxIncrementFinancingAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ce7394e-aab1-4bc0-908d-26df0449908c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_550d3000-a931-4090-9121-8e1f0218e136_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93d9ae79-560c-404c-afb7-c2b91c74387f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c22fc474-9ba6-4ba3-932d-92d9646047a9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c8c2a5f5-de5d-4550-8e5c-5ac24d7e6fa6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e83b6b2-0955-493e-9b28-1744b465e4ef_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_96148c07-637b-4dbf-acf2-cc3df288d428_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SubleaseAgreementMember_8319899c-6001-4a13-9a0c-4acc15a61306_terseLabel_en-US" xlink:label="lab_arwr_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement</link:label>
    <link:label id="lab_arwr_SubleaseAgreementMember_label_en-US" xlink:label="lab_arwr_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:label id="lab_arwr_SubleaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SubleaseAgreementMember" xlink:href="arwr-20220630.xsd#arwr_SubleaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SubleaseAgreementMember" xlink:to="lab_arwr_SubleaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8fa6e940-ae28-4e1e-be90-2961da9c033c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c63fa007-df25-429d-9f98-e961331f4e39_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c34b8994-f1ba-48b2-9247-f6b962cc3234_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_76fb7d76-fd74-4c3c-8af9-c80e2ad0d26e_terseLabel_en-US" xlink:label="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation related to agreement, upfront payment</link:label>
    <link:label id="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_label_en-US" xlink:label="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Related To Agreement Upfront Payment</link:label>
    <link:label id="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation related to agreement, upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" xlink:href="arwr-20220630.xsd#arwr_PerformanceObligationRelatedToAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" xlink:to="lab_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_fc6f8ccc-c915-4a3e-b4f8-05db9baac8a6_terseLabel_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ab3bf818-5f66-45ba-b863-f21b10c0bf09_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalLandSubjectToLease_21cbafac-4e38-4bfa-ae97-54c2abc88039_terseLabel_en-US" xlink:label="lab_arwr_AdditionalLandSubjectToLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional office space for lease</link:label>
    <link:label id="lab_arwr_AdditionalLandSubjectToLease_label_en-US" xlink:label="lab_arwr_AdditionalLandSubjectToLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Land Subject To Lease</link:label>
    <link:label id="lab_arwr_AdditionalLandSubjectToLease_documentation_en-US" xlink:label="lab_arwr_AdditionalLandSubjectToLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional land subject to lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalLandSubjectToLease" xlink:href="arwr-20220630.xsd#arwr_AdditionalLandSubjectToLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalLandSubjectToLease" xlink:to="lab_arwr_AdditionalLandSubjectToLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5bce97ab-d3c0-4b3f-ad00-96188dc4b6be_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_796605dc-00a0-4434-a2ac-f84c54fd2139_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_71c47e19-ac0a-447d-9cc9-7627eb197343_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6d357e45-a3f5-4d27-9200-93aee9b25cd1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROHSDAgreementMember_d5001964-3ee1-4cd1-8cc5-2063ed905607_terseLabel_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-HSD Agreement</link:label>
    <link:label id="lab_arwr_AROHSDAgreementMember_label_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O H S D Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROHSDAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AROHSD agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember" xlink:href="arwr-20220630.xsd#arwr_AROHSDAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROHSDAgreementMember" xlink:to="lab_arwr_AROHSDAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_c47d5a8c-9a01-4cb9-967e-6af386df8341_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares value reserved for future issuance (in shares)</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20220630.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8cc56982-fc8e-49e2-9995-32bccfb6ec11_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_70f14bcb-313e-4325-870e-2f94f90724d8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d73c5cb7-cd45-4d3b-a1cb-86257cfa9814_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remainder of fiscal year)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_016ea15c-440e-4eb7-b8ad-5d01bc90cf8c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_59babb5f-782e-42f7-98d0-84a1cd570641_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b7953667-9f4c-4fc9-91a2-c97d9e066cd5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0023eef8-652c-4f1d-b6c5-2ed106589f30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_76999493-66fa-4fab-8632-a17fa06b4235_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3c04a726-a22a-4275-951a-9e7d6b0a5487_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_7ed166a4-0708-4918-abc9-c6623fe8f7ef_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20220630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_5abae0cd-6ba6-4210-b186-a07aa270f6df_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planned area of the site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_797f79e2-8114-412a-94f2-b70f2eaf2a59_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_a1a1fcae-60f8-4cd2-bdd0-88facdd2a629_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20220630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0ec14613-9ba6-4067-9117-73a64dbc8447_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e67e33be-08fa-44cb-8ba9-4eae97e634fa_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cfcf34aa-abf5-4e9e-af90-3b17b8fe0e23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_08527d45-ba8d-4072-8d30-bae9ca9d49dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_7a9a81d8-13ae-4a82-aa7b-172e23aca2b5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_9cf5a8a9-589e-4e2d-bfea-25f5118330ee_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_aaa119e0-a5b0-452a-a5d7-dd12f16187df_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20220630.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_37c3a76c-5578-4290-80e1-9448a95d354d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2af71622-b2ae-47b3-b439-efde0784e632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d41fb151-044e-4774-801d-8b47a967fcaf_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b90d0d37-633e-4824-9e26-9c6d3aa8b7de_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_5663350c-3533-4a8b-a810-dcdcfc62eea0_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/(accretion) of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_07ea35ad-beb4-4b9f-8cbb-23d9652972de_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e943c08c-5214-49dc-a5f4-be1986ddc3da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_64cd6fcf-621c-4588-a5b2-552e516d1abd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_80c54269-de00-4a21-bb25-64cb24de5b51_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e4dc773-8348-4b72-bbf2-44859a52ec31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_1406c876-0e67-4eb0-b599-01b894153513_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72f6d5dd-f524-455d-9386-e5bafaff5cda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_b41bc86e-00bf-4fae-844e-11609d794e46_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to Maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b04b5081-78c3-4ae7-9a9c-5e6d16c9e006_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_34a2b192-2dfb-40ea-be53-c6a6a42dcc84_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_6293c25e-260e-4917-9ba1-1795f76b46da_verboseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_fe5b870a-06c7-4679-a043-dca117c96f94_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e8c9bde2-b1be-48fd-af77-f684cd725e15_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0763045e-bccd-42f2-bc3b-314eedebd06d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_20336346-cf60-4087-a837-acb4ca00e055_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of license agreements, thereafter</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets amortization expense after year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:href="arwr-20220630.xsd#arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_ccd775f4-eec1-43f4-a38e-8661dbcc2010_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_90d149b6-18cb-470f-af83-8c434483ae7e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_53a7b697-0d34-4b60-9795-d142cd989892_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a39c4bd2-ac47-44b8-9ef5-1cca605ca50d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashEquivalentsGrossUnrealizedGains_b49ebca7-9e67-42da-9b52-781c62e9266a_terseLabel_en-US" xlink:label="lab_arwr_CashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_CashEquivalentsGrossUnrealizedGains_label_en-US" xlink:label="lab_arwr_CashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_CashEquivalentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_arwr_CashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents gross unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedGains" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashEquivalentsGrossUnrealizedGains" xlink:to="lab_arwr_CashEquivalentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ed84f758-180a-4d38-b0ca-c63fcef8dc3e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_dcccd60a-217b-4732-8713-ac6cda4aefb1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_8ce85af3-cea3-408f-9752-3e742a356e3a_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Short-term and Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20220630.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0bf4a1ee-2250-439a-80fd-9f24626fa2b1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesDueWithinNinetyDaysMember_7f179977-0f6f-47a2-a45f-f4a8e93699de_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesDueWithinNinetyDaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes (due within ninety days)</link:label>
    <link:label id="lab_arwr_CommercialNotesDueWithinNinetyDaysMember_label_en-US" xlink:label="lab_arwr_CommercialNotesDueWithinNinetyDaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes Due Within Ninety Days [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesDueWithinNinetyDaysMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesDueWithinNinetyDaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes due within ninety days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesDueWithinNinetyDaysMember" xlink:href="arwr-20220630.xsd#arwr_CommercialNotesDueWithinNinetyDaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesDueWithinNinetyDaysMember" xlink:to="lab_arwr_CommercialNotesDueWithinNinetyDaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7598ad5d-2efa-4bfe-aea0-b8b69ad3e3f7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_74dc0892-d73e-4bd0-8f83-9c25e2c68f0f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_6aed8226-2632-4904-b5ab-46cee3ff174e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued to institutional investors (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c6752aab-5d8e-48d3-8aa0-64e71e68499f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dfeddc76-1ed5-4f41-b8bf-435af0352c39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_64139ba7-d7af-49c0-a6be-fe94a41daaf3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_380c6110-bd6c-4be9-b385-dfbe78738dd0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3cbc3ca0-bdcf-4c62-8f0b-65a001279814_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b4f49a44-6c3f-4023-8199-d24eacdb2bba_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_2fba4c13-ba02-4557-84e4-e9782731b62f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_8ce7eec7-aac4-429d-a857-76955aaec2c4_terseLabel_en-US" xlink:label="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV- NI, Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV- NI, Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46e1645e-b756-41ab-a77c-4b3f74fc1da0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME (LOSS) BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3665f972-3f10-4b60-8034-96c977b11adb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_bd7f2921-c9e3-4b00-96e3-fc98ab7f1893_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to Maturity, Cost Basis</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_afe258e9-dbe0-40a5-99c8-fe8394bbee79_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Receivable As Upfront Payment Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receivable as upfront payment due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:href="arwr-20220630.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_73eabedf-7ee6-4c85-9cbf-d9acb32146e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Value Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_9791c006-6adf-4aec-a93c-a030ad0346ef_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_32dce8a1-7792-44fa-bb2f-fb0361c724e8_verboseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5452165-d860-453f-ac6e-e5ddbfba28da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c725a9d1-630f-4f94-8a3d-fd976b7c56e9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c66d4931-6d87-4ed1-8e26-8e0dc6a05879_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_287d9c02-df48-4f4a-a39b-d0fcf2796fe8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_d1394a93-564e-4b1a-8d6e-829cadd0f9f5_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d9d4c079-3276-42e9-8454-c076a27ffd9b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0c7a8595-1aa6-49ba-8aac-1adfc0db2232_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5b883b4e-8715-4b1c-9ad8-64e4c2ee7daf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_5cc2b261-e642-4b3e-842f-558b569e1a75_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_95389ffd-c777-49d1-b3c7-ced0ced80293_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_46247836-106a-46d2-ac45-1ec18f4a2dd8_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20220630.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8c8c855f-cb07-4cad-8585-f14125b6ebdf_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_65063cc1-3af8-47ba-ac0e-32d7c7deebcb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3e2152c-4a0f-4e6f-8a7d-8d3da116a818_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89337e65-281b-4a78-a0d5-abb118dac0b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81b34ff4-7df4-4c77-8795-99d81618d0d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_28325c6d-a855-440a-93ce-74ff157745b4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_d71b5103-b8ac-4ed9-98f5-68462beeafc4_negatedLabel_en-US" xlink:label="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities FV NI accumulated gross unrealized loss before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_5fb7191f-f3a4-4fbf-9e48-6b197d3fbaa8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_e746d0fd-4669-4d59-8851-76ad29840969_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_53404a6d-ff22-49c1-9a1d-e12fdaee65aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b0976cf1-f503-4a98-8ea7-f1c52716a871_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_169dfa38-b79e-417f-834f-dc78ae5e1861_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_bb0262bf-680b-406b-a5e5-5885bcbfdb13_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran And A R O A M G1 Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:href="arwr-20220630.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:to="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f56dbca9-78cb-49ab-9d79-3ce0911f4ed8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d4488a65-d214-4878-8285-0b3a436ef9e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_fd6f61e2-e4e3-4cbf-84d5-42d53aeb0655_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20220630.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_a35954c7-b4e7-44ac-a688-02528c4b31b1_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20220630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_73eff051-f4d8-4dd1-a1cd-2a682bbc5910_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4bd4d801-f57a-4884-8199-9915b1236159_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_08dd6654-d7fe-461c-8671-876f8e583fe0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e4aca21f-baf4-4a87-a626-ed4179b8e944_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of license agreements in 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e5323e31-e83f-4d0e-8078-1e431708634a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_569c88b9-81b0-4fd1-9196-813ebc3f854b_totalLabel_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Cost Basis</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_label_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Held To Maturity And Marketable Securities Amortized Cost</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents held to maturity and marketable securities amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" xlink:to="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalUnitsAuthorized_557bc8b0-a0e1-4dad-bbe5-79f72cde62d8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalUnitsAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CapitalUnitsAuthorized_label_en-US" xlink:label="lab_us-gaap_CapitalUnitsAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Units, Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitsAuthorized" xlink:to="lab_us-gaap_CapitalUnitsAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_6667ba86-2613-425c-8bec-a16e64c67ae1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9a32253c-795a-44b7-af90-6f7b62087a7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7095b05a-bd5e-4419-ad03-633416dc15fe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_da13fc1d-ffad-4f6b-8cb2-519a9a0ba663_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAgreementMember_c290d6af-75c7-4e28-a35c-13f2511f6646_terseLabel_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember" xlink:href="arwr-20220630.xsd#arwr_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAgreementMember" xlink:to="lab_arwr_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_6575b693-a29d-4a04-b7dd-9a8153d262c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investment in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributedCapital" xlink:to="lab_us-gaap_ProceedsFromContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f8a0558f-591b-4cae-b19d-b73fca945b77_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_ebbb2fb3-d3bb-4fc6-94f9-dcbae8980512_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20220630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e72b030f-f47a-4b66-b676-706112761811_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_2974b400-2c3a-4b70-994e-3350992cbe53_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_731a1bce-cdea-48c2-95a6-949950fae489_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_303ff8b9-ac79-45f5-a9cb-c2538aa232fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b6d366fe-4074-4fcd-b849-e39248e35306_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ad8bd957-ae14-47d8-ab2a-276ab847922a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5cafdeb7-1c2d-4e4e-9660-eed98b157e83_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ce2e9d9c-261f-44cd-b0a4-f19d2270f5da_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS) PER SHARE - BASIC (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_22821a0e-43ca-4f14-b1a3-ee2eed412124_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_aa7fc68e-e84c-433b-a77f-aadbe362a705_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_bbd79169-be25-4ec9-8826-da4a0a34f110_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20220630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3fed5917-7063-4b98-8691-40297906a8ff_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0314d939-e22e-4bb1-bbdf-5ef446501627_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_514e7bff-8a78-4f45-841a-d8d6401ce1d4_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20220630.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a0290275-801c-49eb-97d9-5ef7b8c94db7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ARROWHEAD PHARMACEUTICALS INC. STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_47db576f-c9a4-4d5c-b847-f72120a2ce79_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_54497706-3615-4ae4-ad00-fd1edd577a55_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_04e9ad55-92f3-469a-b735-6aba210f3224_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0c38bbc4-1cc8-4732-b65b-95b75e0e404d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a67b20cc-7e54-4542-8fe3-36ef60dfa2d2_verboseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f074d1e4-a415-4950-81a4-ae811b1e9056_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_680af40a-0f9f-4f71-b409-47840b120228_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a5a786e-8811-40aa-839d-1f921708c487_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_05b9f992-6b72-44d3-b043-99d42a9f4e46_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of license agreements in 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_ea1acebb-6a39-4cc6-b593-774fb0989f36_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20220630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CertificateOfDeposits_cd19cd0c-7a76-4c13-8300-4ed6b73355bc_terseLabel_en-US" xlink:label="lab_arwr_CertificateOfDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_arwr_CertificateOfDeposits_label_en-US" xlink:label="lab_arwr_CertificateOfDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate Of Deposits</link:label>
    <link:label id="lab_arwr_CertificateOfDeposits_documentation_en-US" xlink:label="lab_arwr_CertificateOfDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDeposits" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CertificateOfDeposits" xlink:to="lab_arwr_CertificateOfDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3c2dbe52-380d-4765-ac30-73c033c04f19_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_076726a4-b8a0-48b2-92ac-51b802fe5295_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_1a843d45-6e77-43c5-8ae5-de7df99438cd_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20220630.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1d6fec1c-6576-499e-a1ed-e4ec9bf066ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_88380dad-0c96-4ed7-8c6d-52b93a1fc8d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b9ae2f6c-f7df-4a6a-8f99-6430387e8bb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Share reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f3a2c51b-1918-4f4d-b5e5-8a9a4bbf2c37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a5f372c7-a434-4ad6-9279-4157c3f7336f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_f03ec30a-7ff0-4c1a-bd09-1018b3f30320_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_eb8d921c-8529-44da-97ff-1606c7394f2f_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20220630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_20d5117c-6eca-4453-932e-9cbba6bb2f73_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0a459396-7c7a-4f7a-9cd2-92d19b8b8221_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_3098c26e-79b1-4d21-ae45-575907c53604_terseLabel_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_label_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_documentation_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of leasehold improvements net of tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:href="arwr-20220630.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_49940b61-d15a-4b04-b585-9d1c5df1a49f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_2851f6e4-80e6-494e-91c5-558ed720fc55_terseLabel_en-US" xlink:label="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of other than options granted</link:label>
    <link:label id="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_label_en-US" xlink:label="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date Fair Value Of Other Than Options Granted During Period</link:label>
    <link:label id="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_documentation_en-US" xlink:label="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of the other than options granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" xlink:href="arwr-20220630.xsd#arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" xlink:to="lab_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_043eec9a-ecdc-4630-bb3c-8cc8be4fd967_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20220630.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_03ff5c1b-f91f-4b39-91be-d4ad227e825a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_2186aba7-05ae-48b1-8c13-0afc2b252c35_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4c82a725-c642-413f-b48c-2a86b65125a9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_92636448-76da-4ba3-9027-23339fcd8d4e_totalLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Cost Basis</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f6d1af87-b726-486d-b05f-c31a3be5a569_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a3e1f3c5-c631-4810-8abb-a9997099659f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1b5eb476-5cbc-42e8-b95f-0944d83df962_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1ff46579-f470-43f3-924a-5fee9df36e70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_71b2f6bb-d71b-49e5-a4cd-9b7bf89fc504_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_e228b351-3e3f-4905-84e4-75616fd47e5e_terseLabel_en-US" xlink:label="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes (due within one through three years)</link:label>
    <link:label id="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_label_en-US" xlink:label="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Note Due Within One Through Three Years [Member]</link:label>
    <link:label id="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_documentation_en-US" xlink:label="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Note Due Within One Through Three Years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" xlink:href="arwr-20220630.xsd#arwr_CommercialNoteDueWithinOneThroughThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" xlink:to="lab_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_536d1bb4-23c3-4d54-a67d-22e934159d38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_e86e9da0-bb55-4933-892c-61d4b45bf8ae_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_58226c15-e183-465a-9cbc-5aa3022f669a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_27102c29-9136-4ba9-9272-47e0c135eb7f_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20220630.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_dde396e9-e5a6-4dc7-8107-6ab78ed1a05a_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda License Agreement</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20220630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f475465-e62f-4049-a659-9aad32dcecbb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d970294c-284b-4250-9922-0669df8b49fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e74d88fe-cfee-4d58-8a2e-9cd14ee52e53_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_171417e2-5d15-431e-8e18-205b6003a472_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c5bcfdef-230f-4cb5-8006-8dce1ac43fae_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL OTHER INCOME</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93f444-61c5-4479-b503-3516a1d1629f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_a7a1a4d1-8bf8-4a9c-ab4c-abea34cbbf47_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1b5587eb-9e5c-431d-b120-4aedc917a0ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb419b7e-d8da-44cc-849b-9aad0f4246b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_e8f77112-8460-4a8f-8b6b-b28a244834a4_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland D A C [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20220630.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8a247cf2-c661-48f4-b997-231cf397dd20_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8c026395-b433-4c6a-9e7b-e39e32da6b63_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3a38bf3a-d250-4da0-ba07-a16fbc17d14a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_29e928ac-f39e-4dbb-a8da-324443c13dd6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_4b48da60-641f-4918-bd84-fb8153ad38fe_terseLabel_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived" xlink:href="arwr-20220630.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontMilestonePaymentReceived" xlink:to="lab_arwr_UpfrontMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_98bf3dc3-cfe2-4d0f-bc3f-6c21beb82195_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePayments_e3bf216a-0370-45f9-9ff5-d69708492c3c_verboseLabel_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_label_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_documentation_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments" xlink:href="arwr-20220630.xsd#arwr_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePayments" xlink:to="lab_arwr_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_215a8659-763e-4b5f-856b-0c5fa31020be_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_229f46a6-d02b-45df-9e7a-11a44dd31a01_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72188ba0-59bf-46b7-8fcd-6f4f519cff98_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_d5909cbb-937e-4b52-86bc-d9b35c4ee079_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f64be8a9-ba74-4962-82c4-ca288598c8a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c78cfb81-baa6-461f-9084-f440912e1409_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73f60d68-380d-418d-b0f9-49ed0b07a4ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_72bf57ec-8902-4f41-a426-116646a498f2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_585a2974-cf09-4fbf-bd05-e282270aa6bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_de7d90dd-d35b-4fa0-a640-ae96984194fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04956679-847b-42d2-9f99-ee01ccbe96e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_50d645f7-d364-42e9-b932-325ed7537cda_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_585780a9-8ff9-4b89-95b1-50c097fd00f2_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_20959203-912d-463d-997d-5312a804ea32_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6dee27b8-0e0b-4775-87b7-b75751e25fc7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05829305-6494-4027-8eee-4697455a861d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a175b063-0c1e-46f6-9126-b1c03723931b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5f18e03f-dbcf-493c-8d56-68c644eb6b35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b68400cd-d923-4e60-88d1-68819caedd11_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_e67283df-df77-4ace-9780-deb1c05097d6_terseLabel_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_label_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers Software Office Equipment And Furniture Gross</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_documentation_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:href="arwr-20220630.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:to="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e2b1d4e1-a87b-47c8-b8b5-98d7eabb76b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_16829138-68e1-407f-85df-42da38e51ec1_totalLabel_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_label_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Held To Maturity And Marketable Securities Fair Value</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_documentation_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents held to maturity and marketable securities fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" xlink:to="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72329374-af3a-43a5-8b4f-ce995ef22dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_ba1630e8-4f31-42b1-8d18-5a6436d3581b_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20220630.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e5ce79a7-9394-4679-8e45-ef0abe53fc86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 145,000 shares authorized; 105,795 and 104,327 shares issued and outstanding as of June&#160;30, 2022 and September&#160;30, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_ff2a4838-f106-4358-8ed3-4aa207c66bf7_terseLabel_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of Equity Compensation Plans</link:label>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_label_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of Equity Compensation Plans [Member]</link:label>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_documentation_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of equity compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember" xlink:href="arwr-20220630.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OutsideOfEquityCompensationPlansMember" xlink:to="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_6e5210a3-b5f1-4e71-a05c-88872f39bea2_negatedLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20220630.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_02962f04-0834-41a6-b8d8-c1c45c6fdf84_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20220630.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b92db1d-6945-4baa-be8f-4ca65338a3ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_818b9949-8a1d-4d2a-ac28-5f68fedc6ddb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_90a245c6-c35e-443e-8e9f-d5422f520ebe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashEquivalentsGrossUnrealizedLosses_7d7325d9-9c91-48f2-9568-e5cde7836c02_negatedLabel_en-US" xlink:label="lab_arwr_CashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_CashEquivalentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_arwr_CashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_CashEquivalentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_arwr_CashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedLosses" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashEquivalentsGrossUnrealizedLosses" xlink:to="lab_arwr_CashEquivalentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9fc267d2-fae5-48db-880d-9066fb60df75_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_b240dbf7-68c4-41b8-b61d-7013021149ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_181050f0-112b-43e7-9b23-d8646340f685_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12e3c869-aa75-420c-95c2-78e3ce1d4db0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_df1a785c-8a02-4d98-90c3-60233af7dda9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_58a98dd9-0da4-477b-b3ed-aa3ab86e2c55_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9c9c3845-1e3f-4888-9090-87e865e3ae66_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20220630.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_4af8e500-2a7b-42cb-8fef-ee377a3c80b0_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20220630.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_61e02e23-cb08-4000-8915-d53f4b51e201_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20220630.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6cf8876e-226d-40d7-b270-e5693eca0632_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_73fc53f5-d501-48ff-bc04-3155ed2d14ad_terseLabel_en-US" xlink:label="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label id="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_label_en-US" xlink:label="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:label id="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_documentation_en-US" xlink:label="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected payments of leasehold improvements, net of tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:href="arwr-20220630.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="lab_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_eb45be0f-e5fb-4b65-a553-07a342b7aa9d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4081079c-172c-4128-8364-07a587722b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f43f6afe-5877-4d9a-a760-ed92ce6bfb32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1b35061a-1cce-4831-becf-6cb0b2aebd15_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4d7d7a39-41f0-4d63-9a6e-53119fa01354_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CertificateOfDepositDueWithinOneYearMember_7b00e410-47cf-4263-abc4-d57ff4b64cdc_terseLabel_en-US" xlink:label="lab_arwr_CertificateOfDepositDueWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit (due within one year)</link:label>
    <link:label id="lab_arwr_CertificateOfDepositDueWithinOneYearMember_label_en-US" xlink:label="lab_arwr_CertificateOfDepositDueWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate Of Deposit Due Within One Year [Member]</link:label>
    <link:label id="lab_arwr_CertificateOfDepositDueWithinOneYearMember_documentation_en-US" xlink:label="lab_arwr_CertificateOfDepositDueWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit due within one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDepositDueWithinOneYearMember" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDepositDueWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CertificateOfDepositDueWithinOneYearMember" xlink:to="lab_arwr_CertificateOfDepositDueWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_bb101bbf-5fc3-4bfb-b9a9-25422817afd2_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAgreementMember_44bdc403-2d3d-4812-bef1-f813e99a6b5c_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CollaborationAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember" xlink:href="arwr-20220630.xsd#arwr_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAgreementMember" xlink:to="lab_arwr_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c363df4d-993f-4d2d-9d63-a11887dc8c6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5efb2013-96ff-4717-8c97-545849c818db_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_eb3b134e-8e37-49c7-9d29-50e000ff4060_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20220630.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b969cae3-bd5b-4301-89cc-8068bef92bda_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ccf7edc-f3ff-4351-b16e-23cff52bdb95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_42c536ce-c172-423c-a810-39653db0e351_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROXDHAgreementMember_a31b9ca6-8765-4d95-abe1-7673513afcdc_terseLabel_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_label_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O X D H Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember" xlink:href="arwr-20220630.xsd#arwr_AROXDHAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROXDHAgreementMember" xlink:to="lab_arwr_AROXDHAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3479590f-c111-4d0d-9402-70fac49ffbdd_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_90110205-df71-43fc-a739-27171eb689bc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa91adc6-4489-4634-a646-8e82ea59492a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4c6cf5eb-9741-4ad1-87cb-761f6af65134_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23d643da-708e-493a-9b25-1488c9c0d6fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ba1719a7-81f6-4d96-8dbd-3021891b486f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_30112330-39da-42bf-a891-b6fd55f20d16_terseLabel_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember" xlink:href="arwr-20220630.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockPurchaseAgreementMember" xlink:to="lab_arwr_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_61bdb077-38aa-4cb3-b32c-37decb3df4c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c328e4c9-7eb1-4aa9-b903-18ea4c6bef7c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52b12e8d-32d7-488e-9e61-01a2d14d486d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_88992e8a-3ff6-4852-976f-0bc29ce837d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d03d6a42-e9c2-4f47-9a66-359850633d22_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_d56f9ed0-71ed-4d34-bb9f-499578a2d800_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_b4be58dd-f355-49b0-8749-4cee66afb74e_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_358b8494-7f48-41a5-bb74-65ea0a6d6c4f_negatedTotalLabel_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_label_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Held To Maturity And Marketable Securities Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents held to maturity and marketable securities gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" xlink:to="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_91933a96-5b24-4897-b29d-0fe014abc2de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_38506146-35bf-46ef-8d15-c631f667c61b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4152c2c-e584-49cf-9171-f7d7d2abfd2b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_89f932be-f440-43f7-a8a7-3366a890525d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f2148ba9-f61c-426a-889f-9d2cb8ff2777_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6cd25516-29d4-4330-a202-ce4eeff8201f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_c43ba239-06c0-4040-a2d5-54bd67118d11_terseLabel_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_label_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park [Member]</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_documentation_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona technology park.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember" xlink:href="arwr-20220630.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VeronaTechnologyParkMember" xlink:to="lab_arwr_VeronaTechnologyParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_80a32a4b-c9a2-4036-8249-efbdad96af1a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cash payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8c0754b3-bc07-4259-9ab9-3b5710d3e0f1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_14a10d34-d7ec-4b4b-8a9e-bd03093940a1_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20220630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_edd0d0f3-0aa0-4725-9606-4485ee15cb24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53617a16-55a3-4008-9b0b-1aa8d912eead_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2df61df6-2a17-477a-a1cf-2b58d8ecdacb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f86519b0-c441-46dd-a1d5-07a769b5a8a4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_30294dbb-b510-439d-bda5-11f482e8b157_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_c787c8e0-2615-4c94-a894-2661334df33f_terseLabel_en-US" xlink:label="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Stock Purchase Agreement</link:label>
    <link:label id="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:href="arwr-20220630.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:to="lab_arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_db96ffb0-f9ca-4c52-b11d-b4d6377d9ff3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_01e0d66f-6f7c-4541-b248-43de581c196a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_64e72efa-bdf3-42ca-b80d-8cbe35e9fd1d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_63b5e3c5-7b69-446c-8f3c-3d953df034ad_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aceca72a-cab2-46cc-b49a-39c88cc24ace_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5d55b2ca-6a9e-4016-b0c8-ebd23d7273f8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_60509806-b15f-4030-9fb2-00211941f2c7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_1944106e-7803-476c-b335-d0672be7b6ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_221e621a-e288-49c6-a7fe-12143b04d96a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bcee7326-1a37-429a-a6b1-6183386c103c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4a92a218-6a2d-401b-834c-7201318fc732_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4ce0d8cc-f850-4533-beae-7c9064106082_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredRevenueMember_722786a9-3a6c-451f-8427-bb407e360814_terseLabel_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_label_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_documentation_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember" xlink:href="arwr-20220630.xsd#arwr_DeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredRevenueMember" xlink:to="lab_arwr_DeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b64b0a9e-ffde-445d-b253-72c8d141c43a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_42305acc-5a38-4bb5-b09a-507a76b0b693_periodStartLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, beginning balance</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_617c4337-43ba-47d2-be2f-84fde337a9bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, ending balance</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b6772d-8241-45cd-94ea-90156ed2e912_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8e1abc03-8cbd-4a1a-b03d-705bf298409f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_50236ec7-d409-4d88-ba1b-273948843487_terseLabel_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due year five and after year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="arwr-20220630.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_85104bc5-2783-40fd-b14d-52fe5c117e3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0538e7ae-6ca3-4f8a-98ca-d823896fe3ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e84687ed-c19b-4ffe-85f2-7ceef0d1c461_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c9e57203-253e-4028-90ee-0358be18b64c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotes_81cb371c-4933-405c-9850-fc277f831b2b_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes</link:label>
    <link:label id="lab_arwr_CommercialNotes_label_en-US" xlink:label="lab_arwr_CommercialNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes</link:label>
    <link:label id="lab_arwr_CommercialNotes_documentation_en-US" xlink:label="lab_arwr_CommercialNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotes" xlink:href="arwr-20220630.xsd#arwr_CommercialNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotes" xlink:to="lab_arwr_CommercialNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_65199b71-0938-4d1f-ae34-bbf3795c96d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_11405d62-aad1-4bdf-8e37-a5737576eb1c_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_00f38210-968a-4123-91c6-eef8a411252c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_efb38ab8-4164-4b36-b2cb-18ac188c983a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities (includes current portion)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_0cb9f7a2-def4-42a9-abc0-96746eb172e8_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceived_8d193779-e26d-419d-92a0-7b5370141125_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceived" xlink:to="lab_arwr_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_abe013d2-9d4a-4690-9a4f-ecd473c6ad04_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands four equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:href="arwr-20220630.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_49ccdee8-c8cb-436f-ae12-d5d75d185109_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_09104cd1-321f-489e-8ba0-d36240c35a41_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of license agreements in 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentGross_825237d1-95bd-44cd-9f12-b8269c1d2d3f_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_label_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment Gross</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross" xlink:href="arwr-20220630.xsd#arwr_ResearchEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentGross" xlink:to="lab_arwr_ResearchEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROXDHSupplyAgreementMember_b48e8341-c140-4b26-9017-2af0e676f097_terseLabel_en-US" xlink:label="lab_arwr_AROXDHSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH Supply Agreement</link:label>
    <link:label id="lab_arwr_AROXDHSupplyAgreementMember_label_en-US" xlink:label="lab_arwr_AROXDHSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O X D H Supply Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROXDHSupplyAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROXDHSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHSupplyAgreementMember" xlink:href="arwr-20220630.xsd#arwr_AROXDHSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROXDHSupplyAgreementMember" xlink:to="lab_arwr_AROXDHSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6931bf77-73cb-4cb8-8b88-2907eee5d36d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b0c5f3c-1075-4b84-b37b-1cf09af778f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_9dabdf75-44a0-49b0-b5a0-1802a8f30d87_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20220630.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b68efced-3515-47a7-9b72-39bd7739f2c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_8582cac5-0aba-4e32-8a88-e10e7546578d_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land purchased, number of acres</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_label_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Acres Of Land Purchased</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_documentation_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acres of land purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased" xlink:href="arwr-20220630.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAcresOfLandPurchased" xlink:to="lab_arwr_NumberOfAcresOfLandPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7c172e10-43be-4d80-aec6-b276a7655cfe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_25d5815b-717b-4cea-b9a5-839e823211f6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_53ed8ad2-f036-42c4-bcdb-01a9e2e1b75a_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Cost Basis</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HalozymeIncMember_a54dc401-3a19-4610-98f8-5cdce545d087_terseLabel_en-US" xlink:label="lab_arwr_HalozymeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Halozyme, Inc.</link:label>
    <link:label id="lab_arwr_HalozymeIncMember_label_en-US" xlink:label="lab_arwr_HalozymeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Halozyme Inc [Member]</link:label>
    <link:label id="lab_arwr_HalozymeIncMember_documentation_en-US" xlink:label="lab_arwr_HalozymeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Halozyme, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HalozymeIncMember" xlink:href="arwr-20220630.xsd#arwr_HalozymeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HalozymeIncMember" xlink:to="lab_arwr_HalozymeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d1b52d00-0bbb-44ac-b117-b6d54baa7298_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_594d5fa8-826a-48aa-acb6-e475837a42d2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_daca7ecf-e0ca-4599-bfc3-0042c20199dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b00f7c17-8de4-43fa-872b-b79ccbdb66a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ee47e2d3-c05e-4f07-967a-c7706a2bdd4c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e3f36441-c955-4c24-a5e9-b27efd183f53_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_aba113d5-8dd2-4df6-9680-111c285cbf69_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a67e59ef-a84a-46b9-8e28-a17c7a3db8b0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_25faffd2-a2e0-4191-ad6d-40a4341616ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_780e825c-6655-4eb7-9805-d4685e02c380_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81aac7d5-d961-4f89-84e8-10414f300749_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c34fc73-1055-42b4-8cb8-eafdfb22e68a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_401f0c04-6d74-46fc-bc10-2054284e8bcc_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20220630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_b4bc83b1-cf0f-4ccf-bec8-c474c95ff0ae_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20220630.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4a61cf3c-8290-40f6-ace0-3b81f780c8e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_6eaad224-a885-4b76-8329-4101c3437eef_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e9f4ab9b-9e51-4632-9477-3cf969972ca5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1891dae9-035d-40c5-8de7-87b59ee16a47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_da5d8cae-0b0c-4110-bc73-7cc5a211eb2a_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20220630.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_fa89d3cc-c507-4254-8017-1de4bedc3275_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_64a74185-690d-4c0e-8af5-dd4af6c8e9e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_92966705-ad20-4e6a-a39a-943f26eb7f71_verboseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to Maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_f031d07f-0415-4f0c-9f0a-b14cbbdfcebb_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_263864d8-5a9a-4a7b-baa0-91792c7c174a_terseLabel_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_label_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:href="arwr-20220630.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:to="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_9340b81f-fb5c-46a8-83b5-1d1bcd08de3b_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_e7c6844c-bacc-4916-b4b5-8535655a938e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrollling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNoteDueWithinOneYearMember_dd316377-388f-41a4-a865-378b8393907c_terseLabel_en-US" xlink:label="lab_arwr_CommercialNoteDueWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes (due within one year)</link:label>
    <link:label id="lab_arwr_CommercialNoteDueWithinOneYearMember_label_en-US" xlink:label="lab_arwr_CommercialNoteDueWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Note Due Within One Year [Member]</link:label>
    <link:label id="lab_arwr_CommercialNoteDueWithinOneYearMember_documentation_en-US" xlink:label="lab_arwr_CommercialNoteDueWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Note Due Within One Year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNoteDueWithinOneYearMember" xlink:href="arwr-20220630.xsd#arwr_CommercialNoteDueWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNoteDueWithinOneYearMember" xlink:to="lab_arwr_CommercialNoteDueWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_415e4b45-7d34-47bd-a479-5fb5eec9cd58_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9fcef3b3-90a3-4877-8037-3998bfd3ef5e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_9178cd4f-3974-4696-810d-be2d2ef1ad64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8672587e-a073-412b-866f-03ee64db558d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_76d7d08b-9d90-46bc-8aa5-1c0ed52037a5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_156544bb-2082-4d0f-8b3a-1938fc297ea9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_f7c23675-701c-4af3-94a7-43f26c38300e_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of the facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Intends To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:href="arwr-20220630.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_70decc59-3e5e-4eaf-a600-338cbd49cb75_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_4c40b3f1-7cf6-4f8d-bf1c-09664e9f73f5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_82ba5b71-5ed6-4037-aab4-271390ed3588_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9093e265-e6cd-4610-b161-eed96ad322e0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS) PER SHARE - DILUTED (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d2ab1b9c-5019-4f62-aee9-0bea503f2ede_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f7486a01-24df-477c-bd94-7ddc63ce98fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1a36c90d-466f-4915-a72e-8be302366781_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_263fc9c4-67f4-4606-a83d-9785d473ba88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a40614a8-e5c4-4d56-a7b9-e7a277ecf081_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b8b1924b-7596-4625-a997-8d822161deb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c5393dd2-310b-450e-bd53-09f0103f3b22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_ef2db462-392e-44c6-a8b7-0469fdcb6830_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License agreements</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:to="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_e6e7eeab-2982-4a0c-b9d0-ac26043558b3_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INCOME</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_f2a4dd94-d6a4-4c3b-8938-d84acfc9b9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_913966ec-07c5-4ccf-8b5f-2521abaf9ee5_totalLabel_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_label_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Held To Maturity And Marketable Securities Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_documentation_en-US" xlink:label="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents held to maturity and marketable securities gross unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" xlink:to="lab_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6728b18-79ed-4ed2-8ab8-e4bef30130b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_165f0a1b-0b78-4164-a0a8-5fed3412d7ef_terseLabel_en-US" xlink:label="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit (due within one through two years)</link:label>
    <link:label id="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_label_en-US" xlink:label="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate Of Deposit Due Within One Through Two Years [Member]</link:label>
    <link:label id="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_documentation_en-US" xlink:label="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit due within one through two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" xlink:to="lab_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1a91a2e6-b2c3-4469-b502-f8249a9541e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7e9d5f3a-7741-4269-bb11-0705f989925d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_37fbc23a-19ac-4b70-af98-d54bdd42a238_terseLabel_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-75220795 (ARO-JNJ1)</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_label_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J75220795 A R O J N J1 [Member]</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_documentation_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ 75220795 ARO JNJ1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member" xlink:href="arwr-20220630.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ75220795AROJNJ1Member" xlink:to="lab_arwr_JNJ75220795AROJNJ1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_16010003-79a2-426a-8dcc-83afda016c9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_de9d67cc-8118-4395-8363-ce48cb1a0170_negatedLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gains) losses on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c4730008-98d4-4eba-af83-71213e6b7fe4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_6302c7ee-5b70-4f15-8530-fac4b9681639_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60697b61-164c-4ec2-b491-35c76ea23a13_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2cc020cd-6421-4fb5-8f56-0c7439d9ff56_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_18c31513-17a7-4013-bba3-78d9050b967a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_342d590a-97f0-4041-9ef7-ebcc032034b3_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9bc18c24-c7a2-4ca5-9f57-340349ba09fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted stock units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_f1017fba-81be-4bc1-9cd6-214147347d1e_terseLabel_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JJDC</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20220630.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_84271373-63ad-4edb-b6b8-2ebf25968abd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of license agreements remainder of fiscal year 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_2bb0d584-a0ed-48f8-b73f-6817d7e1b244_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_604006ee-a1d6-4bff-9de7-30c21becc817_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4dd0ae92-3d43-4ec0-903f-8791a1a1fedb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_6d1c7961-41a4-4e94-81ec-97413a1db585_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held To Maturity Securities Fair Value Non Current</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities fair value non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:href="arwr-20220630.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:to="lab_arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f76e861-ceaa-407d-9935-c2e6fefa5216_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_8ff09c54-369b-4774-a397-b2ef4624f8d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d1517bb7-4715-4d01-a82e-184168c36fcc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_57139847-4a3f-449c-a410-fb238cb1606c_terseLabel_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_label_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Payments For Operating Expenses Year One</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_documentation_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:href="arwr-20220630.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:to="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_cbc16b46-3f20-41b5-a0af-c49c51428acd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a0270fd-b4f9-4ffb-a0be-3dcfa0e58a69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_250b7080-e81f-4467-970e-6369ec9283a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_371a5cbd-8f14-48ee-8ac2-d9b12c4bb0ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b37997f6-2cab-4bc8-a2de-f50f9f75dbba_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MarketableSecuritiesMember_4e890fe4-0143-43a6-8fbc-24db9881f5ea_terseLabel_en-US" xlink:label="lab_arwr_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_arwr_MarketableSecuritiesMember_label_en-US" xlink:label="lab_arwr_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_arwr_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_arwr_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MarketableSecuritiesMember" xlink:href="arwr-20220630.xsd#arwr_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MarketableSecuritiesMember" xlink:to="lab_arwr_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_47e5b83f-9101-40ed-9c3b-4aadc68ece80_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_43e619b8-eadd-4b47-90f7-236d1cd9702d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ccd659d0-7861-4780-b9a8-46541229537c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_22ad6ae7-b721-4b4b-a679-4910488983a7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_819b099f-87eb-494b-b8ec-b2e882633cf5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_be24ac80-caaf-49b6-9f45-b8cbe6ce54ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9f1444df-396b-46f0-8485-d5271f09d531_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_8f18f948-53a0-4350-845f-0909df397cec_terseLabel_en-US" xlink:label="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of the options granted</link:label>
    <link:label id="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_label_en-US" xlink:label="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date Fair Value Of Options Granted During Period</link:label>
    <link:label id="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_documentation_en-US" xlink:label="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of the options granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:href="arwr-20220630.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:to="lab_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_321515de-e721-4abd-86ef-fcf325f8274e_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20220630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8383850b-a7b2-493a-8b31-26df6d801661_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_901ddad7-ca8a-4cc0-8a62-e9b019a300d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e112964-6814-4229-b61a-b2b9aefb156e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_73917ebc-e183-4f66-b1a0-3ffc0ab24690_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3cbc6be3-d10e-40b1-b6e5-2b628b274628_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cffd9e41-8d01-45d4-be86-513407228155_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d87dc0ce-6302-4e51-be51-6a0066808713_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of license agreements in 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>arwr-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:368d367d-beb3-477f-87b6-b6cfd3b1dc77,g:0bc56581-7549-4bc1-a0c5-dd60a0bc219c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c1555d6f-6629-44ab-826a-42e3e8b86289" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_DocumentType_c1555d6f-6629-44ab-826a-42e3e8b86289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ad86f9f4-a05c-4d23-a01a-b9e0f81bd91d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_DocumentQuarterlyReport_ad86f9f4-a05c-4d23-a01a-b9e0f81bd91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cb4b7392-c1df-49ee-8e7f-6a1565e59812" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_DocumentPeriodEndDate_cb4b7392-c1df-49ee-8e7f-6a1565e59812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_94a0fddd-2cf4-4a66-b63d-45b7433743eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_DocumentTransitionReport_94a0fddd-2cf4-4a66-b63d-45b7433743eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_19883ef4-a3cd-4441-8e5a-9456e76e02ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityFileNumber_19883ef4-a3cd-4441-8e5a-9456e76e02ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_046c02e0-0e35-4979-a1c2-dffa0e87232c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityRegistrantName_046c02e0-0e35-4979-a1c2-dffa0e87232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fdd815da-6c68-4874-b107-8dcf71e36d28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fdd815da-6c68-4874-b107-8dcf71e36d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cfea314a-ede4-4025-b343-6fea8604cf65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityTaxIdentificationNumber_cfea314a-ede4-4025-b343-6fea8604cf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_19e93ee7-15a5-4a00-8d94-fd4b6979d5dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityAddressAddressLine1_19e93ee7-15a5-4a00-8d94-fd4b6979d5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a53191e4-9664-4828-b0b2-0324104fdb57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityAddressAddressLine2_a53191e4-9664-4828-b0b2-0324104fdb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ec4d4f9a-95b4-4b7e-913b-dac77a841962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityAddressCityOrTown_ec4d4f9a-95b4-4b7e-913b-dac77a841962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_83aebc7d-2bc9-4d07-ad61-99fa157fb079" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityAddressStateOrProvince_83aebc7d-2bc9-4d07-ad61-99fa157fb079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_69ad045b-cf8f-4e88-99af-6ba431c38428" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityAddressPostalZipCode_69ad045b-cf8f-4e88-99af-6ba431c38428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_212c3988-0711-4c5e-a908-81f101a5c2f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_CityAreaCode_212c3988-0711-4c5e-a908-81f101a5c2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b96fa332-b8dc-416c-8e3b-5d70a9ac433e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_LocalPhoneNumber_b96fa332-b8dc-416c-8e3b-5d70a9ac433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9a35284c-a7fa-40c7-9f8b-521f3c2d04eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_Security12bTitle_9a35284c-a7fa-40c7-9f8b-521f3c2d04eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_84b71d38-7746-4222-b0a3-2492cbc83f47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_TradingSymbol_84b71d38-7746-4222-b0a3-2492cbc83f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_eef94098-0289-474b-a818-c60da0888960" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_SecurityExchangeName_eef94098-0289-474b-a818-c60da0888960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f4e95634-d589-488b-849b-7e950d4146f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityCurrentReportingStatus_f4e95634-d589-488b-849b-7e950d4146f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_843cf347-f183-475e-acd8-9f5bf850ba23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityInteractiveDataCurrent_843cf347-f183-475e-acd8-9f5bf850ba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_14a1dd25-1d7a-4689-8e1b-d6e7491a77db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityFilerCategory_14a1dd25-1d7a-4689-8e1b-d6e7491a77db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cd95ce38-2a3d-48fb-b297-68ce3c4472fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityEmergingGrowthCompany_cd95ce38-2a3d-48fb-b297-68ce3c4472fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c66ad248-0b4f-4bef-b1fa-80cd4bd377e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntitySmallBusiness_c66ad248-0b4f-4bef-b1fa-80cd4bd377e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1353a297-8262-4397-afcb-2ce85bf7e906" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityShellCompany_1353a297-8262-4397-afcb-2ce85bf7e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_600b3a83-df6d-47fc-b12f-aab879d99968" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_600b3a83-df6d-47fc-b12f-aab879d99968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a2019c0f-1064-4685-ac65-ff26e650fc40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_EntityCentralIndexKey_a2019c0f-1064-4685-ac65-ff26e650fc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a10911ad-0d1f-4d08-a97b-76634fd88b32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_CurrentFiscalYearEndDate_a10911ad-0d1f-4d08-a97b-76634fd88b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e0f97048-b6c0-48c3-a498-ff96418643a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_DocumentFiscalYearFocus_e0f97048-b6c0-48c3-a498-ff96418643a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ed466c06-eea4-4cd5-b9d0-f4f6377b4d19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ed466c06-eea4-4cd5-b9d0-f4f6377b4d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6f518d8d-904c-4876-9288-f3144b7a2b4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77fb9204-10e0-4e19-9f21-d1d58f461678" xlink:to="loc_dei_AmendmentFlag_6f518d8d-904c-4876-9288-f3144b7a2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c2c4c289-5f0d-41ad-9e48-b07188fc9b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2c4c289-5f0d-41ad-9e48-b07188fc9b66" xlink:to="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cc2d0944-0d4a-4e44-a094-dc08f08e7a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cc2d0944-0d4a-4e44-a094-dc08f08e7a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2e6bd3c3-85b3-447d-8f4e-100c593fea0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2e6bd3c3-85b3-447d-8f4e-100c593fea0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_9b8809df-3125-453c-bab0-d9347c18ced3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_9b8809df-3125-453c-bab0-d9347c18ced3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cea91448-5355-45d8-b574-773c505a9625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_OtherAssetsCurrent_cea91448-5355-45d8-b574-773c505a9625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_16d88231-1dc2-40b8-81e1-20540bdb68c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_16d88231-1dc2-40b8-81e1-20540bdb68c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_24146010-7b1c-4454-981b-fe289b2fdb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_24146010-7b1c-4454-981b-fe289b2fdb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_363a5e19-2bc2-471e-a063-440dc2ec61ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_368ffa18-0127-4de5-9b19-f2aa8e23a302" xlink:to="loc_us-gaap_AssetsCurrent_363a5e19-2bc2-471e-a063-440dc2ec61ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ac76756-f7f0-42f0-9cc2-26f1d2a6bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7ac76756-f7f0-42f0-9cc2-26f1d2a6bb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3914394-acd2-43d6-b280-6dd393a3937e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3914394-acd2-43d6-b280-6dd393a3937e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7b442cd6-07bf-45cb-9791-9c5c0578ec14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7b442cd6-07bf-45cb-9791-9c5c0578ec14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6792f5d4-442a-4be5-8f41-25c9a1f9b62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6792f5d4-442a-4be5-8f41-25c9a1f9b62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75d6d0da-61ec-4d86-83d9-5e56cb235ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75d6d0da-61ec-4d86-83d9-5e56cb235ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5f6f5ad6-aafc-41b9-8478-e98fa5f145f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f7bc1115-554a-4887-9f98-3cc365569d50" xlink:to="loc_us-gaap_Assets_5f6f5ad6-aafc-41b9-8478-e98fa5f145f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2c4c289-5f0d-41ad-9e48-b07188fc9b66" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2d17bc1b-7637-405c-a379-7aa1d6d9b477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:to="loc_us-gaap_AccountsPayableCurrent_2d17bc1b-7637-405c-a379-7aa1d6d9b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1a85b404-e324-4e9f-9ea6-a2ec409b9779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1a85b404-e324-4e9f-9ea6-a2ec409b9779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7dd96ee0-6805-4db1-a08d-d6e8090c9659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7dd96ee0-6805-4db1-a08d-d6e8090c9659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c90f2e9e-dd60-4947-8c40-666ce61fa734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c90f2e9e-dd60-4947-8c40-666ce61fa734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_466fdf64-b59e-4796-9822-6e580bd87a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_466fdf64-b59e-4796-9822-6e580bd87a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_babacc42-16d1-41e8-82b8-7316140193d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d2c65009-0515-422c-89d1-da920c1092a7" xlink:to="loc_us-gaap_LiabilitiesCurrent_babacc42-16d1-41e8-82b8-7316140193d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_b31e84c1-f24c-4144-b1b7-c9a36ae1dc52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_b31e84c1-f24c-4144-b1b7-c9a36ae1dc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a902f1ba-e234-410d-a0eb-bd11901ae423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b31e84c1-f24c-4144-b1b7-c9a36ae1dc52" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a902f1ba-e234-410d-a0eb-bd11901ae423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a6e056a9-4234-44cc-9deb-157159f19780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b31e84c1-f24c-4144-b1b7-c9a36ae1dc52" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a6e056a9-4234-44cc-9deb-157159f19780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_8ca03694-54db-4c5b-9190-14871771491d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b31e84c1-f24c-4144-b1b7-c9a36ae1dc52" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_8ca03694-54db-4c5b-9190-14871771491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4c630285-200a-439c-8438-a6528d5e062b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4c630285-200a-439c-8438-a6528d5e062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c652081b-4c1a-441d-b061-1b680f9c8cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c652081b-4c1a-441d-b061-1b680f9c8cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c652081b-4c1a-441d-b061-1b680f9c8cd7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8f912b0d-c38f-4254-bbec-33e7319e280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:to="loc_us-gaap_CommonStockValue_8f912b0d-c38f-4254-bbec-33e7319e280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8b946326-873a-472f-9950-14e9d4ccc3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8b946326-873a-472f-9950-14e9d4ccc3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33237cb8-4eff-4ee5-a8f0-ebd12ed333cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33237cb8-4eff-4ee5-a8f0-ebd12ed333cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a91fa5db-9bbd-438a-b495-8abc62859be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a91fa5db-9bbd-438a-b495-8abc62859be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_993a1614-e1d4-4b54-85a9-14abc55955b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaf397fb-6757-4fa5-8c4f-55d65c9b2435" xlink:to="loc_us-gaap_StockholdersEquity_993a1614-e1d4-4b54-85a9-14abc55955b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1f6e0a38-eb51-4c27-a480-58d7dc8c86bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c652081b-4c1a-441d-b061-1b680f9c8cd7" xlink:to="loc_us-gaap_MinorityInterest_1f6e0a38-eb51-4c27-a480-58d7dc8c86bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b3796973-6852-40a3-9869-afff430d79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c652081b-4c1a-441d-b061-1b680f9c8cd7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b3796973-6852-40a3-9869-afff430d79c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c4e28cb5-98dd-4beb-831d-b275e140d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b77240e6-b2cb-4cc7-b766-291f5fd91b9d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c4e28cb5-98dd-4beb-831d-b275e140d5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4407c99a-7a23-49a0-a313-b17a77d9b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_abe54d5a-8761-42f0-bfe7-9b6f8acc05e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4407c99a-7a23-49a0-a313-b17a77d9b6d2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_abe54d5a-8761-42f0-bfe7-9b6f8acc05e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0d1a3d6a-206b-4509-a243-78656e0ff579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4407c99a-7a23-49a0-a313-b17a77d9b6d2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0d1a3d6a-206b-4509-a243-78656e0ff579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8e2bbe89-4e6a-4a61-856e-733d9a22f601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4407c99a-7a23-49a0-a313-b17a77d9b6d2" xlink:to="loc_us-gaap_CommonStockSharesIssued_8e2bbe89-4e6a-4a61-856e-733d9a22f601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43836af6-0ef8-4e24-b309-3dd9d3ace9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4407c99a-7a23-49a0-a313-b17a77d9b6d2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43836af6-0ef8-4e24-b309-3dd9d3ace9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f55cc200-3c95-4d17-b4aa-9240b09947c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f55cc200-3c95-4d17-b4aa-9240b09947c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6dd42cd4-f6ef-45d6-82a5-4a956697f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6dd42cd4-f6ef-45d6-82a5-4a956697f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_034d2e86-30b3-418c-94eb-18d7a4cfb04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6dd42cd4-f6ef-45d6-82a5-4a956697f1eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_034d2e86-30b3-418c-94eb-18d7a4cfb04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_600af6c3-c980-4c34-a379-11fa502fe2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6dd42cd4-f6ef-45d6-82a5-4a956697f1eb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_600af6c3-c980-4c34-a379-11fa502fe2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_383da517-49cf-47a6-93c2-d6945e61e553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6dd42cd4-f6ef-45d6-82a5-4a956697f1eb" xlink:to="loc_us-gaap_OperatingExpenses_383da517-49cf-47a6-93c2-d6945e61e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_810863bf-ddd9-4798-af95-0349620bf216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_OperatingIncomeLoss_810863bf-ddd9-4798-af95-0349620bf216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_faefc708-4c81-4938-b2a4-e0327e21d219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_faefc708-4c81-4938-b2a4-e0327e21d219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_60fde32e-9876-4b53-8318-82b1c6f4f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_faefc708-4c81-4938-b2a4-e0327e21d219" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_60fde32e-9876-4b53-8318-82b1c6f4f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0d2dc587-47ab-480f-9225-2aeef5fca572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_faefc708-4c81-4938-b2a4-e0327e21d219" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0d2dc587-47ab-480f-9225-2aeef5fca572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_179b36a3-54ae-4f97-b895-930471bfd923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_faefc708-4c81-4938-b2a4-e0327e21d219" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_179b36a3-54ae-4f97-b895-930471bfd923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54b098b0-53eb-4770-bffe-9023189f17b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54b098b0-53eb-4770-bffe-9023189f17b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16693bf1-4587-4250-9e5c-28e37caa16f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16693bf1-4587-4250-9e5c-28e37caa16f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cafc6990-9934-4726-b82d-6bdda56c8b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_NetIncomeLoss_cafc6990-9934-4726-b82d-6bdda56c8b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_22301251-e4fa-4477-8af8-9424ded8d4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_EarningsPerShareBasic_22301251-e4fa-4477-8af8-9424ded8d4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f2fb2c04-d6a8-41e4-a0b4-4f7c47c63860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f2fb2c04-d6a8-41e4-a0b4-4f7c47c63860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ef3796b-e727-4093-aa25-ed4e45375705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ef3796b-e727-4093-aa25-ed4e45375705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4c33d01-5098-4d79-bca4-8d055f22ca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4c33d01-5098-4d79-bca4-8d055f22ca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_369226d8-3db7-4204-aa62-9323ba264edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_369226d8-3db7-4204-aa62-9323ba264edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6db42c91-ce59-4833-9e2d-1edd8f6f7498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_369226d8-3db7-4204-aa62-9323ba264edd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6db42c91-ce59-4833-9e2d-1edd8f6f7498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_06815860-0586-47f4-be3c-aef6ce3dde64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa355803-39a7-40df-92de-07f665f15e0e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_06815860-0586-47f4-be3c-aef6ce3dde64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cb183a34-5e85-4176-abbc-7e224a70d1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cb183a34-5e85-4176-abbc-7e224a70d1c8" xlink:to="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0973a06d-f49b-4d23-b700-741d78e5913a" xlink:to="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_001f8de1-204c-418f-a597-76ab5d371371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_CommonStockMember_001f8de1-204c-418f-a597-76ab5d371371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cf17cc9e-b050-497b-91c8-1ed5cf6cc341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cf17cc9e-b050-497b-91c8-1ed5cf6cc341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_537a8e56-9c18-44cb-b462-78c044244c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_537a8e56-9c18-44cb-b462-78c044244c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac09d773-8bda-45ae-8a11-0e1754830130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_RetainedEarningsMember_ac09d773-8bda-45ae-8a11-0e1754830130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_38b224ee-7956-4af3-8f73-38664a25a6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b688bcf-234d-47ca-b9ee-e7b1e9d22adc" xlink:to="loc_us-gaap_NoncontrollingInterestMember_38b224ee-7956-4af3-8f73-38664a25a6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d87046b-4cfd-4aec-b1bf-4a33e016e766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504b78bf-7b6f-4fb6-ba6c-980038056859" xlink:to="loc_us-gaap_StatementLineItems_7d87046b-4cfd-4aec-b1bf-4a33e016e766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d87046b-4cfd-4aec-b1bf-4a33e016e766" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49852c58-c53c-463f-8464-2a0268660568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49852c58-c53c-463f-8464-2a0268660568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_688a86fd-2dff-4c57-8283-e989d7528bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_SharesOutstanding_688a86fd-2dff-4c57-8283-e989d7528bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a22e9ac-bd5c-41ed-8912-04896b6385ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a22e9ac-bd5c-41ed-8912-04896b6385ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0bc3421e-a2bf-4832-89fb-4bd9013de783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0bc3421e-a2bf-4832-89fb-4bd9013de783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2d84c45-1030-4f3b-a181-c6d5bf846252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2d84c45-1030-4f3b-a181-c6d5bf846252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9d8a7b7c-e23b-401e-94d3-19e5d5d5107b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9d8a7b7c-e23b-401e-94d3-19e5d5d5107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e2d292c9-88ed-47f4-b959-ea5d20e5fb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e2d292c9-88ed-47f4-b959-ea5d20e5fb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e8f8350-69cb-4f19-8b68-29cddeaca8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e8f8350-69cb-4f19-8b68-29cddeaca8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2b433364-aca2-41ee-a093-fadb25097616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2b433364-aca2-41ee-a093-fadb25097616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2af58dc-92cd-4b5c-8f7f-5ab756e0a02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_NetIncomeLoss_a2af58dc-92cd-4b5c-8f7f-5ab756e0a02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e04d6e0-4a1c-4522-8ad4-336638e36e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e04d6e0-4a1c-4522-8ad4-336638e36e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_65a11dd2-d0ef-4995-8391-661aa844b895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b2239c-c770-4825-a1b9-6327df89bfc9" xlink:to="loc_us-gaap_SharesOutstanding_65a11dd2-d0ef-4995-8391-661aa844b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20220630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2ac7a6f9-7b80-4ace-9a81-a76bbcd1dc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_NetIncomeLoss_2ac7a6f9-7b80-4ace-9a81-a76bbcd1dc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d5586df-ba40-44ec-b458-f530fbe1c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_ShareBasedCompensation_0d5586df-ba40-44ec-b458-f530fbe1c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cfb9038b-d845-41dc-820d-733c01d8e77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_DepreciationAndAmortization_cfb9038b-d845-41dc-820d-733c01d8e77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_deb218a5-7e7f-42d6-b8e3-4d01d8ec8342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_deb218a5-7e7f-42d6-b8e3-4d01d8ec8342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a97805ad-c508-4fb0-a56c-55ff1ef147be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a97805ad-c508-4fb0-a56c-55ff1ef147be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8c73346b-7e3d-4546-a7a2-ed8a5e1b8c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8c73346b-7e3d-4546-a7a2-ed8a5e1b8c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f7bc31f-4d3a-4c5c-8efa-a248997e0ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f7bc31f-4d3a-4c5c-8efa-a248997e0ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ea21d743-f13a-4c56-a2f3-c62ec2d27734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ea21d743-f13a-4c56-a2f3-c62ec2d27734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2a90bf06-8eee-4c39-a03e-ffa7ae3641e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2a90bf06-8eee-4c39-a03e-ffa7ae3641e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bed82be6-4894-4788-800d-86bba816713f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bed82be6-4894-4788-800d-86bba816713f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bdacfc16-6fa6-4db5-9a87-76079fd43b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eaf2e05-f5df-4bac-ab58-06c7b7f852ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bdacfc16-6fa6-4db5-9a87-76079fd43b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_847aed3a-b784-4154-9b8c-47c2ea2221fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c7865cb-c1f3-48a8-981f-5eb6ee60c439" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_847aed3a-b784-4154-9b8c-47c2ea2221fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2d0adabb-420d-428c-8690-92e3bdb1df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2d0adabb-420d-428c-8690-92e3bdb1df0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_975a20f5-f4ff-4eb0-990a-aad109e64f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2d0adabb-420d-428c-8690-92e3bdb1df0f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_975a20f5-f4ff-4eb0-990a-aad109e64f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_eb6ec384-182b-4212-82e3-9a730b4e92d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2d0adabb-420d-428c-8690-92e3bdb1df0f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_eb6ec384-182b-4212-82e3-9a730b4e92d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3935f259-6322-41f7-9da1-9a5d7e4d7da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2d0adabb-420d-428c-8690-92e3bdb1df0f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3935f259-6322-41f7-9da1-9a5d7e4d7da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d88d0827-f2ba-4130-a1a4-c6b0ccfc2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2d0adabb-420d-428c-8690-92e3bdb1df0f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d88d0827-f2ba-4130-a1a4-c6b0ccfc2ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bb606c0a-5594-4d72-826e-57be62a8b8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bb606c0a-5594-4d72-826e-57be62a8b8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_15be1284-30a3-43e6-a714-eaa3af5cf6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bb606c0a-5594-4d72-826e-57be62a8b8d6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_15be1284-30a3-43e6-a714-eaa3af5cf6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_d07bf8b6-0868-4569-9dde-f2c5460bcb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bb606c0a-5594-4d72-826e-57be62a8b8d6" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_d07bf8b6-0868-4569-9dde-f2c5460bcb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc053a16-335f-48ba-9ed8-eb687bae11b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bb606c0a-5594-4d72-826e-57be62a8b8d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc053a16-335f-48ba-9ed8-eb687bae11b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_11efc74b-9fbf-4b10-887e-436f4494cd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_11efc74b-9fbf-4b10-887e-436f4494cd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7eb1548f-dc9d-4d5b-b9e4-44bb4d12adbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7eb1548f-dc9d-4d5b-b9e4-44bb4d12adbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_83ce2387-b3e9-4909-99fe-10414597db75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_49c2aa24-6188-4f12-85f6-fac85705a16e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_83ce2387-b3e9-4909-99fe-10414597db75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20220630.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_473cbff4-7dbf-4cc0-9d68-37ff68fa131f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86c290cf-813c-44fb-8d55-3158615048cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_473cbff4-7dbf-4cc0-9d68-37ff68fa131f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86c290cf-813c-44fb-8d55-3158615048cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20220630.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6261399-1fb6-46bf-a59d-89f7391133a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_942b4ea5-a547-48d1-b197-3d7368cde250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6261399-1fb6-46bf-a59d-89f7391133a5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_942b4ea5-a547-48d1-b197-3d7368cde250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d3c00ca2-a207-482d-9a9c-631d83743470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6261399-1fb6-46bf-a59d-89f7391133a5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d3c00ca2-a207-482d-9a9c-631d83743470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e1e38df-c21b-48ea-99ed-5dea9ab2e968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:href="arwr-20220630.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e1e38df-c21b-48ea-99ed-5dea9ab2e968" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_30a7a1cd-3125-4ba2-b945-314283c25e57" xlink:to="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_6d999041-4bc6-40fd-aa3c-b20bdf7a5869" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:to="loc_stpr_WI_6d999041-4bc6-40fd-aa3c-b20bdf7a5869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_85846856-4b32-43cb-a4e2-61523ca8cb81" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_76137cb2-f1e5-41e0-96fb-708369cf19ee" xlink:to="loc_stpr_CA_85846856-4b32-43cb-a4e2-61523ca8cb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61b4fbba-3e94-45f8-8359-8a6a6039adfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_2d220798-5e25-4232-8170-273acc0c180c" xlink:href="arwr-20220630.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_VeronaTechnologyParkMember_2d220798-5e25-4232-8170-273acc0c180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_1a6fb2c7-96a7-479b-b8e2-f5f8d065f2b9" xlink:href="arwr-20220630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_DrugManufacturingFacilityMember_1a6fb2c7-96a7-479b-b8e2-f5f8d065f2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_46f7a508-4f72-4070-9fef-864844b4b589" xlink:href="arwr-20220630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_46f7a508-4f72-4070-9fef-864844b4b589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_57db959d-dbaa-4bc7-88a5-50990692e40c" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ea8bfea-83ad-42d4-8468-a4e03ed6e998" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_57db959d-dbaa-4bc7-88a5-50990692e40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_07697952-1dbc-417a-aacc-c341a255a3be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f7679bf0-bd59-4b6d-b4fc-f2207b54e84c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_07697952-1dbc-417a-aacc-c341a255a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_22c29f26-a545-4acd-b17e-11e51ee9725e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_07697952-1dbc-417a-aacc-c341a255a3be" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_22c29f26-a545-4acd-b17e-11e51ee9725e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0906a952-ece3-48d1-aff7-ff8c3fa0dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e759d66-7a19-4849-97ef-53488aea7ff3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0906a952-ece3-48d1-aff7-ff8c3fa0dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_8244a88e-0a04-42d4-8089-c3b024e5789a" xlink:href="arwr-20220630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0906a952-ece3-48d1-aff7-ff8c3fa0dd7d" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_8244a88e-0a04-42d4-8089-c3b024e5789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_86210364-aa9c-4223-b2f4-6acda6c97c8a" xlink:to="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_4cd70a6c-d961-4e02-97b7-6210d0b684db" xlink:href="arwr-20220630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_4cd70a6c-d961-4e02-97b7-6210d0b684db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_fefb506b-6f6d-4cb9-9524-5b169267eb44" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4b9fdb9-dc2f-4e00-92ea-ec5dddaa3464" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_fefb506b-6f6d-4cb9-9524-5b169267eb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:href="arwr-20220630.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_3999c6d1-3ce5-4903-8308-c57866f4e57b" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_ffcd6087-c28e-4d22-a8fe-7f5b0fa290df" xlink:href="arwr-20220630.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_ffcd6087-c28e-4d22-a8fe-7f5b0fa290df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_050f3c9d-dc23-4f20-90b7-bd57cee64647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_AreaOfLand_050f3c9d-dc23-4f20-90b7-bd57cee64647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_06e4190d-0bee-45ff-ab2f-751c7dad5d65" xlink:href="arwr-20220630.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_TaxIncrementFinancingAward_06e4190d-0bee-45ff-ab2f-751c7dad5d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7edd9d19-9045-4137-a932-68da0f04c2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7edd9d19-9045-4137-a932-68da0f04c2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_ec9eff69-43e9-452a-a961-a2b539c69734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_ec9eff69-43e9-452a-a961-a2b539c69734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61e8b8fc-8ada-4ed3-a36b-085d35b8a179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61e8b8fc-8ada-4ed3-a36b-085d35b8a179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_48d44b9f-3731-4dca-89eb-7a21ea9a95a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_48d44b9f-3731-4dca-89eb-7a21ea9a95a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ec1f78e-6b08-4326-a056-7d1f220439ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ec1f78e-6b08-4326-a056-7d1f220439ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_893bb336-18f2-477c-9029-fc4c35628e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_893bb336-18f2-477c-9029-fc4c35628e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_d25e5689-c5df-4b84-be74-d6b429e65b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_d25e5689-c5df-4b84-be74-d6b429e65b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_0256a3b2-4e18-4fa1-8643-5a85682dea02" xlink:href="arwr-20220630.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_0256a3b2-4e18-4fa1-8643-5a85682dea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_77f28f08-e096-43d4-9872-ce00a1b75d62" xlink:href="arwr-20220630.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_77f28f08-e096-43d4-9872-ce00a1b75d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_04c22525-a2f2-4971-beba-a9a085e8010a" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_105e64c0-2f52-4b0b-b9d3-766c1968b9d3" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_04c22525-a2f2-4971-beba-a9a085e8010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba6ccd4-dc80-40c9-b6b5-8b000e105be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c58d47a6-8f25-41b7-ba19-397cb1f0f53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba6ccd4-dc80-40c9-b6b5-8b000e105be5" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c58d47a6-8f25-41b7-ba19-397cb1f0f53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f5138f6-95c9-4eba-a54c-08d5b56fc426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f5138f6-95c9-4eba-a54c-08d5b56fc426" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2e5a4d2f-561d-42c0-bb77-38960d1f139f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_60f703f6-b4a7-446d-8b6f-120cef0218a5" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_60f703f6-b4a7-446d-8b6f-120cef0218a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_a613dc50-145b-41aa-9535-c96ccc06511c" xlink:href="arwr-20220630.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_LicenseCollaborationAndStockPurchaseAgreementMember_a613dc50-145b-41aa-9535-c96ccc06511c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_dac6034e-df01-4e5b-8e13-58c246f05488" xlink:href="arwr-20220630.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_dac6034e-df01-4e5b-8e13-58c246f05488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_86daf284-45eb-445e-9cdb-ec9bb4c1b640" xlink:href="arwr-20220630.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fffe3edf-a3e0-4bcd-9f76-fd0cdeebce01" xlink:to="loc_arwr_OlpasiranAgreementMember_86daf284-45eb-445e-9cdb-ec9bb4c1b640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_063910cb-9ac5-4f24-8a3c-5df163d3df2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2ff8039c-fe64-411d-93aa-adac8741b87e" xlink:to="loc_dei_EntityDomain_063910cb-9ac5-4f24-8a3c-5df163d3df2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_ce2372dc-fc55-498c-9c1f-0e43b872ab23" xlink:href="arwr-20220630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_063910cb-9ac5-4f24-8a3c-5df163d3df2e" xlink:to="loc_arwr_AmgenIncorporatedMember_ce2372dc-fc55-498c-9c1f-0e43b872ab23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1caa31b8-9012-4ecb-b2bb-30d5e2030f47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1e953841-2bcd-4861-8810-478d8ba6158c" xlink:to="loc_srt_RangeMember_1caa31b8-9012-4ecb-b2bb-30d5e2030f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae7b3e91-cb3d-44f2-8c00-d027dce6a21d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1caa31b8-9012-4ecb-b2bb-30d5e2030f47" xlink:to="loc_srt_MaximumMember_ae7b3e91-cb3d-44f2-8c00-d027dce6a21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c82edc4-6a5a-40f6-9aef-455fa2dd3ca9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_23e0b417-bf64-4e9e-8f01-d933b65b5b59" xlink:href="arwr-20220630.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_NumberOfAgreements_23e0b417-bf64-4e9e-8f01-d933b65b5b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0f1c5ed5-de7d-4e0b-8d99-80df9b6e41ad" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0f1c5ed5-de7d-4e0b-8d99-80df9b6e41ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30809b22-4348-455f-8140-1e74169d7bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30809b22-4348-455f-8140-1e74169d7bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_10377ebf-40cb-4452-9788-5f040d7bdf0c" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_MilestonePaymentReceived_10377ebf-40cb-4452-9788-5f040d7bdf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_319e939c-57c7-4d18-90d5-adff493547ad" xlink:href="arwr-20220630.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_319e939c-57c7-4d18-90d5-adff493547ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5ad92ba-9d78-47e3-9f38-afeaab2d7342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5ad92ba-9d78-47e3-9f38-afeaab2d7342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e04414c-4729-4145-bcdb-a877e9fb3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e04414c-4729-4145-bcdb-a877e9fb3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1b5ed001-686f-44f7-baa9-f0844e301101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07617cc5-009b-463c-9815-600e13ece9e3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1b5ed001-686f-44f7-baa9-f0844e301101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dd44f48e-df25-4109-9f89-3c7844e2b040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dd44f48e-df25-4109-9f89-3c7844e2b040" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_16545aaf-a4e1-44a5-ba17-d47512b31e9c" xlink:to="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_78b2e6d1-40d5-4de6-a4c9-5b4c19fdf7a6" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_78b2e6d1-40d5-4de6-a4c9-5b4c19fdf7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_824c3dd9-ff47-443e-8bf4-eae5d59ae708" xlink:href="arwr-20220630.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_824c3dd9-ff47-443e-8bf4-eae5d59ae708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_ad200eca-f40c-4582-b432-d5ea778be9fa" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_ad200eca-f40c-4582-b432-d5ea778be9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_5185df26-b7ae-4fca-acb7-acb232aa5432" xlink:href="arwr-20220630.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b9f31d6d-2b4f-45a3-84fb-7c777ac2b156" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_5185df26-b7ae-4fca-acb7-acb232aa5432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d76defdf-877e-472c-a0bf-3dd50943820b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_c40e0e67-6679-4cd5-afaa-a71f5bc7a3b1" xlink:href="arwr-20220630.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_LicenseAgreementMember_c40e0e67-6679-4cd5-afaa-a71f5bc7a3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_cdd103cb-553d-429a-aef0-abb4e1379cf6" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_cdd103cb-553d-429a-aef0-abb4e1379cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember_bd18ddc9-ad20-49ba-bc24-456a9dafa2d5" xlink:href="arwr-20220630.xsd#arwr_CollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_CollaborationAgreementMember_bd18ddc9-ad20-49ba-bc24-456a9dafa2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_8f019598-5469-4388-af72-4605f72464a1" xlink:href="arwr-20220630.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_8f019598-5469-4388-af72-4605f72464a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_d78b1e18-21f0-4065-9881-08a69ec8cafa" xlink:href="arwr-20220630.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cff2ee6-b92f-41bc-88ac-15bc5042020c" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_d78b1e18-21f0-4065-9881-08a69ec8cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a025ef6e-17dd-4f78-845b-c6d0672e2f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e8e75c4-6b2f-4b42-a28b-f60ff94ddb06" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a025ef6e-17dd-4f78-845b-c6d0672e2f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_07a44608-d75b-4b4a-9950-68a09e69e315" xlink:href="arwr-20220630.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a025ef6e-17dd-4f78-845b-c6d0672e2f5f" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_07a44608-d75b-4b4a-9950-68a09e69e315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d957c2e4-6afd-450b-85a5-60df24f84435" xlink:to="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_007082bd-8bde-4f8d-84e4-3a1381af80e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:to="loc_srt_MaximumMember_007082bd-8bde-4f8d-84e4-3a1381af80e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b8873b9-7003-4425-88b8-392ff8b721c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_172398b8-299c-417a-bd05-dab9df9784f4" xlink:to="loc_srt_MinimumMember_3b8873b9-7003-4425-88b8-392ff8b721c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f414f61-88aa-4eed-aec7-d95c1d27cecb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_9dfe72f3-8aad-4ff3-ad66-2ea3740ca113" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_9dfe72f3-8aad-4ff3-ad66-2ea3740ca113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_035b8d8f-d7f7-43f3-adc5-65eb92d006f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_035b8d8f-d7f7-43f3-adc5-65eb92d006f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_1e48dd5e-cecf-4263-b539-21a268da396d" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_MilestonePaymentEarned_1e48dd5e-cecf-4263-b539-21a268da396d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_6061b7cc-f784-4ff4-8cca-29c30cab15b3" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_6061b7cc-f784-4ff4-8cca-29c30cab15b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_45810978-d348-4ad2-a9d9-019510f8a4fd" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_45810978-d348-4ad2-a9d9-019510f8a4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_614b5a68-33f2-4186-a489-42486172e23d" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_arwr_InitialTransactionPrice_614b5a68-33f2-4186-a489-42486172e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fbfda6f-d4cb-4e8f-ac42-c01575a5fcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fbfda6f-d4cb-4e8f-ac42-c01575a5fcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9f29d84c-15fc-4b73-b398-5e7172d846eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9f29d84c-15fc-4b73-b398-5e7172d846eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11e05f00-7f51-4ba7-9389-0b90f6bf33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66b8f5e0-d34c-4b67-9371-c08a33fcb180" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11e05f00-7f51-4ba7-9389-0b90f6bf33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1db1efad-375a-4da0-b2f5-70aaa9192fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1db1efad-375a-4da0-b2f5-70aaa9192fc5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c199179-47e4-491d-989a-4800e332377d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c5c3926d-a118-45a5-b187-162801a598dc" xlink:to="loc_dei_EntityDomain_7c199179-47e4-491d-989a-4800e332377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ec199726-1c45-4e51-ab3f-636e8074a630" xlink:href="arwr-20220630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7c199179-47e4-491d-989a-4800e332377d" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ec199726-1c45-4e51-ab3f-636e8074a630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e31de04-0fe2-426e-a49a-611dcf653543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30278a8b-1b62-4bf8-85dc-4e6b4524ba4c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e31de04-0fe2-426e-a49a-611dcf653543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_43f2003b-8d56-4bd6-8fae-da88e9d2b34c" xlink:href="arwr-20220630.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e31de04-0fe2-426e-a49a-611dcf653543" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_43f2003b-8d56-4bd6-8fae-da88e9d2b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8f46596c-5ddc-438c-aeff-e2d2882b4dde" xlink:to="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04a3a9be-6155-46e0-b87c-cb6c82436a34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:to="loc_srt_MinimumMember_04a3a9be-6155-46e0-b87c-cb6c82436a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_791f7652-014a-40bb-8930-9ac5ed1c61a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8fb045bb-daf6-4484-9878-5ceb0922d40d" xlink:to="loc_srt_MaximumMember_791f7652-014a-40bb-8930-9ac5ed1c61a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9c72133-f7e1-4714-ab85-5e180b31b49b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_de12a286-eb9b-45b4-9cbd-3451d87b9afa" xlink:href="arwr-20220630.xsd#arwr_DeferredRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:to="loc_arwr_DeferredRevenueMember_de12a286-eb9b-45b4-9cbd-3451d87b9afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2ecf3d9b-11f6-4e24-adb9-ad656ce11611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9e42277-c8de-461f-85cb-e241085edf51" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2ecf3d9b-11f6-4e24-adb9-ad656ce11611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce135acc-6f67-4e49-82e0-2d6e61428797" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_e0e7f316-285d-4f91-9456-10fd5b32dd5b" xlink:href="arwr-20220630.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_e0e7f316-285d-4f91-9456-10fd5b32dd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_06f56824-a2b1-444a-80d1-c6da712d0152" xlink:href="arwr-20220630.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_06f56824-a2b1-444a-80d1-c6da712d0152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_7cbee8db-876c-4e61-8ba2-e0fb36af5a66" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_7cbee8db-876c-4e61-8ba2-e0fb36af5a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_b7245ec2-f65d-47ec-9609-d3f4ac8aa934" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_b7245ec2-f65d-47ec-9609-d3f4ac8aa934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_8e220364-a246-4b6a-8202-23581fcf27e1" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_NumberOfDistinctBundle_8e220364-a246-4b6a-8202-23581fcf27e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_cbf53270-a23f-4b6b-9980-a995892104fc" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_arwr_InitialTransactionPrice_cbf53270-a23f-4b6b-9980-a995892104fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acd1e026-3b03-403e-a547-9b2de94eb091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acd1e026-3b03-403e-a547-9b2de94eb091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c4638865-b40f-4117-a1eb-1417c569a33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c4638865-b40f-4117-a1eb-1417c569a33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb0cdd5c-630c-4b34-b9c3-14c03ebcb7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cb0cdd5c-630c-4b34-b9c3-14c03ebcb7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d9035381-7a2b-41a4-a632-37bac11337dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb319588-125f-46d2-a7d0-5583d111c532" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d9035381-7a2b-41a4-a632-37bac11337dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_949b941a-5059-4be0-956b-5a89dcbe50ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_949b941a-5059-4be0-956b-5a89dcbe50ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e7c3fb24-c3b5-44bb-9d4a-0d958e54f6cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ff72ede7-df51-4708-bc20-2a29f6afc937" xlink:to="loc_dei_EntityDomain_e7c3fb24-c3b5-44bb-9d4a-0d958e54f6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_d2c27a6f-032a-4fb4-a4a3-ae995427f989" xlink:href="arwr-20220630.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e7c3fb24-c3b5-44bb-9d4a-0d958e54f6cc" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_d2c27a6f-032a-4fb4-a4a3-ae995427f989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9030304-9605-4844-8737-042e4ef49524" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f324927-352b-4be0-b977-1a4e33f6fb43" xlink:to="loc_srt_RangeMember_c9030304-9605-4844-8737-042e4ef49524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_77f97aaf-a58b-4516-91a6-db750e170744" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c9030304-9605-4844-8737-042e4ef49524" xlink:to="loc_srt_MaximumMember_77f97aaf-a58b-4516-91a6-db750e170744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a324c6f5-ef3b-4f37-97ab-ed73f7a5de46" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_0112135d-786d-41ff-b093-5c0b58f44a53" xlink:href="arwr-20220630.xsd#arwr_AROXDHAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:to="loc_arwr_AROXDHAgreementMember_0112135d-786d-41ff-b093-5c0b58f44a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_e32dd1fb-7d4c-437f-ac15-a2cf0293d158" xlink:href="arwr-20220630.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:to="loc_arwr_LicenseAgreementMember_e32dd1fb-7d4c-437f-ac15-a2cf0293d158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHSupplyAgreementMember_fe4efc26-858f-41cc-9a48-7bbd7f6cf211" xlink:href="arwr-20220630.xsd#arwr_AROXDHSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54b0ae4b-c3d5-4274-9369-a47fa0c291b3" xlink:to="loc_arwr_AROXDHSupplyAgreementMember_fe4efc26-858f-41cc-9a48-7bbd7f6cf211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00a96a8e-0118-4977-9d2a-bbb0b9f2458e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e594ade8-df86-442e-b97f-c02d7b97f077" xlink:href="arwr-20220630.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e594ade8-df86-442e-b97f-c02d7b97f077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_e31b1e22-6d2b-465e-ac66-772708c6d58a" xlink:href="arwr-20220630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_e31b1e22-6d2b-465e-ac66-772708c6d58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_e7b907d8-2cf2-4734-943e-2225622793cb" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_NumberOfDistinctBundle_e7b907d8-2cf2-4734-943e-2225622793cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_689a2603-5480-4353-9875-cdc2388c976f" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_689a2603-5480-4353-9875-cdc2388c976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_1015653f-e695-444f-bb65-2e001909bec1" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_arwr_InitialTransactionPrice_1015653f-e695-444f-bb65-2e001909bec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_181a9590-5acc-492b-8ddd-c125e1c17cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_181a9590-5acc-492b-8ddd-c125e1c17cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_31ceab32-e331-40f7-8bff-b2b51be8d2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_31ceab32-e331-40f7-8bff-b2b51be8d2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4caed521-d220-4ef8-8a0e-e0f05be51dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63e3bd6f-ef51-4ab5-b793-f397c6b93524" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4caed521-d220-4ef8-8a0e-e0f05be51dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efc968b2-52fa-45ee-80bf-eb292a294e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efc968b2-52fa-45ee-80bf-eb292a294e4f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a5194e4b-fa97-4192-8d7b-7e8940e24d3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_52c2f6cf-e788-4152-aab1-1b4f1f1ece1c" xlink:to="loc_dei_EntityDomain_a5194e4b-fa97-4192-8d7b-7e8940e24d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_582f138e-9f72-4f2c-bc01-a27c370f7562" xlink:href="arwr-20220630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a5194e4b-fa97-4192-8d7b-7e8940e24d3b" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_582f138e-9f72-4f2c-bc01-a27c370f7562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_146ebd7e-dba6-4427-b4b8-157f29a1785f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_91859e32-b0dd-4abf-a970-7334bf89d6a2" xlink:href="arwr-20220630.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_91859e32-b0dd-4abf-a970-7334bf89d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember_4c0335d3-b3c0-428d-a251-8910437ff379" xlink:href="arwr-20220630.xsd#arwr_AROHSDAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d100cc2-aa8b-4e82-aa59-558f9a670ec9" xlink:to="loc_arwr_AROHSDAgreementMember_4c0335d3-b3c0-428d-a251-8910437ff379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a19b0c7-e56f-42f7-adf4-e65aae3b983f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_53c179f4-f254-456b-b78c-91472bec043c" xlink:to="loc_srt_RangeMember_5a19b0c7-e56f-42f7-adf4-e65aae3b983f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c680b8f0-778b-439f-8b78-c0713ef1122f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a19b0c7-e56f-42f7-adf4-e65aae3b983f" xlink:to="loc_srt_MaximumMember_c680b8f0-778b-439f-8b78-c0713ef1122f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_820dac49-b70a-4ca6-9472-e1a17fe9f0f5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_69bd73a9-0354-42f5-a109-1396a5b1844a" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_MilestonePaymentEarned_69bd73a9-0354-42f5-a109-1396a5b1844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_d53c007d-0f64-4e08-af44-e4523393df9b" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_d53c007d-0f64-4e08-af44-e4523393df9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_c0052e34-122e-43f7-8aa5-cd458c8beeda" xlink:href="arwr-20220630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_c0052e34-122e-43f7-8aa5-cd458c8beeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_5e58d0df-d7dc-4555-a9b7-61ad310a29aa" xlink:href="arwr-20220630.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_5e58d0df-d7dc-4555-a9b7-61ad310a29aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_b0443e92-b153-4277-a873-5d0667e342f9" xlink:href="arwr-20220630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_SalesRelatedMilestonePayments_b0443e92-b153-4277-a873-5d0667e342f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_23bc2679-de2f-4281-b533-7a7b66ada325" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_23bc2679-de2f-4281-b533-7a7b66ada325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_e0a1a040-77b8-4166-9cd7-d880442285d1" xlink:href="arwr-20220630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_NumberOfDistinctBundle_e0a1a040-77b8-4166-9cd7-d880442285d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_f27952cf-91f3-420c-b086-edd3c46737c0" xlink:href="arwr-20220630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_InitialTransactionPrice_f27952cf-91f3-420c-b086-edd3c46737c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_73d8f381-81f6-4488-a906-3b73a44eb4b0" xlink:href="arwr-20220630.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_73d8f381-81f6-4488-a906-3b73a44eb4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_1c1d513c-44c6-4544-9bf3-b45a24e75139" xlink:href="arwr-20220630.xsd#arwr_PerformanceObligationRelatedToAgreementUpfrontPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment_1c1d513c-44c6-4544-9bf3-b45a24e75139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_26ee633a-7bbe-4baf-9153-baa82d773111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_26ee633a-7bbe-4baf-9153-baa82d773111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3c74c9a0-bf78-4fe3-8438-291051c78dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3c74c9a0-bf78-4fe3-8438-291051c78dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a230438d-4945-49af-a62c-376a22eb1b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da2b7ec5-6bc6-4553-b994-9f6d87ab1c01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a230438d-4945-49af-a62c-376a22eb1b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails" xlink:type="simple" xlink:href="arwr-20220630.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e37950d-edc1-4a6c-b431-11d97bdb6050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e37950d-edc1-4a6c-b431-11d97bdb6050" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93051647-5cc3-4972-9dc0-31a2551dfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fda3b7f0-9f84-477e-99cf-9995724100b6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93051647-5cc3-4972-9dc0-31a2551dfb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_7c94151f-7056-46ff-b6de-a4ba15562eab" xlink:href="arwr-20220630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93051647-5cc3-4972-9dc0-31a2551dfb13" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_7c94151f-7056-46ff-b6de-a4ba15562eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:to="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_230c9b0a-5ae9-497c-b72a-ac432d2e4663" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_814960fb-2b60-4744-a773-45dcb24b38cc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_230c9b0a-5ae9-497c-b72a-ac432d2e4663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_20712ad2-430c-4339-8a8b-6a5b1c951b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_230c9b0a-5ae9-497c-b72a-ac432d2e4663" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_20712ad2-430c-4339-8a8b-6a5b1c951b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f645b33-d8ac-4863-959c-bee23108683f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f1e6166-7ac9-4a61-9c82-88f223394014" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f645b33-d8ac-4863-959c-bee23108683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_03335322-0e71-4aa1-90c6-c2c0c1d67c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f645b33-d8ac-4863-959c-bee23108683f" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_03335322-0e71-4aa1-90c6-c2c0c1d67c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="arwr-20220630.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_616712f3-6b7d-4a59-900c-2e73549d7637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_55c68fd2-029b-405e-997d-96fb022bf5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_616712f3-6b7d-4a59-900c-2e73549d7637" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_55c68fd2-029b-405e-997d-96fb022bf5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="arwr-20220630.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_533211f1-2ef0-4da5-99e9-f9d80e0be9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_966c1604-a13a-4eb2-b61d-ffa5713421d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_533211f1-2ef0-4da5-99e9-f9d80e0be9d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_966c1604-a13a-4eb2-b61d-ffa5713421d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_448e3fbe-7d6b-4e05-817b-be63d4a1e229" xlink:href="arwr-20220630.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_448e3fbe-7d6b-4e05-817b-be63d4a1e229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_e397e9ff-cd70-4ad8-a048-7de62c5e5efc" xlink:href="arwr-20220630.xsd#arwr_ResearchEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_arwr_ResearchEquipmentGross_e397e9ff-cd70-4ad8-a048-7de62c5e5efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_441a8ea4-19db-4559-8090-e1cd715a6e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_441a8ea4-19db-4559-8090-e1cd715a6e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_5d97fda5-8a55-4125-91da-c421e3a56901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_us-gaap_ConstructionInProgressGross_5d97fda5-8a55-4125-91da-c421e3a56901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_2ab3c60f-a1f6-4da9-aef9-3f3e2e0d6f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_us-gaap_Land_2ab3c60f-a1f6-4da9-aef9-3f3e2e0d6f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6feb2b9d-96f1-4e39-950c-40d6d7a9ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6feb2b9d-96f1-4e39-950c-40d6d7a9ea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d784292a-c5f2-484f-a61c-6e771b2f69dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d784292a-c5f2-484f-a61c-6e771b2f69dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5c7536fa-1b66-4f03-b31b-34593091cbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_114396da-981a-4df2-a4d2-1434489a04bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5c7536fa-1b66-4f03-b31b-34593091cbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d8b62de2-03b1-4130-b8f7-ce107e5f844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6f636d68-f82b-4d52-ae19-25b8c2e3dc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d8b62de2-03b1-4130-b8f7-ce107e5f844e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6f636d68-f82b-4d52-ae19-25b8c2e3dc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20220630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81c85850-ae62-4988-ae89-212ee7d0c275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_439dd555-59a7-4413-8e64-b23911c426f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81c85850-ae62-4988-ae89-212ee7d0c275" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_439dd555-59a7-4413-8e64-b23911c426f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20220630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_205e7382-1536-4ff5-b97a-2e7d4c0f984e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_329857d9-3ae3-4460-bf5c-f015dc7ad61c" xlink:href="arwr-20220630.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_205e7382-1536-4ff5-b97a-2e7d4c0f984e" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_329857d9-3ae3-4460-bf5c-f015dc7ad61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a86e5f8-e30d-41f0-9e93-2bd1c951ae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:href="arwr-20220630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a86e5f8-e30d-41f0-9e93-2bd1c951ae20" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_984363a1-2463-46de-be61-862b150bf75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_263da7a1-3b08-4efe-88a5-52dde3ce27c8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_984363a1-2463-46de-be61-862b150bf75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesDueWithinNinetyDaysMember_bd6bd1e8-c01e-4e1c-a58d-7ec7d4ceba27" xlink:href="arwr-20220630.xsd#arwr_CommercialNotesDueWithinNinetyDaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_984363a1-2463-46de-be61-862b150bf75d" xlink:to="loc_arwr_CommercialNotesDueWithinNinetyDaysMember_bd6bd1e8-c01e-4e1c-a58d-7ec7d4ceba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:to="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_35777f64-1945-4f05-8e2b-294ec55b1625" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNoteDueWithinOneYearMember_a3b21d27-74df-4b31-982d-b648459e8fda" xlink:href="arwr-20220630.xsd#arwr_CommercialNoteDueWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CommercialNoteDueWithinOneYearMember_a3b21d27-74df-4b31-982d-b648459e8fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_908ab3bf-3603-4b8a-a829-74607400c2a8" xlink:href="arwr-20220630.xsd#arwr_CommercialNoteDueWithinOneThroughThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CommercialNoteDueWithinOneThroughThreeYearsMember_908ab3bf-3603-4b8a-a829-74607400c2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_470bf9b3-a40d-466a-bbf4-ef5bee7ba82b" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember_470bf9b3-a40d-466a-bbf4-ef5bee7ba82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDepositDueWithinOneYearMember_19246647-6a8c-4a9f-b9a7-f785ebbae64e" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDepositDueWithinOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_CertificateOfDepositDueWithinOneYearMember_19246647-6a8c-4a9f-b9a7-f785ebbae64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MarketableSecuritiesMember_bbbc789c-a997-461a-8521-51ef27f57c9f" xlink:href="arwr-20220630.xsd#arwr_MarketableSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_357ceb18-abed-4100-bf4d-05003c1f6008" xlink:to="loc_arwr_MarketableSecuritiesMember_bbbc789c-a997-461a-8521-51ef27f57c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:href="arwr-20220630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_64367040-6c35-43c3-b734-263df7244d39" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_49eab448-0c92-4a39-b77a-759181136de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_49eab448-0c92-4a39-b77a-759181136de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7fedc2fb-9c44-400f-b3d1-9539dbf266f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7fedc2fb-9c44-400f-b3d1-9539dbf266f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedGains_4c600628-8b14-46e5-811e-0808cc5a4024" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedGains"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedGains_4c600628-8b14-46e5-811e-0808cc5a4024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsGrossUnrealizedLosses_2cffee57-45ec-470b-9f1b-3091dea7aa1d" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsGrossUnrealizedLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsGrossUnrealizedLosses_2cffee57-45ec-470b-9f1b-3091dea7aa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0be80e20-666c-49e2-9bdc-f06d681a24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0be80e20-666c-49e2-9bdc-f06d681a24fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d3247f50-0710-4a72-a7e1-2ee1231c3155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecurities_d3247f50-0710-4a72-a7e1-2ee1231c3155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_57a0ec74-d88a-43c8-b4bf-c3e0af6215fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_57a0ec74-d88a-43c8-b4bf-c3e0af6215fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8da3d180-323b-4cce-b223-aa742d36a611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8da3d180-323b-4cce-b223-aa742d36a611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_20a57fea-34a6-4a5f-941b-7893947aeb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_20a57fea-34a6-4a5f-941b-7893947aeb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_6dc3e9ec-4901-48e2-807b-f0dff52db79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_6dc3e9ec-4901-48e2-807b-f0dff52db79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_cb2ea378-0239-4dcb-bee7-15b5e18a3e9c" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_cb2ea378-0239-4dcb-bee7-15b5e18a3e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_b5364f95-7fd4-49db-ac79-a48050ef5c08" xlink:href="arwr-20220630.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_b5364f95-7fd4-49db-ac79-a48050ef5c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8cc2dd54-8cde-45e6-8e70-b76506d99359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8cc2dd54-8cde-45e6-8e70-b76506d99359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_e41a687a-aaef-46c3-ad74-b75dbb276c0c" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost_e41a687a-aaef-46c3-ad74-b75dbb276c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cfd8f444-753e-4ba1-bfa7-5960ebfe7dc8" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains_cfd8f444-753e-4ba1-bfa7-5960ebfe7dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_ff084a7c-1893-48f3-b2da-30eb1622cf8a" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses_ff084a7c-1893-48f3-b2da-30eb1622cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_ef8eb01c-ef14-4e44-bb43-7e0543acb5c2" xlink:href="arwr-20220630.xsd#arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_ffea5d7b-5fb9-4189-84dd-a55e93e4d7ae" xlink:to="loc_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue_ef8eb01c-ef14-4e44-bb43-7e0543acb5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1" xlink:type="simple" xlink:href="arwr-20220630.xsd#InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20220630.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9bd8fd7-939b-4ba7-beff-f13b3689636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_4e48b852-552e-49a8-b426-785376829851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9bd8fd7-939b-4ba7-beff-f13b3689636c" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_4e48b852-552e-49a8-b426-785376829851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20220630.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ec3936a-ce23-4da3-8250-2436f54c0b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7bde1f5f-4eb0-4799-a8d9-be4cfeb85e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ec3936a-ce23-4da3-8250-2436f54c0b3f" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7bde1f5f-4eb0-4799-a8d9-be4cfeb85e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#IntangibleAssetsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45905d3c-1893-4b43-8404-d98f0ee2aa63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45905d3c-1893-4b43-8404-d98f0ee2aa63" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:to="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_a63efd70-e76a-4bcd-9f1a-9b13adf5fbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_95bb351e-cb23-49bc-89c8-285992ed0566" xlink:to="loc_us-gaap_AssetAcquisitionDomain_a63efd70-e76a-4bcd-9f1a-9b13adf5fbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_28427133-b245-4bd7-abf6-33c24286210f" xlink:href="arwr-20220630.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_a63efd70-e76a-4bcd-9f1a-9b13adf5fbdb" xlink:to="loc_arwr_NovartisMember_28427133-b245-4bd7-abf6-33c24286210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0140623a-fdaa-426e-8d6b-f8b0696521b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_dd676efd-d9c4-4954-8930-d1d13cc71c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:to="loc_us-gaap_LicensingAgreementsMember_dd676efd-d9c4-4954-8930-d1d13cc71c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_4e62cd4b-1f66-42ef-ae8f-c79efaada85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c0b6539-24d2-4dd8-8631-48f2a3b3cb89" xlink:to="loc_us-gaap_PatentsMember_4e62cd4b-1f66-42ef-ae8f-c79efaada85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08238522-a340-4c08-b5b9-519c7f1d3fa9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2da40820-9ae6-40e9-9d4a-b8ada9a82289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2da40820-9ae6-40e9-9d4a-b8ada9a82289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_816c2244-2195-4ecc-b335-f526ed19bcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_816c2244-2195-4ecc-b335-f526ed19bcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6f51e813-4a31-46dc-aae3-31ee1466e806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6f51e813-4a31-46dc-aae3-31ee1466e806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5114baed-36f4-4f7f-85d1-8d46e94eb854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5114baed-36f4-4f7f-85d1-8d46e94eb854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4fd18ae1-e0ba-4525-b88d-4af577b0be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4fd18ae1-e0ba-4525-b88d-4af577b0be2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_806ee7ce-c319-4b4a-912c-f88a74c74764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_806ee7ce-c319-4b4a-912c-f88a74c74764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_187cd2e4-e169-4788-a710-900242f77c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_187cd2e4-e169-4788-a710-900242f77c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6cb1abe5-610e-499b-b6a5-d9777c140651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6cb1abe5-610e-499b-b6a5-d9777c140651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_c9124a9a-15f0-45f2-b29e-e22df419e771" xlink:href="arwr-20220630.xsd#arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dc65dd8-2caa-46dc-85ec-2fd2ecb30032" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_c9124a9a-15f0-45f2-b29e-e22df419e771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_228b06d6-5884-488d-8a57-349c04aca373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_c5f9dcdb-a2eb-40f5-944b-3de185858b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_228b06d6-5884-488d-8a57-349c04aca373" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_c5f9dcdb-a2eb-40f5-944b-3de185858b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_27cab401-1199-42da-808e-f9912190fc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_c5f9dcdb-a2eb-40f5-944b-3de185858b30" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_27cab401-1199-42da-808e-f9912190fc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_34ff3f4b-dca1-4fe4-9934-1a00b0517dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_c5f9dcdb-a2eb-40f5-944b-3de185858b30" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_34ff3f4b-dca1-4fe4-9934-1a00b0517dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_bbea1a95-4a87-427a-a206-a09b1047c296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_c5f9dcdb-a2eb-40f5-944b-3de185858b30" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_bbea1a95-4a87-427a-a206-a09b1047c296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_17246af2-a241-498b-b6dd-0ccd2b4d0685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_c5f9dcdb-a2eb-40f5-944b-3de185858b30" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_17246af2-a241-498b-b6dd-0ccd2b4d0685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8187fd2c-be91-4167-83b9-27240450215d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0a97031e-67cd-475e-ac85-9c820fb97916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8187fd2c-be91-4167-83b9-27240450215d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0a97031e-67cd-475e-ac85-9c820fb97916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_325dd03b-0c66-41f1-b448-d08ba8b3eb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_325dd03b-0c66-41f1-b448-d08ba8b3eb8f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_178fda08-a417-42cf-bea1-de0f891a871d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6cbc469e-df63-445f-adb1-b3b3be9e693e" xlink:to="loc_us-gaap_PlanNameDomain_178fda08-a417-42cf-bea1-de0f891a871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_4af2386c-7e6c-42fb-aa53-0531a840db90" xlink:href="arwr-20220630.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_178fda08-a417-42cf-bea1-de0f891a871d" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_4af2386c-7e6c-42fb-aa53-0531a840db90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_352786b4-1522-4244-90f9-2fc8406a19ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e64ff073-b604-42cc-aa2d-e49afd0812a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_352786b4-1522-4244-90f9-2fc8406a19ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_65e80c2d-b8fc-406d-b91c-0d90d184e849" xlink:href="arwr-20220630.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_352786b4-1522-4244-90f9-2fc8406a19ae" xlink:to="loc_arwr_AtTheMarketAgreementMember_65e80c2d-b8fc-406d-b91c-0d90d184e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_692b0684-4383-4f79-b0e8-73719110f55c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_551dcc9d-7515-4766-a377-6c8fbb72570c" xlink:to="loc_srt_RangeMember_692b0684-4383-4f79-b0e8-73719110f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10418e42-8f77-4072-be4b-d85e4803f706" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_692b0684-4383-4f79-b0e8-73719110f55c" xlink:to="loc_srt_MaximumMember_10418e42-8f77-4072-be4b-d85e4803f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a27fb1fe-6ae5-47ab-9fec-9eb00e189fa8" xlink:to="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitsAuthorized_fce8ca7f-3c42-4d05-8bb6-8546d69be294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CapitalUnitsAuthorized_fce8ca7f-3c42-4d05-8bb6-8546d69be294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4e256cfb-20b9-4e46-a0cf-105401537526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4e256cfb-20b9-4e46-a0cf-105401537526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_54c5b329-56a4-4ea7-bb2a-089fab7cb1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_54c5b329-56a4-4ea7-bb2a-089fab7cb1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3f56c0ef-52ce-4f6c-a4e0-c93acfee8e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3f56c0ef-52ce-4f6c-a4e0-c93acfee8e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fc821fbe-b479-44d0-a86a-5a35b804b6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fc821fbe-b479-44d0-a86a-5a35b804b6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_40f49d25-aa0a-430c-86c1-6a27ce41670a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_40f49d25-aa0a-430c-86c1-6a27ce41670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3e85f86-3299-44cf-82a5-454b9409d7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3e85f86-3299-44cf-82a5-454b9409d7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_64fbd09e-674b-4bf8-975c-d6ba2307957e" xlink:href="arwr-20220630.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_64fbd09e-674b-4bf8-975c-d6ba2307957e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_16198ace-142e-4fb5-aea7-352e65395d95" xlink:href="arwr-20220630.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_16198ace-142e-4fb5-aea7-352e65395d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f22d6854-fa1d-416c-9d18-1914ec3bc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d11a2f40-27ea-49d5-b8e0-a1bf0bcfd348" xlink:to="loc_us-gaap_SharesIssued_f22d6854-fa1d-416c-9d18-1914ec3bc72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71249c11-50be-4f48-b443-c17b994aff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2816b8d8-2b9a-46f0-b270-e998cf457134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71249c11-50be-4f48-b443-c17b994aff0f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2816b8d8-2b9a-46f0-b270-e998cf457134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0154c9e2-5344-485f-82d6-b5cffd0a5ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0154c9e2-5344-485f-82d6-b5cffd0a5ced" xlink:to="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2744d164-e238-4d3f-9e13-6432c36a220e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_ea6ba52e-e54b-4c33-85b0-f590518844f7" xlink:href="arwr-20220630.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_VeronaTechnologyParkMember_ea6ba52e-e54b-4c33-85b0-f590518844f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_09293b28-9b71-4a3d-96ca-c53e9da0559d" xlink:href="arwr-20220630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_DrugManufacturingFacilityMember_09293b28-9b71-4a3d-96ca-c53e9da0559d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_2db4d50b-d56d-4349-93e5-b33d56d7c864" xlink:href="arwr-20220630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_2db4d50b-d56d-4349-93e5-b33d56d7c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_dcf47d58-6b34-48e5-8cbc-80036b077357" xlink:href="arwr-20220630.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d0fdb0a-c6a4-49f0-bcb2-3fe58689b943" xlink:to="loc_arwr_FacilitiesMember_dcf47d58-6b34-48e5-8cbc-80036b077357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_027c5abb-240e-4b57-a0e3-876c3236c29f" xlink:to="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1313a158-00d5-47fd-ac06-95792df736ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:to="loc_srt_MinimumMember_1313a158-00d5-47fd-ac06-95792df736ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6fe5bfad-5285-4eca-b282-95db78600e43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_22f869ad-be0d-43a9-bb84-bb24a5ab2c17" xlink:to="loc_srt_MaximumMember_6fe5bfad-5285-4eca-b282-95db78600e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e258375-2a09-4676-ba42-021cc48aa8d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f22169ed-7bb1-45ef-85e8-4227ebc0b215" xlink:to="loc_srt_SegmentGeographicalDomain_9e258375-2a09-4676-ba42-021cc48aa8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_b2bd3ac3-b270-4f76-b925-1d867ab8f21c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e258375-2a09-4676-ba42-021cc48aa8d3" xlink:to="loc_stpr_WI_b2bd3ac3-b270-4f76-b925-1d867ab8f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_0f2fa07b-cf48-4a53-826e-51e8ff15420b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_61bcd3cc-656f-4693-8017-388fb962b617" xlink:to="loc_us-gaap_OtherCommitmentsDomain_0f2fa07b-cf48-4a53-826e-51e8ff15420b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_55ed6bea-12b8-4fa4-bebc-f7ce0ccd074f" xlink:href="arwr-20220630.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f2fa07b-cf48-4a53-826e-51e8ff15420b" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_55ed6bea-12b8-4fa4-bebc-f7ce0ccd074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_38c4e79c-7e09-4b84-acd9-bf30c9bb854a" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_c6e65586-16b1-4ede-9129-f8d555e56db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_c6e65586-16b1-4ede-9129-f8d555e56db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_2ac3f0cc-ba18-4140-9753-709227dfdbed" xlink:href="arwr-20220630.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_2ac3f0cc-ba18-4140-9753-709227dfdbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_3aec2188-bca6-4918-b86a-ab5eecc45fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_us-gaap_AreaOfLand_3aec2188-bca6-4918-b86a-ab5eecc45fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_ad2b1c7e-da4d-430e-bab9-c06f9641ad1c" xlink:href="arwr-20220630.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_ad2b1c7e-da4d-430e-bab9-c06f9641ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_5b8ced0b-03bb-42bc-8574-292915e7f12e" xlink:href="arwr-20220630.xsd#arwr_MilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e6241fbf-3ecf-46b4-98f4-97dc1464d828" xlink:to="loc_arwr_MilestonePayments_5b8ced0b-03bb-42bc-8574-292915e7f12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_96fedf92-495d-40a0-906f-12569ee57573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_3fc261c7-7c47-4177-9c92-c3589a394240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96fedf92-495d-40a0-906f-12569ee57573" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_3fc261c7-7c47-4177-9c92-c3589a394240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_54045865-6727-4647-bfe0-34a2bdabd969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_800dfcdf-510e-445b-ae37-1834c901aee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_54045865-6727-4647-bfe0-34a2bdabd969" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_800dfcdf-510e-445b-ae37-1834c901aee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_24622e8c-da9b-470f-bebd-385921418498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24622e8c-da9b-470f-bebd-385921418498" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8f105b-9cf1-4262-adbc-bfd5eebf66ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_e428e31f-01d5-428d-9f8c-cac0f9b44199" xlink:href="arwr-20220630.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_e428e31f-01d5-428d-9f8c-cac0f9b44199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_d4f96151-1601-422c-acb8-4e34e6256ff0" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_d4f96151-1601-422c-acb8-4e34e6256ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_528ff223-40a8-4180-bf6d-217a4d05f75a" xlink:href="arwr-20220630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b240d313-78ac-462e-a2b2-88d6869266ab" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_528ff223-40a8-4180-bf6d-217a4d05f75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cdb2ad2c-34e4-450d-86f1-c60db13a28aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_61370f42-b1aa-4c19-991b-84aba6f61ba1" xlink:href="arwr-20220630.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:to="loc_arwr_ColoradoOwnerLLCMember_61370f42-b1aa-4c19-991b-84aba6f61ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HalozymeIncMember_7704bc1b-d62a-4c21-8aec-5bde97101abb" xlink:href="arwr-20220630.xsd#arwr_HalozymeIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a73fbcd-89a7-4f2a-81ca-32da49e20c52" xlink:to="loc_arwr_HalozymeIncMember_7704bc1b-d62a-4c21-8aec-5bde97101abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bde6ea8f-23a5-4d80-8d4f-b1a7dd3fe842" xlink:to="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_36af62be-77d1-4029-b887-e1ab42a4112f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:to="loc_stpr_CA_36af62be-77d1-4029-b887-e1ab42a4112f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_f57d2d4a-8e53-4349-948c-bf5a62627b17" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c58fa75f-1f51-4033-acb0-5c850f2a7f30" xlink:to="loc_stpr_WI_f57d2d4a-8e53-4349-948c-bf5a62627b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6c498d7-d841-4441-99d6-438a3894308f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6962db4b-b11a-42cc-8ffe-4cb025a076f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6c498d7-d841-4441-99d6-438a3894308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SubleaseAgreementMember_c94bda6d-ea68-4020-9d05-b87040e8b4b3" xlink:href="arwr-20220630.xsd#arwr_SubleaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6c498d7-d841-4441-99d6-438a3894308f" xlink:to="loc_arwr_SubleaseAgreementMember_c94bda6d-ea68-4020-9d05-b87040e8b4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ce76e49-fe26-49da-b6ff-6ddeb81c67a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8fdeb3de-fb7d-4283-ba3d-1fc052bd2680" xlink:to="loc_srt_RangeMember_3ce76e49-fe26-49da-b6ff-6ddeb81c67a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_389de7f4-febf-46c7-9586-1c90f2661191" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ce76e49-fe26-49da-b6ff-6ddeb81c67a6" xlink:to="loc_srt_MaximumMember_389de7f4-febf-46c7-9586-1c90f2661191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7adbe136-47db-4f75-8d78-050fc0d5d11f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_454f7d7b-9672-47a8-b1e4-05e6d5a10023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_454f7d7b-9672-47a8-b1e4-05e6d5a10023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_046a7d08-7726-40e3-b617-610669812294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_046a7d08-7726-40e3-b617-610669812294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e74c70f-3695-45c1-b3f4-59b25271e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e74c70f-3695-45c1-b3f4-59b25271e81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_06050efe-8d4a-4e47-86ea-53843315acc0" xlink:href="arwr-20220630.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_06050efe-8d4a-4e47-86ea-53843315acc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_e057f029-ff1a-420b-9fde-9e647e0034e7" xlink:href="arwr-20220630.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_NumberOfOptionsToRenew_e057f029-ff1a-420b-9fde-9e647e0034e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4cc32493-cdba-4369-aee2-bdb6c20cdd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4cc32493-cdba-4369-aee2-bdb6c20cdd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalLandSubjectToLease_3df64b68-e6b5-4416-bd2b-718f080d843d" xlink:href="arwr-20220630.xsd#arwr_AdditionalLandSubjectToLease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_AdditionalLandSubjectToLease_3df64b68-e6b5-4416-bd2b-718f080d843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_84a15e70-b332-49d6-897c-e7667b35ebe0" xlink:href="arwr-20220630.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_84a15e70-b332-49d6-897c-e7667b35ebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_fa01eaf1-b456-4c08-b3f4-8b0bed25e731" xlink:href="arwr-20220630.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_fa01eaf1-b456-4c08-b3f4-8b0bed25e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3319d39d-acf1-4bfb-b490-2cb1c26568c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeaseCost_3319d39d-acf1-4bfb-b490-2cb1c26568c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_03003fb1-b8c4-4c9b-bfe0-3a1befe5dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_VariableLeaseCost_03003fb1-b8c4-4c9b-bfe0-3a1befe5dc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3feb944c-fd53-4a03-a98b-a82473eaced5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_ShortTermLeaseCost_3feb944c-fd53-4a03-a98b-a82473eaced5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7e5dcfcc-d682-4d4a-a4c8-79c6d79fb408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeasePayments_7e5dcfcc-d682-4d4a-a4c8-79c6d79fb408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64311836-66a2-4619-9b0b-243fbfdb9d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64311836-66a2-4619-9b0b-243fbfdb9d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4319d5d-a839-402b-9708-2fe5013e1096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25913d1c-c942-48cb-a443-51c8ad81117c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4319d5d-a839-402b-9708-2fe5013e1096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_541c580e-162e-4fd0-9cd3-2ce51f1b6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_541c580e-162e-4fd0-9cd3-2ce51f1b6e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_81d95499-eb01-4b59-b6d9-d3e6c4c04630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_81d95499-eb01-4b59-b6d9-d3e6c4c04630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d090e38e-d985-46b4-a42b-1d159a58ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d090e38e-d985-46b4-a42b-1d159a58ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a3b036a7-83fc-40bd-964a-c51b00581ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a3b036a7-83fc-40bd-964a-c51b00581ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1cdff30d-b02a-4ecc-8429-adf388bcc686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1cdff30d-b02a-4ecc-8429-adf388bcc686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_40842aea-b1d7-4f30-b3fe-65a3ccd71fcb" xlink:href="arwr-20220630.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_40842aea-b1d7-4f30-b3fe-65a3ccd71fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d31720fa-2e91-4b05-b52b-7c9e6bed7dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d31720fa-2e91-4b05-b52b-7c9e6bed7dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_54d6418a-cd68-40ab-9c09-20a4545e528c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_54d6418a-cd68-40ab-9c09-20a4545e528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2ad54870-33cf-4116-8a0b-a1180a1e7a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e91d925-4702-42df-b168-ed7a5f50a753" xlink:to="loc_us-gaap_OperatingLeaseLiability_2ad54870-33cf-4116-8a0b-a1180a1e7a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1" xlink:type="simple" xlink:href="arwr-20220630.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_110ee664-930c-40aa-800d-767e13a18b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f5e4a826-c2f0-4f16-84eb-ed046609498c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_110ee664-930c-40aa-800d-767e13a18b28" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f5e4a826-c2f0-4f16-84eb-ed046609498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_576e8fa6-49aa-4226-9c80-a17cb678eb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_95971c4e-ddac-43f6-91df-ff9c0e4cdfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_576e8fa6-49aa-4226-9c80-a17cb678eb3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_95971c4e-ddac-43f6-91df-ff9c0e4cdfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4b262902-e6ab-4500-aba5-9de9af5293b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_576e8fa6-49aa-4226-9c80-a17cb678eb3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4b262902-e6ab-4500-aba5-9de9af5293b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bfcf07b5-b939-4aad-ac48-42d9096fa60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_576e8fa6-49aa-4226-9c80-a17cb678eb3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bfcf07b5-b939-4aad-ac48-42d9096fa60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a9bc438-80c3-45ca-9d14-a1502b2f40c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a9bc438-80c3-45ca-9d14-a1502b2f40c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:to="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bf5b31bf-cabc-446d-8db0-62ea8cde5ced" xlink:to="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_6c68ec47-c2b6-424a-bf96-2ffa888a198b" xlink:href="arwr-20220630.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_6c68ec47-c2b6-424a-bf96-2ffa888a198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_f9172ca0-3410-459b-b5a8-5c4506d67b66" xlink:href="arwr-20220630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_f9172ca0-3410-459b-b5a8-5c4506d67b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember_34c8df79-efad-430d-bfa1-7091619fd7c4" xlink:href="arwr-20220630.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_OutsideOfEquityCompensationPlansMember_34c8df79-efad-430d-bfa1-7091619fd7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_01e2a287-6d28-498d-a894-f373df22d5fd" xlink:href="arwr-20220630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ec755684-1c7b-4bc0-8a3e-f14b0d25d703" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_01e2a287-6d28-498d-a894-f373df22d5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:to="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cf66f674-575e-4918-bf46-d4c316602382" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f28928f6-913b-4b95-91d6-381df6fede38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f28928f6-913b-4b95-91d6-381df6fede38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fdbf76d0-6137-4525-b1ef-34debcf066e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e464a0e3-68fe-4e52-9e8e-27e509e65a15" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fdbf76d0-6137-4525-b1ef-34debcf066e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea67f3b5-6a71-43d7-967e-94c928ca416c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_949b6afb-2c93-44d7-91b9-9477267fc92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_949b6afb-2c93-44d7-91b9-9477267fc92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3194832c-52e3-4575-b522-1640f39341e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3194832c-52e3-4575-b522-1640f39341e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e0e2964f-9f37-4a61-8576-478c7e5cfbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e0e2964f-9f37-4a61-8576-478c7e5cfbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_932170ba-8015-41a7-976c-db354396493a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_932170ba-8015-41a7-976c-db354396493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44af3ca3-2d4f-421f-bcc2-697b76c78017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44af3ca3-2d4f-421f-bcc2-697b76c78017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_54ff31e5-59ed-4aac-9edf-8fdb46262ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_54ff31e5-59ed-4aac-9edf-8fdb46262ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_a54863a6-ccfb-4101-93be-bf0064c67ec4" xlink:href="arwr-20220630.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_a54863a6-ccfb-4101-93be-bf0064c67ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35b96e41-99bb-4903-9e67-bc3cf93f2f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35b96e41-99bb-4903-9e67-bc3cf93f2f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0434c210-ba40-4eb1-b3d3-2998779f0710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0434c210-ba40-4eb1-b3d3-2998779f0710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d1641d1-fbd8-4208-8ee4-706c652fa10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d1641d1-fbd8-4208-8ee4-706c652fa10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b91f1f3-a8bd-46f0-b910-8dfef185dcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b91f1f3-a8bd-46f0-b910-8dfef185dcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_b6cd7f47-54a3-41c4-95d8-0b5163b4141a" xlink:href="arwr-20220630.xsd#arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod_b6cd7f47-54a3-41c4-95d8-0b5163b4141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_df0c7a30-f8b8-46a6-8c6d-09e5a810e110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae3024ae-3465-46ba-b686-4df84ffa0557" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_df0c7a30-f8b8-46a6-8c6d-09e5a810e110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1cebf8b-3bcc-4b55-b02d-bbef5b49e199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1cebf8b-3bcc-4b55-b02d-bbef5b49e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_450a0bdc-99d6-4c60-b25e-32fbd3a1df33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_450a0bdc-99d6-4c60-b25e-32fbd3a1df33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_da80ac60-3a99-48be-9979-58cad3c39191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_da80ac60-3a99-48be-9979-58cad3c39191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6167534a-50ef-41eb-94bf-12fc7a43f924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6167534a-50ef-41eb-94bf-12fc7a43f924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2593d742-2fb7-4021-b0bf-70567fb3b039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6838bee-61ff-493f-8bfa-bf14667e4c38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2593d742-2fb7-4021-b0bf-70567fb3b039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3f66df18-59b4-4714-9b5c-49e8829ec6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3f66df18-59b4-4714-9b5c-49e8829ec6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2a5af180-b080-43fc-b615-13ccc53a9548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2a5af180-b080-43fc-b615-13ccc53a9548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bdfb0815-dbfd-48bc-a055-2f00bc620407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bdfb0815-dbfd-48bc-a055-2f00bc620407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_512f2e06-88fa-4607-b141-5cbc83f3362c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_512f2e06-88fa-4607-b141-5cbc83f3362c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0e833509-bed8-437d-8ab1-5ae370627afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0e833509-bed8-437d-8ab1-5ae370627afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91c0b29a-85d6-4140-aa5a-451e292ddfde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c28ceb38-e942-4475-a468-ac485b793e98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91c0b29a-85d6-4140-aa5a-451e292ddfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5dbe3da4-1c8c-46d8-b416-702bda42f66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5dbe3da4-1c8c-46d8-b416-702bda42f66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_137da842-1c43-4958-809e-c84cd36768cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_137da842-1c43-4958-809e-c84cd36768cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e93235af-9b16-41ee-9dc3-439fe9ed3448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e93235af-9b16-41ee-9dc3-439fe9ed3448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378752f-9058-4a42-bf2a-e94a9e720767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378752f-9058-4a42-bf2a-e94a9e720767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_dd537562-5c6f-4c24-8c50-8d551a3d9318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d26e60f6-c58e-427c-a48f-b40ff131b906" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_dd537562-5c6f-4c24-8c50-8d551a3d9318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54fbcf6e-21c2-4370-9622-d6a6fe020fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54fbcf6e-21c2-4370-9622-d6a6fe020fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eac114a2-bb48-4b1c-ad3f-9d5f3eb3bb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eac114a2-bb48-4b1c-ad3f-9d5f3eb3bb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d2160fc3-da70-48e3-9ba9-cceea79e932d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d2160fc3-da70-48e3-9ba9-cceea79e932d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_52c46f23-d60d-4ee1-86fe-4383cca9fc86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_52c46f23-d60d-4ee1-86fe-4383cca9fc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b230a1e4-be6e-4cb6-85d9-142d464b45b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b230a1e4-be6e-4cb6-85d9-142d464b45b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_623359ef-1251-4ab3-af71-b3c510d4ec4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_623359ef-1251-4ab3-af71-b3c510d4ec4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_266bd46f-532b-4186-b110-5d607efe5bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df8c3285-e39f-4854-ba1b-bde8d5dd96c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_266bd46f-532b-4186-b110-5d607efe5bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#StockBasedCompensationSummaryofRSUsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ab00ccf-439d-4595-99c4-6fd258499b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ab00ccf-439d-4595-99c4-6fd258499b41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:to="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a641240-db36-42c4-b179-6ec5c4c157ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47ad2ae2-a0b9-4cac-a72c-99114a809087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a641240-db36-42c4-b179-6ec5c4c157ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_96507221-f3ba-4ab6-bdce-4cc12d0db943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a641240-db36-42c4-b179-6ec5c4c157ba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_96507221-f3ba-4ab6-bdce-4cc12d0db943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4547c5a-0e46-49b4-acb6-0580ebbba122" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67078415-46ec-48cb-bd7c-93b80e3e9f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67078415-46ec-48cb-bd7c-93b80e3e9f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61d13184-c3b3-4dfd-8b18-8d8d61badf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61d13184-c3b3-4dfd-8b18-8d8d61badf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f562fcc-44d5-4ff6-819b-43929e0bfa80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f562fcc-44d5-4ff6-819b-43929e0bfa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5823f338-ffa8-4c04-a007-c59b41ca678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5823f338-ffa8-4c04-a007-c59b41ca678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_818bc719-f4d2-424d-bd55-bb387ffa1b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e584aa92-01b2-4d12-b6b1-b61b917b6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_818bc719-f4d2-424d-bd55-bb387ffa1b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1824cbfc-bb63-4180-9f5e-db78f48b352c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc2b9f36-a3bf-4ee0-b686-7b307a0ba109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc2b9f36-a3bf-4ee0-b686-7b307a0ba109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fa1b806-b031-4dfc-8272-33b7edb4ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fa1b806-b031-4dfc-8272-33b7edb4ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfeb4f37-fb2d-45a7-b004-7d12080e8bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfeb4f37-fb2d-45a7-b004-7d12080e8bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8b2d7886-1482-4194-9d81-7650ee9d97c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8b2d7886-1482-4194-9d81-7650ee9d97c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e1e25b3-1235-4b62-be84-a612698788ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee432249-4725-42cb-837e-f91a0ca65b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e1e25b3-1235-4b62-be84-a612698788ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_45d66a29-a43e-4fb8-9352-bee8e86337cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bca85e05-aba2-4c2e-82dd-2bf8a95a9463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_45d66a29-a43e-4fb8-9352-bee8e86337cf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bca85e05-aba2-4c2e-82dd-2bf8a95a9463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_72c63cdf-ed63-4339-9902-7543fe5db980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f2565e9d-7564-4b54-a48c-7de1490e1a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72c63cdf-ed63-4339-9902-7543fe5db980" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f2565e9d-7564-4b54-a48c-7de1490e1a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="arwr-20220630.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c795df71-2e33-4db0-a094-bfcba0da0c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c795df71-2e33-4db0-a094-bfcba0da0c79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48b483ec-7ab8-4b52-aadd-3c2eb01ba91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_282035b8-7d6d-4463-90ab-908cd4422a1a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48b483ec-7ab8-4b52-aadd-3c2eb01ba91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a91ce80a-ef15-4c17-8dbf-a3e6eaba6ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_48b483ec-7ab8-4b52-aadd-3c2eb01ba91b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a91ce80a-ef15-4c17-8dbf-a3e6eaba6ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_320ca8e2-7f72-4f91-af3e-a963a387a3f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73082eff-7808-4e17-9aa6-14c2df14cee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_73082eff-7808-4e17-9aa6-14c2df14cee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4fb1a803-923b-44a2-af34-2ac18f0a1a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4fb1a803-923b-44a2-af34-2ac18f0a1a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_690dcd18-4aa4-4587-91c5-ca5337879337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8611441-7005-4557-b68c-9275d0aa726f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_690dcd18-4aa4-4587-91c5-ca5337879337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8903a0bf-eb40-4a4b-8dfa-a1025015080d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotes_15dc4556-dcbe-433d-8ea8-a0945c5f2305" xlink:href="arwr-20220630.xsd#arwr_CommercialNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_arwr_CommercialNotes_15dc4556-dcbe-433d-8ea8-a0945c5f2305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d56d2318-c480-4db5-af31-3e527996e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d56d2318-c480-4db5-af31-3e527996e2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_7a8a2f68-3979-403c-be9a-de96c60264de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_7a8a2f68-3979-403c-be9a-de96c60264de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_600eb199-1ecf-4918-99b6-986fc4856894" xlink:href="arwr-20220630.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_arwr_HeldToMaturitySecuritiesFairValueNonCurrent_600eb199-1ecf-4918-99b6-986fc4856894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CertificateOfDeposits_c5f6927f-4e18-4e19-a312-9282386666c5" xlink:href="arwr-20220630.xsd#arwr_CertificateOfDeposits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_arwr_CertificateOfDeposits_c5f6927f-4e18-4e19-a312-9282386666c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b4bf37dd-21ce-43ac-bfa4-002398b25900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1617700f-487d-423c-a370-4e5174e8bb09" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b4bf37dd-21ce-43ac-bfa4-002398b25900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="simple" xlink:href="arwr-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_74403951-e6ff-49a3-91d1-df6a4d625eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_10bc483f-76aa-4d0c-a7d0-cf294933957d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_74403951-e6ff-49a3-91d1-df6a4d625eac" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_10bc483f-76aa-4d0c-a7d0-cf294933957d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473564014448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,848,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473564128976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 139,439<span></span>
</td>
<td class="nump">$ 184,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">10,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,761<span></span>
</td>
<td class="nump">4,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">8,892<span></span>
</td>
<td class="nump">2,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="nump">277,057<span></span>
</td>
<td class="nump">56,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">432,388<span></span>
</td>
<td class="nump">384,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">71,904<span></span>
</td>
<td class="nump">48,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">13,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments</a></td>
<td class="nump">165,920<span></span>
</td>
<td class="nump">245,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">68,908<span></span>
</td>
<td class="nump">17,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">751,782<span></span>
</td>
<td class="nump">710,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,894<span></span>
</td>
<td class="nump">9,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">32,499<span></span>
</td>
<td class="nump">14,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">84,288<span></span>
</td>
<td class="nump">111,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">128,212<span></span>
</td>
<td class="nump">146,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">78,231<span></span>
</td>
<td class="nump">23,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">71,162<span></span>
</td>
<td class="nump">131,495<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">149,393<span></span>
</td>
<td class="nump">154,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 145,000 shares authorized; 105,795 and 104,327 shares issued and outstanding as of June&#160;30, 2022 and September&#160;30, 2021, respectively</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,189,113<span></span>
</td>
<td class="nump">1,053,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(735,244)<span></span>
</td>
<td class="num">(644,692)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL ARROWHEAD PHARMACEUTICALS INC. STOCKHOLDERS' EQUITY</a></td>
<td class="nump">453,927<span></span>
</td>
<td class="nump">408,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest</a></td>
<td class="nump">20,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">474,177<span></span>
</td>
<td class="nump">408,822<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 751,782<span></span>
</td>
<td class="nump">$ 710,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473563850304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">105,795,000<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">105,795,456<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473564504416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUE</a></td>
<td class="nump">$ 32,412<span></span>
</td>
<td class="nump">$ 45,891<span></span>
</td>
<td class="nump">$ 211,656<span></span>
</td>
<td class="nump">$ 100,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">72,180<span></span>
</td>
<td class="nump">59,325<span></span>
</td>
<td class="nump">213,930<span></span>
</td>
<td class="nump">140,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">33,141<span></span>
</td>
<td class="nump">18,434<span></span>
</td>
<td class="nump">92,403<span></span>
</td>
<td class="nump">43,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">105,321<span></span>
</td>
<td class="nump">77,759<span></span>
</td>
<td class="nump">306,333<span></span>
</td>
<td class="nump">184,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="num">(72,909)<span></span>
</td>
<td class="num">(31,868)<span></span>
</td>
<td class="num">(94,677)<span></span>
</td>
<td class="num">(84,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">4,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(377)<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
<td class="nump">6,679<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="num">(72,046)<span></span>
</td>
<td class="num">(29,924)<span></span>
</td>
<td class="num">(90,552)<span></span>
</td>
<td class="num">(77,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="num">$ (72,046)<span></span>
</td>
<td class="num">$ (29,924)<span></span>
</td>
<td class="num">$ (90,552)<span></span>
</td>
<td class="num">$ (77,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">NET INCOME (LOSS) PER SHARE - BASIC (in dollars per share)</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">NET INCOME (LOSS) PER SHARE - DILUTED (in dollars per share)</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">105,753<span></span>
</td>
<td class="nump">104,099<span></span>
</td>
<td class="nump">105,273<span></span>
</td>
<td class="nump">103,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">105,753<span></span>
</td>
<td class="nump">104,099<span></span>
</td>
<td class="nump">105,273<span></span>
</td>
<td class="nump">103,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (33)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (71)<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="num">$ (72,079)<span></span>
</td>
<td class="num">$ (29,964)<span></span>
</td>
<td class="num">$ (90,623)<span></span>
</td>
<td class="num">$ (77,430)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473558074896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity and Noncontrolling Interest - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrollling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2020</a></td>
<td class="nump">$ 461,779<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 965,410<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (503,844)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">42,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">10,490<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(77,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">436,890<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,017,949<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(581,318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">445,549<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">996,645<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="num">(551,394)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">18,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,756<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(29,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">436,890<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,017,949<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(581,318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2021</a></td>
<td class="nump">408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,053,386<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(644,692)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">91,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">506,596<span></span>
</td>
<td class="nump">497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Interest in joint venture</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(90,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">474,177<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,189,113<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(735,244)<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">452,266<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,115,373<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(663,198)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">33,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Interest in joint venture</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(72,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 474,177<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 1,189,113<span></span>
</td>
<td class="num">$ (140)<span></span>
</td>
<td class="num">$ (735,244)<span></span>
</td>
<td class="nump">$ 20,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562341536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (90,552)<span></span>
</td>
<td class="num">$ (77,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">91,697<span></span>
</td>
<td class="nump">42,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,761<span></span>
</td>
<td class="nump">5,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (gains) losses on marketable securities</a></td>
<td class="nump">5,755<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/(accretion) of note premiums/discounts</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">10,016<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(8,876)<span></span>
</td>
<td class="num">(2,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(87,100)<span></span>
</td>
<td class="nump">211,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,563)<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">13,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="nump">3,672<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</a></td>
<td class="num">(67,464)<span></span>
</td>
<td class="nump">195,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(20,066)<span></span>
</td>
<td class="num">(15,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(223,391)<span></span>
</td>
<td class="num">(95,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investments</a></td>
<td class="nump">201,595<span></span>
</td>
<td class="nump">87,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</a></td>
<td class="num">(41,862)<span></span>
</td>
<td class="num">(23,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">4,331<span></span>
</td>
<td class="nump">10,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from investment in joint venture</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">64,331<span></span>
</td>
<td class="nump">10,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="num">(44,995)<span></span>
</td>
<td class="nump">182,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">184,434<span></span>
</td>
<td class="nump">143,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">$ 139,439<span></span>
</td>
<td class="nump">$ 325,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473566251696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Business and Recent Developments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#8217;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC2 for cystic fibrosis, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens, ARO-C3 for complement mediated diseases, ARO-RAGE and ARO-MUC5AC for various muco-obstructive or inflammatory pulmonary conditions and ARO-MMP7 for idiopathic pulmonary fibrosis. ARO-HSD for liver disease was out-licensed to Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;) in November 2021. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;). JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. JNJ-3989 (formerly referred to as ARO-HBV) for chronic hepatitis B virus was out-licensed to Janssen in October 2018. Olpasiran (formerly referred to as AMG 890 or ARO-LPA) for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016. While the Company believes that initial ARO-HIF2 Phase 1 clinical data provides proof of concept for the ability to deliver siRNA to RCC tumors, the Company has decided not to pursue further clinical development of ARO-HIF2 based on a number of factors including the evolving competitive landscape for HIF2 inhibitors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three quarters of fiscal 2022, the Company continued to develop and advance its pipeline and partnered candidates and expanded its facilities to support the Company&#8217;s growing pipeline. Several key recent developments include: </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.9pt">dosed the first patients in its PALISADE study, a phase 3 clinical study to evaluate the safety and efficacy of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.13pt">entered into an exclusive license agreement with GSK for ARO-HSD; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.36pt">Janssen presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989 (JNJ-3989), formerly called ARO-HBV, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB);</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.9pt">filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 and subsequently dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s </span><span style="background-color:#f3f3f3;color:#676767;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nvestigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">presented additional interim clinical data from AROHSD1001, AROAAT2002, and AROAPOC31001; </span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">completed the purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin and held a groundbreaking ceremony on the site. The site is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company's process development and analytical activities. The Company also announced that it received awards for up to $16&#160;million in tax increment financing from the city of Verona, and up to $2.5&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.  Additionally, The Company entered into a lease agreement for a new 144,000 square foot laboratory and office facility in San Diego, California to support discovery activities;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.13pt">completed enrollment in Phase 2b ARCHES-2 study of investigational ARO-ANG3 for patients with mixed dyslipidemia;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">viii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-RAGE for treatment of Asthma;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-MUC5AC for treatment of muco-obstructive lung disease;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">initiated and dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholersterolemia;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">xi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">entered into definitive agreements to form a joint venture, Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;) with Vivo Capital (&#8220;Vivo&#8221;) through which the Company and Vivo intend to expand the reach of innovative medicines in Greater China;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">xii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:22.13pt">hosted a pulmonary research &amp; development (R&amp;D) Day to discuss the Company&#8217;s emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) platform, including an announcement of its previously undisclosed candidate designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF); and</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xiii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt">in conjunction with Takeda, announced results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), and was recently published in the New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress&#8482; 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the three and nine months ended June&#160;30, 2022 were not significantly impacted by COVID-19. Operationally, the Company has experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#8217;s preclinical programs. Additionally, the Company has experienced delays in enrollment in its clinical trials. The Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees and the length and severity of the COVID-19 pandemic. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), which contemplate the continuation of the Company as a going concern. Historically, the Company&#8217;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials, as well as with the Company&#8217;s plans to increase its internal manufacturing capabilities, and expand its footprint in Verona, Wisconsin and San Diego, California. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company had $139.4 million in cash and cash equivalents (including $7.4 million in restricted cash), $277.1 million in short-term investments, $0 in marketable securities and $165.9 million in long-term investments to fund operations. $60&#160;million of our cash balance resulted from the formation of our joint venture, Viserna. During the nine months ended June&#160;30, 2022, the Company&#8217;s cash and investments balance decreased by $31.0 million, which was primarily due to cash being used to fund the Company&#8217;s operations, partially offset by the $120.0 million upfront payment received from GSK, and $60&#160;million cash infusion to Viserna. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company remains eligible for $4.9 billion in developmental, regulatory and sales milestones and various royalties on net sales from its licensing and collaboration agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2 below. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="text-indent:40.8pt"><span><br/></span></div><div style="text-indent:40.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In our opinion, the unaudited consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending September 30, 2022 or any other period.</span></div><div style="text-indent:40.8pt"><span><br/></span></div><div style="text-indent:40.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited consolidated financial statements include the accounts of our wholly owned subsidiaries, as well as the accounts of Visirna, a variable interest entity for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our unaudited consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565455008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;28, 2016, the Company entered into two collaboration and license agreements and a common stock purchase agreement with Amgen. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ARO-AMG1 Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0 million milestone payment to the Company. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company recognized $0 and $0 of revenue associated with its agreement with Amgen, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;3, 2018, the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;) with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company also entered into a stock purchase agreement with JJDC (&#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which Arrowhead would develop clinical candidates. These candidates were subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0 million, and the Company may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $0.6 billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During the three months ended June&#160;30, 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. At the inception of these agreements, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the three months ended June&#160;30, 2022 and 2021, the Company recognized approximately $0 and $0 of revenue associated with this performance obligation, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized approximately $0 and $20.2 million of revenue associated with this performance obligation, respectively. As of June&#160;30, 2022, there were $0 in contract </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets recorded as accounts receivable, and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. During the three months ended June&#160;30, 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement as reported in the second quarter of 2022. During the three months ended June&#160;30, 2022 and 2021, the Company recognized $0.0&#160;million and $0.2 million of revenue associated with these efforts, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized $0.1 million and $0.5 million of revenue associated with these efforts, respectively. In May 2021, Janssen exercised its option right for ARO-JNJ1, which resulted in a $10.0&#160;million milestone payment to the Company. This $10&#160;million milestone payment was recognized entirely during the three months ended June 30, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there were $0 of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, the Company entered into an Exclusive License and Co-funding agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda. Under the Takeda License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. In January 2021, the Company received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $300.0 million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services. Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the three months ended June&#160;30, 2022 and 2021 was $25.5 million and $35.7 million, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $67.1 million and $69.3 million, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, $71.0 million in contract liabilities recorded as deferred revenue and $71.2 million in contract liabilities recorded as deferred revenue, net of the current portion, and $7.8 million in contract liabilities recorded as accrued expenses. The $7.8 million in accrued expenses was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Horizon Therapeutics Ireland DAC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, the Company entered into the Horizon License Agreement with Horizon. Under the Horizon </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of ARO-XDH, and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $40 million as an upfront payment and is eligible to receive up to $660 million in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties, from this transaction price to date. The Company will allocate the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;D Services. Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the three months ended June&#160;30, 2022 and 2021 was $6.7 million and $0, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $20.0 million and $0, respectively. As of June&#160;30, 2022, there were $0 million in contract assets recorded as accounts receivable, $13.3 million in contract liabilities recorded as deferred revenue. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has manufactured ARO-XDH material for Horizon in furtherance of the research plan entered into pursuant to the Horizon License Agreement, for which the Company has been reimbursed for its costs. During the nine months ended June 30, 2022 and 2021, the Company recognized $1.3 million and $0 with these efforts, respectively. As of June&#160;30, 2022, there were $0.0 million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;) with GSK. Under the GSK License Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK has received an exclusive license for ARO-HSD, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the Company&#8217;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">itory. Under the terms of the agreement, the Company has received an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the GSK License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study, (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of these GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0 million, including the upfront payment. The $120.0 million upfront payment was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million will be fully recognized as of the three and nine months ended June&#160;30, 2022. Revenue for the nine months ended June 30, 2022 and 2021 was $120.0 million and $0, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, $0 in contract liabilities recorded as deferred revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2022, the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;) with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of Arrowhead&#8217;s RNAi-based investigational cardiobolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Visirna SPA, entities affiliated with Vivo Capital (&#8220;Vivo&#8221;) also acquired a minority stake in Visirna in exchange for $60&#160;million in upfront capital to support the operations of Visirna.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has determined that Visirna is a variable interest entity upon its formation and as of June 30, 2022, and it has been determined that Arrowhead is the primary beneficiary; accordingly, Arrowhead consolidates the financial statements of Visirna.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565455008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,210&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,170&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,678&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,524&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in Progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,338&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total gross fixed assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,239&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,539&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(29,335)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(22,864)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,675&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation and amortization expense for property and equipment for the three months ended June&#160;30, 2022 and 2021 was $2.2 million and $1.6 million, respectively. Depreciation and amortization expense for property and equipment for the nine months ended June&#160;30, 2022 and 2021 was $6.5 million and $4.5 million, respectively. Construction in Progress relates to the Company&#8217;s Verona and San Diego research facilities. Land relates to the Company&#8217;s Verona, Wisconsin research facility.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565182816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Investments at June&#160;30, 2022 primarily consisted of commercial paper and corporate bonds that have maturities of less than 36 months and a certificate of deposit. Cash and cash equivalents consist of cash on hand and commercial paper purchased with 90-days or less remaining to maturity.  The Company&#8217;s corporate bonds consist of both short-term and long-term bonds and are classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheets. The Company&#8217;s certificate of deposit matures in less than 12 months and is classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheet,&#8217;. The Company&#8217;s marketable equity securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, corporate bonds and other asset-backed debt securities. Dividends from these funds were automatically re-invested. In April 2022, all marketable securities were sold for  $122.3&#160;million. The Company may also invest excess cash balances in money market accounts, and these securities would be classified as cash and cash equivalents on the Company&#8217;s Consolidated Balance Sheet. The Company accounts for its &#8220;held-to-maturity&#8221; investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#8211; Equity Securities. We did not record any impairment charges related to our marketable debt securities during the three and nine months ended June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s short-term and long-term investments and marketable securities as of June&#160;30, 2022 and September&#160;30, 2021 by measurement category: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Cash Equivalents</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within ninety days)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">227,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,588)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">225,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial notes (due within one through three years)</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">165,920&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,380)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,540&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposit (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">468,302&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,968)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">460,366&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September&#160;30, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial notes (due within one through three years)</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">195,595&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,151&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(103)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,643&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit (due within one through two years)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">127,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">429,703&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,954&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(856)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">430,801&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565319168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETSIntangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is $1.1 million. The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortization of the assets is $11.4 million. Amortization expense for the three months ended June 30, 2022 and 2021 was $0.4 million and $0.4&#160;million, respectively. Amortization expense for the nine months ended June 30, 2022 and 2021 was $1.3 million and $1.3&#160;million, respectively. Amortization expense is expected to be $0.4 million for the remainder of fiscal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, $1.7 million in 2023, $1.7 million in 2024, $1.7 million in 2025, $1.7 million in 2026 and $5.2 million thereafter.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details on the Company&#8217;s intangible asset balances: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible<br/>Assets<br/>Subject to<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,663&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,276)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,387&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565321600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, 105,795,456 shares of Common Stock were outstanding. At June&#160;30, 2022, 13,942,716 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At June&#160;30, 2022, no shares have been sold under the ATM Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565182816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of June&#160;30, 2022. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is planned to be the site of an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support process development and analytical activities. Arrowhead intends to invest between $200 million and $250 million into the buildout of the facilities. As part of this acquisition, the Company also entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the TIF district, and will be reimbursed by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay as reimbursements under the TIF program for these improvements is not guaranteed and will depend on future tax revenues generated from the developed property.</span></div>Technology License CommitmentsThe Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon a new drug application and upon certain sales level milestones. These milestone payments could amount to the mid to upper double-digit millions of dollars. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company did not reach any milestones. Under certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of sales of the relevant products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565361312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California. The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. The increased capacity of this new office space compared to the Company&#8217;s prior corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves closer to market. Lease payments began on September&#160;30, 2019 and are estimated to total approximately $8.7 million over the term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease expires on April&#160;30, 2027. The Company has paid approximately $3.5 million for leasehold improvements, net of tenant improvement allowances. The lease contains an option to renew for one term of five years. The exercise of this option was not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at June&#160;30, 2022. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately 24,000 square feet of office space at the same location for its corporate headquarters. Lease payments for the expansion began in July 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the lease for the expansion expires in April 2027. The lease payments for the expansion are expected to total $6.9 million. The Company has paid approximately $4.0 million of leasehold improvements, net of tenant improvement allowances, for the lease expansion. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin. The lease was for approximately 60,000 square feet of office and laboratory space and had an expiration date of September&#160;30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional 40,000 square feet and to extend the lease expiration date to September&#160;30, 2031. Lease payments are estimated to total approximately $26.2 million for the term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $11.0 million of leasehold improvements for the additional 40,000 square feet, net of tenant improvement allowances. The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at June&#160;30, 2022. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional 10,743 square feet and these amendments added a total of approximately $1.2 million of lease payments for the remainder of the term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a sublease agreement for additional research and development facility space in San Diego, California. The Sublease provides additional space needed to accommodate the recent growth of the Company&#8217;s personnel and discovery efforts. The Sublease is for approximately 21,000 rentable square feet. The term of the Sublease commenced on April&#160;1, 2020 and will end on January&#160;14, 2023. Sublease payments are estimated to total approximately $2.0 million over the term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a new lease for a San Diego, California research facility. The 15-year lease is for approximately 144,000 square feet of office and research and development laboratory space to be constructed in San Diego, California. This lease will replace the Company&#8217;s current research facility sublease for property located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for the Company&#8217;s expanding pipeline of current and future drug candidates. The estimated rent commencement date for the lease is in March 2023, after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $31.0 million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. .</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost during the three months ended June&#160;30, 2022 and 2021 was $3.4 million and $1.6 million, respectively. Operating lease cost during the nine months ended June&#160;30, 2022 and 2021 was $6.0 million and $3.6 million, respectively. Variable lease costs for the three months ended June&#160;30, 2022 and 2021 was $0.2 million and $0.1 million, respectively. Variable lease costs for the nine months ended June&#160;30, 2022 and 2021 was $0.5 million and $0.6 million, respectively. There was no short-term lease cost during the three and nine months ended June&#160;30, 2022 and 2021. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 (remainder of fiscal year)</span></div></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,309&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,802&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,094&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,313&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">114,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,427&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72,313)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81,114&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#8217;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#8217;s Consolidated Statements of Cash Flows for the nine months ended June&#160;30, 2022 and 2021 was $3.4 million and $2.2 million, respectively. The weighted-average remaining lease term and weighted-average discount rate for all leases as of June&#160;30, 2022 was 7.3 years and 8.5%, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565248304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATIONArrowhead has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, as of June&#160;30, 2022, 216,607 and 4,114,999 shares, respectively, of Arrowhead&#8217;s Common Stock are reserved for the grant of stock options, stock appreciation rights, and restricted stock unit awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan. As of June&#160;30, 2022, there were options granted and outstanding to purchase 216,607 and 1,806,987 shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were 2,308,012 restricted stock units granted and outstanding under the 2013 Incentive Plan. As of June&#160;30, 2022, there were 816,248 shares reserved for options and 682,500 shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. As of June&#160;30, 2022, there were 3,000 shares of Common Stock reserved for options and 1,507,267 shares of Common Stock reserved for restricted stock units granted and outstanding under the 2021 Incentive Plan. As of June&#160;30, 2022, the total number of shares available under the 2021 Incentive Plan was 6,627,845 shares, which includes 119,612 shares that were forfeited under the 2013 Incentive Plan.<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,456,239</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.60&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(106,801)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43.68&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(506,596)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,842,842</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.60&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1 years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,434,252&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable at June&#160;30, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,370,089</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.14&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.6 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52,941,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options for the three months ended June&#160;30, 2022 and 2021 was $2.6 million and $3.2 million, respectively. Stock-based compensation expense related to stock options for the nine months ended June&#160;30, 2022 and 2021 was $8.3 million and $9.6 million, respectively. For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the options granted by the Company for the three months ended June&#160;30, 2022 and 2021 was $0 and $0.9 million, respectively. The grant date fair value of the options granted by the Company for the nine months ended June&#160;30, 2022 and 2021 was $0 and $9.0 million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of the options exercised during the three months ended June&#160;30, 2022 and 2021 was $1.6 million and $10.2 million, respectively. The intrinsic value of the options exercised during the nine months ended June&#160;30, 2022 and 2021 was $24.9 million and $63.0 million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $14.9 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 1.7 years. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to value stock options are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4% - 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86% - 90.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on that of the U.S. Treasury bond. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including time-based, market condition-based, and performance condition-based awards, have been granted under the Company&#8217;s 2013 Incentive Plan, 2021 Incentive Plan, and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested at September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,831,850</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.24&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,691,367</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56.73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(962,188)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.10&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(95,625)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,465,404</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.97&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 and 2021, the Company recorded $33.7 million and $15.4 million of expense related to RSUs, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recorded $83.4 million and $32.5 million of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For RSUs, the grant date fair value of the award is based on the Company&#8217;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. The grant date fair value of the RSUs granted by the Company for the three months ended June&#160;30, 2022 and 2021 was $42.5 million and $3.1 million, respectively. The grant date fair value of the RSUs granted by the Company for the nine months ended June&#160;30, 2022 and 2021 was $95.2 million and $112.1 million, respectively.</span></div>As of June&#160;30, 2022, the pre-tax compensation expense for all unvested RSUs in the amount of $190.3 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 2.7 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565289680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair value measurements at June&#160;30, 2022 and September&#160;30, 2021 for assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Cash and cash equivalents</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial Notes</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">225,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">225,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term investments</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,540&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,540&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposits</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Contingent Consideration</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term investments</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,643&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,643&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Contingent Consideration</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565343424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTSNone.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565312208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="text-indent:40.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In our opinion, the unaudited consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending September 30, 2022 or any other period.</span></div><div style="text-indent:40.8pt"><span><br/></span></div><div style="text-indent:40.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited consolidated financial statements include the accounts of our wholly owned subsidiaries, as well as the accounts of Visirna, a variable interest entity for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our unaudited consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565368512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,210&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,170&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,678&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,524&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in Progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,338&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total gross fixed assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,239&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,539&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(29,335)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(22,864)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,675&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565343424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Summary of Short-term and Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s short-term and long-term investments and marketable securities as of June&#160;30, 2022 and September&#160;30, 2021 by measurement category: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Cash Equivalents</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within ninety days)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">227,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,588)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">225,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial notes (due within one through three years)</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">165,920&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,380)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,540&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposit (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">468,302&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,968)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">460,366&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September&#160;30, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial notes (due within one year)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial notes (due within one through three years)</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">195,595&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,151&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(103)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,643&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit (due within one through two years)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">127,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">429,703&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,954&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(856)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">430,801&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565343424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details on the Company&#8217;s intangible asset balances: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible<br/>Assets<br/>Subject to<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,663&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,276)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,387&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565368512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 (remainder of fiscal year)</span></div></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,309&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,802&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,094&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,313&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">114,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,427&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72,313)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81,114&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473567468752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,456,239</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.60&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(106,801)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43.68&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(506,596)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,842,842</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.60&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1 years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,434,252&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable at June&#160;30, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,370,089</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.14&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.6 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52,941,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to value stock options are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4% - 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86% - 90.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested at September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,831,850</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.24&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,691,367</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56.73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(962,188)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.10&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(95,625)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,465,404</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.97&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473565248304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair value measurements at June&#160;30, 2022 and September&#160;30, 2021 for assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Cash and cash equivalents</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial Notes</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">225,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">225,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term investments</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,540&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,540&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposits</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Contingent Consideration</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Marketable Securities</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Held to Maturity</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term investments</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,643&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,643&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Certificate of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Classified as Contingent Consideration</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473558239344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_TaxIncrementFinancingAward', window );">Tax increment financing award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">State income tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Decrease in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary | Visirna Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin | Verona Technology Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAcresOfLandPurchased', window );">Land purchased, number of acres | a</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin | Drug Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin | Laboratory and Office Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Research Facility in San Diego</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAcresOfLandPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of acres of land purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAcresOfLandPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxIncrementFinancingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Increment Financing Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxIncrementFinancingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473564250496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,412<span></span>
</td>
<td class="nump">$ 45,891<span></span>
</td>
<td class="nump">$ 211,656<span></span>
</td>
<td class="nump">$ 100,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember', window );">License Collaboration And Stock Purchase Agreement | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember', window );">Olpasiran and ARO-AMG1 Agreement | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember', window );">Olpasiran Agreement | Amgen | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562184224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,412,000<span></span>
</td>
<td class="nump">$ 45,891,000<span></span>
</td>
<td class="nump">$ 211,656,000<span></span>
</td>
<td class="nump">$ 100,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">Janssen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-3989 (ARO-HBV) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-75220795 (ARO-JNJ1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473564153584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,412<span></span>
</td>
<td class="nump">$ 45,891<span></span>
</td>
<td class="nump">$ 211,656<span></span>
</td>
<td class="nump">$ 100,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">67,100<span></span>
</td>
<td class="nump">$ 69,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473559616000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,412<span></span>
</td>
<td class="nump">$ 45,891<span></span>
</td>
<td class="nump">$ 211,656<span></span>
</td>
<td class="nump">$ 100,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | ARO-XDH Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | Maximum | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473564529120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,412<span></span>
</td>
<td class="nump">$ 45,891<span></span>
</td>
<td class="nump">$ 211,656<span></span>
</td>
<td class="nump">$ 100,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo', window );">Milestone payment receivable at start of phase two</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | ARO-HSD Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment', window );">Performance obligation related to agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable at start of phase two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableAtStartOfPhaseTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PerformanceObligationRelatedToAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance obligation related to agreement, upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PerformanceObligationRelatedToAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROHSDAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROHSDAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473566483616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from investment in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from investment in joint venture</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473558079200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross', window );">Computers, software, office equipment and furniture</a></td>
<td class="nump">$ 2,210<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">31,678<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">42,017<span></span>
</td>
<td class="nump">41,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in Progress</a></td>
<td class="nump">22,338<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total gross fixed assets</a></td>
<td class="nump">101,239<span></span>
</td>
<td class="nump">71,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(29,335)<span></span>
</td>
<td class="num">(22,864)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 71,904<span></span>
</td>
<td class="nump">$ 48,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computers, software, office equipment and furniture gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562391648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562039136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi', window );">Equity securities sold</a></td>
<td class="nump">$ 122,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost', window );">Total, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,302<span></span>
</td>
<td class="nump">$ 429,703<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains', window );">Total, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses', window );">Total, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,968)<span></span>
</td>
<td class="num">(856)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue', window );">Total, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,366<span></span>
</td>
<td class="nump">430,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNoteDueWithinOneYearMember', window );">Commercial notes (due within one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,057<span></span>
</td>
<td class="nump">56,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,588)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,490<span></span>
</td>
<td class="nump">57,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNoteDueWithinOneThroughThreeYearsMember', window );">Commercial notes (due within one through three years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,920<span></span>
</td>
<td class="nump">195,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,380)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,540<span></span>
</td>
<td class="nump">196,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember', window );">Certificate of deposit (due within one through two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CertificateOfDepositDueWithinOneYearMember', window );">Certificate of deposit (due within one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable Securities, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">127,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable Securities, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable Securities, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 126,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesDueWithinNinetyDaysMember', window );">Commercial notes (due within ninety days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashEquivalentsGrossUnrealizedGains', window );">Cash Equivalents, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashEquivalentsGrossUnrealizedLosses', window );">Cash Equivalents, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashEquivalentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashEquivalentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashEquivalentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashEquivalentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents held to maturity and marketable securities amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents held to maturity and marketable securities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents held to maturity and marketable securities gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents held to maturity and marketable securities gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV- NI, Accumulated Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FV NI accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNoteDueWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNoteDueWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNoteDueWithinOneThroughThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNoteDueWithinOneThroughThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CertificateOfDepositDueWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CertificateOfDepositDueWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesDueWithinNinetyDaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesDueWithinNinetyDaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562280496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,276<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Amortization of license agreements remainder of fiscal year 2022</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of license agreements in 2023</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of license agreements in 2024</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of license agreements in 2025</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of license agreements in 2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">Amortization of license agreements, thereafter</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets amortization expense after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473557981280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">$ (400)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
<td class="num">$ (1,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, ending balance</a></td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562281904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,795,456<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued to institutional investors (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance (in shares)</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Stock, Share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,942,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562312960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember', window );">Verona Technology Park | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAcresOfLandPurchased', window );">Land purchased, number of acres | a</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendsToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAcresOfLandPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of acres of land purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAcresOfLandPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473559333136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_HalozymeIncMember', window );">Halozyme, Inc. | California | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | Colorado Owner, LLC | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AdditionalLandSubjectToLease', window );">Additional office space for lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Expected leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="nump">$ 119,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="nump">$ 31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne', window );">Estimated payments for operating expenses</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalLandSubjectToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional land subject to lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalLandSubjectToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated payments for operating expenses year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EstimatedPaymentsForOperatingExpensesYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected payments of leasehold improvements, net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_HalozymeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_HalozymeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473559323856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remainder of fiscal year)</a></td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">5,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">11,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">12,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2027 and thereafter</a></td>
<td class="nump">114,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">153,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(72,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 81,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and after year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473559748592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">2,842,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,842,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,456,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod', window );">Grant date fair value of the options granted</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 33.7<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">$ 83.4<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod', window );">Grant date fair value of other than options granted</a></td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">95.2<span></span>
</td>
<td class="nump">$ 112.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 190.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">216,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">216,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">4,114,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,114,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,806,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of restricted stock units outstanding (in shares)</a></td>
<td class="nump">2,308,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">816,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">682,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Stock, Share reserve for issuance (in shares)</a></td>
<td class="nump">6,627,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,627,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of restricted stock units outstanding (in shares)</a></td>
<td class="nump">1,507,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,507,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value of the options granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value of the other than options granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473562239424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,456,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(106,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(506,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,842,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares)</a></td>
<td class="nump">2,370,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 19.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">43.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">8.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">20.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 16.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 55,434,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 52,941,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473566463760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">90.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of options granted</a></td>
<td class="nump">$ 48.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473557981152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Detail) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">3,831,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,691,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(962,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(95,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">4,465,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 61.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">56.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">49.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">69.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 61.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473558012832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommercialNotes', window );">Commercial Notes</a></td>
<td class="nump">$ 25,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 126,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments</a></td>
<td class="nump">225,490<span></span>
</td>
<td class="nump">57,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments</a></td>
<td class="nump">159,540<span></span>
</td>
<td class="nump">196,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CertificateOfDeposits', window );">Certificate of deposits</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommercialNotes', window );">Commercial Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CertificateOfDeposits', window );">Certificate of deposits</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommercialNotes', window );">Commercial Notes</a></td>
<td class="nump">25,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments</a></td>
<td class="nump">225,490<span></span>
</td>
<td class="nump">57,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments</a></td>
<td class="nump">159,540<span></span>
</td>
<td class="nump">196,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CertificateOfDeposits', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommercialNotes', window );">Commercial Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CertificateOfDeposits', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CertificateOfDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Certificate of deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CertificateOfDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities fair value non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesFairValueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>arwr-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20220630.xsd" xlink:type="simple"/>
    <context id="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0eb90c33d05c47c88c1c6aaef59590bb_I20220728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="ib685fad7e1394c24a0d385826599cb7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id07622b31e124512bd809dd85be92060_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb451dbc614647eeae7a8d0e4c8c7be7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e6efb1ddfc5453da4e77a64f7bc884a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id27f4b394fa046b1992266b861dbe1a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia66bad26c2a34d24ad5ca9c5e4eef6da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iff04c31da3124bb8b79f993576b1d6c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icc87ab7199fb4b3894709d1fad320fa4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8144dd9083c8420182eb7611a33d74e6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i986c27fd3f64481193e82610f25e702e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefd3e354c4fb4c46a320a7f30a707610_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6f4268a9aa4a4ceda2df7e5e808d365e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i360a277f7b40494f87b23039e4db0bbb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i548093d511844b36a5a27eaae0e82e44_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib6ded07ed27245818bf9aef5e7ba2a7e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8d32639f7f104939ab0a9725e78b69b4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4651ee9cf1f14481bedc0b2c11215a6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if4f6234a3685486ca994214a4764e7bb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b5dd0c8a3394f31908e92a5913fb593_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7312b8ac99bc4e898fb36582961f90c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i90eb9a8e9b544abd9ab19dcd6a62b233_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i89fedd5fe7074d0ca9d9238d4393208b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie837290bad674840a22e8de24d43f73c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic4a078090d8343278240c419c75f7557_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iefd2cca928df4e10961ee81cc592602f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifd117bd825d749678065575557ebea36_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8a4508cff922436192b0b439cebf0c7c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic4816eaf78464899a0da70c9cb57dd1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3e00d55cfe1d49e8949d5d504a8eb36d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i44ba2ab14d6444fc96945d0ba6cf971a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5c60489a1c8647218a6a815fd8643604_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibce805be2cf34d7588c5ad783725855d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iabf1d96581774db2a2a88ed7dc4eb1c2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2ad6d36250af4ca0b2a87fa8a8832424_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i40d1f89e869e4a68b93c3ebcad9d0749_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4de2006bd97d4d02bf198bf6b206a3f0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84cbcad7ba9d4502ad0c6277ddf1e420_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2764942d41741bfa09cf6591e60e421_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia2cf5b805bdc476da8693441f1133ab1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic62dce18edcc450bb26c92091fc67be4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i30bc05a0d514445b8ab051db8e7aa4dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i75d457b5e22f453999509e78b6199c10_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if399881c34fd417fbed0c60ffc0323c5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icdd56a7531d2463f9a5c4f9801bbc96c_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4717e9d5d29411bb00be37c6e0d8988_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i578cd120a7ab48f790437217bbc8556b_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c9768d66c104f1aa87e005d6db6e1d7_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic75e9e025dbd4b38aa62c9741d197da1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id75ca493ec1f402f850e52443619f642_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1022cf2430e6451eb267b84ac9a5d1c2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd085594814a45419028bebfd289cf4e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3f4cf8a5af7f4d69aa755310016c82ad_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d3a720bc2944c47a2dbc3160113d536_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if5d04990863c4ffebb18aa567f52c795_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="i8557188d4af54eb08dc810e89d94a2af_D20160928-20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="id85c5ae5131b4cf5aee60543418e6dc7_D20160928-20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseCollaborationAndStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="i16d7c8f61f044b1ca180ce2a40fa4c78_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="if6a4c6243f314042b988b3644714d5ae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i642afe5a3db1459fb006b42ac0e0fda2_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ibdbfdc5869124c39b1b3bb71ecfc7d8a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i15de6290b08748d4860a17dafd0dc478_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia535e3b54c9f4258ab014490ba47a9cb_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i56acccdf27c144ef8f241ed180cb1e68_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd831e272413430f8e8bd86d511a426d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9a529c59ccab48439e6e1f6656cfb54b_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i433c47b3f8c8462580eaf03f04ea786f_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i4e1a46243860468ebedfd52732a1d64a_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i058a0e84238747de838a9ae350816175_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="iea7a8bafb0694de299c426ee0b32a895_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i44c2ff8f563d4797bb710b4c5bf60938_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="ib12fd50d833f43e7ab0c3963c67d8c7c_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i683a96e617044dc7a7cfc73242c01f94_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i33863eeccc354ec290037c1feffc9fcd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4ecd1a82934c4324b5fdce6ab2812055_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic59f147408ce4825a0772a7efc899c0a_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4395de79fe9145328658914e46b9ac3b_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife7d1814c3ee4dc8b62b5e12fbdc725a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i45013fbe4c444400b19d92afe847608f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if25fe0bc8a244e299ac437cbe6dd0756_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d15264a4c8a455daaa0f41c6d369f33_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5e11bca521447a3a3b4efbe502f791a_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee335bd52ba2451a8a52d753c51da9f0_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i6f168d9bf5d04ce3988dc7c810cc2a80_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idecd2c5ebb7545b1afca8e3a81415b21_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib729c3113dd941d48caf68aba7dcd82b_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i0e106a6904ed442d9339a7236c68726c_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="ic1e4e7286efe4e7e9875b4571c089f8c_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="iecb6f8d22f8d4f1f9241a3072aac7249_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="if94556e4a361454299073a451c9f3184_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i067c1e4b9a0247c7a50ae4cdf3371c7c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i28b4742bad8448c69d778802996dd6bf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7012433fc1464bb4b1ce9ec8d2e4ea99_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6fc281b2b25f4c18bb40e5a85d4aa480_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic97a79c8293c4fe0bbd8c8743f172820_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9359ec9011884267a96788ac6a2ad3c9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifb2d0e8036de47a38214f8da27a75c2b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic5da86e52d344df6bdd898bbe4acfef7_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ifd0fff411780433c8b41924a087c4995_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i70f76d63dd964a6a80d47beca9e8f6af_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ib336907d2752401e850feece66ae0251_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ifac4cb40a788432a8608233b693cb386_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if864eef3f413411faa9649ecf780d795_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i244740bda57c4515a402b65ce9115249_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfd0e90e113d47a59150ec0852ccdc57_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iceda2f32a68d4891ba199eab359ecbd6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibaf3b5392cc94e35b5172697c4a4b526_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i610703f0575242bebd037f61c55a72f3_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibeba9082710947699803c66c72381300_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="ia4b8212c8479404199b23c9c498f31a9_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="ic540fad5d90642a2b2dda2b6047c73c0_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i63bff98126fe415385b5f094684f04c1_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1956315e881a45299f1a80ddb4410e27_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i97c2718553fd46d69ad19a4d0391e677_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d593f14b6cb41c990078718ee591af5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if56e80163bfa40bc908f0611a5ea88cc_D20220425-20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="i77fd51ba125e419fbba6f8c78ee5dccb_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i1d571372f7da4510a63fa25715f88db4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesDueWithinNinetyDaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iefbbdb15dc3e40fe8077c9625e204afe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8b1f86d220804f7184099925062e5674_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i70569a67857b45de8cf63d09a492b8b0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CertificateOfDepositDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i01d441b649884843a5fd944aaba32e08_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7a7391425e04e84be5220dd1fbd8895_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i12572392d85c4114bacfb1a517b43c1e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNoteDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i48a971a1200644508883665152308229_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CertificateOfDepositDueWithinOneThroughTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70ac20dc1b6c4e8089f4f3a352305d67_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id7dab9325362475c8d7c98474f501710_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35243ae1496c4b5397e5376a54a5213e_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3ea210cb7e064575b12fb0ca788bb100_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7c9c3675bb1c483490de44cfa494ff0d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5c06ed8ba612412c9c704fef2aa0558c_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i505d3506ef1048dfa8e34da8a51f5a14_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i33ee3925344148cf9ff3b0be626dbb9a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i84bb462914da49deab71348a6efb6c40_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="i9cab2225d77f4ca6a233208a8d4c59f5_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i4a16451ca658448c8cea645ec09ff1d2_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i4ba847cf8c8e49c5bddc809e4dc8d3f7_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="if0867bc01dd94d139541c0b51a1ab546_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i376ce739b9c345478ec0d64a72a9dd1e_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i644bf2a958784d90a68f8b4c4f576ef5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if64b93b7539a474baa3e0eb46dbbd950_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifdf66a768eba4ecb8fe84a26654807ed_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6885dc858b074038a02f3117afb66394_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i692059f5d1fe4e29a4e0274f8340c5e5_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i162842da9c754c31a54c9669b0abb806_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ie5cf456b9e5a4cfcb2e90173f201d53f_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="iae3244d52008465399c8cf8280559727_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i773403c141e742faaafdffe0102289bb_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ia255aa9db9e44c3abb416601214d870b_D20201101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied64e4423da840bc99bd1ce7b1418f51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8783fb2c40044c1b857062a070f80527_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="id660743071414df3aeca314c0c062149_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i5fa41fe62302434990f633a5d20b8810_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i05cd815b480347a286bc4f71cff5bbcb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65ce38c05a5f42e5aef4eab075945c1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i379e60ba18ab41bebaf6384f97789684_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if3aae72041c247afb7d654e771941178_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7882ec681e8845bdafe4d93a1da25ae0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4351ec20fd374ac591919ea36aeda735_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9a3423502b6f4eff862ece7e6ce5ab9f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia900dec5d8af437f8940adc4f0279a04_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i10471b52c2b6469eadb29efc00dc46d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib4c1075e233c4c4285d6a3aadd4db3ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4c13269bb6524b0cb33ce18d229e84d4_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bb156c620804981b8a0721dfa56e51a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i259144688fe44f518dbdd195d182b514_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id47421dd3b3e45a88df5bdc71cefa55c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i88e9d9c8bcbb4fcaabd247d4fbea501a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4414d1709ac14596b6a26d0204f04e45_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7214723d69d141009860a51209e72550_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7cc07f5f5684808976783384030924f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic7c4db4499354a50be2f2351fc8b9349_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i224620efc59044b19ba131a63fb0f173_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iffbe6a0a54524c628256db91d4b3fe22_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="option">
        <measure>arwr:Option</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl8yLTEtMS0xLTIyNQ_0ee567be-5f68-42a8-8dc5-42f35fbd2440">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl8zLTEtMS0xLTIyNQ_ff887b4b-0013-4007-9e7c-91d215397f81">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl80LTEtMS0xLTI5NjI_af5967b4-d245-4987-8fcd-fc4d627bb5d0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl80LTEtMS0xLTIyNQ_f02045fd-aaf2-41be-b08f-13baf4354088">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180L2ZyYWc6MzIxOWMyNjdjMTNkNGE0MTliN2MzOTNmMDg0MDJiNWUvdGFibGU6MzIxYmZiZDU3NDdjNDBlNWI5ODg2NGJlZTkwZTI2NWIvdGFibGVyYW5nZTozMjFiZmJkNTc0N2M0MGU1Yjk4ODY0YmVlOTBlMjY1Yl81LTEtMS0xLTIyNQ_2e317707-14d8-4f36-bcbf-376671657606">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjYz_d1d32c20-d7f6-467c-8ad2-218cbb858f99">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6NmQ0YTRmZTA3ZDdiNGZmZThlZmI5ZjRkMzM5ODc1YzYvdGFibGVyYW5nZTo2ZDRhNGZlMDdkN2I0ZmZlOGVmYjlmNGQzMzk4NzVjNl8wLTAtMS0xLTIyNQ_9bd0e20b-1671-4978-9336-569cfc314d45">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN181NDk3NTU4MTYyMDI_6a3d0f19-1b06-4859-a63b-5dd00aaec584">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6N2VlZGU2M2NkNDZiNDNkNGE4YTM0ODE5ZTM5OTJlMDgvdGFibGVyYW5nZTo3ZWVkZTYzY2Q0NmI0M2Q0YThhMzQ4MTllMzk5MmUwOF8wLTAtMS0xLTIyNQ_65058c8d-f9ea-4933-9cd8-03b0abd0b9c5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjY4_0ea36c2c-d6d9-470b-bcc7-bdb8aa65aee5">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjY1_e0682a35-c8f7-4b0f-af15-03382d89a04f">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6MDAzODk2YzA4ZDZmNDZhZTlkNzAyMzZjMjE3OGUxMTgvdGFibGVyYW5nZTowMDM4OTZjMDhkNmY0NmFlOWQ3MDIzNmMyMTc4ZTExOF8wLTAtMS0xLTIyNQ_052f127e-a356-40c7-8c90-74cc0cfbc559">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6MDAzODk2YzA4ZDZmNDZhZTlkNzAyMzZjMjE3OGUxMTgvdGFibGVyYW5nZTowMDM4OTZjMDhkNmY0NmFlOWQ3MDIzNmMyMTc4ZTExOF8wLTItMS0xLTIyNQ_d1cbd591-6673-4dc7-a90d-6c09767ca5d7">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180Nzc_ba7defbd-2254-449a-aab8-f159e44cba5c">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180ODE_06b5110a-1782-49bc-aa96-f6760aac68cf">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180ODQ_96f66a4b-f08e-490d-a366-a07bf5596b18">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180ODg_936f04ce-3c55-4037-848e-af8187dd2fc3">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180OTE_115fa39c-c23e-4e04-941b-3a890939983f">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180OTU_27f366f0-8fbe-40cc-b38d-5504e57857d2">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN180OTk_67f989dd-5aa5-48e5-8af5-45574649293d">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6YTkyMWQ4ODlhNTUzNGJmN2IzOWJjZjViOWJhNjkwMjUvdGFibGVyYW5nZTphOTIxZDg4OWE1NTM0YmY3YjM5YmNmNWI5YmE2OTAyNV8xLTAtMS0xLTIyNQ_4495d374-1de0-4692-acf7-0e5e24c80b6a">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6YTkyMWQ4ODlhNTUzNGJmN2IzOWJjZjViOWJhNjkwMjUvdGFibGVyYW5nZTphOTIxZDg4OWE1NTM0YmY3YjM5YmNmNWI5YmE2OTAyNV8xLTItMS0xLTIyNS90ZXh0cmVnaW9uOjg0ZmViNzMwZWUwYTQ2YWI4ZmIyYTc3NGJmZTZmNWE5XzQ_fb309160-e540-4c5a-bf6e-0819e77f1ab2">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6YTkyMWQ4ODlhNTUzNGJmN2IzOWJjZjViOWJhNjkwMjUvdGFibGVyYW5nZTphOTIxZDg4OWE1NTM0YmY3YjM5YmNmNWI5YmE2OTAyNV8xLTQtMS0xLTIyNQ_0e8ee536-c348-41a5-82e0-7e1cf19c37db">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjU5_ae7badca-c5f5-4418-b829-42cf9386b5a3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjY2_dfcba5ee-5898-4227-a38b-86dcc0c5bbce">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6Yzc1NDNiZDJjMTQxNDIxYTg2N2NiMDdmNGYxYTkyNjMvdGFibGVyYW5nZTpjNzU0M2JkMmMxNDE0MjFhODY3Y2IwN2Y0ZjFhOTI2M18wLTAtMS0xLTIyNS90ZXh0cmVnaW9uOjBiODAzMjZiMjAyNzRhZWY5MzkwY2Y0NDBmMDU5YTQxXzQ_0445aa17-6cf3-4793-8802-1502c6697da2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6Yzc1NDNiZDJjMTQxNDIxYTg2N2NiMDdmNGYxYTkyNjMvdGFibGVyYW5nZTpjNzU0M2JkMmMxNDE0MjFhODY3Y2IwN2Y0ZjFhOTI2M18yLTMtMS0xLTIyNQ_eded1000-a882-4c0d-9fcd-012431157f90">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGFibGU6Yzc1NDNiZDJjMTQxNDIxYTg2N2NiMDdmNGYxYTkyNjMvdGFibGVyYW5nZTpjNzU0M2JkMmMxNDE0MjFhODY3Y2IwN2Y0ZjFhOTI2M180LTEtMS0xLTIyNQ_2ec3edb8-2884-406c-bb73-86422ecfd79d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMjYx_3eff7b80-b6a1-4e54-81b6-f87d7916a08b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0eb90c33d05c47c88c1c6aaef59590bb_I20220728"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xL2ZyYWc6M2IwYzM5ZGQ1M2E0NDNhZTgxNThiMzIwMDkyNDViZjcvdGV4dHJlZ2lvbjozYjBjMzlkZDUzYTQ0M2FlODE1OGIzMjAwOTI0NWJmN18yMTk5MDIzMjU3OTUz_69c75aa7-bb02-4b9b-9223-4a5e93233357"
      unitRef="shares">105848963</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMy0xLTEtMS0yMjU_20446129-27cf-4ab9-a718-8398b20fc271"
      unitRef="usd">139439000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMy0zLTEtMS0yMjU_127207e1-4284-4bd7-9434-0a0ec1dba9ef"
      unitRef="usd">184434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNC0xLTEtMS0yMjU_9dcb1297-c637-4728-95e0-738189a7a81a"
      unitRef="usd">239000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNC0zLTEtMS0yMjU_450a63aa-886a-412b-b13f-ceba321e1a9a"
      unitRef="usd">10255000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNS0xLTEtMS0yMjU_4647e5e9-df8a-48d1-b7b7-6c71eda33040"
      unitRef="usd">6761000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNS0zLTEtMS0yMjU_a9b4cca1-1c67-494c-86ec-18882f6babad"
      unitRef="usd">4362000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNi0xLTEtMS0yMjU_457a20b6-d94f-4ae0-8666-60cc5a82435f"
      unitRef="usd">8892000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNi0zLTEtMS0yMjU_f7e3b736-7ea8-420d-a4af-e318a6723a83"
      unitRef="usd">2191000</us-gaap:OtherAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNy0xLTEtMS0yMjU_1194abbd-b145-4509-8055-ed8adb07e325"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfNy0zLTEtMS0yMjU_81727d85-c844-4c31-951c-e81a3878dd78"
      unitRef="usd">126728000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOC0xLTEtMS0yMjU_9ba4bb89-36e0-4c63-93f5-2b30b129423c"
      unitRef="usd">277057000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOC0zLTEtMS0yMjU_9fbef565-1059-48e4-8cdf-136187393629"
      unitRef="usd">56627000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOS0xLTEtMS0yMjU_f1639adc-3f5f-48f9-be4a-38478de92a09"
      unitRef="usd">432388000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfOS0zLTEtMS0yMjU_7a318fe8-6083-4704-a636-6f47180d96e5"
      unitRef="usd">384597000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTAtMS0xLTEtMjI1_27c5a3af-0c4c-4230-b82c-b132717aa4ff"
      unitRef="usd">71904000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTAtMy0xLTEtMjI1_6803e639-50c3-4472-822f-43e81a1f3ee5"
      unitRef="usd">48675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTEtMS0xLTEtMjI1_6a085d09-e3ef-4b14-9325-6a1a835dacd2"
      unitRef="usd">12387000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTEtMy0xLTEtMjI1_ff58bcdc-f9ef-466f-a14b-ee0daf79ff4b"
      unitRef="usd">13663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTItMS0xLTEtMjI1_cd02148a-306d-47af-bc73-4c945c6f29a2"
      unitRef="usd">165920000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTItMy0xLTEtMjI1_f8801a81-2320-442a-98ef-90af0b1b1fec"
      unitRef="usd">245595000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTMtMS0xLTEtMjI1_11d86e7c-204b-4b6e-8f70-0eb0bb0f82da"
      unitRef="usd">68908000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTMtMy0xLTEtMjI1_65a76b4f-1e29-4e9a-bab8-c152c824982f"
      unitRef="usd">17346000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTQtMS0xLTEtMjI1_15877e4f-1d49-45f5-936b-042b67ca3c92"
      unitRef="usd">275000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTQtMy0xLTEtMjI1_889504cc-565e-4867-bb8d-3a7a680979d5"
      unitRef="usd">272000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTUtMS0xLTEtMjI1_83d03fec-dae4-4678-9249-96665f939f99"
      unitRef="usd">751782000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTUtMy0xLTEtMjI1_9ce54122-6771-4ebb-9847-0916d352038a"
      unitRef="usd">710148000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTgtMS0xLTEtMjI1_95e6084c-d2c7-4d2c-a96e-5ba449899b8a"
      unitRef="usd">5894000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTgtMy0xLTEtMjI1_6d956b66-e562-4fe0-acf0-a76a190eafa8"
      unitRef="usd">9457000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTktMS0xLTEtMjI1_5609593b-b402-481e-a811-699c4c393ba2"
      unitRef="usd">32499000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMTktMy0xLTEtMjI1_7c3010d3-b18e-4649-b01c-536ebec6e142"
      unitRef="usd">14001000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjAtMS0xLTEtMjI1_00bbe890-94e5-43e0-a237-f4b51ef5dc27"
      unitRef="usd">2648000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjAtMy0xLTEtMjI1_6aaad85f-ad6d-4588-9370-39c84a4b54b5"
      unitRef="usd">9773000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjEtMS0xLTEtMjI1_09be5ca0-91c1-4ffb-9951-14e399188f54"
      unitRef="usd">2883000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjEtMy0xLTEtMjI1_054b2bbf-fd2c-4696-84b6-2d3accc6b5da"
      unitRef="usd">2250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjItMS0xLTEtMjI1_9f3223b5-f24d-407a-af5e-609fea7e9667"
      unitRef="usd">84288000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjItMy0xLTEtMjI1_b3ad6243-3dba-4387-a32d-67665326ae5d"
      unitRef="usd">111055000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjMtMS0xLTEtMjI1_0fa5c83c-45ad-4be1-b6a6-24c52ab3b3b4"
      unitRef="usd">128212000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjMtMy0xLTEtMjI1_07359fdd-8a28-4463-baf1-e70abe8ee4fa"
      unitRef="usd">146536000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjUtMS0xLTEtMjI1_bea85cb5-5909-4891-bb78-0708a73ba8cf"
      unitRef="usd">78231000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjUtMy0xLTEtMjI1_bbe7d507-ba7e-4123-a6a9-097a94770334"
      unitRef="usd">23295000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjYtMS0xLTEtMjI1_f8655530-cf7d-4fc7-b9df-a283b023673c"
      unitRef="usd">71162000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjYtMy0xLTEtMjI1_d71ce60f-8207-43bd-9d0a-9c10a8f1105f"
      unitRef="usd">131495000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjctMS0xLTEtMjI1_474ede3d-94e2-4b77-9bc4-48f789ebab21"
      unitRef="usd">149393000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjctMy0xLTEtMjI1_0710e99c-57c4-4fe2-9455-3b02179f514d"
      unitRef="usd">154790000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjgtMS0xLTEtMjI1_2debe0ef-39fe-47e8-8329-3beb5e23672f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMjgtMy0xLTEtMjI1_c38f95dc-4626-4077-84ce-d29bc12f5854"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMTg_4527fa5a-2726-45ca-aa0c-9aaf5b54fbf6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMTg_a6491fb4-7c79-4136-9080-ca56ced7a7c3"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMzI_d186e1c3-6718-4e02-b8a4-4833ee7f4d9e"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfMzI_fe3f6d7e-afbf-404b-bb10-8f0ebb5f4d4e"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNTQ_35390206-f7eb-47b7-bae5-1d3dbb072bac"
      unitRef="shares">105795000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNTQ_b04a506e-38f1-4d1f-a3aa-47189786cacc"
      unitRef="shares">105795000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNjE_8127097f-6660-4cd3-b90b-b817ba5e7364"
      unitRef="shares">104327000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMC0xLTEtMjI1L3RleHRyZWdpb246ZjVhZmMzZTI5OTcyNDVhOWFlMWM2ODEyNjcwZWU3MDlfNjE_f5a41eb5-be0b-49da-a3f5-dcd385b1b6be"
      unitRef="shares">104327000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMS0xLTEtMjI1_d49b316c-e9cd-4dda-aa9f-5d022c365a20"
      unitRef="usd">198000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzEtMy0xLTEtMjI1_dac28f79-9a45-413b-8957-1013be216554"
      unitRef="usd">197000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzItMS0xLTEtMjI1_a0a1819a-d255-4d68-8592-26d403a7ffe3"
      unitRef="usd">1189113000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzItMy0xLTEtMjI1_dad98d50-e600-472a-89ac-bcf0e11298b0"
      unitRef="usd">1053386000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzMtMS0xLTEtMjI1_60c273d7-aa68-4667-bde5-bac24e084856"
      unitRef="usd">-140000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzMtMy0xLTEtMjI1_a07cf1ff-a46d-449e-a20f-4f4db9a637a3"
      unitRef="usd">-69000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMS0xLTEtNTQ3NA_9094dd1b-d939-4bec-8a18-8dbc8511687c"
      unitRef="usd">-735244000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMy0xLTEtNTQ3NA_88ca647c-adb5-4967-8b2c-9abadb1ffce1"
      unitRef="usd">-644692000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMS0xLTEtNzA3NQ_be4700a3-c0f5-4e16-9cac-ce05858c7874"
      unitRef="usd">453927000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMy0xLTEtNzA3NQ_8894e6ec-18ee-46cc-91d0-88dbf6a96899"
      unitRef="usd">408822000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMS0xLTEtMjI1_c4cc5b6b-a38f-40a4-ae81-52035d86d838"
      unitRef="usd">20250000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzQtMy0xLTEtMjI1_20c88a86-f43d-42a1-a597-a2cc85529917"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMS0xLTEtMjI1_25b5252f-af05-4fa1-bdbd-f8089fb608b3"
      unitRef="usd">474177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzUtMy0xLTEtMjI1_cc4cc334-4cd9-4eca-a998-3fb03021f2db"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzYtMS0xLTEtMjI1_cda1d37d-d31c-4923-9c1f-2f8778909569"
      unitRef="usd">751782000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xNi9mcmFnOjVhMmFhMjA0MzZlZTQ1M2M4NTExODAxMjJiNzg4NTMzL3RhYmxlOjQwZTgwYjcwMGYwYjQ2NjhiYTZmOThiOGNjMzgwYmY2L3RhYmxlcmFuZ2U6NDBlODBiNzAwZjBiNDY2OGJhNmY5OGI4Y2MzODBiZjZfMzYtMy0xLTEtMjI1_3b71008c-af33-40c8-8d32-97599ee1a77f"
      unitRef="usd">710148000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi0xLTEtMS0yMjU_4ff87c1c-f73f-4a2a-b891-d67071c76c7b"
      unitRef="usd">32412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi0zLTEtMS0yMjU_ac97b1fc-d8d3-4cb0-b161-a8ebdce6e364"
      unitRef="usd">45891000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi01LTEtMS0yMjU_3a6e8325-ec3d-4ac9-a6ed-926e6dfcf270"
      unitRef="usd">211656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMi03LTEtMS0yMjU_f0de4194-708e-49e9-b35f-f4ac4d2a6cd9"
      unitRef="usd">100004000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC0xLTEtMS0yMjU_4f54ea1c-1e38-49fa-825c-d26b714861c5"
      unitRef="usd">72180000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC0zLTEtMS0yMjU_7c6d0d03-2bce-4e80-ba53-6db43b37e73e"
      unitRef="usd">59325000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC01LTEtMS0yMjU_d8111596-0e73-41fa-b594-ef3d37f7403c"
      unitRef="usd">213930000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNC03LTEtMS0yMjU_d61fab63-3c37-4f25-b14f-da9eca8fd7dc"
      unitRef="usd">140576000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS0xLTEtMS0yMjU_36d888a4-46f5-4bb5-8f52-d8e12768dc7b"
      unitRef="usd">33141000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS0zLTEtMS0yMjU_4dbf50c1-fa1a-44aa-b409-62dcfbbe52f1"
      unitRef="usd">18434000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS01LTEtMS0yMjU_bf72ed4c-e0c4-4703-aeb4-9857428a4c18"
      unitRef="usd">92403000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNS03LTEtMS0yMjU_446d6b29-9d44-414c-af82-5530858f6c2d"
      unitRef="usd">43581000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi0xLTEtMS0yMjU_64a80447-9d61-4e61-b143-a3ff47259206"
      unitRef="usd">105321000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi0zLTEtMS0yMjU_ae450bd2-0301-474e-9ceb-4135956bc178"
      unitRef="usd">77759000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi01LTEtMS0yMjU_ddf38e7b-7eed-42cc-8e7a-f5a181ffd67b"
      unitRef="usd">306333000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNi03LTEtMS0yMjU_0c16766d-4c27-494f-be54-8794b78a5b18"
      unitRef="usd">184157000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy0xLTEtMS0yMjU_911dc241-1834-4168-b54f-0d152fb2f0ab"
      unitRef="usd">-72909000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy0zLTEtMS0yMjU_b4511077-ae55-470e-9da2-82bb564cdc68"
      unitRef="usd">-31868000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy01LTEtMS0yMjU_4426d91b-459b-42e5-ab25-be6b1cbeed39"
      unitRef="usd">-94677000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfNy03LTEtMS0yMjU_60563785-4864-4cbc-b991-289ed46cb059"
      unitRef="usd">-84153000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS0xLTEtMS0yMjU_bd62d596-1ba3-40d3-ba56-68adbb02f0af"
      unitRef="usd">1240000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS0zLTEtMS0yMjU_38ba2e27-27ca-4ee5-abe4-9b0e27b898ca"
      unitRef="usd">1280000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS01LTEtMS0yMjU_a0320a54-73ab-4d04-90d3-fcbacfad3e48"
      unitRef="usd">3450000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfOS03LTEtMS0yMjU_16244bae-9be5-4be5-8a0e-6d31a041776c"
      unitRef="usd">4972000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtMS0xLTEtMjI1_ead78237-669f-4235-ad56-dadfba771459"
      unitRef="usd">-377000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtMy0xLTEtMjI1_ee9ba2de-1cba-4309-a05a-ac1da1bcd835"
      unitRef="usd">664000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtNS0xLTEtMjI1_82afbdcf-5fe3-49e8-b3eb-29c7d5ec1825"
      unitRef="usd">675000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTAtNy0xLTEtMjI1_1b807f57-c1aa-4cdd-87ac-7c6c3d673d6a"
      unitRef="usd">1707000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtMS0xLTEtMjI1_acbfaef2-4c1b-4e97-91f2-45231a161873"
      unitRef="usd">863000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtMy0xLTEtMjI1_192e1021-8465-4567-a839-69dc00473fb1"
      unitRef="usd">1944000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtNS0xLTEtMjI1_55ee762f-fa3b-4b8a-9270-f297d2817d29"
      unitRef="usd">4125000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTEtNy0xLTEtMjI1_5fe3f444-4cf0-4fc9-b0ed-8ed50c016b4d"
      unitRef="usd">6679000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItMS0xLTEtMjI1_045e2348-85f4-49bf-af8c-1aca1e68e424"
      unitRef="usd">-72046000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItMy0xLTEtMjI1_7f0da18b-3b0a-46e8-bc64-a01c97bc7258"
      unitRef="usd">-29924000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItNS0xLTEtMjI1_0928f40e-15e5-4817-a84b-d193fe3f17b3"
      unitRef="usd">-90552000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTItNy0xLTEtMjI1_15f85c6d-24ee-42c8-b491-93c0c3c11720"
      unitRef="usd">-77474000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtMS0xLTEtMjI1_a1b761ea-b7fb-46ae-957a-4c2e95188589"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtMy0xLTEtMjI1_3b105bbb-21d2-49bf-b10b-83279a88ed0b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtNS0xLTEtMjI1_b3bfe7c5-12bd-4c4b-b2e3-9bde1f5df755"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTMtNy0xLTEtMjI1_cfb7b07d-33cc-4c4f-b3ea-3226748be149"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtMS0xLTEtMjI1_b035d0ad-0a30-4039-849e-4c5b73d2114d"
      unitRef="usd">-72046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtMy0xLTEtMjI1_0f882455-e6a2-40ce-ba4a-8ad5d4f85dc0"
      unitRef="usd">-29924000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtNS0xLTEtMjI1_521df68a-2f75-49fd-81fb-35192cea43cd"
      unitRef="usd">-90552000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTQtNy0xLTEtMjI1_a8106991-38b3-45c7-bd98-a8273bd40c3c"
      unitRef="usd">-77474000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtMS0xLTEtMjI1_744d917e-eedc-4ad8-8e9c-d06d18bc5b53"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtMy0xLTEtMjI1_b7bc2abf-e81d-4329-a2cb-c1ccd42b4e02"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtNS0xLTEtMjI1_42a88be2-695d-4544-bd55-a45d9e08748c"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTUtNy0xLTEtMjI1_8b97687a-852f-4aad-9ee3-f41e5e7b5cc2"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtMS0xLTEtMjI1_f282c6e4-83bb-4487-8e06-78aadf050632"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtMy0xLTEtMjI1_3db488ea-fe10-4ebd-a0a0-b297e3ddfc92"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtNS0xLTEtMjI1_7e26b059-a3ca-4be9-9e49-0187f1b79a67"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTYtNy0xLTEtMjI1_063b471c-a89b-4251-9788-e4234e6c3b8a"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctMS0xLTEtMjI1_15671269-a5ca-4aef-9383-0ad031c635b0"
      unitRef="shares">105753000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctMy0xLTEtMjI1_c1eb8c16-cc20-40fb-b2f5-9548708a2062"
      unitRef="shares">104099000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctNS0xLTEtMjI1_38de0f6b-6d5f-4a8b-8984-f1a0d32ed794"
      unitRef="shares">105273000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTctNy0xLTEtMjI1_7b35a2d7-596e-4039-8e7c-da8a4c9021ff"
      unitRef="shares">103569000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtMS0xLTEtMjI1_f0af838e-92ea-411c-bd71-69291c72a335"
      unitRef="shares">105753000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtMy0xLTEtMjI1_f033b684-ebb8-490e-a009-c7361a608423"
      unitRef="shares">104099000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtNS0xLTEtMjI1_7de91ff2-241b-4285-a081-0d9088e81248"
      unitRef="shares">105273000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMTgtNy0xLTEtMjI1_b2bf66f7-6461-413e-ba3c-ea72261a5d16"
      unitRef="shares">103569000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtMS0xLTEtMjI1_099070c9-96af-4729-9ebe-7f2308d72906"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtMy0xLTEtMjI1_87aff911-3537-4bbe-9924-ee03c215e34d"
      unitRef="usd">-40000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtNS0xLTEtMjI1_25fa3908-e88c-4286-86f4-3eecce372bde"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjAtNy0xLTEtMjI1_a6c56a2f-e0ef-45ff-9cbd-ee3aaac70d9e"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtMS0xLTEtMjI1_d5ad7c7c-c426-4a61-910e-499650284b5f"
      unitRef="usd">-72079000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtMy0xLTEtMjI1_8677e62f-8e13-4afa-99ac-600bfe8d2394"
      unitRef="usd">-29964000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtNS0xLTEtMjI1_6926f006-ce78-4f48-afb9-f9677b3c7f47"
      unitRef="usd">-90623000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18xOS9mcmFnOjIyNmE3ZmU0ZDE3YTQ1ZjBiZDA3OGExZWRkMzMxMDU0L3RhYmxlOmZkZDY2MWRjZTU3MDQ0MTU4MmIzNzVlYzlhYjU0NDIyL3RhYmxlcmFuZ2U6ZmRkNjYxZGNlNTcwNDQxNTgyYjM3NWVjOWFiNTQ0MjJfMjEtNy0xLTEtMjI1_cf76cc72-8972-4dd1-8f14-2c314aea0277"
      unitRef="usd">-77430000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="icb451dbc614647eeae7a8d0e4c8c7be7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0xLTEtMS0yMjU_4501c6ce-af87-4226-88bc-b2907277a74e"
      unitRef="shares">104020000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb451dbc614647eeae7a8d0e4c8c7be7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0zLTEtMS0yMjU_a451330d-c7a9-4de6-9b7f-1d3b888c49b8"
      unitRef="usd">196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e6efb1ddfc5453da4e77a64f7bc884a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS01LTEtMS0yMjU_de44c02b-e0e8-4091-bf7a-a016e52c6293"
      unitRef="usd">996645000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id27f4b394fa046b1992266b861dbe1a0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS03LTEtMS0yMjU_7b341ab8-055e-4919-be4d-64a8bf7dd9d2"
      unitRef="usd">102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia66bad26c2a34d24ad5ca9c5e4eef6da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS05LTEtMS0yMjU_9cacc995-01b2-4f55-a530-d2acd5e23d5e"
      unitRef="usd">-551394000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff04c31da3124bb8b79f993576b1d6c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0xMS0xLTEtNDU3Ng_1a888223-f500-4ddd-a01f-b9de529b4fd2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc87ab7199fb4b3894709d1fad320fa4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMS0xMS0xLTEtMjI1_4bbd5b66-6863-4642-bd32-8bd086491e91"
      unitRef="usd">445549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8144dd9083c8420182eb7611a33d74e6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMi01LTEtMS0yMjU_dbb20bbd-5417-4b56-8521-80857ec536e0"
      unitRef="usd">18549000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMi0xMS0xLTEtMjI1_67a03888-7df5-4ae5-b887-7e43f27093aa"
      unitRef="usd">18549000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy0xLTEtMS0yMjU_4d5c2297-b554-4450-9fe0-74dfd05dc5f5"
      unitRef="shares">161000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy0zLTEtMS0yMjU_1f6ef0de-5642-4e97-9176-181893af346d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8144dd9083c8420182eb7611a33d74e6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy01LTEtMS0yMjU_bb3c21a1-9f1c-4f7e-bded-a5bba8197f90"
      unitRef="usd">2755000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfMy0xMS0xLTEtMjI1_843fc0cd-4b19-446c-8279-8bb628c937f5"
      unitRef="usd">2756000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="id11977aa8c1a47de9c5c27f17259d507_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNC0xLTEtMS0yMjU_263654fe-03be-47fe-8fac-c749b3ec471a"
      unitRef="shares">28000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i986c27fd3f64481193e82610f25e702e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNS03LTEtMS0yMjU_28b73b0f-40a8-452c-bed5-dd53693b3dcf"
      unitRef="usd">-40000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNS0xMS0xLTEtMjI1_e2f99992-465c-4803-8126-8e1be2ac4c37"
      unitRef="usd">-40000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iefd3e354c4fb4c46a320a7f30a707610_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNi05LTEtMS0yMjU_93e4ef1f-e777-414f-b5a3-e73b33b3e91a"
      unitRef="usd">-29924000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNi0xMS0xLTEtMjI1_8af8c125-87b8-478a-aac0-4d74f05039c0"
      unitRef="usd">-29924000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0xLTEtMS0yMjU_fd26cea0-b1da-45b1-96a0-a17559b130d0"
      unitRef="shares">104209000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0zLTEtMS0yMjU_179197d2-4231-4741-8e42-3a86b4dae4f2"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f4268a9aa4a4ceda2df7e5e808d365e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy01LTEtMS0yMjU_c2ff586f-b88d-40b8-967e-e5e52861030f"
      unitRef="usd">1017949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i360a277f7b40494f87b23039e4db0bbb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy03LTEtMS0yMjU_a916867b-ac0a-4c62-866f-27476de94b3c"
      unitRef="usd">62000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i548093d511844b36a5a27eaae0e82e44_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy05LTEtMS0yMjU_41c6d085-90fd-4cb4-8531-ad1a78df7b20"
      unitRef="usd">-581318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6ded07ed27245818bf9aef5e7ba2a7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0xMS0xLTEtNDU3Ng_adae2bbb-5f17-4ce5-abee-ded803e244ff"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d32639f7f104939ab0a9725e78b69b4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjRlZWQxN2UyNTEzNzQyZjQ5NmY5MTgzYWQxYWU1ZDllL3RhYmxlcmFuZ2U6NGVlZDE3ZTI1MTM3NDJmNDk2ZjkxODNhZDFhZTVkOWVfNy0xMS0xLTEtMjI1_00c0d97a-7717-4651-9248-3273fe02d43e"
      unitRef="usd">436890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4651ee9cf1f14481bedc0b2c11215a6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0xLTEtMS0yMjU_0ac8b00f-048f-4650-a844-080d7f2f5d98"
      unitRef="shares">105702000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4651ee9cf1f14481bedc0b2c11215a6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0zLTEtMS0yMjU_d09cdc6c-a31f-4e41-af89-09c427404681"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4f6234a3685486ca994214a4764e7bb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS01LTEtMS0yMjU_9e712b57-5507-48b1-a61a-d5321bfedee6"
      unitRef="usd">1115373000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b5dd0c8a3394f31908e92a5913fb593_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS03LTEtMS0yMjU_2537eaa9-77e6-4cc1-95a2-ac955574eca5"
      unitRef="usd">-107000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7312b8ac99bc4e898fb36582961f90c2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS05LTEtMS0yMjU_f14de943-893a-44cd-998f-e23a2362988c"
      unitRef="usd">-663198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90eb9a8e9b544abd9ab19dcd6a62b233_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0xMS0xLTEtNDYxMQ_ca024a8f-326a-42b4-8cf3-fdb246258e73"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89fedd5fe7074d0ca9d9238d4393208b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMS0xMS0xLTEtMjI1_339c62b1-47c2-4340-8ed5-8efecffbb19f"
      unitRef="usd">452266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMi01LTEtMS0yMjU_c4a39206-6114-4660-8a60-34091274f2a8"
      unitRef="usd">33391000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMi0xMS0xLTEtMjI1_62649527-1ce1-49f7-b07c-f81faef18b41"
      unitRef="usd">33391000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie837290bad674840a22e8de24d43f73c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMy0xLTEtMS0yMjU_502b5bf9-a125-4601-8424-a639b8b958d3"
      unitRef="shares">53000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMy01LTEtMS0yMjU_027de726-d0a7-4418-b92d-27c813fe263b"
      unitRef="usd">599000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfMy0xMS0xLTEtMjI1_606b4d87-bba1-493e-bb3c-fd3ed6cb2d11"
      unitRef="usd">599000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie837290bad674840a22e8de24d43f73c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNC0xLTEtMS0yMjU_a4d39797-b682-4b1d-a16f-15558c7f7714"
      unitRef="shares">40000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNC0xMS0xLTEtMjI1_e9e4cc5e-8fac-42ba-9e8b-c1c9d707491c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic4a078090d8343278240c419c75f7557_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNS03LTEtMS0yMjU_f57374ac-cc96-4186-ad7a-e11d5725b87f"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNS0xMS0xLTEtMjI1_77a04ce2-340a-4338-a38c-1b1eb89d29f8"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iea9d7b8f30054408ab4dd767d80ffad1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi01LTEtMS01OTU5_917b657a-7ee1-4975-93a1-b3ebb6779902"
      unitRef="usd">39750000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iefd2cca928df4e10961ee81cc592602f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi0xMS0xLTEtNTk1OQ_8a88160a-9dca-497f-bb70-510a4e8346da"
      unitRef="usd">20250000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi0xMy0xLTEtNTk1OQ_d10688c3-bb2c-44db-8236-58d756b11dc2"
      unitRef="usd">60000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLoss
      contextRef="ifd117bd825d749678065575557ebea36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi05LTEtMS0yMjU_a73bb06d-8efa-4b7a-b48b-2301f29d053a"
      unitRef="usd">-72046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNi0xMS0xLTEtMjI1_c6442e18-5a29-45f5-a7c9-720e14b09268"
      unitRef="usd">-72046000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0xLTEtMS0yMjU_9f95c4ad-236b-4055-9fa7-d69d7bd32d0d"
      unitRef="shares">105795000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0zLTEtMS0yMjU_7d731aed-16a7-453d-be49-2018009b9aa6"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4816eaf78464899a0da70c9cb57dd1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy01LTEtMS0yMjU_f00c0f9e-8bdc-495a-9cba-36a9e9cada8e"
      unitRef="usd">1189113000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e00d55cfe1d49e8949d5d504a8eb36d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy03LTEtMS0yMjU_f3dba0d7-56d0-43da-8ef0-7d820ee6bf6a"
      unitRef="usd">-140000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44ba2ab14d6444fc96945d0ba6cf971a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy05LTEtMS0yMjU_f9df3a19-10ea-479c-9fb9-bccd6fe91c3c"
      unitRef="usd">-735244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c60489a1c8647218a6a815fd8643604_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0xMS0xLTEtNDYxMQ_22e2d6db-b19e-4fb6-8610-a6388b3e1a55"
      unitRef="usd">20250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOjc2Nzc4ZDc1NTA5NTQzZmFhOGQxM2VjNTdmN2JjYjlkL3RhYmxlcmFuZ2U6NzY3NzhkNzU1MDk1NDNmYWE4ZDEzZWM1N2Y3YmNiOWRfNy0xMS0xLTEtMjI1_e4e58976-4889-4dad-ba19-76cfbed3d3a5"
      unitRef="usd">474177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ibce805be2cf34d7588c5ad783725855d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0xLTEtMS0yMjU_b6a2bb6e-c916-46e9-9e5e-66691b1c6c66"
      unitRef="shares">102376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibce805be2cf34d7588c5ad783725855d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0zLTEtMS0yMjU_39b2048c-4860-4f1f-a016-af302d3cb9aa"
      unitRef="usd">195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabf1d96581774db2a2a88ed7dc4eb1c2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS01LTEtMS0yMjU_c4d865c2-c9ba-4962-b6e3-91677da0e632"
      unitRef="usd">965410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ad6d36250af4ca0b2a87fa8a8832424_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS03LTEtMS0yMjU_e8adc1f2-9253-437a-8d62-827698c0c325"
      unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40d1f89e869e4a68b93c3ebcad9d0749_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS05LTEtMS0yMjU_4ff4839f-2838-437e-b42a-a3aab18ab669"
      unitRef="usd">-503844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4de2006bd97d4d02bf198bf6b206a3f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0xMS0xLTEtNDYyMQ_5f7a507b-4e94-4545-8d9a-37289aae9cec"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMS0xMS0xLTEtMjI1_f6c1014d-a277-403e-9a8c-b44f57617502"
      unitRef="usd">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMi01LTEtMS0yMjU_5530e6a6-b3e8-45a3-a9c0-69b4a568a38e"
      unitRef="usd">42051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMi0xMS0xLTEtMjI1_7b121b78-dfdf-4e63-8ae2-2304f96403b4"
      unitRef="usd">42051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy0xLTEtMS0yMjU_f28580b0-bb8f-43f1-a3cb-c8fb05a4b302"
      unitRef="shares">981000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy0zLTEtMS0yMjU_d3e10415-1f45-4498-8d08-ec83817869d0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy01LTEtMS0yMjU_245b754d-a80b-4c81-ad32-750ea36d5a3d"
      unitRef="usd">10489000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfMy0xMS0xLTEtMjI1_fd4641f0-a201-4b98-a07a-d490850861a5"
      unitRef="usd">10490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC0xLTEtMS0yMjU_f37cae06-e3be-486f-8abb-f19cdebeef92"
      unitRef="shares">852000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i12ad815a2ae64e2eaa416a54e1391c10_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC0zLTEtMS0yMjU_19b5bd43-ede2-4dd0-8527-73be0c05a2ca"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i54cc9a118fed4f459c51babee954a9ee_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC01LTEtMS0yMjU_d8930e5a-1bc7-47fd-b589-f72c57e0d886"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNC0xMS0xLTEtMjI1_237a6b32-eb17-4ebc-910b-74866293ca01"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i84cbcad7ba9d4502ad0c6277ddf1e420_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNi03LTEtMS0yMjU_089e9ae5-81e5-444e-a494-af82c77f42eb"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNi0xMS0xLTEtMjI1_e9d8c828-2a10-4a97-a178-dba5c18d4dfc"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="id2764942d41741bfa09cf6591e60e421_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNy05LTEtMS0yMjU_968aeca9-e27f-405c-8c99-c8443ec7560d"
      unitRef="usd">-77474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfNy0xMS0xLTEtMjI1_3f6d3654-5129-44b5-b0dc-d14cd3d6480c"
      unitRef="usd">-77474000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0xLTEtMS0yMjU_6e806a8f-fb7e-4758-9689-ab9d32e1f878"
      unitRef="shares">104209000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a4b7a28f2ef42a5a1b87de3160753cb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0zLTEtMS0yMjU_ce99495e-0567-4854-acc3-855b441540b0"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f4268a9aa4a4ceda2df7e5e808d365e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC01LTEtMS0yMjU_0f932d92-ce6e-48d6-ab2f-ab0390721277"
      unitRef="usd">1017949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i360a277f7b40494f87b23039e4db0bbb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC03LTEtMS0yMjU_e9fddd14-014d-4099-8912-f21c0ba91bfd"
      unitRef="usd">62000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i548093d511844b36a5a27eaae0e82e44_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC05LTEtMS0yMjU_b12a92d6-9c66-4753-8537-83180a18a51b"
      unitRef="usd">-581318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6ded07ed27245818bf9aef5e7ba2a7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0xMS0xLTEtNDYyMQ_8a177277-b77c-49be-aec4-de25aeb68d62"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d32639f7f104939ab0a9725e78b69b4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmM2MzY5OTdiNWQ1MjRjMGI4MTI3M2Y0NzI4YjhlY2ViL3RhYmxlcmFuZ2U6YzYzNjk5N2I1ZDUyNGMwYjgxMjczZjQ3MjhiOGVjZWJfOC0xMS0xLTEtMjI1_394c4ab8-24f6-4b1b-a017-41bb960cfe51"
      unitRef="usd">436890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia2cf5b805bdc476da8693441f1133ab1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0xLTEtMS0yMjU_c7094f76-0a6e-43e3-b3a7-9365d16b0081"
      unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2cf5b805bdc476da8693441f1133ab1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0zLTEtMS0yMjU_78b7e742-3878-4277-a888-b80478b10272"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic62dce18edcc450bb26c92091fc67be4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS01LTEtMS0yMjU_335201fc-9abd-4a0a-8236-3f07292b2e0d"
      unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30bc05a0d514445b8ab051db8e7aa4dc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS03LTEtMS0yMjU_5298b10f-4a78-4ede-b977-1e58cf98931f"
      unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75d457b5e22f453999509e78b6199c10_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS05LTEtMS0yMjU_bef8a58a-2759-4662-8f2f-670774e1d172"
      unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if399881c34fd417fbed0c60ffc0323c5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0xMS0xLTEtNDYzMA_820762b8-eb15-4294-b005-be2393a0cc84"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMS0xMS0xLTEtMjI1_a55a6df4-3eb6-4d69-bc21-d73d0c4a7e82"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMi01LTEtMS0yMjU_0ff58dac-b650-4527-841c-8fa4c05136a9"
      unitRef="usd">91697000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMi0xMS0xLTEtMjI1_440ab4c2-1365-413c-9654-3b9428f5a1b9"
      unitRef="usd">91697000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMy0xLTEtMS0yMjU_3928c876-f7ba-4dd9-9263-ae1cfa12037e"
      unitRef="shares">497000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMy01LTEtMS0yMjU_e5aac727-f84f-4be5-8bd2-ef2cf362ac19"
      unitRef="usd">4281000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfMy0xMS0xLTEtMjI1_002ccac7-5d97-452c-a7cd-3932da68a62a"
      unitRef="usd">4281000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC0xLTEtMS0yMjU_68996ccc-6672-4546-8164-fffdd4019559"
      unitRef="shares">971000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ifb45e923841a4c389b8589fdf79be234_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC0zLTEtMS0yMjU_e6d5ee38-5638-42a6-95b7-a15898e9a7f0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC01LTEtMS0yMjU_7377c1c1-25ff-4bd5-b206-71d1f8833931"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNC0xMS0xLTEtMjI1_c72502ca-e6fd-4228-b5d5-9166fbcd2f05"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icdd56a7531d2463f9a5c4f9801bbc96c_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNS03LTEtMS0yMjU_2b547628-bfe9-45c3-b6d3-aaf6b6b68744"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNS0xMS0xLTEtMjI1_16d97d20-af11-4ec6-8f2d-ce37670adfb8"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i6cb77f9850f246ce9c45230d9fb12d23_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi01LTEtMS01OTcw_1036ae15-b8c2-4785-9d91-31919f56e0fa"
      unitRef="usd">39750000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ia4717e9d5d29411bb00be37c6e0d8988_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi0xMS0xLTEtNTk3MA_6361f4c6-accc-4204-a530-81c8c7a6270a"
      unitRef="usd">20250000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi0xMy0xLTEtNTk3MA_b12d6142-549e-4a17-817a-9cb1c3078334"
      unitRef="usd">60000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLoss
      contextRef="i578cd120a7ab48f790437217bbc8556b_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi05LTEtMS0yMjU_378ba4a9-4097-4a4c-b606-5eafd9387b1c"
      unitRef="usd">-90552000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNi0xMS0xLTEtMjI1_1ee0924c-7c81-4493-9283-5a99a72ca889"
      unitRef="usd">-90552000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0xLTEtMS0yMjU_ac5f2c5d-9504-42ee-8a9e-6cd5b15bbce0"
      unitRef="shares">105795000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a4508cff922436192b0b439cebf0c7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0zLTEtMS0yMjU_7e386eef-bc60-4294-a739-4ad4112a1392"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4816eaf78464899a0da70c9cb57dd1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy01LTEtMS0yMjU_039ec94d-1174-430b-b6c1-ea03a7840a4f"
      unitRef="usd">1189113000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e00d55cfe1d49e8949d5d504a8eb36d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy03LTEtMS0yMjU_7ff15845-8573-458a-b79e-dba01fbdf304"
      unitRef="usd">-140000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44ba2ab14d6444fc96945d0ba6cf971a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy05LTEtMS0yMjU_0ef9e742-b99a-46aa-9e32-1d1a8ba74c70"
      unitRef="usd">-735244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c60489a1c8647218a6a815fd8643604_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0xMS0xLTEtNDYzMA_0d46b5fe-fd64-4818-a5ab-9f64cef7f253"
      unitRef="usd">20250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yMi9mcmFnOmMyODlkMTcwNTY3ZTQ5YTFiZTIxM2UwMjA4M2UxMmI1L3RhYmxlOmFmMTYzMGZmYWI3YjRkMTc5NmU3MjcyNzA2NGFiYmRhL3RhYmxlcmFuZ2U6YWYxNjMwZmZhYjdiNGQxNzk2ZTcyNzI3MDY0YWJiZGFfNy0xMS0xLTEtMjI1_f6b603bc-da9c-4e08-bbc6-a03f50089970"
      unitRef="usd">474177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMy0xLTEtMS0yMjU_3cdce52f-0f03-49d8-819c-35ed384fc07d"
      unitRef="usd">-90552000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMy0zLTEtMS0yMjU_56b91241-f509-49a6-b716-056214ad6423"
      unitRef="usd">-77474000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNC0xLTEtMS0yMjU_e9393d77-87b7-47fe-b93f-b2d5310eeb2d"
      unitRef="usd">91697000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNC0zLTEtMS0yMjU_02d014b0-b72f-4eb7-a606-10c8076eb034"
      unitRef="usd">42051000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNS0xLTEtMS0yMjU_33fbcd0f-06da-423c-af95-9b71d2253eb6"
      unitRef="usd">7761000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNS0zLTEtMS0yMjU_d1b3d1ba-f0e7-431d-837b-db5c16572d99"
      unitRef="usd">5763000</us-gaap:DepreciationAndAmortization>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNi0xLTEtMS0yMjU_054a293d-e084-410a-8acd-3ff0f70869ad"
      unitRef="usd">-5755000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNi0zLTEtMS0yMjU_91563402-5311-43ac-b196-6d159c5fc33d"
      unitRef="usd">1387000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNy0xLTEtMS0yMjU_67725ea6-4d18-49b3-b3c1-a2e5923fd60c"
      unitRef="usd">-2013000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfNy0zLTEtMS0yMjU_2b121916-f56f-4957-8f12-6b163e5a7797"
      unitRef="usd">-142000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfOS0xLTEtMS0yMjU_23b35063-a4e3-4204-9d78-5bf99c879a10"
      unitRef="usd">-10016000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfOS0zLTEtMS0yMjU_eeaa8437-5c5e-4a0d-876f-2820a0138b89"
      unitRef="usd">-174000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTAtMS0xLTEtMjI1_b399a76f-5027-4526-ae8c-ea7ba6e8fd48"
      unitRef="usd">8876000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTAtMy0xLTEtMjI1_c0d9775a-7b6d-4c20-8432-2a8f8fa13b51"
      unitRef="usd">2895000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTEtMS0xLTEtMjI1_cd9b1545-9728-4488-b060-f1f62a5d40fd"
      unitRef="usd">-87100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTEtMy0xLTEtMjI1_c4d0df23-faa5-41c9-b711-5c17714780ce"
      unitRef="usd">211392000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTItMS0xLTEtMjI1_87028446-d059-4237-81e7-4aa9ad2129e6"
      unitRef="usd">-3563000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTItMy0xLTEtMjI1_8fd82025-e875-40c4-b63c-591d558f446d"
      unitRef="usd">3208000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTMtMS0xLTEtMjI1_e4df4dbb-2621-4189-8301-7e0807408f86"
      unitRef="usd">1713000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTMtMy0xLTEtMjI1_793618fc-7f40-4a43-bb67-41db12e896b9"
      unitRef="usd">13682000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTQtMS0xLTEtMjI1_ed1a18f5-d245-49cb-a441-c2d3863c303d"
      unitRef="usd">3672000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTQtMy0xLTEtMjI1_bc4df4ba-4fca-4646-9c62-fde2cb5b8037"
      unitRef="usd">685000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTUtMS0xLTEtMjI1_670339e8-3075-424c-a187-a7d40436bff4"
      unitRef="usd">-67464000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTUtMy0xLTEtMjI1_36959fa0-5cc1-47e0-9f3e-581e9d43ccef"
      unitRef="usd">195341000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTctMS0xLTEtMjI1_53dd497c-82ba-4dab-9243-f1ad7463d9fd"
      unitRef="usd">20066000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTctMy0xLTEtMjI1_7e9c979c-938c-4330-83e6-8ddf58c16a98"
      unitRef="usd">15368000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTgtMS0xLTEtMjI1_5a44361b-ea9e-4966-902a-cd18560b424b"
      unitRef="usd">223391000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTgtMy0xLTEtMjI1_e11db30b-9739-4cae-a809-fbdc1d9eaba8"
      unitRef="usd">95195000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTktMS0xLTEtMjI1_a8be1784-ab50-4799-8dea-3c68d6fdd61f"
      unitRef="usd">201595000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMTktMy0xLTEtMjI1_8b6ee0de-9330-4515-8f04-f1a1e2123567"
      unitRef="usd">87130000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjAtMS0xLTEtMjI1_cde698ad-11d4-46d3-9bfb-af3f02e5584a"
      unitRef="usd">-41862000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjAtMy0xLTEtMjI1_49cdbfd8-621b-45c4-ba05-79621d1a844e"
      unitRef="usd">-23433000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjItMS0xLTEtMjI1_e6df9b15-9e6c-41e9-91f4-c6a15e420029"
      unitRef="usd">4331000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjItMy0xLTEtMjI1_81d4d0c1-8107-41a6-bf64-3628e9a740dd"
      unitRef="usd">10490000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMS0xLTEtNTY0MA_526e43d8-f1ab-46a4-b3c3-223e4ec88489"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMy0xLTEtNTY0MA_0920472d-322d-414a-bb88-27f85a423941"
      unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMS0xLTEtMjI1_4f533e29-5d02-4b49-94aa-c89befeff812"
      unitRef="usd">64331000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjMtMy0xLTEtMjI1_d3224d52-77e6-4bb4-b132-39d14430207f"
      unitRef="usd">10490000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjQtMS0xLTEtMjI1_bff4ec38-ee70-4011-a658-41025ba87fe2"
      unitRef="usd">-44995000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjQtMy0xLTEtMjI1_c797c40e-cfde-4c22-a530-2c4cdbc01988"
      unitRef="usd">182398000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjUtMS0xLTEtMjI1_3b7c6b30-ff39-4639-9f05-03ce8dd62cd9"
      unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjUtMy0xLTEtMjI1_84d67f04-1eab-4fcb-8e66-431f84fc3662"
      unitRef="usd">143583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjYtMS0xLTEtMjI1_68d3ff2f-efb4-48d0-929b-a3cc3d521751"
      unitRef="usd">139439000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i8d32639f7f104939ab0a9725e78b69b4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18yNS9mcmFnOjI4YjczZmJmYWI4NjQ2ODRiMDczNjRhNmYyMGZiNDI5L3RhYmxlOmE2NjA4YTAyMjViYjRhZTM4YTk4OTQ3NmQ5OGIwOTRiL3RhYmxlcmFuZ2U6YTY2MDhhMDIyNWJiNGFlMzhhOTg5NDc2ZDk4YjA5NGJfMjYtMy0xLTEtMjI1_1ca32518-f7d2-4db0-9791-308bdb6d548e"
      unitRef="usd">325981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfODE1OQ_e3568006-4290-44cc-a8d9-794f77357516">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nature of Business and Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#x2019;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#x2019;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC2 for cystic fibrosis, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens, ARO-C3 for complement mediated diseases, ARO-RAGE and ARO-MUC5AC for various muco-obstructive or inflammatory pulmonary conditions and ARO-MMP7 for idiopathic pulmonary fibrosis. ARO-HSD for liver disease was out-licensed to Glaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;) in November 2021. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;). JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;) in October 2020. JNJ-3989 (formerly referred to as ARO-HBV) for chronic hepatitis B virus was out-licensed to Janssen in October 2018. Olpasiran (formerly referred to as AMG 890 or ARO-LPA) for cardiovascular disease was out-licensed to Amgen Inc. (&#x201c;Amgen&#x201d;) in 2016. While the Company believes that initial ARO-HIF2 Phase 1 clinical data provides proof of concept for the ability to deliver siRNA to RCC tumors, the Company has decided not to pursue further clinical development of ARO-HIF2 based on a number of factors including the evolving competitive landscape for HIF2 inhibitors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#x2019;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first three quarters of fiscal 2022, the Company continued to develop and advance its pipeline and partnered candidates and expanded its facilities to support the Company&#x2019;s growing pipeline. Several key recent developments include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.9pt"&gt;dosed the first patients in its PALISADE study, a phase 3 clinical study to evaluate the safety and efficacy of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;entered into an exclusive license agreement with GSK for ARO-HSD; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.36pt"&gt;Janssen presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989 (JNJ-3989), formerly called ARO-HBV, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.9pt"&gt;filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 and subsequently dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#f3f3f3;color:#676767;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;nvestigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt"&gt;presented additional interim clinical data from AROHSD1001, AROAAT2002, and AROAPOC31001; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vi)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt"&gt;completed the purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin and held a groundbreaking ceremony on the site. The site is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company's process development and analytical activities. The Company also announced that it received awards for up to $16&#160;million in tax increment financing from the city of Verona, and up to $2.5&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.  Additionally, The Company entered into a lease agreement for a new 144,000 square foot laboratory and office facility in San Diego, California to support discovery activities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.13pt"&gt;completed enrollment in Phase 2b ARCHES-2 study of investigational ARO-ANG3 for patients with mixed dyslipidemia;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;viii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt"&gt;filed for regulatory clearance to initiate Phase 1/2a study of ARO-RAGE for treatment of Asthma;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ix)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt"&gt;filed for regulatory clearance to initiate Phase 1/2a study of ARO-MUC5AC for treatment of muco-obstructive lung disease;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;x)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt"&gt;initiated and dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholersterolemia;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;xi)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt"&gt;entered into definitive agreements to form a joint venture, Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;) with Vivo Capital (&#x201c;Vivo&#x201d;) through which the Company and Vivo intend to expand the reach of innovative medicines in Greater China;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;xii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:22.13pt"&gt;hosted a pulmonary research &amp;amp; development (R&amp;amp;D) Day to discuss the Company&#x2019;s emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;) platform, including an announcement of its previously undisclosed candidate designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;xiii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.36pt"&gt;in conjunction with Takeda, announced results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), and was recently published in the New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress&#x2122; 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the three and nine months ended June&#160;30, 2022 were not significantly impacted by COVID-19. Operationally, the Company has experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#x2019;s preclinical programs. Additionally, the Company has experienced delays in enrollment in its clinical trials. The Company&#x2019;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#x2019;s clinical sites to continue to enroll subjects, the ability of the Company&#x2019;s suppliers to continue to operate, the continued good health and safety of the Company&#x2019;s employees and the length and severity of the COVID-19 pandemic. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), which contemplate the continuation of the Company as a going concern. Historically, the Company&#x2019;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials, as well as with the Company&#x2019;s plans to increase its internal manufacturing capabilities, and expand its footprint in Verona, Wisconsin and San Diego, California. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, the Company had $139.4 million in cash and cash equivalents (including $7.4 million in restricted cash), $277.1 million in short-term investments, $0 in marketable securities and $165.9 million in long-term investments to fund operations. $60&#160;million of our cash balance resulted from the formation of our joint venture, Viserna. During the nine months ended June&#160;30, 2022, the Company&#x2019;s cash and investments balance decreased by $31.0 million, which was primarily due to cash being used to fund the Company&#x2019;s operations, partially offset by the $120.0 million upfront payment received from GSK, and $60&#160;million cash infusion to Viserna. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company remains eligible for $4.9 billion in developmental, regulatory and sales milestones and various royalties on net sales from its licensing and collaboration agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2 below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the significant accounting policies disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In our opinion, the unaudited consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending September 30, 2022 or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited consolidated financial statements include the accounts of our wholly owned subsidiaries, as well as the accounts of Visirna, a variable interest entity for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our unaudited consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:NumberOfAcresOfLandPurchased
      contextRef="i5c9768d66c104f1aa87e005d6db6e1d7_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMzc0MQ_c5622f1a-583b-4c86-936e-2740dc07c008"
      unitRef="acre">13</arwr:NumberOfAcresOfLandPurchased>
    <us-gaap:AreaOfLand
      contextRef="ic75e9e025dbd4b38aa62c9741d197da1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1NTI1NQ_439964a0-795f-4e96-b728-104456d877a4"
      unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="id75ca493ec1f402f850e52443619f642_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1NTI1OQ_308528a2-e298-40f3-a69e-b8c454209c62"
      unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:TaxIncrementFinancingAward
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTM5NTY_9ab23105-4aa9-4e28-af2f-eade0be5b2e6"
      unitRef="usd">16000000</arwr:TaxIncrementFinancingAward>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTM5NjA_2891ea1f-1234-4251-a745-67bf5931d881"
      unitRef="usd">2500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i1022cf2430e6451eb267b84ac9a5d1c2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNDAxNw_b0fdb20a-12ab-45e5-825f-690540854b65"
      unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzU3Ng_72fc57ec-73a2-4aa9-b732-f6dade9fb463"
      unitRef="usd">139400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMjE5OTAyMzI2NzQwNQ_9a1443fa-8717-42a9-9459-dba38820be57"
      unitRef="usd">7400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzU4NA_b5f8d857-5668-485a-a259-af7ddd3298d6"
      unitRef="usd">277100000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzU5Mg_13ffc8a0-702e-4686-8d32-d6f195c8971c"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMTY0OTI2NzQ1MzYwMA_7b3ed07d-06ac-48bb-8702-eb4045492395"
      unitRef="usd">165900000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idd085594814a45419028bebfd289cf4e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNTQ5NzU1ODM0MzU2_4a620ac1-8bd2-425e-9cef-efb100dc8441"
      unitRef="usd">60000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arwr:IncreaseDecreaseInCashAndInvestments
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfMjE5OTAyMzI2NzQyNw_9c288ff6-1214-4786-9e86-6913461a4bae"
      unitRef="usd">-31000000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i3f4cf8a5af7f4d69aa755310016c82ad_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNzQzMQ_ba1e7fcf-4723-462f-9edb-9f9b26eac80b"
      unitRef="usd">120000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idd085594814a45419028bebfd289cf4e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNTQ5NzU1ODM0MzY5_12de1424-e7a5-4dbb-9328-7db3a4d4f52c"
      unitRef="usd">60000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i8d3a720bc2944c47a2dbc3160113d536_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNzUxMw_3b49c2b2-04d4-473c-90e8-05e9c6b75e7e"
      unitRef="usd">4900000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfODE1OA_7da720f2-0c8a-454c-820c-483fda7d9d7a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zMS9mcmFnOjJjNDBmOGUyNjlkZTQ4NDFhNWYyNjY4YzI1YTZhODJmL3RleHRyZWdpb246MmM0MGY4ZTI2OWRlNDg0MWE1ZjI2NjhjMjVhNmE4MmZfNTQ5NzU1ODM4NDI1_a7a6ef9c-a539-4401-a4ab-67c6f76046c2">Basis of Presentation&lt;div style="text-indent:40.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In our opinion, the unaudited consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending September 30, 2022 or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited consolidated financial statements include the accounts of our wholly owned subsidiaries, as well as the accounts of Visirna, a variable interest entity for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our unaudited consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgxOTA_8361ce8a-3185-4d5d-ac6d-06b8ed4f25f3">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;28, 2016, the Company entered into two collaboration and license agreements and a common stock purchase agreement with Amgen. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen has received a worldwide, exclusive license to Arrowhead&#x2019;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#x201c;First Collaboration and License Agreement&#x201d; or the &#x201c;ARO-AMG1 Agreement&#x201d;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#x2019;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the ARO-AMG1 Agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated these agreements in accordance with FASB Topics 808 &#x2013; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0 million milestone payment to the Company. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company recognized $0 and $0 of revenue associated with its agreement with Amgen, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janssen Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;3, 2018, the Company entered into a License Agreement (the &#x201c;Janssen License Agreement&#x201d;) and a Research Collaboration and Option Agreement (the &#x201c;Janssen Collaboration Agreement&#x201d;) with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company also entered into a stock purchase agreement with JJDC (&#x201c;JJDC Stock Purchase Agreement&#x201d;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which Arrowhead would develop clinical candidates. These candidates were subject to certain restrictions and do not include candidates that already were in the Company&#x2019;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0 million, and the Company may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $0.6 billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During the three months ended June&#160;30, 2022, Janssen&#x2019;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated these agreements in accordance with FASB Topics 808 &#x2013; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. At the inception of these agreements, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Janssen R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#x2019;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the three months ended June&#160;30, 2022 and 2021, the Company recognized approximately $0 and $0 of revenue associated with this performance obligation, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized approximately $0 and $20.2 million of revenue associated with this performance obligation, respectively. As of June&#160;30, 2022, there were $0 in contract &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets recorded as accounts receivable, and $0 of contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. During the three months ended June&#160;30, 2022, Janssen&#x2019;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement as reported in the second quarter of 2022. During the three months ended June&#160;30, 2022 and 2021, the Company recognized $0.0&#160;million and $0.2 million of revenue associated with these efforts, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recognized $0.1 million and $0.5 million of revenue associated with these efforts, respectively. In May 2021, Janssen exercised its option right for ARO-JNJ1, which resulted in a $10.0&#160;million milestone payment to the Company. This $10&#160;million milestone payment was recognized entirely during the three months ended June 30, 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, there were $0 of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Takeda Pharmaceuticals U.S.A., Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;7, 2020, the Company entered into an Exclusive License and Co-funding agreement (the &#x201c;Takeda License Agreement&#x201d;) with Takeda. Under the Takeda License Agreement, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda and the Company will co-develop the Company&#x2019;s ARO-AAT program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50/50 profit sharing&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. In January 2021, the Company received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#x2013; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $300.0 million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;amp;D Services. Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the three months ended June&#160;30, 2022 and 2021 was $25.5 million and $35.7 million, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $67.1 million and $69.3 million, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, $71.0 million in contract liabilities recorded as deferred revenue and $71.2 million in contract liabilities recorded as deferred revenue, net of the current portion, and $7.8 million in contract liabilities recorded as accrued expenses. The $7.8 million in accrued expenses was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Horizon Therapeutics Ireland DAC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;18, 2021, the Company entered into the Horizon License Agreement with Horizon. Under the Horizon &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Agreement, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of ARO-XDH, and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $40 million as an upfront payment and is eligible to receive up to $660 million in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#x2013; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#x201c;Horizon R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Horizon R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $40.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties, from this transaction price to date. The Company will allocate the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;amp;D Services. Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the three months ended June&#160;30, 2022 and 2021 was $6.7 million and $0, respectively. Revenue for the nine months ended June&#160;30, 2022 and 2021 was $20.0 million and $0, respectively. As of June&#160;30, 2022, there were $0 million in contract assets recorded as accounts receivable, $13.3 million in contract liabilities recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has manufactured ARO-XDH material for Horizon in furtherance of the research plan entered into pursuant to the Horizon License Agreement, for which the Company has been reimbursed for its costs. During the nine months ended June 30, 2022 and 2021, the Company recognized $1.3 million and $0 with these efforts, respectively. As of June&#160;30, 2022, there were $0.0 million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glaxosmithkline Intellectual Property (No. 3) Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;22, 2021, the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;) with GSK. Under the GSK License Agreement, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GSK has received an exclusive license for ARO-HSD, the Company&#x2019;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beyond the Company&#x2019;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;itory. Under the terms of the agreement, the Company has received an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the GSK License Agreement in accordance with FASB Topics 808 &#x2013; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibility to complete the Phase 1/2 study, (the &#x201c;GSK R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these GSK R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $120.0 million, including the upfront payment. The $120.0 million upfront payment was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million will be fully recognized as of the three and nine months ended June&#160;30, 2022. Revenue for the nine months ended June 30, 2022 and 2021 was $120.0 million and $0, respectively. As of June&#160;30, 2022, there were $0 in contract assets recorded as accounts receivable, $0 in contract liabilities recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Joint Venture and License Agreement with Visirna Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 25, 2022, the Company entered into a License Agreement (the &#x201c;Visirna License Agreement&#x201d;) with Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of Arrowhead&#x2019;s RNAi-based investigational cardiobolic medicines in Greater China (including the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#x201c;Visirna SPA&#x201d;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#x2019;s employee stock ownership plan) as partial consideration for the Visirna License Agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the Visirna SPA, entities affiliated with Vivo Capital (&#x201c;Vivo&#x201d;) also acquired a minority stake in Visirna in exchange for $60&#160;million in upfront capital to support the operations of Visirna.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has determined that Visirna is a variable interest entity upon its formation and as of June 30, 2022, and it has been determined that Arrowhead is the primary beneficiary; accordingly, Arrowhead consolidates the financial statements of Visirna.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <arwr:NumberOfAgreements
      contextRef="if5d04990863c4ffebb18aa567f52c795_I20160928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTM_3ff4c268-c583-438d-8e8d-c29f91b7a6c6"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="i8557188d4af54eb08dc810e89d94a2af_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTAzNg_449dfdbc-c756-481b-ad59-febc03ac6d51"
      unitRef="usd">35000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id85c5ae5131b4cf5aee60543418e6dc7_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTA2MA_aee5cd4c-3bcf-4a26-a8c9-f91ea5527861"
      unitRef="usd">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="i16d7c8f61f044b1ca180ce2a40fa4c78_I20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE0Mw_70914a06-1c6c-469b-880f-52d9aaff53df"
      unitRef="usd">30000000</arwr:MilestonePaymentReceived>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="if6a4c6243f314042b988b3644714d5ae_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTIwNQ_075b3325-dc28-4a53-bc32-d7fde692b6ec"
      unitRef="usd">400000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:MilestonePaymentReceived
      contextRef="i642afe5a3db1459fb006b42ac0e0fda2_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjA4MQ_65e50155-6885-4ba2-86e4-00415843ad55"
      unitRef="usd">20000000</arwr:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdbfdc5869124c39b1b3bb71ecfc7d8a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE3OQ_0312a6b5-ab47-47e1-b4bc-8bbdc3b752b9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15de6290b08748d4860a17dafd0dc478_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE3OQ_ccf9593b-1854-4456-8421-6b1145ae1a3d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia535e3b54c9f4258ab014490ba47a9cb_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE4Ng_893adb70-c25c-4b21-b268-24eaf6e13b31"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56acccdf27c144ef8f241ed180cb1e68_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjE4Ng_c0571178-9a15-4630-882a-b7f5f9f3840e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icd831e272413430f8e8bd86d511a426d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjI3Nw_b1e6ca02-3e04-46a3-a62d-f99eb1779dea"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="icd831e272413430f8e8bd86d511a426d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMjMzNQ_37cfd1a1-89f9-4ff2-8924-dd540ac2950d"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="i9a529c59ccab48439e6e1f6656cfb54b_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDIyNA_a5d95de5-3dd5-4470-a422-5a6f98bec02e"
      unitRef="usd">175000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i433c47b3f8c8462580eaf03f04ea786f_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDI1MA_7ba8a6dd-ddfb-47ea-b3b0-a479bf061d6b"
      unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="i4e1a46243860468ebedfd52732a1d64a_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDQwNw_b1ff7490-c02e-4ad1-a21f-c46b9c40b0ec"
      unitRef="usd">73000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i058a0e84238747de838a9ae350816175_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDQ0NQ_80ffea3b-1ee4-4277-828a-d7693b82a971"
      unitRef="usd">1600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="iea7a8bafb0694de299c426ee0b32a895_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNDUzOA_0a712a1f-e11b-4f55-8119-536acb35fbe0"
      unitRef="usd">600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i44c2ff8f563d4797bb710b4c5bf60938_D20181003-20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTI0Ng_2ab34bc8-649f-43be-b60d-37e72b029c28"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="ib12fd50d833f43e7ab0c3963c67d8c7c_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjI0OA_3fd54729-eb2d-4281-883b-1213062cacaa"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned
      contextRef="i683a96e617044dc7a7cfc73242c01f94_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjM1OQ_cc520f60-2678-4fa6-ba57-f6350923d74d"
      unitRef="usd">25000000</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice
      contextRef="ib12fd50d833f43e7ab0c3963c67d8c7c_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjUyNg_29e4d673-7a4f-484d-9131-eed2add38083"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33863eeccc354ec290037c1feffc9fcd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNjk5Ng_ce196b7d-a937-4c2f-906c-dbe0e4d43bf4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ecd1a82934c4324b5fdce6ab2812055_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzAwMw_a8ccfafe-a86b-4963-8d69-29186f96e310"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic59f147408ce4825a0772a7efc899c0a_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzE1MQ_e572b45b-6088-413b-ab35-7101f94ab081"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4395de79fe9145328658914e46b9ac3b_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzE1OA_a6f21c53-af31-44b6-a081-c4d3df917d51"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ife7d1814c3ee4dc8b62b5e12fbdc725a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzI1Mg_24dc2368-133e-4b32-84fc-30b8b97d1709"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ife7d1814c3ee4dc8b62b5e12fbdc725a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzMxMQ_6e456463-5e78-4468-8495-346d6fea4af1"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45013fbe4c444400b19d92afe847608f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzkzNg_81fee451-1ea7-4ef7-a19a-327575683b89"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if25fe0bc8a244e299ac437cbe6dd0756_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNzk0Mw_74f59184-9e78-4bb2-a55e-f9fd99ae5d4c"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d15264a4c8a455daaa0f41c6d369f33_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODA2Mw_e12e6f48-3b75-41c0-b697-3c711c796f1f"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5e11bca521447a3a3b4efbe502f791a_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODA3MA_5e7a388a-bf9c-464c-9240-b6c7d512264a"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <arwr:MilestonePaymentEarned
      contextRef="iee335bd52ba2451a8a52d753c51da9f0_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTQ5NzU1ODg1MTAw_a6c102cc-85a6-4bfb-b019-3b1b315cd2c5"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentEarned
      contextRef="i6f168d9bf5d04ce3988dc7c810cc2a80_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTQ5NzU1ODg1MTE1_dbad744c-8fba-401f-a14d-828f9ccd9dcc"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="idecd2c5ebb7545b1afca8e3a81415b21_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODE1MA_5a0b3e57-76a8-4703-8d8b-ee181d13fa86"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idecd2c5ebb7545b1afca8e3a81415b21_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODIwOA_9ab5f476-6ca8-4154-b4ae-7c07543770e9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="ib729c3113dd941d48caf68aba7dcd82b_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTA3Nw_15516732-9e3d-4aaa-8759-3c178fdc49a2"
      unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="i0e106a6904ed442d9339a7236c68726c_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTA4Mw_2ba7c5a8-0ae3-45ae-91a0-76d5dcb7b668"
      unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="ic1e4e7286efe4e7e9875b4571c089f8c_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTEyOA_70a825b4-415c-494e-bb52-ed220cdefe8c"
      unitRef="usd">300000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="iecb6f8d22f8d4f1f9241a3072aac7249_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTI0OQ_6a4ec9cb-22a6-4358-b68f-5dcee3260ce5"
      unitRef="usd">740000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfOTQ5NA_893db1e3-5a87-4cfd-9680-cbd6e6c0aa92"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTAwNzA_a84dacf0-de7f-4624-957a-05b1bc4c88ff"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:InitialTransactionPrice
      contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTA4OTk_c3619794-fe91-42a6-9311-fabf15a511bd"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="if94556e4a361454299073a451c9f3184_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTEwNzI_5721a85f-85b8-4087-812b-e8849b59397b"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i067c1e4b9a0247c7a50ae4cdf3371c7c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE0NjQ_59883535-666a-4d20-ae8b-a875ca65364a"
      unitRef="usd">25500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28b4742bad8448c69d778802996dd6bf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE0NzE_d3a9dde3-9b90-4b3d-8613-b38f6c9596bc"
      unitRef="usd">35700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7012433fc1464bb4b1ce9ec8d2e4ea99_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE1MzU_bf60bcd9-6878-4992-991d-e35cdc9ff68d"
      unitRef="usd">67100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fc281b2b25f4c18bb40e5a85d4aa480_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE1NDI_807c94df-8a39-4413-a580-0489aa511c86"
      unitRef="usd">69300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ic97a79c8293c4fe0bbd8c8743f172820_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE1ODE_1a3327e3-0605-4561-b5ff-ed09f59f71f9"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9359ec9011884267a96788ac6a2ad3c9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE2MzY_1ca1029f-16a2-4a29-b903-53a5ce54c9cb"
      unitRef="usd">71000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9359ec9011884267a96788ac6a2ad3c9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE2OTY_935ffca3-ee0b-4914-9156-78a69d393b76"
      unitRef="usd">71200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifb2d0e8036de47a38214f8da27a75c2b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE3ODU_26604eea-b11e-456f-8413-569c24939d38"
      unitRef="usd">7800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifb2d0e8036de47a38214f8da27a75c2b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTE4NDY_5d7a2bdf-213d-4434-9fdc-70d87316804f"
      unitRef="usd">7800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="ic5da86e52d344df6bdd898bbe4acfef7_I20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTI1NDA_3857120b-a9a2-4f6e-9478-983135e8a37f"
      unitRef="usd">40000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="ifd0fff411780433c8b41924a087c4995_I20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTI1OTg_6f7f5497-c7ae-4150-a43f-87605bb61026"
      unitRef="usd">660000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="i70f76d63dd964a6a80d47beca9e8f6af_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM0NzE_a259373b-bc26-4fe6-8374-ca33ae2964c7"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i70f76d63dd964a6a80d47beca9e8f6af_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM1MDE_9a34d4ee-b81b-445a-b292-3e39e59b9f67"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="ib336907d2752401e850feece66ae0251_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM3NzE_28c8dbe4-6253-428b-b2f3-69b29a36e831"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="ib336907d2752401e850feece66ae0251_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM5NTA_ecd02fa8-d034-433f-b880-9b422742e612"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="ib336907d2752401e850feece66ae0251_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTM5ODY_cae3146e-6bc4-4de9-b614-fd966b35d2e3"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifac4cb40a788432a8608233b693cb386_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ0MjI_aa7bbfd8-911f-43a7-b41d-65cbae8352fe"
      unitRef="usd">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if864eef3f413411faa9649ecf780d795_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ0Mjk_4c3cc7d0-9cd5-469a-adae-0af73e8a013c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i244740bda57c4515a402b65ce9115249_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ0OTM_272e006d-1d6c-4f1e-8318-328add2f2a86"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfd0e90e113d47a59150ec0852ccdc57_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ1MDA_d1da98d1-2cea-4e9f-b4b4-0dfb9f9e403a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iceda2f32a68d4891ba199eab359ecbd6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ1Mzk_f0477b56-b744-45b7-9aa9-bafdc57449d9"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iceda2f32a68d4891ba199eab359ecbd6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ1OTQ_2b8593c0-651b-4497-9c44-d7774d804dd6"
      unitRef="usd">13300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf3b5392cc94e35b5172697c4a4b526_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ5MjA_dd921b88-3676-4438-9c1b-ad06b7752c70"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i610703f0575242bebd037f61c55a72f3_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ5Mjc_fb30cedf-46f6-43cd-81d9-d643b620d1e2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ibeba9082710947699803c66c72381300_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTQ5ODU_c48054c2-7046-4465-9f72-42dbfbc98ec4"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibeba9082710947699803c66c72381300_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTUwNDM_de0834fb-c8cf-443b-bef4-5ec4d0686f7a"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:MilestonePaymentEarned
      contextRef="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTYwMTQ_2d539b51-a3fc-4cf2-a1e0-753dcbb97b4c"
      unitRef="usd">120000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentReceivableAtStartOfPhaseTwo
      contextRef="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTYwNjg_210389ea-4842-4e09-ba0d-971f6fbd9b21"
      unitRef="usd">30000000</arwr:MilestonePaymentReceivableAtStartOfPhaseTwo>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree
      contextRef="ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTYxMDc_0da342bf-26d6-4f04-964c-4c5b0c9adc43"
      unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale
      contextRef="ia4b8212c8479404199b23c9c498f31a9_I20211122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTY0Mjk_5a26c4b7-d491-4c52-8147-84b1e220284b"
      unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments
      contextRef="ia4b8212c8479404199b23c9c498f31a9_I20211122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTY0Njg_3676cdc5-a8b1-421f-80a9-a75d4f9d4565"
      unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTY3NTM_7d70a35e-b641-48bf-a161-442a654c3b15"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTcxNTc_5dab0b02-a319-4337-8113-67e9f9baaaa8"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:InitialTransactionPrice
      contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc0NTY_48942d3c-7cff-416e-84e8-7929326850b0"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="ic540fad5d90642a2b2dda2b6047c73c0_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc0OTU_ae39a3d3-5485-4ac5-8ce5-fc37faa29550"
      unitRef="usd">120000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:InitialTransactionPrice
      contextRef="i6c61be4b0f6c43c3aeb69cc8f8328d3c_D20211122-20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfODI0NjMzNzIyNjUyOQ_464092ee-94fe-4557-8202-2bb084d2808d"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:PerformanceObligationRelatedToAgreementUpfrontPayment
      contextRef="i63bff98126fe415385b5f094684f04c1_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc5Mjk_b619bc53-f838-4b10-8fc7-623b1b916554"
      unitRef="usd">120000000</arwr:PerformanceObligationRelatedToAgreementUpfrontPayment>
    <arwr:PerformanceObligationRelatedToAgreementUpfrontPayment
      contextRef="i1956315e881a45299f1a80ddb4410e27_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTc5Mjk_dba72b20-2907-4215-8a86-5c7951ea468a"
      unitRef="usd">120000000</arwr:PerformanceObligationRelatedToAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63bff98126fe415385b5f094684f04c1_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgwMzM_f6ccab50-7abe-4cdb-bc28-40e54cce0cb9"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97c2718553fd46d69ad19a4d0391e677_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgwNDA_430ea673-33a7-48b8-9042-2c22e4bbcfed"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i9d593f14b6cb41c990078718ee591af5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgwNzk_7a3ea3a6-57fa-4bdd-91fb-e446c5106570"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9d593f14b6cb41c990078718ee591af5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfMTgxMzQ_85aefe4d-d1ea-455d-a1b3-38288a7dd56e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="if56e80163bfa40bc908f0611a5ea88cc_D20220425-20220425"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNC9mcmFnOjg1ZjQ5MDNjNjMwZDQxNWE4OTM1YzVjMDRhMjcwM2E0L3RleHRyZWdpb246ODVmNDkwM2M2MzBkNDE1YTg5MzVjNWMwNGEyNzAzYTRfNTQ5NzU1ODM1Mzkw_15840624-95fd-4f09-af8b-d5ee90d9a439"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfNTQy_20064ad5-73df-4289-8d07-f813906d8dac">PROPERTY AND EQUIPMENT&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computers, software, office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in Progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total gross fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(29,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expense for property and equipment for the three months ended June&#160;30, 2022 and 2021 was $2.2 million and $1.6 million, respectively. Depreciation and amortization expense for property and equipment for the nine months ended June&#160;30, 2022 and 2021 was $6.5 million and $4.5 million, respectively. Construction in Progress relates to the Company&#x2019;s Verona and San Diego research facilities. Land relates to the Company&#x2019;s Verona, Wisconsin research facility.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfNTQz_5be3a51e-f862-4a49-8387-85b9ff9a92ed">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computers, software, office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in Progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total gross fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(29,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMi0xLTEtMS0yMjU_fec55f91-a74f-4f3d-94f1-8aa208bf5be3"
      unitRef="usd">2210000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMi0zLTEtMS0yMjU_08169f85-bf28-4071-b7d0-4d5c9827f2c5"
      unitRef="usd">2170000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <arwr:ResearchEquipmentGross
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMy0xLTEtMS0yMjU_785f6753-a67f-4599-b0a6-b5b3988d4cf0"
      unitRef="usd">31678000</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfMy0zLTEtMS0yMjU_23f35696-fbde-46f7-997c-650b21c306b4"
      unitRef="usd">27500000</arwr:ResearchEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNC0xLTEtMS0yMjU_e00fe314-2958-4804-94c4-80b8ce6295be"
      unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNC0zLTEtMS0yMjU_7b502d37-5ecd-4726-8ab7-c2f9841f8cc5"
      unitRef="usd">41524000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNS0xLTEtMS0yMjU_9c8b6636-d501-4108-b82f-faeb34c5d0e4"
      unitRef="usd">22338000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNS0zLTEtMS0yMjU_b5b63ac3-7a7d-4261-a1a0-b71894c5ed3d"
      unitRef="usd">345000</us-gaap:ConstructionInProgressGross>
    <us-gaap:Land
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNi0xLTEtMS0yMjU_48a313ae-2a5c-4c60-b2f9-cd140ab6253b"
      unitRef="usd">2996000</us-gaap:Land>
    <us-gaap:Land
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNi0zLTEtMS0yMjU_3bd66a68-ed63-4519-bf69-4075a944c3fb"
      unitRef="usd">0</us-gaap:Land>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNy0xLTEtMS0yMjU_fbd8e53e-dc7b-411e-b532-b0ce25310748"
      unitRef="usd">101239000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfNy0zLTEtMS0yMjU_90620d06-46bf-4fe9-aa17-2cbaa0ae8798"
      unitRef="usd">71539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOC0xLTEtMS0yMjU_6a5c21bb-1ea5-4abb-8b52-f3c6ab283c9d"
      unitRef="usd">29335000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOC0zLTEtMS0yMjU_156955d2-4220-4d38-8e62-e2fedf7baa79"
      unitRef="usd">22864000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOS0xLTEtMS0yMjU_080f3127-089c-4e78-a92d-062e60d66e47"
      unitRef="usd">71904000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RhYmxlOjIyNmE0ODZmYTZjYTRmMjlhMzViYTViNjA3YzkzNjg5L3RhYmxlcmFuZ2U6MjI2YTQ4NmZhNmNhNGYyOWEzNWJhNWI2MDdjOTM2ODlfOS0zLTEtMS0yMjU_3a3776c4-a6be-4914-947e-259448a93758"
      unitRef="usd">48675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMjMx_af1c8cf7-a310-4ef7-a01b-3e7839b2fc16"
      unitRef="usd">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMjM4_24b71162-6fee-4be2-8ebf-1332f3a21f9b"
      unitRef="usd">1600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMzU5_3a59ddef-4f8d-479d-8249-eb5f571d8dec"
      unitRef="usd">6500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM18zNy9mcmFnOmI2N2Q1NGRkY2E2NzQ3YWY5M2I5NzVhOGFiZDk5OTcyL3RleHRyZWdpb246YjY3ZDU0ZGRjYTY3NDdhZjkzYjk3NWE4YWJkOTk5NzJfMzY2_43e5e8cc-7966-4810-aac3-7afdbec6fffc"
      unitRef="usd">4500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RleHRyZWdpb246ZTgxMWVmZTk0MjgwNGJhOGE2NTYwMjU2MmY0NGQwYjdfMTYxNw_37405903-92f6-4740-8779-f19d84a3ddb1">INVESTMENTS&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Investments at June&#160;30, 2022 primarily consisted of commercial paper and corporate bonds that have maturities of less than 36 months and a certificate of deposit. Cash and cash equivalents consist of cash on hand and commercial paper purchased with 90-days or less remaining to maturity.  The Company&#x2019;s corporate bonds consist of both short-term and long-term bonds and are classified as &#x201c;held-to-maturity&#x201d; on the Company&#x2019;s Consolidated Balance Sheets. The Company&#x2019;s certificate of deposit matures in less than 12 months and is classified as &#x201c;held-to-maturity&#x201d; on the Company&#x2019;s Consolidated Balance Sheet,&#x2019;. The Company&#x2019;s marketable equity securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, corporate bonds and other asset-backed debt securities. Dividends from these funds were automatically re-invested. In April 2022, all marketable securities were sold for  $122.3&#160;million. The Company may also invest excess cash balances in money market accounts, and these securities would be classified as cash and cash equivalents on the Company&#x2019;s Consolidated Balance Sheet. The Company accounts for its &#x201c;held-to-maturity&#x201d; investments in accordance with FASB ASC 320, Investments &#x2013; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#x2013; Equity Securities. We did not record any impairment charges related to our marketable debt securities during the three and nine months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s short-term and long-term investments and marketable securities as of June&#160;30, 2022 and September&#160;30, 2021 by measurement category: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial notes (due within ninety days)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial notes (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;227,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;225,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial notes (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;165,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Certificate of deposit (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;468,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial notes (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial notes (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;195,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit (due within one through two years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;127,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;429,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;430,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i77fd51ba125e419fbba6f8c78ee5dccb_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RleHRyZWdpb246ZTgxMWVmZTk0MjgwNGJhOGE2NTYwMjU2MmY0NGQwYjdfNTQ5NzU1ODIyOTc0_356dc724-9557-4958-8983-d03d4595e23c"
      unitRef="usd">122300000</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RleHRyZWdpb246ZTgxMWVmZTk0MjgwNGJhOGE2NTYwMjU2MmY0NGQwYjdfMTYxOQ_b94d170c-562e-40f5-9094-239b43c7138f">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s short-term and long-term investments and marketable securities as of June&#160;30, 2022 and September&#160;30, 2021 by measurement category: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial notes (due within ninety days)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial notes (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;227,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;225,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial notes (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;165,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Certificate of deposit (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;468,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial notes (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial notes (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;195,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit (due within one through two years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;127,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;429,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;430,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC0xLTEtMS0yMjU_b829ddf8-8cde-4089-8a6b-516a51fbd6f9"
      unitRef="usd">25325000</us-gaap:CashEquivalentsAtCarryingValue>
    <arwr:CashEquivalentsGrossUnrealizedGains
      contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC0zLTEtMS0yMjU_a010ca97-e3d5-45b9-84a7-82b76bc91369"
      unitRef="usd">11000</arwr:CashEquivalentsGrossUnrealizedGains>
    <arwr:CashEquivalentsGrossUnrealizedLosses
      contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC01LTEtMS0yMjU_6c2feb52-14e5-413c-8d2f-4726a95ac864"
      unitRef="usd">0</arwr:CashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d571372f7da4510a63fa25715f88db4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNC03LTEtMS0yMjU_35dc31e2-21f3-4ee8-b893-3d1f64e2f39c"
      unitRef="usd">25336000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi0xLTEtMS0yMjU_7e14aedf-16e8-444a-aa79-22586bb7bed0"
      unitRef="usd">227057000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi0zLTEtMS0yMjU_74f33d97-7922-413d-9257-cf8dc7377236"
      unitRef="usd">21000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi01LTEtMS0yMjU_6c17ba81-8ee7-4d60-86a5-067a9b372435"
      unitRef="usd">1588000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iefbbdb15dc3e40fe8077c9625e204afe_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNi03LTEtMS0yMjU_f4cc8169-e968-4749-9b9e-0a5f0207cdfc"
      unitRef="usd">225490000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8b1f86d220804f7184099925062e5674_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy0xLTEtMS0yMjU_17eecd03-ffd8-4e10-b8dd-515895e85be9"
      unitRef="usd">165920000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i8b1f86d220804f7184099925062e5674_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy0zLTEtMS0yMjU_6f48d16b-ae3c-4b6a-b06f-5ffb97c076be"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i8b1f86d220804f7184099925062e5674_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy01LTEtMS0yMjU_3a1a6079-7cc6-406f-8bb0-566650368420"
      unitRef="usd">6380000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8b1f86d220804f7184099925062e5674_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfNy03LTEtMS0yMjU_4b6cf064-fdea-4d92-aeae-a040c7188617"
      unitRef="usd">159540000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC0xLTEtMS0yMjU_3554ce4d-e83c-4879-9144-ad6527c90089"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC0zLTEtMS0yMjU_0dd6286c-4a50-4495-bfa5-f2df82545314"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC01LTEtMS0yMjU_4920c1d4-c7f1-41d0-99d2-837bc6a3fa32"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i70569a67857b45de8cf63d09a492b8b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfOC03LTEtMS0yMjU_d7a0be98-cafd-4aac-a135-a38d6a161560"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i01d441b649884843a5fd944aaba32e08_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtMS0xLTEtMjI1_503f7eee-e5a5-4f19-b3b8-e349b67f7a1e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01d441b649884843a5fd944aaba32e08_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtMy0xLTEtMjI1_6ad5ae4b-8a99-4471-b164-568729c0a2f7"
      unitRef="usd">0</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01d441b649884843a5fd944aaba32e08_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtNS0xLTEtMjI1_0b13a84d-59ef-4f99-8095-489aa0d87b14"
      unitRef="usd">0</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i01d441b649884843a5fd944aaba32e08_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTAtNy0xLTEtMjI1_94b3d304-d82d-4600-a42d-f1188a9104a4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtMS0xLTEtMjI1_0ee6bb03-0bcd-4da2-bfdd-b2f6ff020fab"
      unitRef="usd">468302000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtMy0xLTEtMjI1_155bea63-0b45-47c4-b176-b6ea8a0ed25c"
      unitRef="usd">32000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtNS0xLTEtMjI1_6984e230-66bd-4d23-b891-830e8f576d80"
      unitRef="usd">7968000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTEtNy0xLTEtMjI1_f82a6e7d-9e27-4f76-bb1d-771c8473a643"
      unitRef="usd">460366000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctMS0xLTEtMjI1_cd3577a1-c3f4-434a-8c97-e637f5f3ef98"
      unitRef="usd">56627000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctMy0xLTEtMjI1_d650487a-415f-4735-9896-55d48914248a"
      unitRef="usd">803000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctNS0xLTEtMjI1_50a92b95-d682-4313-b351-5a87dca765ed"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if7a7391425e04e84be5220dd1fbd8895_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTctNy0xLTEtMjI1_48325303-cf38-494f-8afc-4e18fe78d89b"
      unitRef="usd">57430000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtMS0xLTEtMjI1_3213941a-9d4c-468c-ae95-7acd04ebdb5f"
      unitRef="usd">195595000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtMy0xLTEtMjI1_0a0d6072-640f-44a1-bddd-230382adf03b"
      unitRef="usd">1151000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtNS0xLTEtMjI1_63737211-d02e-4cca-bc05-7f2c5e64a6b7"
      unitRef="usd">103000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i12572392d85c4114bacfb1a517b43c1e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTgtNy0xLTEtMjI1_a5fc8efb-0ab6-4dae-8872-617fca381740"
      unitRef="usd">196643000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i48a971a1200644508883665152308229_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktMS0xLTEtMjI1_8cc2be63-f387-45e8-95f3-8f4f423c9f30"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i48a971a1200644508883665152308229_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktMy0xLTEtMjI1_7023ecf1-d707-422c-bb0a-fff0062ad1e6"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i48a971a1200644508883665152308229_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktNS0xLTEtMjI1_2e1a53db-b302-4241-b45a-bd6afdf80eea"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i48a971a1200644508883665152308229_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMTktNy0xLTEtMjI1_4fd7dc02-aca0-4407-80b8-a7cf3b4f7e89"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtMS0xLTEtMjI1_9b68eb77-d5fa-408d-9eab-aeb2213b259a"
      unitRef="usd">127481000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtMy0xLTEtMjI1_5a0603b5-2023-45d5-9b98-a20bbf013f8b"
      unitRef="usd">0</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtNS0xLTEtMjI1_33c5cef7-abc5-478b-bcdf-139085eab225"
      unitRef="usd">753000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0dfaac00a70f43a08cbf8b90bc2fafa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjEtNy0xLTEtMjI1_fba9a974-5367-49d0-89bc-419ba58d6887"
      unitRef="usd">126728000</us-gaap:EquitySecuritiesFvNi>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItMS0xLTEtMjI1_fde05d23-b1ea-48aa-88d1-e59e96c8c340"
      unitRef="usd">429703000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItMy0xLTEtMjI1_30cc184c-db9e-488a-acbc-f3629ec29da1"
      unitRef="usd">1954000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItNS0xLTEtMjI1_520247d5-7883-4bd2-b253-4ce6a696980b"
      unitRef="usd">856000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses>
    <arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180MC9mcmFnOmU4MTFlZmU5NDI4MDRiYThhNjU2MDI1NjJmNDRkMGI3L3RhYmxlOjhjODg1N2RjZDVjODQxZDY5YmUyNmI1YTA0NmJmN2E3L3RhYmxlcmFuZ2U6OGM4ODU3ZGNkNWM4NDFkNjliZTI2YjVhMDQ2YmY3YTdfMjItNy0xLTEtMjI1_6aa67dac-7bfa-498f-a4ee-9be732439b81"
      unitRef="usd">430801000</arwr:CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTAxOA_7295d091-ee8d-44c4-a150-e7c3b3925fc3">INTANGIBLE ASSETSIntangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is $1.1 million. The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortization of the assets is $11.4 million. Amortization expense for the three months ended June 30, 2022 and 2021 was $0.4 million and $0.4&#160;million, respectively. Amortization expense for the nine months ended June 30, 2022 and 2021 was $1.3 million and $1.3&#160;million, respectively. Amortization expense is expected to be $0.4 million for the remainder of fiscal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, $1.7 million in 2023, $1.7 million in 2024, $1.7 million in 2025, $1.7 million in 2026 and $5.2 million thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides details on the Company&#x2019;s intangible asset balances: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;Assets&lt;br/&gt;Subject to&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i70ac20dc1b6c4e8089f4f3a352305d67_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMzUy_27ad1956-cda4-4a4b-9d15-d09c8ce7c29e">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id7dab9325362475c8d7c98474f501710_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjY5Ng_0a4bab9c-6d30-4793-82ec-6f8c22bb17ed"
      unitRef="usd">1100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i35243ae1496c4b5397e5376a54a5213e_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfNTY1_c582f75f-40ad-4117-8515-718bed641965">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3ea210cb7e064575b12fb0ca788bb100_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjY4Nw_971eac0b-c2b7-4a43-9e8e-386beb95f053"
      unitRef="usd">11400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjgyMQ_9d2957b0-f77e-43f8-8d78-ddd944d29927"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjgxNA_4771c0b7-9c6e-4e27-a811-0d0ad10b9bad"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0Mjc5NQ_3a916449-22ff-4215-9167-d6aad3665741"
      unitRef="usd">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0MjgwNg_59a9a312-8e29-4e5f-bb05-ac3289a38825"
      unitRef="usd">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTY0OTI2NzQ0Mjc4Ng_ebb68a9e-8371-42c8-99df-d7a1738a10d1"
      unitRef="usd">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfODcw_b03f357a-3421-4f22-90dc-7691119a24f1"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfODgy_a8df05e2-62af-42bb-8256-c8919c28d6da"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfODk0_5c75f804-0049-4cef-a00b-a597754c6328"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfOTA2_a5a55f9a-7ddd-4c63-9de1-b61ced337fae"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <arwr:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfOTIx_863ead87-754f-49b5-90b3-5a5f3f139517"
      unitRef="usd">5200000</arwr:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RleHRyZWdpb246NzY5NzZhMzdhMGRkNDVmNjk1OTFlNDRlZDU0YzE1ZTZfMTAxOQ_ace99f1f-3c6c-4a96-aa49-6ddb394407be">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides details on the Company&#x2019;s intangible asset balances: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;Assets&lt;br/&gt;Subject to&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfMi0xLTEtMS0yMjU_ad3e3af3-f188-4d9c-b2d8-82f73fad1924"
      unitRef="usd">13663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfMy0xLTEtMS0yMjU_550e4e0e-ffc3-4b37-9fa9-e3d0ce9c8768"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfNC0xLTEtMS0yMjU_a7125727-1f47-422d-8a31-2d4a99df23b5"
      unitRef="usd">1276000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180My9mcmFnOjc2OTc2YTM3YTBkZDQ1ZjY5NTkxZTQ0ZWQ1NGMxNWU2L3RhYmxlOmQzNzdiYzhmZjFkYTRlMDJiMWJjOTMzYWViNzNjYzgxL3RhYmxlcmFuZ2U6ZDM3N2JjOGZmMWRhNGUwMmIxYmM5MzNhZWI3M2NjODFfNS0xLTEtMS0yMjU_0fcb22bd-cec1-406e-87eb-aea15e9c2f09"
      unitRef="usd">12387000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTM3NA_8553ded5-7617-4024-9ab7-3855abe34d90">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, 105,795,456 shares of Common Stock were outstanding. At June&#160;30, 2022, 13,942,716 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement (the &#x201c;ATM Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At June&#160;30, 2022, no shares have been sold under the ATM Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfNjg_9073d62d-91ab-4a94-945c-2f7a3d66105b"
      unitRef="shares">150000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTM0_1b8580af-d1d4-464b-ac86-29cc0200958a"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTcx_2eff5d6a-bd2c-40cd-9cff-d50a6197c407"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTg5_3977253b-916a-4b4e-addd-bc1647fce604"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMjI5_b99ba519-ea5e-4cb9-8d81-041a0c449ce2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMjUx_e52f3797-0c12-442e-a342-f5e8208463b6"
      unitRef="shares">105795456</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i7c9c3675bb1c483490de44cfa494ff0d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMzAy_5aa8473e-d2ee-4695-8463-c0a48505cc72"
      unitRef="shares">13942716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="i5c06ed8ba612412c9c704fef2aa0558c_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfNzk4_9fa912ef-185e-444b-95d8-bdc589fbe02d"
      unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock
      contextRef="i505d3506ef1048dfa8e34da8a51f5a14_D20200801-20200831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTA2Mw_37d815e3-7809-48ca-a925-160e140896ea"
      unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="i33ee3925344148cf9ff3b0be626dbb9a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180Ni9mcmFnOjMwYzViNTAxMmVlNjRlMTNiNGFkODAzYWFjZWJiODYwL3RleHRyZWdpb246MzBjNWI1MDEyZWU2NGUxM2I0YWQ4MDNhYWNlYmI4NjBfMTMyNg_807fcf87-3bc4-49bc-b4f0-fd7ceb2c35a7"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjMzNA_446ca3e5-da48-4617-9602-3eb0c2451dd0">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is planned to be the site of an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support process development and analytical activities. Arrowhead intends to invest between $200 million and $250 million into the buildout of the facilities. As part of this acquisition, the Company also entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the TIF district, and will be reimbursed by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay as reimbursements under the TIF program for these improvements is not guaranteed and will depend on future tax revenues generated from the developed property.&lt;/span&gt;&lt;/div&gt;Technology License CommitmentsThe Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon a new drug application and upon certain sales level milestones. These milestone payments could amount to the mid to upper double-digit millions of dollars. During the three and nine  months ended June&#160;30, 2022 and 2021, the Company did not reach any milestones. Under certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of sales of the relevant products.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMzky_186195d7-3625-4d5f-af04-ae150d8941b0"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arwr:NumberOfAcresOfLandPurchased
      contextRef="i84bb462914da49deab71348a6efb6c40_D20211220-20211220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfNDkz_f31607af-e135-48d1-879f-8584bae7e774"
      unitRef="acre">13</arwr:NumberOfAcresOfLandPurchased>
    <us-gaap:AreaOfLand
      contextRef="i9cab2225d77f4ca6a233208a8d4c59f5_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfNjA3_b41bff40-1a6e-4360-a316-55deb14c647e"
      unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="i4a16451ca658448c8cea645ec09ff1d2_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfNjcx_09dea1a8-c789-462f-bbd5-9948ec3e4e9d"
      unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="i4ba847cf8c8e49c5bddc809e4dc8d3f7_I20211220"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfODEx_3648c059-a702-4533-af83-0f94dc9d6f6b"
      unitRef="usd">200000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="if0867bc01dd94d139541c0b51a1ab546_I20211220"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfODE4_fe70e7fe-2fe5-4238-89ea-a4472aa75ca6"
      unitRef="usd">250000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:MilestonePayments
      contextRef="i376ce739b9c345478ec0d64a72a9dd1e_D20201001-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_3eea0e5e-7057-42b7-a861-4ddfb3739711"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="i644bf2a958784d90a68f8b4c4f576ef5_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_a7985c55-c9b2-40ee-a6b6-251065140974"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="if64b93b7539a474baa3e0eb46dbbd950_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_b5e7b575-4dfa-49f6-b929-a7f977aaba25"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="ifdf66a768eba4ecb8fe84a26654807ed_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM180OS9mcmFnOjYxZTJjOTk4NjIxOTRiMWRhNDI3MGVjNjUxNDkyNmMxL3RleHRyZWdpb246NjFlMmM5OTg2MjE5NGIxZGE0MjcwZWM2NTE0OTI2YzFfMjEzOA_f0f1f404-2060-4a80-b238-1b96feaedfa8"
      unitRef="usd">0</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0Mw_db92695d-00ea-4813-9b8b-f2913146467a">LEASES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California. The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. The increased capacity of this new office space compared to the Company&#x2019;s prior corporate headquarters will accommodate increased personnel as the Company&#x2019;s pipeline of drug candidates expands and moves closer to market. Lease payments began on September&#160;30, 2019 and are estimated to total approximately $8.7 million over the term. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease expires on April&#160;30, 2027. The Company has paid approximately $3.5 million for leasehold improvements, net of tenant improvement allowances. The lease contains an option to renew for one term of five years. The exercise of this option was not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#x2019;s Consolidated Balance Sheet at June&#160;30, 2022. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately 24,000 square feet of office space at the same location for its corporate headquarters. Lease payments for the expansion began in July 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the lease for the expansion expires in April 2027. The lease payments for the expansion are expected to total $6.9 million. The Company has paid approximately $4.0 million of leasehold improvements, net of tenant improvement allowances, for the lease expansion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin. The lease was for approximately 60,000 square feet of office and laboratory space and had an expiration date of September&#160;30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional 40,000 square feet and to extend the lease expiration date to September&#160;30, 2031. Lease payments are estimated to total approximately $26.2 million for the term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred approximately $11.0 million of leasehold improvements for the additional 40,000 square feet, net of tenant improvement allowances. The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#x2019;s Consolidated Balance Sheet at June&#160;30, 2022. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional 10,743 square feet and these amendments added a total of approximately $1.2 million of lease payments for the remainder of the term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company entered into a sublease agreement for additional research and development facility space in San Diego, California. The Sublease provides additional space needed to accommodate the recent growth of the Company&#x2019;s personnel and discovery efforts. The Sublease is for approximately 21,000 rentable square feet. The term of the Sublease commenced on April&#160;1, 2020 and will end on January&#160;14, 2023. Sublease payments are estimated to total approximately $2.0 million over the term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company entered into a new lease for a San Diego, California research facility. The 15-year lease is for approximately 144,000 square feet of office and research and development laboratory space to be constructed in San Diego, California. This lease will replace the Company&#x2019;s current research facility sublease for property located in San Diego, California. The increased capacity of this new facility compared to the Company&#x2019;s current research facility in San Diego will accommodate increased personnel for the Company&#x2019;s expanding pipeline of current and future drug candidates. The estimated rent commencement date for the lease is in March 2023, after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $31.0 million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. .&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost during the three months ended June&#160;30, 2022 and 2021 was $3.4 million and $1.6 million, respectively. Operating lease cost during the nine months ended June&#160;30, 2022 and 2021 was $6.0 million and $3.6 million, respectively. Variable lease costs for the three months ended June&#160;30, 2022 and 2021 was $0.2 million and $0.1 million, respectively. Variable lease costs for the nine months ended June&#160;30, 2022 and 2021 was $0.5 million and $0.6 million, respectively. There was no short-term lease cost during the three and nine months ended June&#160;30, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents payments of operating lease liabilities on an undiscounted basis as of June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 (remainder of fiscal year)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(72,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#x2019;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#x2019;s Consolidated Statements of Cash Flows for the nine months ended June&#160;30, 2022 and 2021 was $3.4 million and $2.2 million, respectively. The weighted-average remaining lease term and weighted-average discount rate for all leases as of June&#160;30, 2022 was 7.3 years and 8.5%, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6885dc858b074038a02f3117afb66394_I20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTI3_3826b52c-b590-4f42-ba6a-f3e64ad94a5d">P91M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i6885dc858b074038a02f3117afb66394_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjI3_06015124-d6f8-425e-8145-7ec6d48baa0a"
      unitRef="sqft">24000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6885dc858b074038a02f3117afb66394_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNjAy_e30f400f-8d44-4a35-939a-0710552d11ff"
      unitRef="usd">8700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="i692059f5d1fe4e29a4e0274f8340c5e5_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNjgx_9694e7c1-a1f5-4e99-a52c-1d5a911574d3"
      unitRef="usd">3500000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <arwr:NumberOfOptionsToRenew
      contextRef="i6885dc858b074038a02f3117afb66394_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNzky_800e683a-e85e-4eb0-99f0-eadf8ceaf514"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6885dc858b074038a02f3117afb66394_I20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfODAz_3b64576b-27f6-43ff-a837-9f5609b1e432">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i162842da9c754c31a54c9669b0abb806_I20201023"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTA2Mg_31b120e0-df75-467f-9faa-7ee983078d5a"
      unitRef="sqft">24000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i162842da9c754c31a54c9669b0abb806_I20201023"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTI5Nw_87d6c57f-1def-4a77-88f6-76cc846c1068"
      unitRef="usd">6900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="ie5cf456b9e5a4cfcb2e90173f201d53f_D20201023-20201023"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTMzNg_45e0b461-9ce4-4a89-9b76-c9ad9f5906d9"
      unitRef="usd">4000000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="iae3244d52008465399c8cf8280559727_I20160131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTgwMg_db7aa983-a194-43ca-a5d2-2bf72d407d52"
      unitRef="sqft">60000</us-gaap:LandSubjectToGroundLeases>
    <arwr:AdditionalLandSubjectToLease
      contextRef="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMTk3OQ_b72c9f99-f38c-413d-b99b-2cc524c7fbd0"
      unitRef="sqft">40000</arwr:AdditionalLandSubjectToLease>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i773403c141e742faaafdffe0102289bb_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjA5Mw_f8654e78-25da-4d19-a627-fc6e85cc1eb4"
      unitRef="usd">26200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjE0NQ_db0356e5-2b1d-430d-bda1-a5b5d364e06a"
      unitRef="usd">11000000</arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <arwr:AdditionalLandSubjectToLease
      contextRef="i9a93f2d81d964f41a2bfacbe6ca71af7_D20190101-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjE5OTAyMzI2MjAyMg_b72c9f99-f38c-413d-b99b-2cc524c7fbd0"
      unitRef="sqft">40000</arwr:AdditionalLandSubjectToLease>
    <arwr:NumberOfOptionsToRenew
      contextRef="iae3244d52008465399c8cf8280559727_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjI3MA_d1334bd9-a889-4385-a4f6-c5b1e2e5ade3"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iae3244d52008465399c8cf8280559727_I20160131"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjMwNw_24d063fa-1f83-468c-b566-474d4233db1f">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:AdditionalLandSubjectToLease
      contextRef="ia255aa9db9e44c3abb416601214d870b_D20201101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjU5OA_7af466b5-c328-47a2-a658-17c895a0c341"
      unitRef="sqft">10743</arwr:AdditionalLandSubjectToLease>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ied64e4423da840bc99bd1ce7b1418f51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMjY2NQ_bb349ab5-9266-440f-bd29-f88e183d63da"
      unitRef="usd">1200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i8783fb2c40044c1b857062a070f80527_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzAxNA_fd562ad9-e49f-43e7-bf16-7e4854dfb263"
      unitRef="sqft">21000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8783fb2c40044c1b857062a070f80527_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzE1NQ_68c8aadb-a354-419f-b56f-c54eaeb0c15c"
      unitRef="usd">2000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0NA_7831165b-b8c7-4a3a-a8a8-7c1eff2870ed">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzMwMw_a2b51c99-0450-4f0f-b9db-eb04d1220b6e"
      unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfMzk3Mw_9c4eb206-1376-493f-ae38-272f23dbff64"
      unitRef="usd">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5NTU3_59e3f9d4-263b-4b2e-88cc-f8eadf4615e9">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:EstimatedPaymentsForOperatingExpensesYearOne
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDA4Ng_bc41b418-194c-40ef-8725-ead1540aa0df"
      unitRef="usd">3000000</arwr:EstimatedPaymentsForOperatingExpensesYearOne>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5NTU4_9df21d12-c4fe-493b-b5e0-c31177ac2675">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="id660743071414df3aeca314c0c062149_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDIzMw_e0c8392e-4fb6-4774-a622-4c2a9b5ae5c4"
      unitRef="usd">31000000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5NTU5_7ca50ae2-ce2e-4cae-a02e-738dec050582">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="i5fa41fe62302434990f633a5d20b8810_I20211119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDQ1MA_da1a5ad3-4811-44ba-8f7a-c499aca56e6f"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2f6c6428986c4ea29b4feb287b7c9dc3_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0MQ_14b6eeac-2317-47d5-b716-a5a098e5c356">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDY4OQ_b16b2b56-39da-42f4-bb25-c7a9450dc35c"
      unitRef="usd">3400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDY5Ng_2ab86a88-c1fd-4b7f-a3e4-a30d2dcc9b9a"
      unitRef="usd">1600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDc3Ng_f7c23786-0df3-4099-8be0-9602785bada9"
      unitRef="usd">6000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDc4Mw_297e3f5c-f70e-4184-ac03-b13948fefe7f"
      unitRef="usd">3600000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDg2Mw_cb36ecf4-35b0-4366-a7f8-eb9bc2dfb811"
      unitRef="usd">200000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDg3MA_199a7655-0b17-4979-87dd-b248bc8a670c"
      unitRef="usd">100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk0Nw_4554bc32-b627-41d3-a6a8-cf7da2c7ba3c"
      unitRef="usd">500000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk1NA_04f676de-096b-4c47-ac3b-c9a2a1616ab5"
      unitRef="usd">600000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i310c20b290184b028f4e1378831a6bb8_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_446fe3f9-f185-48f0-86a7-41fe19096ac1"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="id07622b31e124512bd809dd85be92060_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_9148194f-ee73-46e0-a578-c3b475f43741"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_c0e701e6-da9c-4d63-9117-e2bb541c37b4"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNDk4Mg_c23d5431-685b-4c2d-806b-dfeaeff9092d"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTY0Mg_1565e87b-ae33-45d8-b698-e02de8b3ce85">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents payments of operating lease liabilities on an undiscounted basis as of June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 (remainder of fiscal year)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(72,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfMS0xLTEtMS0yMjU_40f7f87e-f776-46a6-800f-e7eedd2bc26f"
      unitRef="usd">1309000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfMi0xLTEtMS0yMjU_e6872276-2702-4546-87ef-bf054363f882"
      unitRef="usd">5802000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfMy0xLTEtMS0yMjU_cd89258d-e6b0-4ce4-ae3a-a6ae410f24e8"
      unitRef="usd">8094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNC0xLTEtMS0yMjU_aa2f8da9-bca3-4174-babc-bee8bd636cc8"
      unitRef="usd">11800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNS0xLTEtMS0yMjU_cdb2f434-3775-4655-a90e-04646631d650"
      unitRef="usd">12313000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNi0xLTEtMS0yMjU_53293171-9c35-45b1-8c95-6f5c02435c92"
      unitRef="usd">114109000</arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfNy0xLTEtMS0yMjU_e7753204-2d2d-4564-8e5d-ea97d385c1ee"
      unitRef="usd">153427000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfOC0xLTEtMS0yMjU_a19d3357-17b9-47b1-9824-af764ef321ad"
      unitRef="usd">72313000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RhYmxlOjQwOTQ2ZTc0MjA2YzQzNWE5OTg1Mjk1MGZiMjRhZWI1L3RhYmxlcmFuZ2U6NDA5NDZlNzQyMDZjNDM1YTk5ODUyOTUwZmIyNGFlYjVfOS0xLTEtMS0yMjU_08a4d170-bd35-4514-a63c-3f519dc15c33"
      unitRef="usd">81114000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ4OA_34c46053-d953-45aa-89a3-a21f320f037c"
      unitRef="usd">3400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NQ_104dafad-a8b2-46e5-959e-73a22e8d607a"
      unitRef="usd">2200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTQ5NzU1ODE5ODIz_eaead4a4-0126-4876-8be9-2c2ef501bef7">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181Mi9mcmFnOjY3MjMwOTEzNGU3ZDQzNTY4YTJjYzZhOTBmOTA1MWQ4L3RleHRyZWdpb246NjcyMzA5MTM0ZTdkNDM1NjhhMmNjNmE5MGY5MDUxZDhfNTYyNQ_a38177dc-bdf3-4337-9227-41d9594d0d84"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTI0MA_6a2a79e6-f3b6-4b1b-b467-29a490d4cd60">STOCK-BASED COMPENSATIONArrowhead has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, as of June&#160;30, 2022, 216,607 and 4,114,999 shares, respectively, of Arrowhead&#x2019;s Common Stock are reserved for the grant of stock options, stock appreciation rights, and restricted stock unit awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan. As of June&#160;30, 2022, there were options granted and outstanding to purchase 216,607 and 1,806,987 shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were 2,308,012 restricted stock units granted and outstanding under the 2013 Incentive Plan. As of June&#160;30, 2022, there were 816,248 shares reserved for options and 682,500 shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. As of June&#160;30, 2022, there were 3,000 shares of Common Stock reserved for options and 1,507,267 shares of Common Stock reserved for restricted stock units granted and outstanding under the 2021 Incentive Plan. As of June&#160;30, 2022, the total number of shares available under the 2021 Incentive Plan was 6,627,845 shares, which includes 119,612 shares that were forfeited under the 2013 Incentive Plan.&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,456,239&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(106,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506,596)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,842,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,434,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,370,089&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52,941,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options for the three months ended June&#160;30, 2022 and 2021 was $2.6 million and $3.2 million, respectively. Stock-based compensation expense related to stock options for the nine months ended June&#160;30, 2022 and 2021 was $8.3 million and $9.6 million, respectively. For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the options granted by the Company for the three months ended June&#160;30, 2022 and 2021 was $0 and $0.9 million, respectively. The grant date fair value of the options granted by the Company for the nine months ended June&#160;30, 2022 and 2021 was $0 and $9.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of the options exercised during the three months ended June&#160;30, 2022 and 2021 was $1.6 million and $10.2 million, respectively. The intrinsic value of the options exercised during the nine months ended June&#160;30, 2022 and 2021 was $24.9 million and $63.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $14.9 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 1.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to value stock options are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86% - 90.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on that of the U.S. Treasury bond. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility is estimated based on volatility average of the Company&#x2019;s Common Stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including time-based, market condition-based, and performance condition-based awards, have been granted under the Company&#x2019;s 2013 Incentive Plan, 2021 Incentive Plan, and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,831,850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,691,367&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(962,188)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(95,625)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,465,404&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2022 and 2021, the Company recorded $33.7 million and $15.4 million of expense related to RSUs, respectively. During the nine months ended June&#160;30, 2022 and 2021, the Company recorded $83.4 million and $32.5 million of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For RSUs, the grant date fair value of the award is based on the Company&#x2019;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. The grant date fair value of the RSUs granted by the Company for the three months ended June&#160;30, 2022 and 2021 was $42.5 million and $3.1 million, respectively. The grant date fair value of the RSUs granted by the Company for the nine months ended June&#160;30, 2022 and 2021 was $95.2 million and $112.1 million, respectively.&lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2022, the pre-tax compensation expense for all unvested RSUs in the amount of $190.3 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 2.7 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i05cd815b480347a286bc4f71cff5bbcb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTg0_2fa4bd7a-f380-4cd3-84ee-ac9874b7c66a"
      unitRef="shares">216607</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i65ce38c05a5f42e5aef4eab075945c1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTkx_24a1d0ae-68eb-4439-b5f5-6127b33b1655"
      unitRef="shares">4114999</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i379e60ba18ab41bebaf6384f97789684_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIw_4e41dba9-addc-4cc6-b6f0-9611663dcec8"
      unitRef="shares">216607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if3aae72041c247afb7d654e771941178_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTI3_68da07c9-b9db-4a58-9462-32a1e06071b7"
      unitRef="shares">1806987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i7882ec681e8845bdafe4d93a1da25ae0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNjQ4_b074c95c-48cc-43fa-8fb0-ad75a82694f1"
      unitRef="shares">2308012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4351ec20fd374ac591919ea36aeda735_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNzUw_3a8d9fe5-ba8c-480a-9bac-55b5cb2beb5b"
      unitRef="shares">816248</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9a3423502b6f4eff862ece7e6ce5ab9f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNzg1_97f664f5-e71f-4eb5-8548-dc32708a0ac2"
      unitRef="shares">682500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia900dec5d8af437f8940adc4f0279a04_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfOTM1_99624040-59d4-4e78-8404-4f8a5e2500e9"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i10471b52c2b6469eadb29efc00dc46d7_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfOTg2_53817e84-3395-4e2c-981a-31ba55f1db0c"
      unitRef="shares">1507267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib4c1075e233c4c4285d6a3aadd4db3ea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTE4NA_5f15aa51-7ffe-4cf9-a67b-4472b7645dad"
      unitRef="shares">6627845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4c13269bb6524b0cb33ce18d229e84d4_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTIxMA_02a47e4a-e738-47a6-8028-1de2ea1c8c36"
      unitRef="shares">119612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTI0MQ_bc245659-0c78-4876-b558-f5bd74a6e7be">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,456,239&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(106,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506,596)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,842,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,434,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,370,089&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52,941,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMS0xLTEtMS0yMjU_38901d1c-b04a-4f2a-b094-96ce8624169b"
      unitRef="shares">3456239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id7cf968fbe86467e988f3c9ca0c77d2d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMS0zLTEtMS0yMjU_c942710e-211c-4908-ac7d-8ab5115f5e3a"
      unitRef="usdPerShare">19.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMi0xLTEtMS0yMjU_eb75b7b5-14f1-4079-ade0-e72c213ea89f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMi0zLTEtMS0yMjU_5a749439-4718-41f1-9a8b-ea434476ffc0"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMy0xLTEtMS0yMjU_47d19cfa-d822-459b-abf9-9c8f70807d2c"
      unitRef="shares">106801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfMy0zLTEtMS0yMjU_fe6e8079-a844-4b1a-aa29-14423897c696"
      unitRef="usdPerShare">43.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNC0xLTEtMS0yMjU_5b7e7573-0596-40e1-b7ef-74b0c7320d32"
      unitRef="shares">506596</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNC0zLTEtMS0yMjU_34d38d62-5cd8-48a7-bc68-0e49a5a5267d"
      unitRef="usdPerShare">8.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS0xLTEtMS0yMjU_bab7d6d4-8ca9-47c2-a8fd-09a1c725ffd8"
      unitRef="shares">2842842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS0zLTEtMS0yMjU_fe59dc11-5804-4234-933d-6c0d711fceaa"
      unitRef="usdPerShare">20.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS01LTEtMS0yMjU_08fd8be5-2dfd-4d31-9092-913717495237">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNS03LTEtMS0yMjU_b64eb440-8815-434c-b2ed-bc6d766bc964"
      unitRef="usd">55434252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi0xLTEtMS0yMjU_cc6e61fd-32e4-495f-9a50-2a8dc61a67e4"
      unitRef="shares">2370089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi0zLTEtMS0yMjU_f641ed51-1f2e-4dc7-ba1f-03df4d3e24ad"
      unitRef="usdPerShare">16.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi01LTEtMS0yMjU_6546d593-2a12-481a-9fcb-63fcd0853a44">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib685fad7e1394c24a0d385826599cb7b_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmE4Y2RjOGI0YmUzMzRkOGI5MTRjODdjMjg1OTk4ZTRlL3RhYmxlcmFuZ2U6YThjZGM4YjRiZTMzNGQ4YjkxNGM4N2MyODU5OThlNGVfNi03LTEtMS0yMjU_4511ecdc-cafe-4df1-a0cd-78b79bc778ba"
      unitRef="usd">52941990</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTQ1MA_5cd99336-0fd4-4de9-905d-2605e996bf1d"
      unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTQ1Nw_42f30ada-4166-425b-9585-96e89b019a81"
      unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTU3MQ_b2cf6d91-b66c-4685-82db-0fc736f4b3c3"
      unitRef="usd">8300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTU3OA_49a2510c-c106-4073-957f-d32eb1acb615"
      unitRef="usd">9600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTg2MQ_b2f84a0d-5ebf-4689-88f9-c37bbd7577b3"
      unitRef="usd">0</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTg2OA_2ea3f03b-f748-4149-b70b-21810b2c4131"
      unitRef="usd">900000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTk4OA_7e8e4435-c023-46d7-9146-59b6b9275518"
      unitRef="usd">0</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMTk5NQ_6d9180dc-3e3a-4def-bd35-56564bdf9d98"
      unitRef="usd">9000000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjEwMw_5f39e3ff-6a38-4e3b-af7a-889d573dd038"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ifa28ed28f19042f9a2f4b6ec917b3544_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjExMA_3e8c6a18-141d-4591-930f-e74546b3b62d"
      unitRef="usd">10200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjIyOA_3fcbc27b-8deb-4c5c-ae08-9bc431535356"
      unitRef="usd">24900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia17c3b5969cd41b4861d972fcf86b286_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjIzNQ_d1d155cd-79f7-4497-b1d1-ae3a653a93c7"
      unitRef="usd">63000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3bb156c620804981b8a0721dfa56e51a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjM1Nw_cea942d6-cfd1-48c0-a07e-bb0101bf966f"
      unitRef="usd">14900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMjQ1Mg_77c6e450-a1ad-47bc-98a2-02909ed8a122">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIzOA_845b75be-6f3e-426e-a1a5-91c585f28ddf">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to value stock options are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86% - 90.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfMi0zLTEtMS0yMjU_35bce74a-1978-44ac-9664-931051125daf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfMy0zLTEtMS0yMjUvdGV4dHJlZ2lvbjpiNmQ2NTkyMzVhMjI0ZTQ4ODI1N2FlOWI0ZTQxMTAyNF8yMTk5MDIzMjU1NTY5_0ac6d5d7-0185-4aed-bd85-a1ebb22be82d"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfMy0zLTEtMS0yMjUvdGV4dHJlZ2lvbjpiNmQ2NTkyMzVhMjI0ZTQ4ODI1N2FlOWI0ZTQxMTAyNF8yMTk5MDIzMjU1NTgw_84c9bb0f-e9a9-4809-bbba-8932ad338eaf"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNC0zLTEtMS0yMjUvdGV4dHJlZ2lvbjplNzNlNDRhMGU4NWQ0NTNiYTE3NzI4M2E3MzhmMDlhM18yMTk5MDIzMjU1NTcy_edec214b-c53e-4b47-b4a7-70400285109f"
      unitRef="number">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNC0zLTEtMS0yMjUvdGV4dHJlZ2lvbjplNzNlNDRhMGU4NWQ0NTNiYTE3NzI4M2E3MzhmMDlhM18yMTk5MDIzMjU1NTg1_96143cd1-9f7e-45ab-a75c-8d87aa730f23"
      unitRef="number">0.904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNS0zLTEtMS0yMjU_bfe0d769-3824-44ee-937f-3acbec9bbdc6">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOmQwZTM0YjhlMmU1NDQ4NWU4OTgxMjEzNjMxMjZiMzA0L3RhYmxlcmFuZ2U6ZDBlMzRiOGUyZTU0NDg1ZTg5ODEyMTM2MzEyNmIzMDRfNi0zLTEtMS0yMjU_db3d82cd-57c4-4a7e-9c2a-0151c8568c6a"
      unitRef="usdPerShare">48.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibd59f63184a24e49857a364bf6736d30_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfMzQxOQ_a333a29d-7c79-4944-bb23-7aca56cdf7ae"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIzOQ_8bba572e-b3cc-4fa8-b817-ecb77345e4db">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,831,850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,691,367&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(962,188)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(95,625)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,465,404&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i259144688fe44f518dbdd195d182b514_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMS0xLTEtMS0yMjU_868eb9bd-40bc-4814-a23c-825a4a32d2fe"
      unitRef="shares">3831850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i259144688fe44f518dbdd195d182b514_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMS0zLTEtMS0yMjU_f7847e90-e677-430a-a7a8-1a462b0574b1"
      unitRef="usdPerShare">61.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMi0xLTEtMS0yMjU_184b4764-43a5-4916-bccb-4f947264cf2a"
      unitRef="shares">1691367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMi0zLTEtMS0yMjU_845cf8df-df6e-4de4-be59-a713489dfffc"
      unitRef="usdPerShare">56.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMy0xLTEtMS0yMjU_2e02f6ed-9af9-4153-bd22-2cee003b105e"
      unitRef="shares">962188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfMy0zLTEtMS0yMjU_bb0ff0d9-efc2-489c-8cfd-8d28811a151d"
      unitRef="usdPerShare">49.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNC0xLTEtMS0yMjU_2c0dbec7-c7d0-4e78-a92e-fa577d1dd637"
      unitRef="shares">95625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNC0zLTEtMS0yMjU_05d8a92c-a943-4f62-805a-6fe2848d121e"
      unitRef="usdPerShare">69.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id47421dd3b3e45a88df5bdc71cefa55c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNS0xLTEtMS0yMjU_c3193888-fae8-4b85-b306-dce7eae2a4fa"
      unitRef="shares">4465404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id47421dd3b3e45a88df5bdc71cefa55c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RhYmxlOjIxYjZkODAxZDQ2MjQ0ZWJiYjhhZDBhODA4ZDhlMzY5L3RhYmxlcmFuZ2U6MjFiNmQ4MDFkNDYyNDRlYmJiOGFkMGE4MDhkOGUzNjlfNS0zLTEtMS0yMjU_4059f196-cd64-4f0c-8106-d811c84b8ca1"
      unitRef="usdPerShare">61.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDEzNA_3f626865-7135-4848-8730-f04c585fd210"
      unitRef="usd">33700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88e9d9c8bcbb4fcaabd247d4fbea501a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDE0MQ_89265620-720a-4b46-85b2-42fbc82ee397"
      unitRef="usd">15400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDI0NQ_26a8e63b-fd5e-4be6-b866-78f7b5a0b1d6"
      unitRef="usd">83400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4414d1709ac14596b6a26d0204f04e45_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDI1Mg_f0359171-95ec-4d28-a3fe-042bfe066d52"
      unitRef="usd">32500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod
      contextRef="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDkwOQ_2eaa488f-189e-45ed-9587-4030fc005fff"
      unitRef="usd">42500000</arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod
      contextRef="i88e9d9c8bcbb4fcaabd247d4fbea501a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNDkxNg_4cead625-1423-47c9-9acc-599630f81945"
      unitRef="usd">3100000</arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod
      contextRef="i42387e344e3543e292ff0c21772fd75d_D20211001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTAzMw_aee6e93f-6c55-4276-a34c-50a9a0474da5"
      unitRef="usd">95200000</arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod
      contextRef="i4414d1709ac14596b6a26d0204f04e45_D20201001-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTA0MA_30d1ea1e-9988-4067-96a0-f120adc2d0a7"
      unitRef="usd">112100000</arwr:GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id47421dd3b3e45a88df5bdc71cefa55c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTE0MA_e829a408-cde1-440b-b6fd-d41f28191db6"
      unitRef="usd">190300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i56bc3776911e49c1b914eb75f168cafa_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM181OC9mcmFnOmZjNDhkNTYyNjBiOTRhMjQ4NTkxNzE0M2E4OWNlMDNhL3RleHRyZWdpb246ZmM0OGQ1NjI2MGI5NGEyNDg1OTE3MTQzYTg5Y2UwM2FfNTIzNQ_70987eb0-32bb-4ace-8cd2-3bf2c647f9c8">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RleHRyZWdpb246NmVmOWQ5MWI1MjI2NDJjZmFlZjlmOTBmYThlN2JiOWJfMTY0OQ_faa32bfc-f995-47a1-a291-5ea3ad34f9e0">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#x2019;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair value measurements at June&#160;30, 2022 and September&#160;30, 2021 for assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;225,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;225,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RleHRyZWdpb246NmVmOWQ5MWI1MjI2NDJjZmFlZjlmOTBmYThlN2JiOWJfMTY1MA_6a39c43d-c60b-4dcf-be6b-3157dcc6dd05">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair value measurements at June&#160;30, 2022 and September&#160;30, 2021 for assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Commercial Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;225,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;225,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Held to Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%"&gt;Classified as Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <arwr:CommercialNotes
      contextRef="i7214723d69d141009860a51209e72550_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy0xLTEtMS0yMjU_985ad0bd-c568-4f18-b490-445f3fd05ac1"
      unitRef="usd">0</arwr:CommercialNotes>
    <arwr:CommercialNotes
      contextRef="if7cc07f5f5684808976783384030924f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy0zLTEtMS0yMjU_c6baeb63-40b9-458e-b42d-cdf404a2bfcc"
      unitRef="usd">25336000</arwr:CommercialNotes>
    <arwr:CommercialNotes
      contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy01LTEtMS0yMjU_5a3ad241-cfdd-4bab-95d0-91baf678d67a"
      unitRef="usd">0</arwr:CommercialNotes>
    <arwr:CommercialNotes
      contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMy03LTEtMS0yMjU_705e1298-1546-4921-a370-a85666d0d2f0"
      unitRef="usd">25336000</arwr:CommercialNotes>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7214723d69d141009860a51209e72550_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS0xLTEtMS0yMjU_d911b7b3-ccf4-442c-91d3-0b4c57f6d44b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7cc07f5f5684808976783384030924f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS0zLTEtMS0yMjU_2ac298b1-8864-479c-8b44-4bdfd713ee3c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS01LTEtMS0yMjU_13396b41-5aeb-4ca9-b501-b39598f2d071"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNS03LTEtMS0yMjU_0e4c47ad-2835-4175-b21f-40946f0ac4fc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i7214723d69d141009860a51209e72550_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy0xLTEtMS0yMjU_bdcdafad-7bb6-4b6e-9c2e-b27ae4dbebfd"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if7cc07f5f5684808976783384030924f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy0zLTEtMS0yMjU_b82aad49-b17d-4d66-9e81-ff3e3d5eecc5"
      unitRef="usd">225490000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy01LTEtMS0yMjU_1de5bf43-a1f2-4f5c-9bf4-05af0aaacb2c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfNy03LTEtMS0yMjU_1a6c7641-d1df-4292-95e2-95a3e31a1598"
      unitRef="usd">225490000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="i7214723d69d141009860a51209e72550_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC0xLTEtMS0yMjU_55cabc80-c54e-4699-a930-7fae33fbe3d2"
      unitRef="usd">0</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="if7cc07f5f5684808976783384030924f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC0zLTEtMS0yMjU_c40f8df2-62b2-4926-8f42-8e62f4f87ab2"
      unitRef="usd">159540000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC01LTEtMS0yMjU_cab67ed2-8599-43a7-b457-ffeae4031524"
      unitRef="usd">0</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOC03LTEtMS0yMjU_4394bd93-ac9c-4786-8886-7fc21316b341"
      unitRef="usd">159540000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:CertificateOfDeposits
      contextRef="i7214723d69d141009860a51209e72550_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS0xLTEtMS0yMjU_4eae3ad6-3e97-4f4d-8e89-5df8ccb55de6"
      unitRef="usd">50000000</arwr:CertificateOfDeposits>
    <arwr:CertificateOfDeposits
      contextRef="if7cc07f5f5684808976783384030924f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS0zLTEtMS0yMjU_e9a41ea3-6ec5-4f47-aa70-e576521808a8"
      unitRef="usd">0</arwr:CertificateOfDeposits>
    <arwr:CertificateOfDeposits
      contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS01LTEtMS0yMjU_ce344730-3cc5-4aec-baa7-7145af2d0e7e"
      unitRef="usd">0</arwr:CertificateOfDeposits>
    <arwr:CertificateOfDeposits
      contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfOS03LTEtMS0yMjU_c3029687-0ee6-4c10-9067-c18a0954d4fd"
      unitRef="usd">50000000</arwr:CertificateOfDeposits>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7214723d69d141009860a51209e72550_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtMS0xLTEtMjI1_2b4f8fb1-e965-42e3-9847-ef8adaa8d702"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if7cc07f5f5684808976783384030924f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtMy0xLTEtMjI1_e3f9edd6-9abc-43ba-ad4c-94c07bf55e42"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic4df8704ede34d46af5c314aa1eb7c4a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtNS0xLTEtMjI1_61b69a33-48ef-407e-a2f2-12db7163396a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjVjOTY1ZjgyMjM0YzRiZDk4OWZmNzcxYzhiZTkzY2MyL3RhYmxlcmFuZ2U6NWM5NjVmODIyMzRjNGJkOTg5ZmY3NzFjOGJlOTNjYzJfMTEtNy0xLTEtMjI1_2f82a9c9-40c0-4212-9356-4a26e87f08bb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy0xLTEtMS0yMjU_aa9f5ba4-950f-4eaa-b3d6-4771190821cc"
      unitRef="usd">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i224620efc59044b19ba131a63fb0f173_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy0zLTEtMS0yMjU_0e71801b-dec2-4f32-99ea-1096819742d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy01LTEtMS0yMjU_f2059a9a-f935-495b-bd90-e126fbbca50f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfMy03LTEtMS0yMjU_615eff32-7f55-4209-a864-d10167030197"
      unitRef="usd">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS0xLTEtMS0yMjU_ed5a6542-1751-4f0d-bc44-f47a91e7b6cd"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i224620efc59044b19ba131a63fb0f173_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS0zLTEtMS0yMjU_7760a33b-ddb8-444f-8d4d-6c9e1bd046de"
      unitRef="usd">57430000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS01LTEtMS0yMjU_cec8a69c-200f-489d-b27f-02dbe2e2441d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNS03LTEtMS0yMjU_0168d38d-d67c-491b-94f8-1c9d5afcf682"
      unitRef="usd">57430000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi0xLTEtMS0yMjU_8d0a1609-34e6-4fc1-a3d7-0128fadf7400"
      unitRef="usd">0</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="i224620efc59044b19ba131a63fb0f173_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi0zLTEtMS0yMjU_90743d87-90bd-43f3-b17d-2f9cbe188d2a"
      unitRef="usd">196643000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi01LTEtMS0yMjU_dccc3c86-589e-4a08-893f-e45bde229ce6"
      unitRef="usd">0</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNi03LTEtMS0yMjU_570b8fa8-b2da-4c8a-bfdf-61cca47d90eb"
      unitRef="usd">196643000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:CertificateOfDeposits
      contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy0xLTEtMS0yMjU_c91312a4-091c-46bc-95e4-22893d9e7346"
      unitRef="usd">50000000</arwr:CertificateOfDeposits>
    <arwr:CertificateOfDeposits
      contextRef="i224620efc59044b19ba131a63fb0f173_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy0zLTEtMS0yMjU_189eee30-00d2-40e0-9711-fea7218a91f4"
      unitRef="usd">0</arwr:CertificateOfDeposits>
    <arwr:CertificateOfDeposits
      contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy01LTEtMS0yMjU_cedbea6a-b84e-42b0-925c-47e9d2691fa3"
      unitRef="usd">0</arwr:CertificateOfDeposits>
    <arwr:CertificateOfDeposits
      contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfNy03LTEtMS0yMjU_5df4eceb-b3fe-4c3d-929f-ddcf170f4477"
      unitRef="usd">50000000</arwr:CertificateOfDeposits>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic7c4db4499354a50be2f2351fc8b9349_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS0xLTEtMS0yMjU_206d63c0-6ca6-4bab-8df8-c15af5495f87"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i224620efc59044b19ba131a63fb0f173_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS0zLTEtMS0yMjU_ce52393f-d108-4389-9880-de9afb0e4dd4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iffbe6a0a54524c628256db91d4b3fe22_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS01LTEtMS0yMjU_48df7cb3-8ef2-4652-aa26-d2626d035f21"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5587e3a468684317b7c2e9a7dd3e8b9b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182MS9mcmFnOjZlZjlkOTFiNTIyNjQyY2ZhZWY5ZjkwZmE4ZTdiYjliL3RhYmxlOjgxNTFiYWE5NTQxYjQxZTNiMGQ4NjE3Y2FkNmRmMzQxL3RhYmxlcmFuZ2U6ODE1MWJhYTk1NDFiNDFlM2IwZDg2MTdjYWQ2ZGYzNDFfOS03LTEtMS0yMjU_d0c495b0-ea4a-49fe-b09a-da396c83f78f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i0d90bfff39604327a3c812002f6027c4_D20211001-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY2ODZhNmM0Zjg1MTQwZjQ5MTIzMDY1NTJjOTZjNzIzL3NlYzpmNjg2YTZjNGY4NTE0MGY0OTEyMzA2NTUyYzk2YzcyM182NC9mcmFnOmZjNGQwMjI4YmJiYjQyZGE5MmFlN2ZmZThlOWE3ODIwL3RleHRyZWdpb246ZmM0ZDAyMjhiYmJiNDJkYTkyYWU3ZmZlOGU5YTc4MjBfNzc0_5f2fe5a1-b9fe-4396-bc8c-062b3cf4686d">SUBSEQUENT EVENTSNone.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!'H4$I@'C(V'*Q7CKG+@H?$-.?L%9[]FSY0,EI!\!:AN1UQKSJ+4V)!H6$/
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M[\.,)[=;QML3)5;YKNN34$K$^>&2LX!+_0#<GPNA]B?Z!<7&_? _4$L#!!0
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M=&I_6^\OE]:[8DM">M43:Z>@^8[V!F]>0==ZKTON%P4[214?4L6FZ(,1*39
MO#00R@OZO8QW)*$9U[[$.I1;A9+K?S> .+!Q<-G?'>>C,?-M&]L'LQ.D]@&I
M;40Z#$-6"F"B.814H+Q+J YC'<0Y&API %4;:"''T>-S#O@<([Z;G&Y)' 'Z
M0[30@FH+Z"@#NYX+6^A4(QN[2 _./8!SC>#F?$-ST2_R7+Q;0(J"ZM^PJXSM
M^P%J 52-$ R@'J!W .@9 7XA^3?*Y4L%!14X8Q[K2^@I@ULM>*H%1*Z'?#U
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M#W?PP^Z>LZ+Y$H(-G1GH78 ;^1)1B#_T<;UOTH0^)&D1=V/K"=^S];R3L8-
M8*MB,ZL[DU&9'I@P(I8\Z5UGY"BKF07+PEXM5R:QMN:#]Q@7=V*<";:F28S8
M=]UY6)DCKE9, .$+ ?2[39X1.6X60!#X#>0&,1*$;@MV4F$GK_2D!0.(,<3W
MB>4;<W") :(/\:UC;,H1C.VPI1IP1<&XD]^J3;"F/UIW@-T$:;M>O5H-8C:Q
M@A:$%47B;HX$A&+#JBU@1.@8-E^CG9BD;"]HBV%%D;B;(Z_U?C3":G*=[?EU
MXC9(>4';[JL($7<SXG1\BXH!:W9S?3^Y'%^BBW_1T=T<%I/IL7'6,KK0Y, 3
MSW<\I^Y$4PZ'KNVT\#JNZ!+[;QH2)]/[\?Q7AD3<R<-O;=7O9>TP"A7IXF[6
MG6U$M*+%E+  AM74I7X4S9!]VR1K_1UBC$&304_T1VNC!1KDL NUT9*]BFUQ
M)X<=XD[R)R95\<UD!!L:P!+;#NMCF4DP='%;QR85(Y)N1IP)'C$62[00/$.2
MPACV.FS2)#X89=RP/HT9Y*#3VU8+Z(HB23=%OE+HIGHQNF%@00<'7KU;F>2(
M[=@M8S&IZ)*0-Q7ZU60ZG(Y^H=!))PV_M=#?R]IA%"H^)MU\?+@%@5B ]YB(
MDFT)2?TY!I.K'KG-N[%)PI";>@49I+#EA&U[L>)JTLW5A^BKPM'C]G\\@05,
M0FHCC&,&:=*S9UF-4<@@UH:[8G#2S>#&&C)M0"-N W^;8MX4ZXIY1?3D=:*?
M3$<WX^%\C(XNQ^5*%W[ADA&Q@=0=)VRV+ .I!\0.6VB!5*1.NC^"BU@/IY=E
MT,=_WTWNAU_&T]LY&MZBB_&GR72JXWY]A6!,F5Q?&IUH?M[BP''L^F1BDG-L
M-VAK6!4GDVY.[G1B#,^[X0>-\QJ8YQT[K,-ORMG$#8/Z8-7?.]?,F%@6Q[T2
M%=-]>4*X>[H[4AX6!ZFUYQ?X=%0>#%=FRG/JKU0LDURBE"W I/71AYB*\NBW
MO%%\79R>/G"E>%8L5XS&3&@!^'_!N7JYT2_8'< /_@=02P,$%     @ /8$$
M5>?N1O.=$P  1#,  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM6VU3
M&[FR_BLJ#G<O5!EC&P)A\U+E&$+(!L+!)#GGWKH?Y!G95I@9S4HS!N^OOT^W
M-"\VAF3/;M76QGBD5K_WTZWQZWMC[]Q<J4(\I$GFWFS-BR+_=7_?17.52M<U
MN<KP9&IL*@O\:6?[+K=*QKPI3?8'O=[1?BIUMO7V-7]W;=^^-F61Z$Q=6^'*
M-)5V^4XEYO[-5G^K^N)&S^8%?;'_]G4N9VJLBB_YM<5?^S656*<J<]IDPJKI
MFZUA_]=WA[2>%WS5ZMZU/@N29&+,'?UQ$;_9ZA%#*E%1010D_EFHD4H2(@0V
M?@\TM^HC:6/[<T7]/<L.62;2J9%)ONFXF+_9>KDE8C6595+<F/L/*LCS@NA%
M)G'\?W'OUQZ>;(FH=(5)PV9PD.K,_RL?@AY:&U[VGM@P"!L&S+<_B+D\E85\
M^]J:>V%I-:C1!Q:5=X,YG9%1QH7%4XU]Q=O/=B8S_8?T*LIB,=:S3$]U)+-"
M#*/(E%FALYFX-HF.M'*O]PN<2GOWHW#".W_"X(D33L2ER8JY$V=9K.+5_?O@
MMF9Y4+'\;O LP8]EUA4'O8X8] :#9^@=U"HX8'H'3]#;(*7XW^'$%18N\W^;
M!/;T#C?3HS#ZU>4R4F^V$"=.V87:>OO+/_I'O5?/<'M8<WOX'/6_Q6 _..'F
M?'AU\3_#VXO/5V)X=2K&%^=7%^\O1L.K6S$<C3Y_N;J]N#H7UY\_78PNSL;B
M2A:E5<),Q;O2@9ASS-B-BA1X.E4+A'Z.0"Z<&%J(.T?R$-=SB:"*5%F ]<1U
MQ$46=1%/O-B)5,5@'[1$,9>%*)!P"J$SMHF<)$K$VBE$HQ.3I7 Z45E$4A=S
M)6:JWA;)TBGZ,NV*+XX62#&Q!L?GQA93J,@0VS=70T'93L/F9'WB7DVGI#\(
MD)H8WV%9K!)D$+OLM,0 ;2MSVH2MLYFRS (1!+/*3I4%9PKB1'.8S:6B,'@2
ME_B.]L4=4%4YGQB7EB6[RTQT%YO[C,XLI)TA-;-,W<=T=W[YQ\O!H/<*#S1_
M[+_:%1H2M$YD)\Q(>P+\DQ(B),&@(9W-]407CME6#[26\RV.EL+E*B+7XN,[
M+*N"NN5T2CDUJ#NW!N(4CS?A0:$T8K76%G'8/W[E2 Z]1\FT4B"[@1,)S&]1
M"_ MA,C(KV0B<EG,[^62R!,CC;F[XA8,C$R:RVQ9$\]UKLBG(5N4E&2[X<WG
MO>'UY]&!0!43\V6N+%DK64;*ZAAVEQV_YNK<+XF7+M%Y^]'9E1P-^%FT=.!5
M3#4<R6GG'Y]^^=<A/YW*2!L7R;Q,S+Q,%?&?EBXJ$\ED"VOR^=)O&GW^RGM(
MBY&Q)I,+;<NVZSJ!-1>G>_T3]A!#RH+KPD3D*-.2XPY'I=AKEWL38R$VJ<M
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M<R1;,9HC5Y$&H(*Y<6RZUHBE[B-^D6G^:B6S[MSP=Z>[XE3Z7@T15SJW$0=
M@W;6!L=LK_H8/[#$V3\##UIHG?-T/?]CA&\-VA!5$-7;%E4M+F%MM,,@>7MS
M<2EN+\4N-3,%F;0-$*E4A4)0.98GK!:$'E"[D)XA:L+>73.S";6LCD91^:Q^
M@!E@;2C1#SHI H[%#@VZ'F.7E;'+LR,PL7-Q_1Y8D>S_P,D&-D8=^ XQ..>S
MO_DY1Z=5Z, >(W\N(S6P7H_$'0]J]@C5[&Z*RZG\ Q'N9Q6WP]_V3DY.]L/(
MYPG\^]>&0#3]"<B;9AJ^MTIHF#A)M)NK&CE=H<"<93,&4Q]-:8E9G'X90@$
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MNO!@NU(E%VYVF+K][OP,15:7)HNM$0O3Q4ZX(:H,-C.&&D.9%-Z=@DV>H*Z
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M(P&"TP)"5BIGL9D$YLH#P2!&WH%5HZP3!3-D0L9['!A;SF4P9Q(>9,"AR&3
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M+L[9GN,#/U R9-=N?(,+/^MW"K97_'1/R-MF1I\N/^T?OCA]P?8P,GTX^ZW
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ML W .?X)@VP8_ 8@%1ZC(VMISS':8W)J\,,==DH=Y (I^<W.HH7%V='@X&B
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M!:(T%P$7Y;4=WA:1J5C-R@Y>?<7RS0@RM?M6>%A@!:-C.FH-?[^T5008*9:
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MY+^8 O4&D-;60B480J)IRUHG5>:A>OT-4!2WI#WI58=0"0,OHJ@1/D>M*.I
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M:T<W$__*S04-&]#Z1&NW&'" Y>5R^!]02P,$%     @ /8$$52FN/Q*K!
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M[,94>CCA>O1J@4[!_0VDRJMA38Y W2),=SS4F0"-!7)[_HY*#3E=Q$ER-?4
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M[2I^7EHOCQ_I,"HMZ2ROQ );D]')T8#9^.$K_O"F"A^;YL9[4X9+>KTG+"W
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M2[EJ^SUUC- W X^E, %X8?1"I,#2AF(^3@EJF6LC_H5]T:MLIMMA1#]0J5;
M] S-&B#-,_2?H$E8@*308H=.A9KC/@\-+91Y07!M'1JABM+9UZRT:$&$;62
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MT>C]!4:ZZXAN854=JG"CK*OI,*W<3P2T#W#G6Z7L8>$O&'Y+V1]02P,$%
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MH>18 .=+"T[:#3OH_MV8_@U02P,$%     @ /8$$57Y-7! K P  L 8  !D
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M>BC;>AT49TJ+M PV(T@9+_Z2[Z40&P'XN0!<!N#M@-$S 4$9$&P%^,\%],J
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MEY3,J+0-S/=S(?33CNV@>I]E\C]02P,$%     @ /8$$58X*:PLT!@  930
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MZHO8"["L P&T"J O B@]$&!5 =:I 8,J8'!JP+ *&)X:,*H"1J<&C*N \<L
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M"Y$6)\C/'Y(D?WY3)-CMKCW[%U!+ P04    "  ]@015?4T\Z'P'   P1@
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M_J>/U878"AB]%&!6 >9.@&F^$#"L H9= T95P*AKP+@*&'<-F%0!DZX!)U7
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M-:,^XWD!]?U=DLCGG3S!9OGV[#]02P,$%     @ /8$$5=I53B:T!P  [DL
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M0R*8T3S15V+Y"<IX.H8O%(FR_V19VGH."7.E15J"T8.4\>))[TL=U@#-]@Z
M7P+\IX#.#D"K!+2>NT.[!+2M,D4H5H<QU33H2[$DTE@CFQE8,2T:PV?<I/U:
M2WS+$*<#U"NA4R%ID04>D0L68E:!#.<2 !.L%7E#S@7CFMSA+)>PW0P=US&Y
M8XI)3LE-#))FD&L6JF-RQL,&L@RCB)E]:((KQ9$UNQZ.05.6'*T&Z@AM;Z_'
MY/#@B!P0QI%-Y IW57U78]#&=3<L QP5 ?H[ GQ'+@77L2(?> 31)MY%L2K%
M_)5BIWXMX3"3#>)WCHGO^?XV?^KAYSEOD):W$SY^/KQ9$TVKRG_+\K7^GO\%
M)E-*RN=EUH>8Y<^"A[LLR T.%;7UJ\C7"V0F9QI2]6U+6*>%&^WM;IC+[41E
M-(2!@[>7 KD )WC]JMGUWF^3>)]DXSV1;<C?KN1OU[$'$RE"@$B1F10IGO0%
M*&VUQ4/_W=;<HJBY;9+64K]4TH*L:\G,MV(1=#W\]=W%NE9_6CU:; C0J03H
MU I0<U_\(G=4,CI-\%AQ#1B#QB+63#\<DXEDYBM%3H'#C(4,Q]L4JMW[I0KM
MDVR\)[(-S;N5YMW_H^:[^Y1_GV3C/9%MR-^KY._]NYKO/:=,1[4.O%2K/9$5
M6KEKK4H*<FY;/D5"D7-=?(.KU:JK'-IFZLGZ"+O-HCE\I"E:U4LJYPQ/9P(S
MI/0:/:PU6;1_Q42+S#9$4Z&QO;+#&#MFD,8 W\^$T*N)V:#JP8/?4$L#!!0
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M:%1 (7T65/E X?+A6!8 ;71:0%!]YUZCP71$)QC8SJ3*[5-X:W^ B0/"Y]3
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MJIKA66.:#21;IYW7G$G5QZ6O*]7+ ]<;U/J",;D;: /%OX/A;U!+ P04
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MVE8"QO&O<H;=V6EG4H,D#';6]DQBO4MI,LVTO=C9"P6.C:8@$4FVD\Y^^)4
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MUW.@V$K%ZU98$]24-4_RM0W$B4 87! (6H' <C>&+.5[HD@^$7P/PNS6VLS
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  ]@015T6]42M4#   T'@
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M']*7$\0VM@PS1?;2IMA*B"DC(U9&U^-MQ4*G&\2VV-7U/8)"3,P7&;$O=O2
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M)F:AXB66R[9CMOE"3,Q"Q;[F0H.V@VH@)F:A@MA":)J]T7N!?GXAMM"N*=N
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M82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3
M%+(F*&1-_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"% ,4    "  ]@015
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( #V!!%43&E,^[P   "L"   1              "  :\
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M2P$"% ,4    "  ]@01555H.A:$"  !L!P  &               @(&<%0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ /8$$53) C4%"
M!@  N!P  !@              ("!<Q@  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( #V!!%54QXGQA@H   ]B   8              "
M@>L>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  ]@015
MW9O+\!,&  ",%P  &               @(&G*0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ /8$$5>?N1O.=$P  1#,  !@
M     ("!\"\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M #V!!%7%3ZMS,A4  #U8   8              " @<-#  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  ]@015V[3\%S4#  "S!@  &
M            @($K60  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#
M%     @ /8$$59RNCLW/!0  [ \  !D              ("!EEP  'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  ]@015XMA5[> #  #6
M"0  &0              @(&<8@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;%!+ 0(4 Q0    ( #V!!%6!<O#GE 0  &@*   9              " @;-F
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ /8$$52FN
M/Q*K!   1@H  !D              ("!?FL  'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q02P$"% ,4    "  ]@0152^>\F1H)  ")'   &0
M    @(%@<   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M #V!!%56.=Y[-0H  %8>   9              " @;%Y  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ /8$$50VGG;J!!0  60\  !D
M             ("!'80  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  ]@015ZO.%Z08"  "B!   &0              @('5B0  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #V!!%5S/'R6^@0
M 'H,   9              " @1*,  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ /8$$57Y-7! K P  L 8  !D              ("!
M0Y$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  ]@015
MP4,H/=8#  #R"0  &0              @(&EE   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( #V!!%4M? 3*F0(  + %   9
M      " @;*8  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ /8$$50, XRG8 @  .P8  !D              ("!@IL  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  ]@015^: R8BP$  #:"0
M&0              @(&1G@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( #V!!%5-*=VJ:@,  ,@)   9              " @?2B  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ /8$$5;YRB4KT
M!@  VS(  !D              ("!E:8  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  ]@015C@IK"S0&  !E-   &0
M@(' K0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #V!
M!%4UU6)*>P@  &E;   9              " @2NT  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ /8$$57U-/.A\!P  ,$8  !D
M         ("!W;P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  ]@015F*BQX*X&  #*/0  &0              @(&0Q   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #V!!%7:54XFM <  .Y+
M   9              " @77+  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ /8$$5;0UVJPQ P  CPL  !D              ("!8-,
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  ]@015M+N#
MZ%0#  #>"0  &0              @('(U@  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( #V!!%4S)VG>M (   \(   9
M  " @5/:  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M/8$$5;H,:N<$!P  !38  !D              ("!/MT  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  ]@015'2I7?H<$  !/'   &0
M            @(%YY   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( #V!!%4_82F?) ,  "D,   9              " @3?I  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ /8$$59CH1R^R!
M=1D  !D              ("!DNP  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  ]@015PA<8(F8%  #/*0  &0              @(%[
M\0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #V!!%5
M$N0T,0P  +BH   9              " @1CW  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ /8$$59!6>1;P @  ) @  !D
M     ("!@ ,! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #V!!%67"(+.R 0  &P;   9              "
M@3D; 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ /8$$
M55065:]' P  RA0   T              ( !." ! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  ]@015EXJ[',     3 @  "P              @ &J(P$
M7W)E;',O+G)E;'-02P$"% ,4    "  ]@015T6]42M4#   T'@  #P
M        @ &3) $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ /8$$5;@V
MQ-RI 0  +AL  !H              ( !E2@! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ /8$$55/9*RFR 0  4QL  !,
M     ( !=BH! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@
&62P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>200</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Stockholders??? Equity and Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity and Noncontrolling Interest</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/PropertyandEquipment</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails</Role>
      <ShortName>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414409 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail</Role>
      <ShortName>Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="arwr-20220630.htm">arwr-20220630.htm</File>
    <File>arwr-20220630.xsd</File>
    <File>arwr-20220630_cal.xml</File>
    <File>arwr-20220630_def.xml</File>
    <File>arwr-20220630_lab.xml</File>
    <File>arwr-20220630_pre.xml</File>
    <File>arwr-20220630xexx311.htm</File>
    <File>arwr-20220630xexx312.htm</File>
    <File>arwr-20220630xexx321.htm</File>
    <File>arwr-20220630xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="571">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 200,
   "dts": {
    "calculationLink": {
     "local": [
      "arwr-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 425,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 47,
   "keyStandard": 219,
   "memberCustom": 46,
   "memberStandard": 19,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Investments",
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Intangible Assets",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Leases",
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Fair Value Measurements",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Subsequent Events",
     "role": "http://www.arrowheadresearch.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - Investments (Tables)",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Leases (Tables)",
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "arwr:TaxIncrementFinancingAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "arwr:TaxIncrementFinancingAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "if5d04990863c4ffebb18aa567f52c795_I20160928",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:NumberOfAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i433c47b3f8c8462580eaf03f04ea786f_D20181003-20181003",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ic1e4e7286efe4e7e9875b4571c089f8c_I20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ic5da86e52d344df6bdd898bbe4acfef7_I20210731",
      "decimals": "-6",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib4c2b3f20fb4481d8356d6ede05aeb89_I20211122",
      "decimals": "-6",
      "lang": "en-US",
      "name": "arwr:MilestonePaymentEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
     "shortName": "Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "if56e80163bfa40bc908f0611a5ea88cc_D20220425-20220425",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414409 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i77fd51ba125e419fbba6f8c78ee5dccb_D20220401-20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail)",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail",
     "shortName": "Investments - Summary of Short-term and Long-term Investments and Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i77fd51ba125e419fbba6f8c78ee5dccb_D20220401-20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Intangible Assets - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail",
     "shortName": "Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i70ac20dc1b6c4e8089f4f3a352305d67_D20211001-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "id7cf968fbe86467e988f3c9ca0c77d2d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "arwr:MilestonePayments",
       "arwr:MilestonePayments",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "if64b93b7539a474baa3e0eb46dbbd950_D20220401-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:MilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i310c20b290184b028f4e1378831a6bb8_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)",
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "ib685fad7e1394c24a0d385826599cb7b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i5e52725fc1f243d2a8c80beb3848ef5c_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "id7cf968fbe86467e988f3c9ca0c77d2d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i1bb905d8b72f4aaa9545079faa129817_D20201001-20210630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i259144688fe44f518dbdd195d182b514_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i259144688fe44f518dbdd195d182b514_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:CommercialNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i9c7f7a45d3574bcda999dd4b9a2c2d8d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:CommercialNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Stockholders\u2019 Equity and Noncontrolling Interest",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity and Noncontrolling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i9dcb1e0452764f4bbe1c66162ba7ec95_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Property and Equipment",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220630.htm",
      "contextRef": "i0d90bfff39604327a3c812002f6027c4_D20211001-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "arwr_AROHSDAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AROHSD agreement.",
        "label": "A R O H S D Agreement [Member]",
        "terseLabel": "ARO-HSD Agreement"
       }
      }
     },
     "localname": "AROHSDAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROXDHAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH Agreement.",
        "label": "A R O X D H Agreement [Member]",
        "terseLabel": "ARO-XDH"
       }
      }
     },
     "localname": "AROXDHAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROXDHSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH supply agreement.",
        "label": "A R O X D H Supply Agreement [Member]",
        "terseLabel": "ARO-XDH Supply Agreement"
       }
      }
     },
     "localname": "AROXDHSupplyAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AdditionalLandSubjectToLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional land subject to lease.",
        "label": "Additional Land Subject To Lease",
        "terseLabel": "Additional office space for lease"
       }
      }
     },
     "localname": "AdditionalLandSubjectToLease",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional remaining development regulatory and sales milestones payments.",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Additional remaining development regulatory and sales milestones payments"
       }
      }
     },
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Incorporated.",
        "label": "Amgen Incorporated [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AmountIntendsToInvestForBuildoutOfFacilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount intends to invest for buildout of facilities.",
        "label": "Amount Intends To Invest For Buildout Of Facilities",
        "terseLabel": "Amount intends to invest for buildout of the facilities"
       }
      }
     },
     "localname": "AmountIntendsToInvestForBuildoutOfFacilities",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market agreement.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "At The Market Agreement"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CashEquivalentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents gross unrealized gains.",
        "label": "Cash Equivalents Gross Unrealized Gains",
        "terseLabel": "Cash Equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedGains",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashEquivalentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents gross unrealized losses.",
        "label": "Cash Equivalents Gross Unrealized Losses",
        "negatedLabel": "Cash Equivalents, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedLosses",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents held to maturity and marketable securities amortized cost.",
        "label": "Cash Equivalents Held To Maturity And Marketable Securities Amortized Cost",
        "totalLabel": "Total, Cost Basis"
       }
      }
     },
     "localname": "CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents held to maturity and marketable securities fair value.",
        "label": "Cash Equivalents Held To Maturity And Marketable Securities Fair Value",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents held to maturity and marketable securities gross unrealized gains.",
        "label": "Cash Equivalents Held To Maturity And Marketable Securities Gross Unrealized Gains",
        "totalLabel": "Total, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents held to maturity and marketable securities gross unrealized losses.",
        "label": "Cash Equivalents Held To Maturity And Marketable Securities Gross Unrealized Losses",
        "negatedTotalLabel": "Total, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receivable as upfront payment due under collaboration agreement.",
        "label": "Cash Receivable As Upfront Payment Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as due under collaboration agreement.",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CertificateOfDepositDueWithinOneThroughTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of deposit due within one through two years.",
        "label": "Certificate Of Deposit Due Within One Through Two Years [Member]",
        "terseLabel": "Certificate of deposit (due within one through two years)"
       }
      }
     },
     "localname": "CertificateOfDepositDueWithinOneThroughTwoYearsMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CertificateOfDepositDueWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of deposit due within one year.",
        "label": "Certificate Of Deposit Due Within One Year [Member]",
        "terseLabel": "Certificate of deposit (due within one year)"
       }
      }
     },
     "localname": "CertificateOfDepositDueWithinOneYearMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CertificateOfDeposits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of deposits.",
        "label": "Certificate Of Deposits",
        "terseLabel": "Certificate of deposits"
       }
      }
     },
     "localname": "CertificateOfDeposits",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ColoradoOwnerLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Colorado Owner, LLC.",
        "label": "Colorado Owner L L C [Member]",
        "terseLabel": "Colorado Owner, LLC"
       }
      }
     },
     "localname": "ColoradoOwnerLLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments at first commercial sale.",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "terseLabel": "Commercial milestone payments at first commercial sale"
       }
      }
     },
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommercialNoteDueWithinOneThroughThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Note Due Within One Through Three Years.",
        "label": "Commercial Note Due Within One Through Three Years [Member]",
        "terseLabel": "Commercial notes (due within one through three years)"
       }
      }
     },
     "localname": "CommercialNoteDueWithinOneThroughThreeYearsMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialNoteDueWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Note Due Within One Year.",
        "label": "Commercial Note Due Within One Year [Member]",
        "terseLabel": "Commercial notes (due within one year)"
       }
      }
     },
     "localname": "CommercialNoteDueWithinOneYearMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Notes.",
        "label": "Commercial Notes",
        "terseLabel": "Commercial Notes"
       }
      }
     },
     "localname": "CommercialNotes",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommercialNotesDueWithinNinetyDaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial notes due within ninety days.",
        "label": "Commercial Notes Due Within Ninety Days [Member]",
        "terseLabel": "Commercial notes (due within ninety days)"
       }
      }
     },
     "localname": "CommercialNotesDueWithinNinetyDaysMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock shares value reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers, software, office equipment and furniture gross.",
        "label": "Computers Software Office Equipment And Furniture Gross",
        "terseLabel": "Computers, software, office equipment and furniture"
       }
      }
     },
     "localname": "ComputersSoftwareOfficeEquipmentAndFurnitureGross",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Headquarters in Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "terseLabel": "Corporate Headquarters In Pasadena"
       }
      }
     },
     "localname": "CorporateHeadquartersInPasadenaMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and sales milestones payments.",
        "label": "Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DrugManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug manufacturing facility.",
        "label": "Drug Manufacturing Facility [Member]",
        "terseLabel": "Drug Manufacturing Facility"
       }
      }
     },
     "localname": "DrugManufacturingFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedGains",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV- NI, Accumulated Gross Unrealized Gain Before Tax",
        "label": "Equity Securities, FV- NI, Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Marketable Securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesGrossUnrealizedLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities FV NI accumulated gross unrealized loss before tax.",
        "label": "Equity Securities, FV-NI, Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Marketable Securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EstimatedPaymentsForOperatingExpensesYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated payments for operating expenses year one.",
        "label": "Estimated Payments For Operating Expenses Year One",
        "terseLabel": "Estimated payments for operating expenses"
       }
      }
     },
     "localname": "EstimatedPaymentsForOperatingExpensesYearOne",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected payments of leasehold improvements, net of tenant improvement allowances.",
        "label": "Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Expected leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities.",
        "label": "Facilities [Member]",
        "terseLabel": "Facilities"
       }
      }
     },
     "localname": "FacilitiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets amortization expense after year four.",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "Amortization of license agreements, thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxosmithkline Intellectual Property Limited.",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value of the options granted during the period.",
        "label": "Grant Date Fair Value Of Options Granted During Period",
        "terseLabel": "Grant date fair value of the options granted"
       }
      }
     },
     "localname": "GrantDateFairValueOfOptionsGrantedDuringPeriod",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value of the other than options granted during the period.",
        "label": "Grant Date Fair Value Of Other Than Options Granted During Period",
        "terseLabel": "Grant date fair value of other than options granted"
       }
      }
     },
     "localname": "GrantDateFairValueOfOtherThanOptionsGrantedDuringPeriod",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_HalozymeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Halozyme, Inc.",
        "label": "Halozyme Inc [Member]",
        "terseLabel": "Halozyme, Inc."
       }
      }
     },
     "localname": "HalozymeIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities and marketable securities.",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "terseLabel": "Summary of Short-term and Long-term Investments and Marketable Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_HeldToMaturitySecuritiesFairValueNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities fair value non current.",
        "label": "Held To Maturity Securities Fair Value Non Current",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValueNonCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics Ireland DAC.",
        "label": "Horizon Therapeutics Ireland D A C [Member]",
        "terseLabel": "Horizon Therapeutics Ireland DAC"
       }
      }
     },
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in cash and investments.",
        "label": "Increase (Decrease) In Cash And Investments",
        "negatedLabel": "Decrease in cash and investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial transaction price.",
        "label": "Initial Transaction Price",
        "terseLabel": "Initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ-3989 (ARO-HBV) Agreement.",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "terseLabel": "JNJ-3989 (ARO-HBV) Agreement"
       }
      }
     },
     "localname": "JNJ3989AROHBVAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JNJ75220795AROJNJ1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ 75220795 ARO JNJ1.",
        "label": "J N J75220795 A R O J N J1 [Member]",
        "terseLabel": "JNJ-75220795 (ARO-JNJ1)"
       }
      }
     },
     "localname": "JNJ75220795AROJNJ1Member",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.",
        "label": "Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Incorporation.",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Janssen",
        "verboseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation.",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "JJDC"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and office facility.",
        "label": "Laboratory And Office Facility [Member]",
        "terseLabel": "Laboratory and Office Facility"
       }
      }
     },
     "localname": "LaboratoryAndOfficeFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year five and after year five.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and co-funding agreement.",
        "label": "License And Co Funding Agreement [Member]",
        "terseLabel": "License and Co-Funding Agreement"
       }
      }
     },
     "localname": "LicenseAndCoFundingAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseCollaborationAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and stock purchase agreement.",
        "label": "License Collaboration And Stock Purchase Agreement [Member]",
        "terseLabel": "License Collaboration And Stock Purchase Agreement"
       }
      }
     },
     "localname": "LicenseCollaborationAndStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment earned.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableAtStartOfPhaseTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable at start of phase two.",
        "label": "Milestone Payment Receivable At Start Of Phase Two",
        "terseLabel": "Milestone payment receivable at start of phase two"
       }
      }
     },
     "localname": "MilestonePaymentReceivableAtStartOfPhaseTwo",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_NumberOfAcresOfLandPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of acres of land purchased.",
        "label": "Number Of Acres Of Land Purchased",
        "terseLabel": "Land purchased, number of acres"
       }
      }
     },
     "localname": "NumberOfAcresOfLandPurchased",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctBundle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct bundle.",
        "label": "Number Of Distinct Bundle",
        "terseLabel": "Number of distinct bundle"
       }
      }
     },
     "localname": "NumberOfDistinctBundle",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct performance obligations.",
        "label": "Number Of Distinct Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfDistinctPerformanceObligations",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to renew.",
        "label": "Number Of Options To Renew",
        "terseLabel": "Number of options to renew"
       }
      }
     },
     "localname": "NumberOfOptionsToRenew",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_OlpasiranAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran agreement.",
        "label": "Olpasiran Agreement [Member]",
        "terseLabel": "Olpasiran Agreement"
       }
      }
     },
     "localname": "OlpasiranAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OlpasiranAndAROAMG1AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran and ARO-AMG1 agreement.",
        "label": "Olpasiran And A R O A M G1 Agreement [Member]",
        "terseLabel": "Olpasiran and ARO-AMG1 Agreement"
       }
      }
     },
     "localname": "OlpasiranAndAROAMG1AgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OutsideOfEquityCompensationPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside of equity compensation plans.",
        "label": "Outside Of Equity Compensation Plans [Member]",
        "terseLabel": "Outside Of Equity Compensation Plans"
       }
      }
     },
     "localname": "OutsideOfEquityCompensationPlansMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of leasehold improvements net of tenant improvement allowances.",
        "label": "Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Payments for leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock.",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Percentage of commission to sales agent"
       }
      }
     },
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible to receive tiered royalties on net sales.",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PerformanceObligationRelatedToAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance obligation related to agreement, upfront payment.",
        "label": "Performance Obligation Related To Agreement Upfront Payment",
        "terseLabel": "Performance obligation related to agreement, upfront payment"
       }
      }
     },
     "localname": "PerformanceObligationRelatedToAgreementUpfrontPayment",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment gross.",
        "label": "Research Equipment Gross",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentGross",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research facility in Madison.",
        "label": "Research Facility In Madison [Member]",
        "terseLabel": "Research Facility in Madison"
       }
      }
     },
     "localname": "ResearchFacilityInMadisonMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Facility in San Diego.",
        "label": "Research Facility In San Diego [Member]",
        "terseLabel": "Research Facility in San Diego"
       }
      }
     },
     "localname": "ResearchFacilityInSanDiegoMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SalesRelatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-related milestone payments.",
        "label": "Sales Related Milestone Payments",
        "terseLabel": "Sales-related milestone payments"
       }
      }
     },
     "localname": "SalesRelatedMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Agreement.",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated.",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "terseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TaxIncrementFinancingAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Increment Financing Award",
        "label": "Tax Increment Financing Award",
        "terseLabel": "Tax increment financing award"
       }
      }
     },
     "localname": "TaxIncrementFinancingAward",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology license commitments.",
        "label": "Technology License Commitments [Member]",
        "terseLabel": "Technology License Commitments"
       }
      }
     },
     "localname": "TechnologyLicenseCommitmentsMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants"
       }
      }
     },
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one incentive plan.",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "terseLabel": "2021 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands four equity incentive plan.",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "terseLabel": "2004 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands thirteen incentive plan.",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "terseLabel": "2013 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_UpfrontMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront milestone payment received.",
        "label": "Upfront Milestone Payment Received",
        "terseLabel": "Upfront milestone payment received"
       }
      }
     },
     "localname": "UpfrontMilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_VeronaTechnologyParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verona technology park.",
        "label": "Verona Technology Park [Member]",
        "terseLabel": "Verona Technology Park"
       }
      }
     },
     "localname": "VeronaTechnologyParkMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "terseLabel": "Visirna Therapeutics, Inc."
       }
      }
     },
     "localname": "VisirnaTherapeuticsIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20220630",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "verboseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r83",
      "r192",
      "r196",
      "r201",
      "r323",
      "r324",
      "r327",
      "r328",
      "r370",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r83",
      "r192",
      "r196",
      "r201",
      "r323",
      "r324",
      "r327",
      "r328",
      "r370",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r81",
      "r82",
      "r204",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r214",
      "r254",
      "r255",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r406",
      "r437",
      "r439",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r214",
      "r254",
      "r255",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r406",
      "r437",
      "r439",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r214",
      "r245",
      "r254",
      "r255",
      "r286",
      "r287",
      "r288",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r406",
      "r437",
      "r439",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r214",
      "r245",
      "r254",
      "r255",
      "r286",
      "r287",
      "r288",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r406",
      "r437",
      "r439",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r81",
      "r82",
      "r204",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r126",
      "r127",
      "r242",
      "r244",
      "r438",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r126",
      "r127",
      "r242",
      "r244",
      "r438",
      "r448",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN",
        "terseLabel": "Wisconsin"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r373"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r14",
      "r178"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r45",
      "r46",
      "r47",
      "r426",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r53",
      "r54",
      "r55",
      "r85",
      "r86",
      "r87",
      "r326",
      "r369",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r297",
      "r298",
      "r299",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r257",
      "r300",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r73",
      "r166",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Planned area of the site (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r17",
      "r79",
      "r115",
      "r118",
      "r123",
      "r150",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r323",
      "r327",
      "r347",
      "r371",
      "r373",
      "r413",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r32",
      "r79",
      "r150",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r323",
      "r327",
      "r347",
      "r371",
      "r373"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r133",
      "r135",
      "r158",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r312",
      "r313",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units, Authorized",
        "terseLabel": "Capital stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r12",
      "r75"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash Equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r70",
      "r75",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r348"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, Cost Basis"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r316",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r417",
      "r431"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r191",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserve for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r373"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 145,000 shares authorized; 105,795 and 104,327 shares issued and outstanding as of June\u00a030, 2022 and September\u00a030, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r58",
      "r420",
      "r433"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r238",
      "r240",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r238",
      "r239",
      "r243"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r238",
      "r239",
      "r243"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r73",
      "r176"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r73",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense for property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r259",
      "r260",
      "r291",
      "r292",
      "r294",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r98",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r337",
      "r338",
      "r421",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "NET INCOME (LOSS) PER SHARE - BASIC (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r337",
      "r338",
      "r421",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "NET INCOME (LOSS) PER SHARE - DILUTED (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r107",
      "r151",
      "r228",
      "r235",
      "r297",
      "r298",
      "r299",
      "r306",
      "r307",
      "r336",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r369",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r5",
      "r18",
      "r346"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable Securities, Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Marketable Securities, Cost Basis"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r339",
      "r340",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r340",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r205",
      "r246",
      "r247",
      "r252",
      "r253",
      "r340",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r246",
      "r247",
      "r252",
      "r253",
      "r340",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r340",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r140",
      "r144",
      "r147",
      "r148",
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r206",
      "r226",
      "r334",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization period of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r15",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Amortization of license agreements in 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Amortization of license agreements remainder of fiscal year 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Amortization of license agreements in 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Amortization of license agreements in 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Amortization of license agreements in 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r170",
      "r173",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r167",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r170",
      "r409"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Intangible assets subject to amortization, ending balance",
        "periodStartLabel": "Intangible assets subject to amortization, beginning balance",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Finite-Lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r131",
      "r136",
      "r152",
      "r155"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "arwr_CashEquivalentsHeldToMaturityAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held to Maturity, Cost Basis"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r138",
      "r142"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held to Maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r139",
      "r143"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held to Maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r134",
      "r136",
      "r152"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Short term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r137",
      "r141",
      "r416"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Held to Maturity, Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r134",
      "r136",
      "r152"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r73",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "negatedTerseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r115",
      "r117",
      "r119",
      "r122",
      "r124",
      "r411",
      "r418",
      "r422",
      "r435"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r80",
      "r96",
      "r97",
      "r114",
      "r304",
      "r308",
      "r309",
      "r436"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "State income tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r72",
      "r407"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization/(accretion) of note premiums/discounts"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r412",
      "r423",
      "r447",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Office space leases (in sq ft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remainder of fiscal year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r79",
      "r150",
      "r347",
      "r373",
      "r415",
      "r429"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r35",
      "r79",
      "r150",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r324",
      "r327",
      "r328",
      "r347",
      "r371",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r19",
      "r20",
      "r79",
      "r150",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r324",
      "r327",
      "r328",
      "r347",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreement"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized (gains) losses on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r79",
      "r150",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r347",
      "r414",
      "r428"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r50",
      "r55",
      "r57",
      "r74",
      "r79",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r101",
      "r115",
      "r117",
      "r119",
      "r122",
      "r124",
      "r150",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r338",
      "r347",
      "r419",
      "r432"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r236",
      "r322",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Interest in joint venture"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r235",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrollling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "TOTAL OTHER INCOME"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r115",
      "r117",
      "r119",
      "r122",
      "r124"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r360",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities (includes current portion)"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r357",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r364",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r84",
      "r110",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r31",
      "r373"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r30",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from investment in joint venture"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
     "auth_ref": [
      "r69",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Proceeds from Sale of Equity Securities, FV-NI",
        "terseLabel": "Equity securities sold"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r296"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r13",
      "r177"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Total gross fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r179",
      "r373",
      "r424",
      "r430"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r12",
      "r75",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r235",
      "r373",
      "r427",
      "r443",
      "r445"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r151",
      "r297",
      "r298",
      "r299",
      "r306",
      "r307",
      "r336",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r111",
      "r112",
      "r116",
      "r120",
      "r121",
      "r125",
      "r126",
      "r128",
      "r241",
      "r242",
      "r408"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r167",
      "r169",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r256",
      "r258",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Share Activity Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r263",
      "r278",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r77",
      "r108",
      "r109",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r221",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of period (in shares)",
        "periodStartLabel": "Beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Number of restricted stock units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common Stock, Share reserve for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of shares forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued to institutional investors (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r361",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r53",
      "r54",
      "r55",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r107",
      "r151",
      "r228",
      "r235",
      "r297",
      "r298",
      "r299",
      "r306",
      "r307",
      "r336",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r369",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r107",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r228",
      "r235",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r22",
      "r23",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r79",
      "r132",
      "r150",
      "r347",
      "r373"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "TOTAL ARROWHEAD PHARMACEUTICALS INC. STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Arrowhead Pharmaceuticals, Inc. stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r54",
      "r79",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r150",
      "r151",
      "r235",
      "r297",
      "r298",
      "r299",
      "r306",
      "r307",
      "r320",
      "r321",
      "r330",
      "r336",
      "r347",
      "r349",
      "r350",
      "r354",
      "r369",
      "r441",
      "r442"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityandNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r235",
      "r237",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r140",
      "r144",
      "r147",
      "r148",
      "r149",
      "r206",
      "r226",
      "r334",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermandLongtermInvestmentsandMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r323",
      "r324",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncAdditionalInformationDetailDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r362",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r465": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r466": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r467": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r468": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r469": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r472": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r473": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r475": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r476": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r477": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r478": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001628280-22-021068-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-021068-xbrl.zip
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M3>]#)_\(QZN@='I--WK^^6 _Q+_6FLAK9&.,5 O$*)&&.H7A+4D4B$C'/N[
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MXS#[*I!F'M!A>F0BQ@M/!>'(1.8, D(I&8T"8E'""%L=,LT9.DR/9 QY'!7
M/*$#,T)931T-UAFO/0*_>&5(]J3088KT\2&5X[->2\\\(J (M;)16( +AD:T
M,O29 W28'I6T=Q8'Q#B1@D5F;<!.""R(-3(XS9^.2O.: <Z< X"+50P>9H!K
MQ[$U-@3-F=$AS&%S_*J8ZOGOX,=@V,%? =05! LD&,.P,#R5V]#8C7<[K!1Q
MGRZ!-1>"*N:2B9?6:,\X O(B)XB4WD<<&%E!@LX_@3470OMDD#0CGF')L(T&
M:1<%US@(!(3&JT?H)TYRS(6JAKC(;0I6@ ,LA3> WBEC.&),J;'XZ2I>+;,:
MGE8IKIM)#D&\"U@%[QQH5FN)<)H@C:-+M8_9RI!F3ON4ID0FBJQ#W"#/,6,,
M9,E8E(H4J2 !W'BW.F2:_SZE*9%,<H JTO) "/@75&O-D<ZW5V"M$PA=%9(]
M]3ZE*=$G DF4PHZRF-!&M"&!2A2C0Y10QU>&/O/9IS0E*@EGI8Q:<10)$RYH
ML%*$(J^CQ<03.H<BN*MBJ&[M7Y]#I=YH&0]IY33#ACFJM%5<Z>BCU#80.H\*
MQ\L,$.=/4.<]%T9RBCU(*XW:<,= >A&V-O4J6CV"SM]/GPNA#9-8AK30AFB&
M@;H(V4"E$P%Y!69U]0@]EX6F<Z$ME\IYG.K#&,L4Z&+$J"18@@@KSH5=/=H^
M>:V8>5#5:2F4%P)<#Q:Q,4H&A+@7WHJ O5PBJK[M=>'%!Q=O6P JMSH^$?<L
MW>/516KF-:)MZLGP\GWH 9"J!]?H=%O=DXNWIO<SN_O34?1[@Z]\]29T3WKF
MK-%TIC5Z;FHW]_)#>>F9YZI@NW'7*K5/:J(/![V7Z<#DXGL7OW<2$%] A'OK
M4X5$8P0!SF388RV]P8N_M.S^W+?3&YY43&<8C1L,>Z!87AO7;,&[+!\+3KVI
M0O_?.+B3J]*!!W.5E]P9IFEP.#)$(KB+@1.6+ZB/@I'%Y:I'DG(&7+MG;#=O
MG7 !I]5B;+IP3[Z=(U_=3/_"S5PDC*(@&,?!$B&M8L:!.^*Q6W)NV-YZ2F[8
M'_?OG+! N7-@.CO-<-)=$F;P'@%JU4RE^B&<88V(LL%&3Y1VD87%988)L1)%
M:G&KUS.=DYPQK@.<9K_9 X0#GJ<Y"\-!T_7!Z9R&?=GN=OK=5C/UD/2[:4*:
MX19J?F]Z36-;8>(+Y6==O.TUVZ9W\2IT JB.)GQ<$D:AD;FH##=11N:%-D9R
M3A,@%DX1XY< (*<.<WOAQ+1&I+C&)V]:YKS;;S<'C4^IJVXB6:L5 ):8UD07
M[#7A</"KZ/LH3XTDJ9^V9LPQ:8BW+E7)Q)AZ3L7BZH#O4_0?T^GW0^=MP_3:
MQN6B;UI)^+N]LV2_X?(E$;S(/6):(R6H8S$&:S&X!5S(R(F3H\6(0"L]^WYM
MTZ/.5OLD=+X2XZ=B-15CL-UMM4;@#2X!J[X'T*W3#ULGO9"?.DM^P"*E?![=
MO<Y,QOJ-;Y"_X=7A!WL(@ $D5LHS$SD+%BGO%$9!::^9(2;?&3]BLJS@M@7E
MMNN&Y#:__<"0W#[U,<O3%'?<!(XIMH 6X&,0B#/*L K".UEPT4.Y:,PUMYDI
MSY"]'8+C85:<I;#PTJDH<$2,6>P,5L@%8ECJ%^*D*JS?/3FIUCHSX R9Q#Y;
M^[6MRAN\!);O)A(20')!&(T4,\2(U4I9*AB3F'E0-HN+4Q]&H'N299$X,+G$
M^^FEQI$8^%HQY\WVL+TD*%LP0#F!&^HM9EQ'FW9IP6\.!12]F6Q)E8M76;#0
M,U>;G^1TJO=9;Z-W7 F-"7-46VRIM1('%YWTRBQ!*:%GS13S+UN$N0\BU0@$
MDC+PJI1 !DMOHD=IB?\RK/\H.&B^*X@XY8%:SIR.C/"TH!TSEJI.,FFTLTNP
MTZ?@H+GN*N+"..=\)-(!YX2H(F$X^.0_61R$6H*>5@4'S;5_EO.*XI#ZE&#*
M*(HJ*.N52+UE#".+7#KL63/.3/PC;3C1CFOGTJI'1G40 4<AN' 1K%1NC[ "
M>T2SR8=%8XHGB-H^@C'O3EC!$/[I-CK]?##C3^5.I_LY'^ __^QLSSBE=2,"
MJ'([1N\3 ;QUZB.T$*,4(+.E43G%!$ A%$Q$-"(6C%0B+@'G_8#JTR/NO?G_
M8&C[39^6'AR8%DA"'DR^(0-7FS">.L0\'P8+8,Y26!&\-"94L,%'SXFDQ& O
M6%YN<>GX:K[I[]O4>83A0>#[H* 8H>!*2Q\436TC ^5(88$E7USJ_'),=*YT
MGXH9?=+4^O1X#0R*4=9$BX1.E;JT=H!S0T 6=('2!:\M(J_=A&Q+QG&,.1+!
M->>">B:U3&%F9)GC-@JDJ5IN<+,8#/)/]1^JE0;'Z^]7[U<-R5PM#>K:5O,D
MG].[UP9]/3ZYT[T7!UE, !"E[B@T,AJDL<A1+:A+#8U2$?[%9](E6+$S%^PK
M%#5:! !2B#'OI)$IQY6JNSJ$HV:+:_$*M3-+NT3!&:(A..<H9\$1#1P@'8XA
M1J>C\TN= GUF##+_="APD,=&$4V98Z!<+(_>!6$L49@@SI<Z%?&<N6D^:0FN
M(V:2(>4"4X0;)&7JG!Z= H<-F:5.KC]O;II#HIU1S7V0.@:-&:=$":[@4V#"
M:N/H<B?:GS,WS27I'H/T@)>9 _ $>%I902P/X#]9 ->@JI8Q9?K,F&@V+9TX
M2EW? ^ ?^ >AU+9:IQ6GBDF!U#)TGEP&!I$<YDYJ#DP"W_ J8NE(> S(.F4(
M8RE$;0!22V>#\!Y)+@HLO82<-!<<33SF1###7.JRR;TQ!D6&7>KYHR-=AMJ1
M!2<M!(8V '&P=883S)@TU%#+ E@[CDB4&IL"0R\A)\T%/X= *;>>$POFC6.C
M@*>\Y-1Q[(V.DZK0?)FVX3PC!KI9XYA/9SN.B%@HKVU>",$%< (4.%-I?[IS
MQ*@)3Q1*91EX8EIEBX+SQ/%@K>2,6VRB,RI0 ZXWYI8L<)V\@B=FY6-;2;2C
MJ6:-UPQ[IIR)0AEKI'=>D:^1/)E-/BP:<]RUC*?9F<8RGH>LVNKX[>[K8<<W
M.R=/L/"Y;CX%;VYQ_6$G%5O*:[WU8;AMX )G'K!L?SK@YXJF/P(_MT[]Q>4;
MG6$:^#=+-\;W&/Y"*5$4P"8:H1$+GC'B-:7:2$*%$TJ2<;'QQ1:'>3/M/%;5
M/6MQN)GGPX$%290(,7T(6DEN&9?8(:6CFC3UP8OG"\R;;Q>?NVZ"0CP=1R$X
M*Z+RA, ?+.*H"<.&(DF,<9*,FQ\7#%,HNMFS8M2,<Q&8H0(SSHC62%+#.'8Z
M4JQ887Q7@'/FBQ@MS'?KV]+S^0R-CCT<,@J9C*[5!A$FG30<F<"<CY2"U1TM
M]%WP+&7!M0_BVKFD,(FR3#)BC5<,O'2AO91*(5"2PGMAXQ*D, LV>Q";S26_
M*1$FC-+H,!/,VE0],.C@ """.V&T7H+\9L%F#V2S.20_171$84LLX9$YK(#3
M4.!&<<^,86J9FJ\7;+:XF5&GI9':I47TCJ450-8KIR2C$4NB"%K<C$?!70]P
M0:=8L85RL'8:8:P4(T(:+0!E&2<,,9XZ73#,@C#,O>?CE6F9C@L'C1 &>UTW
MVJ=XK9]6B*'7"WX_? Z=X6S[@$^QO8$E'@6%J/ AK1U2!+.HO"&@[K@CMF#3
MU6'3:UUA>\/@]YK&IJY)S3#;INC38U;'O5$B<.(I8SX*ZU,[5VL#,RZ&*,<1
MY@6L$GP?9MW:K_UGY^\GX,^_N[WF9;=SHRU3+P#7^)VM[5E'>*=4)#AZ%&-D
M&$N%4HDJ91G6A!F@F6-Z5"ND8(4YYA=6@<DDBE)XD5:T"&:$4<@S:8,S.J@H
MS"12)K#*)A\6C=MF0Z"I&N>GVRPK,GR?_AFW3WV$VV@I%1I)3R0G#.&@.(HA
MN""$26UF\1)PT',V7?-GH&@<<Y8A \XC2V6P!%*$4BLT=98JL2(YH6?!0//9
ML*8$"R'2F*H(8QR- 5NF@XL G'SJ7[<:V9YGP4#SV:?&4K$'ZPT'9,TQ-PP1
M*[@+&F.>EO6L1A[GF3#0'#(T%GRUH%%(2\.9-%QCCH)#BA/GO.-R13(TSX*!
MYI-["=Z0".!'I%XN&EN#M0[&YA%VZQ>X0>YSYIO9;#(QD5I.-:@.S0+EEF-)
MA ;+9)CE1"R!,5I@CWS$B@?#L[/6Q4I7'1(8R53#GB>WG-A@/:(R"NPX-Q)4
MS1*8I(*-YF^8@'&,!G]<8J29%%HK1)T03A*J,$4+O"B@X)[9F"?FB*61H&@9
M4]@KRH47P0?$3;!JO 4"8T*6AR'>M,QYM]]N#AJ?6LU.*,/KMEK!#8:F];;7
MA<D97.PUV\V5[>M]([. P2"0*3 *H!5%,'&*)0HRP+.64*<=TRI2; I&F5,^
MZQFQH' "V\ LBL(QZB@H**&=4U%1HCQU8R@-+)@5O/AHD_;WP<X3(NKK+/)C
M*'3CU$=5A4TMX3WW&J5>SL02#TZ[%2AM9*$.C?,4>.*8+> NP(*;OI.TP/?W
MSZ[OWWN,?T9MC%IA(F)@F%,%CGX$C"T4BX@YO-1N_G/FIKEX^UAS03$/2F'#
M.-$ZXK24PP-&QR@0N00YU(*;%B:AJJ4#AU]Q3J-GX-UIX[$VS".J<1!R&=(9
M!3<M3 A)>ZYIQ,P*9QEV6B,D%;!7"%QC$_DRAI">&1/-9ET^%T$AG("08<@Z
MC51$ F/#@U'*7>T%)SR;?%@T!KD/<=XW^\U>Q]R(-G;<-.(#V]U.O]MJ^K2T
M/N?09NC?7 ;_WO2:QK9R_NR%_F#$QV][S;;I7;P*G1#A[O#Q*8P8X?<T8M=/
M?<SF7!D]3XE4P@%@ZVBM$5$YF?2.=\[>AD1L]OIGML:?30E*>BXQE21*G\J)
M("-H- 1^XU$I )2+JZXG7+]M^HVT'P;^VOUWV/QL6G!]_U;_X= #SF]5NX/0
MWQF&#Z#)FYTJJ/+!Q8ZY6);=(@&XVEL,_$P#0Q'4J91."^!XX&<3P^+3ZG6S
M8SJ)$F68A=[PFSCD=4)=T:G6"4?!]):$2,KBJ(0'.BC$(@ ?AK36A"-! A=R
M"03J5XE4;_2ZPY,&_!5R@BV+6$G$P><14G%I&?=!N2BH1^ ":6*57>"DYSTI
M!O@4'N# 0M3B3CCK]IN#)14NA#UCV JFE6**4<.CUXP98PTE :EE)U7%]#Z%
M0<)P!\$->\NTE3%*(ZG& -L#8D$Q&U+17^]QM%ZIJ_UK>EE),T?C!,ZYG@Z1
M !U+0C7QBCN&P4DW+EIPP3!H/NIP6%TB/:UQFA[%F#):8G!K$!*,<:24HD)P
MS E%BA"]]!3[B7&:T.U+=YFHAGPTQB%D)(I@I9!R-BJKD74DFFB67AD^N9V:
M'FDD,@[LD@,4X<!.I=*_+%)#DT!Q+^029.*NRA[T^V&PY<#I!:&Y6;NCVOUL
M0+!^1I2'L$-S$/::GX,O=V#J3YI ^_SY_5<7%7/:[6VW3/]6/&JTCN1ZB8H9
M,,G\LW%>>F,U)9P*PB1WRH-7KIADD2,L\1+X#P4CS0H5@UH!_1\PTZ!MTCI_
M&3B5PG"6FEO1L$3:YI<H]Q9DZN?4>D)&74H-0X,!M."L#  "N>0V-8!%+FVA
MMA8O\K+L9\\\LXE8.>VH #ZPV#%%F48^,.:B89K%B/SB\\/;ENE433M<+S+U
MI5MO=(=]T_&ON\->BN4/+LH=EQ[V.:0+KIU1;S1[@Q Z/SGK"_Q\ 5[$':=M
M=8 3_=#EYN1-SRR/3>$.B>"5-0(3A@GP@D0LADB,09R/^U@ T19O0>+LESD?
M#&V_Z5.2\\"TP*,\&'3=I^NY\T&]$4;>R],DT,%8J.G4[N'@GE .I(\8,04.
MI@J4^=31$$=N\+@% %(C*%'0?X[TO[4*!SC@?HCA%K,\!C'0$*@&EX0QS)2+
M.D9JD0V""&^M7N"^\8M%R=FD"%/U<$$T!O%EV@=C):9,&1#M%)1 8Z< Z)--
M/BPJE2;+GY)%'8!)38;V+-WCU45:)7-]84SH=3NF'ERCTVUU3R[> NFFL2PF
M+T"9V_#0/>F9LT8J3CG6+X.SWLL/Y5GZ FDKR7TD^]:ICUE?YXPEA' O963.
M"$,H)4@9Y9GC>KR^;D5X9J<W/*F8SC :-QCVP/]_;5PJ\/FS%4P+R#@W=SQ=
MYX7') <,%JD'D!$\[WRA7##P0W (]#WV9'%YX9$$F &O[8UVP'5[%W!:+<:F
M"_?DMH7A!FL4DRX"'P2F';?>.X5T8/"7IY-BLHO*#;-M4WI_/A@3??8)C6F1
M/2(EI'4(IS:U'E/-&7;(<FRPL9R)Q27[#(DS.U=D4<A.I7!!4FVUHXPSJ4#K
M>\&,)$9[C\,2[-J8T+\V:(1>2MTW!WEL_WI0Z HOCC<E7SMM%7=/",9L! IR
M)17S&AFAHK+,L<@EN ?+5-QP,:DZEXJ#43"KJ96<:L,DV&E# PK@ X(O[C5'
M2[!?;[&I.I]"I#X*8:10P1H6G%4Q*&:($)PI)(-?HMS>8E)U/I6TE.( F+FR
M2#)$E4$D4HREB58(JO/UVU@_Q?Z16?A4VUM/B:6W)[U _@[&_SL$\H5>O]QY
M:_H&WM-,9U?4,.UV.H-[7]Q**&T#U_:,[]:^=$)O;V^F%0&QOKDCYS%E3#1!
M*9#C<6I33L!B!$0DBXHRY'C((4!BP%RM%)Q8<.)MO3GBQ7OIS=ML^XNM@[MG
M*9]^=^O@6GYL<H=[MP[&@BA&O-%.<N8H-O"G%D);9*Q5:.35@GM#:,'\LV7^
MQ^8_P883.@6]&+B+C NK S?,16=)T C+5)P.>T[CQ.$E-"M88V%9XUL7^RMS
M_#@U>N/41P \$RAAS/.4(F<"7#+ME(N**,2YEB0/DV*QB/6<%B]HOA_ZP?1<
M8Q(I+W<JQC?[W<Y,L9:X69;I,3TMC0;]X15._9 BPX;8:)P-PAF)391CK(4G
M:RIXP10+Q12W8<]]"WN!6\FGL]!"2H#EU&&&@V0D&F.BCS$D\T.4MG:\&*M@
MG,5BG)LKM/ATM(DAG!NC/4 4!I@5@"K# BP)P<PKB>P8H4RT"28%4RP44]S&
M)O?7)IA,1YL$+QCP#J'>J+Q(CK8>NR MZ!<5.1Y[/07C+!;CW/1WR'2TB9**
M1DL<0PBT";:*2R2(01)%@*HCG J6A2XG+SS&S?E)M.5OT^I>7K3#%.HNW:?B
MT\'0MH)YJG+)8*WH=/B+1.$$ Y"BTD9(0[1E,5BBI)5.>T<G%;NQ?F[\-0U=
M<V Z.\UPTIWU:@+X3T^!&3S@%,DHDF!HF(_4!&<H9@XYT#GXJB<:,$-6<,4B
M<L6W!;._\L5/"V9_/?41V(5'PW ,@E!$&&5:HR@H-=P39)4:;X-]EIPS^VT/
MB\F3,]%4B#NO,+=,(<JD(4I8E^ILN1BYM<XN_LZ&'^]]ZW]G\]N2[&U(?32I
M<H@;'AD)W(0(X,(BR37C#B_!QI.?D&>R\W 9B4.E#@)9@Y6Q#*=F3Z"B%8M:
M2J6%6H+:=#.1G7L_?>N+Z?FO"G7R\V[[K-6]""'?HC3*=RX)0P#0,T$2Q+ C
M+"UQD5YP%J3$FF$LEZ">V@RD]?FR@U2*!"<4#DHQ;KV)@7E-#?:&@"9?@CH#
M"\@.@+@&O:8;!)\SQ&&G.>CO'QPN"4LPRG%P!$5/)3..:PS_!D.%"=Y(NL#E
MW'_ $K7AH ^WKL61K=CNML_@JKS]53I[60H!:$,9H3QU+P>0%:,2(+U!!N$
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M+,X<4QM\%.U]L#?WXV,,_=I=?SI8-6,?<43"IX#:/Q7!6?N*(]U>[KAQ?SF
M6GF%[;QM0^]BN^MO!HK@%5S:>#((9[WNYW2?)8T0C=S'RL[696TGW6N+'>\<
MM\&%A&M:GZJ76_"LX]/*Z2ZMO3D\K]2_<1_A?A66QEW9:7RJMH_ A03[\>$=
MK>R4+^%=+RIUQX[KN^=WN(^(DXB)#!E8$Y$Q!.!*.8TRR9Q#+EK'N5[;W DM
M\\7TPB.\R!OK(0HY^)D<U,UY>;QLRN6RL,1.P%,S>/DZ@WOL4OD6G DA:<8\
M,+C1R&?"H;3]QQGNY=HF$QEB2"'"?LCB2Z#(U;WX][=<M9:ZO5(W]7$OG0Y[
MS;YONCQ" -BJ>5T-YZ?U3DRG>9E__WWUQ/Z>LU;>V-\XV"B-BW3T2C=%M%3M
M;OR^_#&CF>NV+>][H=\?_[4' \!+J==^V8E#U4OWT1KI0[0^(X2SC#%M,F.L
MRL"/RYL!6L/=VB:6LK2[49JT R^]:GWVMU74^NS#4-^2C#PSDL'O'Y&P'&;*
M9%@JDC%M'9!,BRP**9 Q3B@';O?!L FJ%61KZ1SLIV*C;?A8ZX%=7T[ _A@F
M>O=1BRB$83:+2 5@(L BA@J1&21MY*E& 59KFY-VVO.3]1PAU'IOP;D"-+"B
MOM=C2'GR45,1$7,AH^ F@?-$P7EB0%03%5;2>Q(=7=O<!LF&N>LTOR'FD]'R
M;1>(U3INGHV\Z.=%J/KN1XQY-%2[S!$*,A<0RS3#-J-&::2IUHJ"XM8PFWSI
ME/9O,V2BI*BW>L$\2[8Y_$AD!,T<4::B#2DXXC)+E<\X1RQPJ;CT9&U3$'&;
M:7Z?I63O=<$5>MOH=IYE8A#&\>FCD%$K[8$2QH#B58%GRD3XQ+ED@FFBJ5_;
MI"#FE"T2#ONIFSF2Z+'6+IF.+PU"*YPE8D]2SN"=G_7 (C?/3*L4SH,;IF+8
M\#.XH:'_@W3'4[N;MU_V[N3':T 5\%:)O==SB %?S.C]U_,)&/\6FWU@^U):
M"KA>:L:4WNF<!%_J)W!2:IG^H-3+UQ:]+%5?;"V0UEZ^;0+WX]*#M)^R.6C"
M#4>9N- #<IP->_UA2LD-NB4X(P^+8/*;_3WQ;5J)LGL^HEQIRPU>/H>D%I4;
MA-(E26H1.$A^=4!//=A\9MFJ9.#N%X*L-P>M//L=C&N4'.B]_NRBL61#JCMG
M(_^EV4G1SY<9VE!W2-#<)JAGTOA+!Q=MVVW]UI]AL)ILT+NG9U'FHCI>*9'S
M2I@H7M#(7QI-^.6KVGY(DF.L:I-JAMDJ];NMIK^Y]7GQI6B&Z'QL%B\PL;FL
M+B4Z'V7LCNJ?+BH?WK':3JL!][VLO@$$3LJ7M0__G!Z?OF_"WXWJZ:<OE=/#
M6QF[LP8@]O/CG1-6^[ +[U!!1^TC>G1:X4?M:KOZH0Q_[Y):?>NB^A[&>#,E
MS9CFJ75@AGU &1.:9,9%F:'  V&I%XHPHP69P,EYT<OUTIGIE3ZGB@^E_T8;
M0)JTRK74;\P\9?U+PO#]U=/7$-#X^BR=#%8PUS23WWHC5OZ.^EDYD1JK])%&
M+^3I'O)T+0-^H-'Q?QK(M=]WS <]K)V>H./V^V;ULO+E^,/A%_"VR=&',CMN
MER^.ZHZF,1W7C^&>N_P_E^\^1DN1Q@)E@3,01L=-9J,(&5)8!RDC-I:DE88?
M]G_L93^EN"V\77X"\S-QLT8K9&^'[A,66.*H_5.+T[L;*Z:""H%3D3G*5,:P
MX9DB8*ADP"YB[:CT%F HN+I5T_?FW]*;5M>:%GC#+?"'2VEO?1C\?)7)/5<-
MS"E\4>[XM.@AE.Q%R36"^U1JIYH!7QHA7TZ2'/UKRW-_P[^7&J:?[YSP)=-J
MC4,U*7+P[["9X@:#;LF&\0EPSZO0 4V+3T:;=L8!A&MQA^NQA'0XW[3CAZG(
M4W[J62^XD'L#F)3R+:7]TF]P/Q"'4G\("+C?Z*8UPI,],8.&&=P>^Q=S<Y3Y
M[H_\XO$[_#X*4_U&1N]H0:C@N#U-Q(;S\U/AHC2*\7WR<E3Y(/)!IM"51B5O
M+OH;L\\(;0][/7C^:!]>LJH#,QCVEU(-/&81_2'_:(*TQCN3.9Y"QPRKS"JB
M,T9<U%0)RPU=VSP*_6_3=F-IG=8^S?O)W/D#'SM5@2]5NW-Z[>ZB%$N9AB9,
M&@*40[LY&( ZR2U"K]M)F*1U40J 3RY*Y015C,N#^CMF8$II"]AM1?GU'M<#
MKOM#.),AGG3A?C@9MD;+T@ZR>NFWM.]._E$BE&R,SQ@TFODNB;-\E\2,U>9H
MP%?:,/1_?P)==VTJTTR.5=^STW5'Y*./:3U9"!E7&D +(3(S5-E,"9_6>7-K
M72AT7:'KIJGK0+N84@O&'4K&.=!U/9,45I+^7L),=_Y: M[+[CS0;X.2A*?T
M)L@%%$8;)N%B/4%$N!W@JC1')Z637O?+H#$YO &(,>1C\R$V._DFZ'[2?__[
MOQ0HCC^^-\+\,/YC<MI/3_CN^";G)90X/O<[0YV<V>R,5#DF-B-W)<XV'I7E
M79;,&6,;:@8UO&93,F2&@R5S*T1R51?V"37-T^RO2:"JMPW2?-+M72PE(A@'
M02X=AO.:QSO_G,*XSJL[Y?.C^@FIDFJSLN/;\/SS%"BIGE9N!T%@O(> '/[Y
M5&E7X#H8X^GK1FWGB![!.*KD"-[U=0J4$!CCS6UCW\047S5K.UN /(Z;@#XN
MJI?[C>,/1[QR^>G+$=RGNO.J7=DYY(!4SE-,$3'&C<$R$R[2C$E-,Z40R3!'
MQ FAI3=D;7,OU\M;U]1N3K-'AQGG4HGG?EQ__H#DQ!RKLMSO9>Z@W&Q>[B%*
M:@J$XM_BM%\L)/T+:><G.'6.!:VFRG]5 )+/C0>7G&0'8PA]%9PL;8^ \0J1
M;>;()I_$5\,^/+G?7\5":T\$>2[VZI7K>9_@@X>I1YE1:?.70S[3T?D,8<(H
MT%9&C7Y4:*VP%(NJ=G8GWOB;D3=>*)T'*YW)%(YF<#R!A?+Y9>6#]NJ[UY4/
M"8X&;U5&E&(90\)EUDKPFP0C<"QZJ?W]E,\,5<&"IZSC#X*$ZZ7FW;'-9KPK
MA9,G;@!3=KIYWF78'P480:9&%93O*+?8[>7/:EVDAW]IPJ/AL:4.O%LWQ0P_
M-_MY8+%C.JYI6BD>F>K>I)-3!R%O>KY?2ILMF_Y[J^SI;^;.5?8;\PYFSR6&
MOW*1]'XCM%H3?BW]!ER8Q[-'!<]^'"[^?:-T!&-_CFPPMU3.['%^XH>5M+2/
MRG6>?Z0A1FD5RJPP.&.!LTQA*[*H))A)+ Q2]D>M#Q928:3U9%\W .8KF_L3
M4?^J*5(""<L_^DE-I-71_;0ZNM0=#G(;DHR)R:_Z9]BZ&!7B)6I4*3Y/V(]Y
M]G6>,X?+AYWFB&-'SUN[Q<7!:N0H]8@[)IU2#CMA3(A<<^!O.^YE+(E: U7E
MFN"7]O]:*U=?W[$H*1]NOI;[(']4[>N0;_(VS$'FNX-L?$- )0"OX5[HN7%Z
M_1-/U:\JIX>T5C^\_"BTD]P8";@0@7MJM<TT(31CA@=-":64R]12B:\KIM:U
MH!/^GU![\XZDXO+D"A_=\8\]9<>_FZT8S[HCK/BR%]**G<_AF^:,7P>2CP!]
MO<38?K<U''Q[R<_Z.3ZTK:1<FUS3Z'UU!4Y"9GO!?,I,'(3>2]/Z8B[Z:R^^
MUWN2_6+GR1_MWGUB#M4;(#^_PJ%*;3 R@XY4&U1.M2'5+"JVC:9P/HOMWP*3
MWMX&^-2Y\AAG4P $7G T.#"'XV)]+X?@@?;263 FLS!C*35Z"33\USWZUR*@
MV=9^O53.5\M@\D?I=;FZ5=TN;^V5 #W4]BM;];R=I[E_?./G&T?NBFS>4M=Z
MAA':)>7(NP*J\^+(!X[E 1Q)P6&O[U9*>.,:*^9]<2N[U?I!Z4&L^$!27JG.
MN\U@OA5P3G'S.XDYPR=^0TQ KP^E(_X.K9X^)S,CB;]S_RB]6@HXV;2/:8*>
MWV><0C\\@*]$VH[<R8U*OM3@E6F95)7FH!'"H%_Z[;!CAKX)1WXO-,5R: I1
M:(I"4\Q 4^A;FB(OLCG:#]B-I=I9&-U\5/HK!7=[H1$Z_;07*'5&:(?2;WO=
M?O_W0J<LGTX!VI-"IQ0Z9<HZA9 ?ZI0\J-[HMN#&_7%ZH+3[[[ YN,AU3+7;
M24']7K>5[U#.=\R%_J#0*4NA4Q+M::%3"ITR;9W"?ZA3MDV_47K=ZG[I%WIB
M.?0$T),5>J+0$]/6$RKMLQC F ;=T@V%\?IJ)=M7U5$HB^50%D!4ONK*XLG%
MGZ#%$?\?C^7^G"+D.#%"-DJ5K>K6FSP?,O8R#DH[Y8/MPX.#U'Q]J[H#_V_M
M'1V4#U)[]:]IE.U:=6?4NSV=L[][<+A7ST^IO=W=SQ-]17YE211'8@>L"\U1
M:(Z?LHI28\U!-TKO#K>J]7(=9/W];JX$X(>]R?>D0_9J!X>@&$I;KVJ'=5 T
M^_^S6R_MEP_^I] +2Z$7$K$I*O1"H1=^RBH:C_4"VTC(H+Y?VSO(=<+;_=KV
M[DY2 X70+X70)TH60E^L^+L/J[#)BK^O2_YJ];]W]W]YN5\A]G,3>Z E7?DT
M9V'KIR'V\NNRRKW=-UM[(R._NU.NOBFL_)*(NRS$O1#W>Z[K1Q-YW]K(W??2
MZZWM>FV_D/7ED/6<@(6P%\)^+UZA7U,#A]7]W3?E@_KN_NY.Z6!K;S>/[^^^
M.RS7CTH'N]N'^^5Z>7?DYQ\>[*:#8R10J(9E40VT4 V%:K@GKXBOL?^=W==;
M><+O\&VM"KJ@6J[M7U,)A?@OB?B+0OP+\;\GK^BO(?Y*N;H+B.#U+@"!:YF^
M0NR71.QU(?:%V-^/5S 9BSW?*(+[RRKPB8B%P!<"?R]>X6.!%QNEW?_\77Y5
MKA>&?5GD'&A'5WYC42'G4Y%SM;9Y4'Y3W:H#="\$?$D$/"W)^^&.H)_5KF-+
M4[DN%91Z?.DZK*9?NFZVK/K->IV\LN)HH<W&W36U[JB:?,\YIFO7+IK/FXW7
M$HSJFG[[YW<J-_WB^XJU.VA\K5(L)G?5Q9L3S;=ZO>Z71C"^]+9A>FWCPC!7
MK/WU5%5BX[N5;Q=E_#\JKK/P@_^MW"D-&MTAW,/#A(=S%\X&J2S\J(IOR;13
MH?=K!0I_A:N>N BFW.#HE\JT2KK!&9UZ$4R,-XC^M=O^^!@5TZ_8F0^6+T[)
MSE_ 6K,1J)_7\TRS]MOPJO)-Z9]A)XRT.T6C.M:S['BQ%.5.#T"[A+Q.^'A*
M\$,JGUKC/IWT0"'Y;#Q>YT( '^3!<_ 4[7SNGH&M@X/=%&JX]M8/?-D'5@O]
MQ:E\S#U^K9[I_1\3\W]^1/7%:N&T?;B_#X"N] C:WWKE7Z+.K.\Q)>DMI;^)
M6FB"IA(CJ4"12Q_"O\/F9],:%1&X2=N'O#HJW9.1VTWO6V%.K_[?CWK%/VZ'
M1!;JW;[;86+8][?:2UBA>#1>!DPU<X09Y*GBB@BNM;-RTEXB[XWRM;U$1B?=
M)8;][,28LY>)D[8Z/OVU^Y6-M@;;IM=+S9C>F]8PW*_)!)USDXEJ4[==^W6G
M=OJ^46F_;E1.MU#E\KAU7$_-)BKI^O/:SM9YY?2?9O7R!+Y7X#G[C:/V>:MV
M"F.IGWPY.G5?X!GP]SM2/6TTX=GM6KW1K+VIGE8NX3B\P^0:>-;PF!R*ZLZK
M5FWG%=QS"]X'_MZ!]WSS#[SG$:^]*;,C4KE,QX]/CV/E(C4MRYN7751.#S\2
MQ)C 1&=$NI@Q8W5F)%:9HEI9@J(C$J]M HW7&=7?]*08@;O'",1$W3U ,*9I
MU OUM*+JR0,[:Z&B#4HP(8-6*E*GG4%.2D]\KIXPTH5Z6C3U='E=/6$B"0(;
MDS&2&BM:+S/-*,N00<%A;XT.$=238J">V *IIRDA^B5 @ENC3HC]4B^X /)A
M6^&[^)X\; +N5+A+K96F!9HFD[Y_->?5,-@>]GJ@G I]\P!]4]V^"8>T=Q;0
MD,R<H#)CDJA,\X R2156VDBCL%G;)(^'0C^0]UE!H?MZO\]>2J>%'7XLI05D
MF)H(WX ,C",CJ#&94L)D+'5=M9C&S 5K*,$!&VU2I[UUPOD"2?'SB1V][84S
MT_2E<'X6.OWP3<CH7HKHOO[94BNB:<&%\8SOCB:\T$#3UD '-T$$$TP&'G3F
MHP(-I#S.@%@R$T[BX VEB*&U3;$N!5X@EV7::9)G+[W3@A&%],Y:>F_@!Z,M
M<\[@##L!+@ HWDR)X#*LE")16&.-7]MDZU20!9+>YQ-PJ T:H5=R(S$HF7X_
M?)MU*GR9:4.(?-:W\LDN--"T-5#S%G[@TA!D1>8U2SF9@$ #"9$)Y!PWBC#*
MX]JF6E?ZT1JH"$,LKNA."S\4HCM3T;T!'J(,U$HJ,AF,RAA!/C/,Q"Q0K(R0
MA!I%US;).M:/AOY%[.$7Q*]B>I_">#5N  S1'#2+ ,3LT</7:3^XFO4[=5%L
MG@>?789>MU!##U%#MU9U8*R9L=9G%C.>,8YTIA#G6?#*>(M 2:660^-BK@OD
MQ10QB 7%$/<6X ),/$J*;X )A2617O',*<8RYBC.-,<N"PH;JJ3R7JJU34S$
MNB1J@:3X^<0B#AK=WJ T"+UVJ=GY'/J#]EUK8 N79MIXXN_0\O5NQ0R2*KHH
M5-+,5%+M]OH(:YBU2F=4! 0J2=!,T\@S8BE*"R<8H0[\&RG7$9<+Y.$4P8D%
M!1:%)#^=)-\ %QI(%[G@&49<9TP%EBGG8X:IP$I23071:YM<K NR2((\S5 %
ME8N,+>JU>NJ_=[^=4_=P='Z^)VTU-=74UEP6$=29Z*5;BR<B%E0;[S* %1'T
M4M29#<QD5#'P>((F)I4U9)2L4S4MI^=^HK%$08WG*NM36[E9R/J,9/T&!I&&
M8A6#R@12-&,2L<P(*C(1F<0*>2U"JG2FV#K7CP8A3R+K*[^3^VVO>P9CN<@W
M_Z9]OV<IY+%>ZH1!$?:8_3K.T>2_;9G.8*OC=R?S7PV%EIK>'K3Z5M)0(U1R
M6L8?B73<4!,SY)C+&*$HLXJXM*R<2"R-83&N;4J\KM&C]Z 5,8_%%>/I+>@L
MQ/B)Q/CBFA@+A6@ YR+CR ':8))DBA#P,6A*J.!(0T(;3*T+N8(;0Q874I0[
M ],Y::8U&:/5G+^.)IY%3G=::.)U$YX1]IJ?@_]*@I'G4RBBJ2JBW9MX0ABD
MN$<Z"S2 ^K&899H2G@F#C:+<&^=)RNNN4S4MKV=)XQBK+<C3PA.%(#^A(%]'
M%#%R99UW6=1)D(6(F<',9B$@;Z+4,3*;BN>L"T$72)!7/DBQU^V<%*LR%F95
M1K7;<44H==JZJ'P35#@/MH(IDU$D?,:DB9EU$OP<IQEW(A)M$J@0?%T3M$#N
M31&E6%!444CS$TOS#62A% )G &>$$I0Q1DRF%6 ,C4Q$%EL<0UIGQ?@ZUT6P
MX@D%<3]]SKHQ&_;#8S:?/@L'9VJ;3\]":J32.=D+IA]R$M3B87_DXQ1::'I:
MJ'(34V#LE0C2902!5\.L")F*$F4H6&0MBHIXL[8IU+I&B[3^O A4+"BD*.3X
MZ>3X1N:#&RDLBQD.1&<L:)-98U7F,"=.$:85254TY3IE8H'D>.7C%*-2%D4)
MBR<O87'=ARD4RP,4R[M; ($K*4-2+)Z!8N&19YH*FR%&K)#.@)$@:3O((KDH
M1<!A4=%!(9_3D,_KAE\IS1%S+N."AXPI(3-KE<^HD48HI*7V/,GG(M61F>8.
M#\X7IEK_W<V01IL\[M[<,<-%WC_L*3:/>7APUX)[OOQ/>6^N;SVW72R%KS4]
ME7MX$Q(IZA&-P67>!):!/529!@\KTT(('C754>NU3<GQNE3?JMV)&,S#Y"_&
M>OHK@7S*-B^%*GU&JG2ZFX0*53I557H=O6H7.,.$9$)*G+%@;:85DQG26'C*
M":+*I'7W:!VS;^//A2J]J4IG$$V[N[7H7 'U7GGK57FO7"_O'JR7JK7J=JU:
MWZ_M[96K;TIEX/+]W8-Z::NZ4SJHU[;_Y^_:WL[N_D%>"$O^4=I]=UBN'SVF
M/>4U$E*@D^\.T[+FQ_<FO6\P8@9#7/F4[F2+_376>4QWVD7I03O+3K-+4)KI
MJB_5F;FXJRG5HV-V2]SY[ZY77)EPY+1[;+T=\4^Q&7SJ<._DIN>L>1!(,?"<
MB9,9@S\SHT7(N#6,::6U37"/KRN]@KLL"W6THNIHVLW$"G4T0W5T8]&$UUQ8
M(;+ !<E8#"@S+L(?4ABL43#1J+5-O<X6JM#=\RGE#0+1&X:BC=B3(J(TXWM-
M8YNMHDK?;+30IYN@B NDN:8VLPR!%E(X9$9AG D@'7,4CJ1M'92L,[V"[=D+
M&9X!C"AD^ ED^#J2D(XB##HWLUB%C FF,XNPRS@5P08G F9I:Q9;1VB1&@(^
MJUA1#B7.S$6OVVKEM:ULZ(38+-9ESAY6[+;/6MV+$/9#RPP*U313U71ZJ[05
M0A8LBD:99H&G2CC@WQ JL\@LQR%R[XA,_8K$'0FVI8^Y%*(\;711B/+3BO*-
M>(4QQH-&SHQ/&\"Y4IFF$F54.\4,R#/\E^(54CZZ%D41K_B5HA1ISU.I]54D
MBH#%T^X;G6BCBT(735T7W:IPA;0-'*Q'IK'#&8O19EISG&$6J-88K MG"58H
MM4AU<8J@Q8+"BD*.GU".KV,*!*"!6!NSF+*Q3&B1*69%1CPUSCEA>=H 3M8)
M?W1)F2)P\0NRN!-B !GPI5[X'#K#;Q:Y%![.M"'%-MPT/>Y#<]#8'O8'W7;H
M%0II=@KI5I4K'2DAU/(L$@9.#I(F,Y&'3" =@P$+(X1<VU1LG3R^.4@1L%A<
M<9X6LBC$^<G%^3J^L-1X01C-J+<F8U3)S%#B,R&%X)0($[A?V\08KR.^2'O(
MGVL7LOLLD2[:$\T<A!1QU5GJJ%M%L% TW"D*[@\W #ELP)D5!GP@YC@QEL*_
M+%7K5NL$/WH??=&0;+4D?EHXI9#X&4O\C:B'I%Q'[S-EB,H8$S2S)N(L2&2
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M12BI''9.]A-$T :[J6B$!ZK\VE\<.1JY0.*5A&W\ZV_FD3 ( 99 TX&L[J*
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M9(R!)5IJ$J6;A*Q39?N2@[:F?D/!\Y+Q/.YF>*T\QR@(C!%(:I*;81RR+N)
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MM9%H9:.P% O#(E[EXC^VOP>/?H1>MS#@C)M<5S(+S_???.)1&HZE11 T(.#
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MX?/N)V@RTEZ8_E'CY7'W6[^Q]H_QVT]"^'W][W6ODUBL>Y;.X=-K$KZ[D&:
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MKZ9W ]:C-EO_G(!.R8*XUB; 4ITV\--83;8S^^2]V/V=X=[#0VG+ SW@[K?
M@K&H\K N<8 _@+:"_X&,\/%L.);SUK4[;1!)L+H:3H Z0[4.OWCSXD5K.#KM
M]0<;,TN!1^606H"WZO:&>.G9J#\8H0;H5UZ7\2HFT#";U,UR*UV+TJC5'649
M!Y^"K@*Y/:CU9*//XZ=>IT()\/B(9PRB'J531O[Y1?(M:^0 -UCM=[T__]\U
M46CEY(([@\#.NKN3BT>1,&JGT4;KGQQ;1%Y%$?T6EKO=CL>]C=8+0/.P'5W$
M".>(C:9/;0Q'$'W9OC^I,-[4^=AQK>K&W!',G2*BI1F<!.0!7-TZZP#SK\!
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M5I6;O=X0.6^X.LMPJ6:?%[KK'/!I,:D>>@[X-^5T/Q!=M#5<8BC,H^;P/;+
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MZR][KX^<I;%,/@&!,0X(C"6@LN"(2<8Q%:W7A0-ERXI+R*PUJ@X 2"-O_*0
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ML\M;LMU0H(#\*J(I(K;M%*65ALHB^D)+YGWPLOP^!1@_[\'3O>VMHX"34G2
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MKT<$4TEE\P=;]?>F_VK:>L/+/ZTIX=G&DI=N#Q;K=,91SXW,&KB_MU71 \M
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MY[Z [);*]>]G$-Y:O-W?0/'MW0+N_P76>['_X=W%P>LCH41A6,2V@PF[@TL
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MGCEFJ$B>55 />A##3H97QV.0A'&O./Q#B(W!^4AM,$9&)_Q&(P+:GL'T#_N
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MPB)2)*G-%,TY!#NQ1%X;8CS500:[E#SP%R,/V>U12\1BB?B"#X57(FG,$<;
MW+F/"5F,';+"*"6XET#8EI((\5(DXDWOO*9:BP7B8(<>6F&%2,8BE5N?90%
M)D2"G"0^!L94LG$I@9 K6W,/E8D2BKB:0.SD<XA:*FZ7BKUOAUJR:(-6"# !
M-@[CP+;'CB$0EL02K)<@:F-;;-&;I0+H=C^6<Y^MV6.;QPT@^^"/8SCOQ.O6
M_$XWO.WUP@6,[R#'$_[2 67O#JV/QB22$//2(VZ-1-;"GB!#<*"/'"L7YP/$
M;@J2I,\GYBN'#:1>I].[R,?Y5;6^LW[O:SO ,T(<VG9GT*C$L_&J=PHCO"P%
M?M3O P"RV3BNAK,=V_5Q\%MCF<BW/ WPUJ,*@>-#WA(="V_?L6>#^-OXA]]#
M>W#6L9>_M;OE'<J7?A_=;'0RG$]#Y]/J\R17'U\=E&[AZK!TE-4_>O+HXZWR
MT5PP;_69%EN*Z!L_QEODQL]NNRVA6UC3I6Z[9&7(>U7.O+N54W6$_F,"^?52
M(;]7D%6.NRO<*C]^F 045I],;6WWJ;6YS(PN&]?];*>T2@)K9UWOG<,MPN#?
MC54FZ[I,^91P\O>KA3$)9?C1R2%_5""60YL^Q+-A/'6Q7[E=1V<S9"ZLHN[(
M^'-W9'QH"M 2ME@KOI3Z%O<C7U6:S^F[[ZWOH?WI^_'IYY,W7SX=O.\T=__;
M;OZ3Q]3\_NF?O]NM[ZV33]^/OLVG^7S>;;(6A>O>?CYM_O/^N/7VXT7S=._;
MI].F:'YO'7_^9X\U:>MD?_=-:K9'*3X?\&7SY..A#2PRFQA*1&O$@_'(T:!1
MCH%C*4?N4@XF&]N4\@4U8WR&!886:]H>D,9V/X?1WU@5G"Y\JX4@^:*1Y*%'
M\]<@Y6INK]MO%=QT,MP\_W*H+P%6+F=A10@<><01I>1SVC13R"1K4&0!@ZWH
MM9+Z":NA_D2%RQ;KW8V<?C&RW)^7/3_(6:U^ZIHQ9QTQ(#7>W(TWK5=S-$:5
MUN *D<1+%\. M&6P:H';?+Y/F<M!(YM4K:%0PXOK)OT<S,4<P#=C*<Z'_<]-
M?N4Q&'FO&,QRZ)UG7UCQ&OP252;6,0//&ZH?_WRGMC.?"J _S (T3MY1Z@#.
MHB>(8QF15C$WVK!$ "&D"9N<"[3)]/73P=OMS#7HR7.M*"&?>44)^8M5E/@P
M[/DOQ[T.B-2@*H7=Z@WC\ZLKT6J/$:)Y\>D[:/3!SK?FZ=^=U@EH^T&KW7K[
MYLO^[@YH^YN3S__\M[V_^^EB_ABP^?V/D]8_>Z2Y^QK^]I&"MG]KTCW\Z9]W
MO+G;.O[T#XSK=(^W3OY(34"@ULZA%H*%F(ME20(L#%..C'4* 5(+ZR+CL +S
M%1$$EUC$%$7PF,-%FD18("8BL<R$P.>/#3\<[+_Z__YG_\_=U^\_C [;&J_?
M?=P[^'1[@8F%J7UW/OP%%*;86<2M-J?/)!O'-E>&&.9BUCE6]<9M=W!L^[E@
MW!IVWKW6FWGE>575H?@(3QOLG ^/>_V<1[W<EHM_,86"L1T:K%B08,D88ET^
M5 =MXL(CF@"Z@I0$"P=;9M46=6%KU$:UH'G-1T5 0#@!G1IV,OTEFKD]&)QG
MGKZ95W[0'@SS<?<3"DKO]+37+5C[H3RHEI8[X1<?$@>3C6U"@02.N.1 KKR6
MB!KO,6QS1N@<G\G%,N)2+4&CK,%F+AG3^)K+K=T>DO57[)?U^@%R\9?M[_<_
M#'/.<*D#=_7H7U8$_+=#&E,20>:&Z]3#_NL!.WP"B1#82F* X^"2M8D7%&QK
MG,5^)0!5"8,GTOV_^K =]_LQU.J_PMH?B4-FE**"N9PW9Q%W/"*;HS"=)Y*K
MY".0WHWMI91_L@;/3/]G9:.&@'DQ.-D3A\[DSC#$H&A%1-P[@W30!&%.+/:<
M&Q_IW1"PM72,VC-GP<^%P>R?#P=#@%4@5C6&+1;>C]\.HZ")*:,0]H0BSBE@
M&.,4)1$UQ9I+YB10&"PVE1&;?$'1Y1LH3.,B]F.C=[4(6XVU"(SRQC.IA'/$
M<\VXP2%R[I/EAJ>$P]("4Z3D#SO([5Q.<W1Y,5)W^GW;/2I5]OZXO+KD+WN9
M_[1S8?L!C%V74T%'.^57V^YD;]2;7O\M?'=)A^8O)VS?=RX/A;6:*Q91H!&0
M4AJ!LH0ACRW7 @OO%2V1+X;33456E#7X(/:_SME7C?.SDGP<^[X]*#7!>F?Y
M5E7MQJ]Q8GC!MX?]=DE+K@RV+(:#QE%>TEQZK-^PXY4N#R@?P$4Y&16$IG=Q
M'&V8A"(#^>>-REW5V.OFL,KVU]CXJV.[6>H)N_;'27F%:Q\,X.TZG?S?\E[=
M<.ZK(I!E!(/&J0TQ9U)W =7CZ5FG=QEAAJJ!O3^'T0K)Q+_\O__%_SVI06D'
MP?YOX\^1V9FO&KR\_6>OV]@Y/SH?#//$X5GW2XECA65K=W,)SVYC'Q2\496U
M;GP !6SL3&II_BM_+R\<Q;_O'#2O/BE_([__&\C8>3]+4ZD'6E61FW[6J;W<
M;*1^[[0J.P?7Y/]N-@9YV<[/\A]62:L1'LL8M /S@7)" >X4YBDF:BT60OL"
M<!AK1FX N*K$]]5V.'("57!5>-O[D:8 9+TY'Y[WX]Y(6VKL6N@9^OZ%'^98
M&@+6'B(ZLSR>:VJ*H,'N\T*;Y"*F86.;WN8::G>G\&M1 L,,I@V/^[WSH^/&
M?\'"! 6!;_WYYRO  U]T%N @WV$ "P)0=E2*PG;#?P ASOKMKF^?V<YF?B#(
MOATBN!2=5M+?*W?+V_'!E RW!XUN;P@@")#5KRHS%/$=C;="D_S &0V9O4?.
MS &[Y7)VQ T+XGUZ"G@\*HQ6:<2-"M$MN^N\3F 1F "]2 1S'9+5V;-M-=#N
M)"RISA% )ZISA&O*,5O]'JR6#+$P:?OIU61H^]V=(WBO(S!N2D^/O_H]'V,8
MO '%SHA173M2J8DJ(/J+Z4+S8(<V+PZ9 @M'1(:4Q@9Q[2VRA@H$S"X2CK61
MT6YLLZWK6O!_)\7QQM,-&QG,=\[R*1,.0NACN^SC&5-MEL(BY:/O^4I)QIOT
M#8+YL0M?@>_D-+:+O//#?G#:[F;3=?/Z]9,#DBSJPW:G*C)J^YUV56HBZT+1
MNBN5N&(#-XPA4X9=>)4LS@U:D=TU<6#&8LPUPQGG!.8^F928PRY**H-SQJ[&
M@0<9_9<(ROS58+]YT+QL'1UJK))/6B'F/,^YE!XYGC!*0?GHJ&?"JHWM;N]&
MLGILO^92MD! !KU.N%%DYV)S'G*&;9[Y&;;ZQ<ZPRRXSS*N<LUA?E66%+=O#
M%OG\#K+W/XS5[-.WS^5>7T =]K[M'[QOEQ"4W3W6?/OW2>ODX[?6[I=+&,>W
M:_FL)V\ZS=.FV#\XHLV3UZ+U=N_;Y[>O<T6@B\__-&D>0ZX2].G[F]0\:7[/
M->^X])9%@0+8@F ;$H5@PBEBT6&?JQ.&<.T@VPO'@(VQ -#'C0].:9X,UE8G
MBADF\P?9K_:;S;V#YNO6P8?&3FNW\6J_=;#7>ONZ]6KO]1W-$A:>9=_]_-GQ
MJB1H$-)BIAA<;ZWC(G&I< P2P$0]35G;&W5EL=GU9WO8/IJ-<GX9[23>7#?1
MYLRX7(ULJO7#5]MO]\X'#=^Q[=/*8= !QM(94Q50XIQT7.[2Z\.OMG\)*P[&
M8G$TN/,!C&$ EO5>Q5S.>KD<>AMNT,F$IZ(W\.1R_\V2L]P?^1K.N^/?-O.O
M\X_-?+V<&X=BY<('KE"122'LTQ[PF'Q5/]I!KPL?7HZ*IL-EL^]=:+OU'C2D
M]+*PKMW);HMQS:VI6NN]_#('N3! Y7%Y]&#"!90E=]B[0M#+G3QPV]D9OK+]
M_B7\<4&/JF?(97XXR'[_<GE(M"1@LP*3D4#5>1 )V80YLI$('+3AQ.'%3,:/
M)WPX$9!LW@%3S[%^I<<)"/QU8KND4^E1Z<B*\#:U5[\P?-OO3NR-:A7H*#]X
M5M_!?CKKQ-+2(SNV_+&MX.I&9;;^VOFBYLYQ20T!(YR;$*U3A'%MP4#/;5Y&
MA8,)*#0:_W";LVKL4=_Q^=PF_0DP]M=H9.&755FXQ_?#Q& AE4T(<!-4-G=!
MU\HD!-#)G8TJ*E5R1:^K;%ZUHI6=O"F,=JF_ 0.[MG$0_7$7I/+HLO&7[7_)
MGU:?;#;^ 3Z:-Y9)OPS80\[@%MU)N<[B=FH/J_X:W88]@]WG6]DA8(^YV8[]
MWS2<$R(@0(Y2"H"D$O=66LH8S>0I<"],$E4>\[SL+$@ @CVN$IJ7X;[\X8)T
MLL,.'8![2APC8G-):28QLB!;2(@0'>%><I7K1,F;(A7^]SPW9$F]WK 1^N='
MP):ZYPD^/<^^Q ;\5)&&TA#K(4+!+9% ]D$<0,*YSNV*+/PA>FQ2(H'60K$N
MH?#?#G&&;F(U\DH;L+EHKOL;!#*&Z^A9Y-'D/C]\":'H6-?KVV&O7\E +Z6V
MCU=RD?W)YV=GO?ZP8K&#7,SG:^STSDY'KFOXO^U<EKC_XN/^6BC&UM796C[+
MB=TPR/=J=_/)':#1\"+[558Y7@'8U%SY!*(5P083+@2OL8D<_A-84C<(F)S9
ML'8*O]ZK!G30VRO#>=/K_W'>[H3>^7 _O:G>O!U?2+W3'RU_^[NOOQTR"1J.
MA4%6@:7/!6- 2#5#.!E8#A-DDBX7NET@>_<M09ZPELIY3')7A9 KH?%<:E\0
MT ,GN*R7_T<M/S],4>&H4D0T12 WE&FD3;3(<JZHM4K +E".U&ZK79AM>6 D
M;C3UXU."-%D @)#I#HS 9V:Z@DU38UCKWMS1\2Q,37S[DS9FKS*ZP8U'S J^
MDNG3L'_NAPT/!KQMYT&FOJW^=@YXV3[-!<W*?0;E1B-R=K#WIA':511"%1!0
M3'.7(QO:IRZ[%4+#72YZ+/PUE8/<QM!^RUTJ^]4P^S#X+MCU8+G%?K'AJW-J
MN,/HO2KOP1F,]+(ZS:M2%D8.A%QE^[Q$[\!W['#^L9,3/SNX&F/U7E=>[OQ:
M\(BCOCT=^Q0&<Y,P.GT\@NTD1UMDTV3\]B&>Q;R?=*=?</1:@R7?:QG/^B_;
M"HP]GU9@+\ [L-@/?*=?=\X/+)G! A J..4XX]QF J*(2?!%&G+0\)2%]N>H
M^^N,8V+IWG;/TU6Q>!J7F):9#*O!N#/N1/W;_5"@/CNG2K^ _,S"&,]A!L=X
M/!Q/;KZL!%4-!R5ZK/3=S= S _H3,CH3C%5B*RXSR 3 ]<$U5_+H%HWL!#X:
M@=YDN-,C*+ [W=VW\C27DVLPM&'V;7_ZPQXH8'<<J9$W0N >O6[E^^WW+FT'
M(/JL"E>$>S<GGX__MEE>.7ZSV0VT.79[3R(_1H$E-T['F+X72(<?RDQ7D2IC
M?_D@QU84W\/4%S?! ,BW@QD\AO%[$(K"]7V.#@V X8-JYVV4$);JWI,[3ZZ&
MS1$VZ<TJJL^6F+=BCH+!"9-;R5(><?E\O-Y5^$ GC^5JOB;S?GIMAK(/OQ/&
M>^"(8)RVBP,$C!@88Y7NC$+[J#T<<Y'JA7-]T#[<>[<RC*]:N>51E1Y+UYLL
MS?I,)Z& L]P$)FD5?SO+'105,\YXQ@578,_A(+D%8F5"(/&.5COS'KJ)&(T"
M80>UA_W:,>;K[_L[ARQ&BZ.(2&&1JZ*XW+I+$L1#2 ZV!Z,(6:D*@^3<)5@T
MH97.R;Q6ZJ0=]SP))6,2=_1HJQ?RG@MIE='""X&\<6";XAB1E4XB*F".<^"%
MR9[752Q/R9UA3@EF+%?<6<LBCH[GD)U@!+ZC[V*]D/=<2">B<D+E Z]D$3=)
M(F=H]CDDHQ1P-9N;6ZVRD"%):974T5D>O=,I:FZIE()KK&*XHX)5O9#W7,B$
M$TD<<Y1;4Z+,#I'+/@/BC$S1QAP6FH\OA]?<!??X0SXX+^SG<H8R?"QF[9A8
M7+&RA:$$T]&TI_;+A$,< RMM9%HXH1!GDY#4:Q2NX?(I6*/0G:G+<E#B=%0D
MV*CQJZWX62&D6S<;"4_:*NO*0EDNF$W09Q[,IG^Q8+8_,^F/^V?9\0(R_&<$
M^1P\D^ UTIS$B,)33YH7<-WWUMN/[//NN^^M@T_\$]S_T_?/Q_L'?YSN'^R0
MYC_O^'5H\OG>(J?X?SX(7UJ[3=(Z.3YNPDA:IZ\%/%\T=S]^^[Q[G-O7X^;%
M88 =11H1$,81]AA-&#)..Y2H(8SP7*;97G,")$DCB<$F&K@!;A! "; 76&I#
ML+?SP6M_OM[Y<*\HM;L?-#LPK'#P+"@P3W*V%M4^<1U)$D%H8X1\&5%J12Q?
MF%LD9S2=]=N=G")F;DMH F/6CGKWMHN]VC_+IV^QD0_*\JD<7%Q<%'_9@86W
MLIN-5S!Q<'VW;2L_[VTH(;46P6NA'58<,VT!'Q@ARB8G)3,\'Y(0 P"R%#@<
MQ/YISI[H#O/F.L-N8*+\;^&\7TSB7PPZ8-SLD&DJ'6QVR D#G"9QBIR5%B46
MP5@/AEL1-K8-F5?[RHDP/F8MAQ_9W5")Q?A8=.9HHQL:1"GX'439AEYC_Z(;
M^YLE0Z==><'N?VB_BKS<=FB?C^M'G3(.>F]++<Y*CU_$&?Z/EZ 3D"#@PD00
MRE&022-.142:<(%4]#)P#68FMAO;E-]^A!]+9MA8G@#[X-^PG9>C%3LLDO-Z
MZTIX_NA\#9NW@$LY@2J\%78PZT>G1N7P+;OL9AZ3X]'LB"4O2HH#0 3AO 'B
MQL&K.2<H.Q&GG@P8-.AUN[$S=FE>NW'[+&8,+GZ[[$2<=D5^.\L-1XK:G/:^
MQAP$W!OD$ZU,Y7,BW5:CB.843X]'L&/D]+U%73J(J8(<^M,!M?F-J^.V&=5;
MY3S[GJIWK3'?(N#^<QP+/+9,=^<C:Y_I<?:/IX$G.Y>'D8']@G%".G .]BD3
MR#!C$58$@T$3"$EI8UO?UHH/)*TZ-,W9:H]E5[R WL890ZJ]#!2Q70(91]1H
MQE>N9A-0\XG0F04;^P'J9"C.L8>!I,@C-99'> SP9<:!,<?B;<WJ5.RCV_2J
MRC0=Z<U^*OJ4JUCN39U[M^)P/QT @':'4W_>R<W/2MNR6M<6Z]K1MT,C#8_*
M$V3!+D$\&H-LIE$D"&L($8H'EO-/Q>T]Q3OC99F)1]B$3:J*%BEK,_U9S@ =
MK4XE>Y649AFR[5)48E1?(F-[/^;-+C_G1@FL+EX+IM\45+U?U;LXZ+W/P[E.
MOT&N+GK],(C=7Y9(M7)VA ;;76IF42P)_M%A9$S"".A&RE&H21"^L=WKQNLB
ME=%Z*H3^!]A492UM)YM6"PVJR8K^4NN8LW\/F9-<*.D054DBSE)"5I=F*$)B
MXTCDC&YLIUQAY3+:_F#>M*KT>KIB3.&M([6^L%6L4HA50ODD+'XJT6KB'B[9
M6.>#R9> G';.0['B1\ QG4US0U=+,)Q+">W"&,?5_3\<9\:^L,;_5F._V]CW
MP]Y5'@C;O+-$RM5V"]OV"+]LJ(*Y0RA!3==XZBHF(I%4<QJL\;E--2,6_FVD
M- Y;YS2NXBXQP935)N):G0P[M'ETR(@#8A4Q"BD?A$F5<F\@"T9B-)IAI6';
MO)^1"")8U2$Y'1F,XZWU9K_4-<MIDFDX$;[*E@(M^>\YR-ETC\-?C@J/4SJO
M/'ZS4S4FR.TKW^&8%W?NFN9BC7X[BW[&&%V%+]]3K6OS<]VN1-&Z.-0J2"]
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M<2F=0)Y1#;IB*<HUKQ!17AMAL6><Y,8[FXHOJ.YVS72N4LBOY BD(\YT('V
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MHM>".FNCC37JK$\"1.O=838?- X>L<AL]F<DY ((A) "=# D$XS.W'&!#-R
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M&*6V!9JA 6BI$)<HAFT$Q,3LCOYL7'GS%H+ BGO "N7DX!]="51*5"J[KN.
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M;.CPEC# AI9C$<LW0L=4#24T7%73%<LT-=^U?%O3_['49[>X6.ZUDNCB<E@
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M86E./SS*@(T-6,I3<8CPM]H9[EX(B$-)NP5*3= @(+((%D/2;C#, J^';\P
MN( L8X\X(3:1R#_$27@$KH[3G+S9NXF'\3@D66"($9J3P#& M6)'"CRI4?';
MKAZ*?LNAY'!,TEHP<D+]P2CZ=TISH.;LJ8!;"6A6XGLZJF#(N%$']T"K#WT5
M\[C(.SYP2L,8JX]7G*^T)CUD4T5/">14U[B(+J'$!>24AXMQKB+II12.E22<
M*\!$LXD%S2;L+6\VL81>^5!5Y.NMAH!''8R"ORH&=Y+K,&>C3Q3[X "B_D&R
M*-NF&O*;L'S4DX-_+**[OJ$'LF\IGFP$?BA[U/)D737MP/>M(%#,QU=#OIL_
M9MW7RABSG5//F'N'5U*=,5B#1@5'1!00T0[J:[-@>I3U]@VC#Z:UJ+<O%GMO
MBS4?N)/!KI3B9_>W<K-PS5T*&O=LEK_*NZW@T01X%H%'%^#I!@\+MZW2I^+V
M*B%J&TRK79;?/ACM,<=>,H4A@FQ_%6#M1/W'Y2-3#!J'E<.39-(AR0:Y&QE^
M0-\%:+BH1S^9DI'=]SS76K9/@$R 3(!L#2![+*7RL,4D35EHZC29T!EFNVR9
MKIVI7_%(RDVT<@!M335L30\L-U -55%<QU*(J6J*2VW--)4Y.8!Z(^^VP@6&
M"K<V4M=WT\F9UX'X&^;^JL*Z;DZ^GRA??WV*OAW],,Z^?!N>_O)_?OTUB+Y=
M_/CU53NY:=>!./UR8IY^_WMX=O0.UO4)UOH>YKXTOPV_ZJ>_WGP_>_L^/KLX
M_?[UU_N9FKZN8Y) \8 =FI8C&Z'JR)[A*K)AF*$>!HI)?!49#HO^/'SAK]4T
M=<$<=H(YA+;O*W9HAH!RAJ,XKFW9CJX[>'W)U8SP]YG#O)Q=P2&6XA"-2C&^
MY1'J63IV9'-EPW0H< @-&$80&HI!,+',?_9:,WNZ;@D&(1C$&AB$;P2A8RL&
M#:AN!(9%0M/758,0E7JV;Q"A/6R.-ZAUWF!B JEFJ+(?!H%L>,2373-09%?U
M2 A,/;!L(K0'P1S6R1Q<WPYM8IB!CKWU_("XKAL$AN<2S=<")Q#:PX8YA%[G
M$+9B4E5S'5DU#4LV7$V5B6XK,G%,R[(")=!"97/:PY-W<I^PU#>6KW".21LL
MMT,XN(7K48!,@&RK0/98'-PUCIO-Y;A"%=T)5?1WO=QE_;DK$L6($F^2]!Q4
MS4H4'U%O4OTF;-@U:*CMLN^!JZJ>[>FR[X>&;!B:#^9KH,N*9_BF'5J!87C"
MAA6,8YL\X()Q;(9Q-!SC&O'!L/54V7&PA+J-/?4\ W[R@C"P59U2W1>,0S".
M;?*,"\:Q&<;1\)JKNNY:GJ'*)J&>;/C$E3U3465/=TW7";5 L47,73".K?*:
M"\:Q&<;1<*8KU/ -FP2RYF#'!]4V94]30]E07,,*%>(;X28UCB?O3?^3QJP>
MR0F9(!G<"$>Z<'$*D F0;17('HLC_7R0I!-Y0M.A%+$ZB\.NRSE"/=T)]71=
MGG24P!=)(7\K=;36-%#HI;^OE[:2R+T #(H0]%+;\RS9\"PJN[Y&03FU"34"
MCWIA( Q:P3&VT86^(L<0N6&_Q38:#G3/T0@)#%?V5#N0C<"R9)<ZJAR&.M4#
MDU+?-Y^]UC2S9[B*8!N";6R1 UTH&@_$,9J>\X":7FCH,E%#33;@[&07?I<5
MDX0*(<3W-!%R$QQC*SWG0M%X2+;1\)NKQ/)MRU#E0 U"V=!<#=M4XC\$- V5
MJ*;K;%#1> Q^\X74]E<RNES64[/4;G>;3RZWQ4?#0-=2"^!6[GF:C ZG*99H
M%YK7&ECHV6'3Q6.:/O%\1Y%]TZ"R8;FN3%Q=D>V04%T//3#8M#MJ7LORMS6J
M9"L'" 1S>J3,:2VU".[,G(22]UL<JEFGP%!")P"ST-(\#6\:6K(3&IKL4$L+
M#3#ZB0<<"E2]GFFLJ.0)#B4XU,YZK(3ZM!GFU'!<@?)DV30 ;F2"YF3HQ)8]
MP[3E,*2$@JQ13<T0ZI-@3ENQMX<NQB#4I\UPJ(:/S-!=PPM<72:^Z\N&[8#Z
MY, _=NAKJJY:GFZHVZ@^/99TID-<"/8[XHV) LI:^HA\IBW:PH/7OZQ0XBP\
MRA%"<,"U<<#616 #5#&=!):L4]>6C= (P'9T7-D$_=OW/=,,J/7LM:GT ,M$
M;%&PB6WQ/BW!)H05=U<.T7 Q49<8*B6Z;%'?1 YARX38BDQ-VS(U%0Z0."+]
M0+"(K7/_"!9QCRRBZ>B!4S)L79%U'UD$H;[L 8^0;=4P"5[MI385+$*PB*US
MP@ACX[[Y1,/=XNN*YEJ.+2N46K+AJXKL*I8M^ZI#%-<$3H]7)C9E;#R&C*3?
MNLE[F& [X$MLY0P_9E% 4]8:6-SH%7<M!<@$R+8*9(_&!5XQ77\1TQ5JZ4ZH
MI>NZT_O'-(-E9-EA,O2B$<.("E,:TOFOO#_YC3!MUU'*G:NKW$?^_9WZC^89
MH1-ZJDQ="VQ;C>JRZQBV3$.'!(0X@:W<-0=4V+:"B=SK-5_!1#;(1&YJ3(3J
MH4N#P))=XOFRH7M$)H'ARZX!Y^R%IDD-P40$$]DJ'[I@(IMG(J=U3<12/<LE
MNBX;#L7R=S:5B19JLJH%GJU:6%]3])T23&2KO.R"B6P!$ZEK(EKH:,3U7> ?
MO@+FC*K)KFY:LD$TBSIVJ#C>)@O_,Z_."]8I!/X;1%>O_PO_%#,,27H9C>1)
M,GZI:@6?B$8!X-!+W6+\Y8'I25.P*!L=3^C0HRD'CZ[T)* *]:54 NJ6C<"Z
M\^8HN=,N28$<T&$7DW%&7Q8_O JB;!R3FY?1B*V"??0J'XP#\J4YGG5N(9CX
MXU?743 9P,:4/L $>4'N0LMGSA_WV:/6^?)GAM'736/N8Z6OSGVV:%A5ZRO.
M_$\7#;OXF:%88K&[M5ASJ6&7=  OX2-?X"OV@;70]&&DM]-B-MTAN[_H%8TE
M=8GPP2I1 LYP<A:"S#M+XBB0<#>+(@7;"AY-@&<1>'0!GF[P7"03$M\ES#07
M2IK:!A,3^CL,H[UH)$T&R12&"++]58#U^#,H1&=1$=@6(!,@VWZ0/9;T"=%9
M]/$X&WW;-P+/,%Q7-PUB*A[50DTWU=!W/%<W7.9L5!7W?MKU/,Y$W\N?I_#^
MUR_'YNG%QY]?OW_\^>WB-#IY^]$X_7ZL?]7>_#@=?AJ>_/KXL^UF/#LZ5D^^
MO!]\O?BAGA[!G$=OXA/MW?6WHTOMY"+X_O7+1^W;VZ^_X._A2:LV.B%N:'K$
MD%U3"66#$B)[>F#)AFVKJJLXFNK[SUZKFM6S-4>$*@3W6 /WT#3#TA0:^J:K
M&(:GNAY1=958>N@IH6KK]\L]'EU\XL$8QZ]FLR];=1350RZ,M8YU379=2F0X
M-\M17=O0 G'94#".]69;A1ZUB$),P]0,W](<S;0"SU4#P]-#JFF"<6PGXVA<
M00PUQ72)2^30Q2Z!KNG)7N J,@4E(_0\']3)4# .P3C6R3A,T[&I3@S+L1Q#
M5VW/]C7J$CL(= H6BR?LE2WF'HV+B99JTA"5#3LT,<E;<66"_<T#55$M6]$5
M4#TV:*\\>;^ZZ#$JG)T"9 )D6PVRQ^)2%SU&'Y&.NBZ?^E-O_?4P>NEIJSH?
M#4QBF88FJ[:IRD:H!++G&X8<&C9Q56I[EB]ZC J.L95^=-'ZZR'91L.+;MN6
M0G3=DX/ <V3#,$+9"8Q MGR7JEZ@&%9 G[TV[9ZABZ*>@FMLDQ-=Z!D/Q#!:
M!?Q\AUBN+VL*QNL=-\ VYJ&L: $HC%0S#%7H&8)C;*7W7.@9#\DV&FYS1;6<
M0'<".;!L7S9<U9-=(W1DU7?!< G]T'*TS>D9C\%K+CJ,BBXT]^39$2VR-L%!
MHZ:#QPD4 FS0E74#*Z*&OBH3/;!E1=6<D 2A#6@B6F0)YK05>WM )Y)HD;5!
M#M7P);F*;>B!8\NNX@6RH8>Z[*EV(&NAZWM4=9Q (\]>JZ[5LPQ=<"C!H7:$
M0_VNPTJH3YMA3@V_5>#[ONX[EFPZ+I4-HCBRX^JA3 W3"^ 071^[5PGU23"G
M+=C; _K&A/JT00[5<)&9MN*!)>?(GA80V? =(GMA$,J6ZOO$L -7H=XVJD^/
M)9FIN\.H2&;:GBT\M,OKR?;\>2 &V+H*[+M@^&O$D!57]67#\GS9-:DA:QIH
M:H%+;=T0#48%F]@ZY]-3[![X8!RBX6%2P7:C5%=D10DTV5"H(KNVJLHA);:F
M.L150T,D'P@6L77>'\$B[I%%M/*3 H\2"VPGQZ"RH7G (C03U F;NH%F 8<@
MNF 1@D5LG0]&&!OWS2>:WI8@-*A//1FYN&SX>@!\P@WE(/!!\5-"P[!MT6!T
M8]=X18-1<=%2@$R ;"= ]F@\X(EH,/J(U-)U7>@5'7DVH[*>M:[X:HH56+JO
MR)9/+-GPB"<[0>C(OFJ2T#1<,W1L8=H*'K)-#G+!0S;.0WXUW6.FIF/>4Z J
MCFSHCBN[CJ/( 74)'"DU@D!XT 4/V2H/NN A&^<A#1>[ 5J'[7NZ[-!0DPW+
MU&1"-$L.-$NS D4W0TT5/$3PD&URL0L>LG$>TG"_!XJ/E7<5F1*#R(8;4ME3
M7"('1'<MW]%#V]ED$=Z.YJ+Y&DZG0T!VG__N,]29,GSA73L9(H2 I<3RC= Q
M54,)#5?5=,4R3<V'O=F:_H]E/'N]N-6G\P M2F?\\*Q%Z2F@F:2J_;(EZ<;#
M VQ9_VV O\D<E,!5O# , 7440]=LHOL.?*5HH:5HMF_\<X3,05445:YZ$#?Y
MPOG4R^B_4V "QU=X-_H"!O\C3OP?&Z;MT\.<MH?X_L?KD^_OC*_#]T##'V^^
MO3TV3X9OXE/MV_#;Q2 ^^W*LGQV]NP8ZC>F?GVZ^?0G&'MAOWW!M1P= =X,(
MOST]>O\#:/;FZY?/.GP9G[W];'Z]\(V3[W^$I[]\Y1\0X"$UB2I[2)<&@%7V
M?,>7%4OS=#]$)ISS9T!^&AP@:[2)XGHZ"8-0\PW;(L13@.D[CF%KAN.KUC.)
M KL< \@GZ90^>WW^^8_SXX^?CT\OI.._X=_S60++J7L!F5C;T]GWORUVP-'F
M5JB\/DU&M-_!3.;M/I_4P.:]+$8,;[],:0R?7=&J9R^NJ/95WG!1J3XA7I;$
MT\G\3V8Z"VX(L*K3A$7]WQ4XKEURW$%:28I+$#LI)3]D$L(.7Y+XFMQDSUXT
M\0V0K0[U-L X6%[_UTM?O.Y:ZM9Q^'<7QR>2UN="=/;?DX/3@[?')T"33/S:
MK\ZEHW?GAY_/S]^=G4H'IT?P_P=_?3U_=RZ=O9'>O#L].#U\=_"7='AV>O3N
MHGCGT_'YY[\NV"MG'XX_'>"#\Z7:7"]!U+.1I)#]SZN'D$_=:'HQB#+IXY2D
M@$?QC?2)CI-T(@$?> /*HZ0J\D?&,$DTRB0?5 _X ?7*:Y(&<IPD/T!C@=V1
M"66E.:3K:#)@W3.I-*1DA$^3$#M%,MZBV0?X*SZM+NM(!_X$_ZJZNBZ145"]
MK1YWO'W\TQ\04'MKGQD]]MTUE2(@>/AI,B 3*9OZ@T5+]2B\XGV'R;#N-LZ2
MD9!* Y)Z20J;!?J:4!R+IM2[Z2- X!> UGB: CNB..E-?< <3O -@\"M<*4_
M?0IZ'BQ1@I<G28IJ'7S+U7:$P)#<X#(#"C.PZN#PR_P=]:4O$;8MG4AQ-(S0
M-F"[ @L!3 .T" IHPA#T,H'G/>DZ28.,@XID$A*.IKR":7OL1_55\:?K*([;
M?Z,_QP"\]E\]&D?TBK;_3$!(^-$8UMI^PL^L_==Q3$8S?TN3[QTS^LDTGOF>
M9A,PIF9GFP#!TIDA$"(^R:J_PYF4HW-UH?8$83BBETQTY3#-: Y*>)P@RDA7
M)(W8*68<A> ]>.8GPS%)63,_+&L3C8#P+V\DDA:XR\\Y0@X2A3<+3_O=2$*3
M >>8P45& 2D-82$P7 XXMAA<QS25PNED"I.&8$R._ CP;DQ3AG@C'S![DL)2
M,L1C?-?+C<]>M3N@031J@ O](N6X^9B4::)LMU'J3X>P+!@T8YM<L)]E>*RJ
M/:CFM#(O7;1!@*8?3_& $1T M @/CV3P!R!UGU]3E#A1D<99P5)!XN,@U?ND
MZ*C18!C(!J/151(#8A)I-!UZ<%8P2AIE/S+V=#K*N3@R4T";.,;GUX,(.0 L
M*(C",/*G\03/+QH"H\LBAJV(132(@%L2'Q8+NXIO.-\=(NXU!O'H30(/<.U(
M/FD2M["U^(13SIS5%>R/_B3P5X]Q8^^&4=_AV=_OCF35E>#< SH$PPJ_QD&!
M"C-:R!W&_N+$ _0N<)B]2&%5"7Y%1U=1FHP8:('_$2"9#/;>EPXX4^RQ/0"B
M3V$(_HPO"\%$\620! "(0*EI,L2NT1DN&$"595P0X*(64?$G2@(*\B8;(!N3
M?(!?.,4!4WH5 :8RA@TK0)F4LX6(C\Q0(\F0SE'3E0Y&(USFK*CY7X!K0#G?
M EN&84K.W3X!Z*4W?/B"PP$@KBG@!6&<JSPUA,"<@PK 1DHC+U\68Q!! I3/
M50+D,H!!'$! @4S<XG]166B+=QR\%/&'R7 8 0+">O?R!9\?'^;KW._E%,4%
MW:WB-LPY][_\+8DSV_?3$95TI2>AA<VP-$:*+K G SN"9;<"?.?M/AHA0<,+
MN>+3/NTZ@;9X0(]]P/[(=@FS,EE<_R1'C%$R06( R0UC\V1#1%?$-)B;OPK4
M,66,EY$7.P=@ZUDRJFE$!1:C1,<!B3] >1UP6DYS;$0J]LD41Z5\;F0 ,1 B
MXM(4UQ%'R-81QIV:5FT+?3Q15'5(2=,I_7<:I9R@8W+=0RP)HLR/231DJV?2
MD,V*= !$U0793N4KYZ[LRS!&]6ZN0$+CB0T<X.792DK7OL6GB<^YL\^D_714
MZ3)!/G:'\%K.OK.5[?6H'3&JYNP"]EVXH)<RAK9;4'\>Q;@11B'7B%R X$@!
M>^H^.W!6<3!G. =IFEP/@"P*]LBTJ@QQI'PD?0!U: C$,66N69"K[T9^'RA*
M.J* W8R8$C :TIJ4!H1$YUT41* HHBC>TZK)2U7\$/7%T:PZ/J/73K/R+SA\
M_E<0$;W&N@M3)QDQ Z 2B\DXCQ\PK:/:6?=:X1E7 T',3WUN)H%=>SFH?8EL
M""TL_ME-8UC8K3X+ZOH<BZ!]0H!5 !P1R*5@F'E<B8F_HRQ*1T0"_2PE8W9(
M6?[QL_S9LWW._ZI1#J;9!,TF(GT R^FO2= Q4_E.-=>>,;LO%&.PW/-)XO]8
ML*_<;9%)]?=[H.*@,1$#SWVN]!5%198.0@&0"F8S9V?[P(9&WKKTA*U/%L^)
M8-JS.DX//QTD,<B/O6Q_=EI\GS]NHECGMN_.4/7M9:AG5S1E.MV.^8AOX7.@
M_EW1.!F#<$<# ?D)US<FZ$)!28ZF(K-5@# I6# 9BOT,E$(P/6M>BOPST#NX
MO!_VI<\9OD D+TU@>E3JPB2.$D2@3Z<'8(:"\@\T6&B.%(V7"!6'80)**:^'
M$8.9GH*M4FUCPA@!?@2?7E[F2@ .B&I'&E(N[(<4]= H&S*3'#D=*"[P';"O
M@-(QFS&8<FO^QPBP-DBNF:CD3@:^I_[LN 4C@0=1P3FD"/6Y:L9<KT.=$M:/
M0/!!)\\A!!IGY$43KI_GUD8NI8'E@@&)*BN;OE?XKT#9"=$%D(-[G";(N&<_
M@@<34)_Z'?2)RY6Y 3JI<](8CC\% Y4KX2.LQH/^!#(97!/&]G$AU7'WD0]+
MN6 K!Q]'8XJ85VC(F73PZ4P^^'!VJ',/V0VP(#RM^ 9T[PB-/M+C[YR^Y:\$
M-UD<C>N/CD_)H<:>^3<9K!4,$4"D+,KXXZ//_V>PIV!?10F&>:9Q,L X#JQ_
M.,W #"9L6+!@QX,;_A&8GJ4I 4(=["(P(:=UU,TJ\Q0Q)-?#"T,Z=Y+ 5,#L
M0"[*7I+"MA%<"0 J7UJ^:W07Q=SR1]IB&F=!0_S%3P=OC[GD@E]./A^:!X?L
M2W0_);"LX=1/Y,2#+>!QH[\J1=4\)D/0S1,0R^5"F#"/N I0#GCRP6;#@5A.
M<(F((>4'!33[[-T_SX_8JXS<BE5*UZ#S)].)#(H9;(Y[M][&Y&>2#<'Z^\&.
M_!T01XS:-IJO'U)414#D[ITF?0FTA+_0F4DK\?OV_'\KHAE)I\D596X.C)7R
ME?S?T9](3AY%;,^9$PR BP/+C3LD8OC#)?I*N6E,,/<F)EZIHEVFE,.=&:E_
M)FGT"_[<U" P? 6 .@*0%XO+7RP6V)?>G[Z7;1,>V:XI[>'JX"_J?M?Z@$C?
M Y<&LN?&W3A!$PA]<XR1LM7@'N <HM+9#JKK2":QGX!HA</))O!F,J#XS@3F
MV#L]./]SO]\5$W^(8,1"L7+?D?K%,@TYQ\%%!\:2+$M\3FH,P"0>#XBL2FCU
M3=*;,4@D.#0N9_R;2BL\N#@J\;(+ZR_(#QJ0M@B5/O?/^P?]7E.9Y>_6T?S,
MGR0YEBL<JW37<:4]-+*9RZ-4X6 JPKGGGW_\O<_9""CG(\"."B_^D#C7ZEIH
M@82-656G+YW%8P+:,AS6_&E/WDJ.JR"7P17\]>$@7P&8[5%R10J>NH [' R!
M#;9T>_Q3'1JP'JLO?1F@7VE221,I#SZ48C)BY,-@\>Z-AK"'257)!WQ@P1:P
M^PF*O*L()0[\@/9_B)RP#,TP%QC/J,+5Y>H$B#,4Z_"'3X>'TF0Z3-*LUU@*
M3,4RNH*:_V2:9E.4 "DWGLI5<!; "!PUXV*YE;.WYLHM?8$UWQ?ZW).8:PDP
M/<4S!E:/W(DE+["-L"%SS0$&F.]O?WJA>G=^J'Y+HNX/ZTY9TAK@/@,8&00G
MTZ'B*'>(%C9X3_H29>Q.'O=ZG,-RCR)ZF?2D0SAX0,L1ZFK7J*/6J:=4"U$+
M)BF&%5#7KM$)9M1=13R(T22%%C6AUMK05X%,@;MR9^8<732%$:,Q4";]2?UI
M'N8#CI\'L>+$9^(!-O6!9 0.A-3WT]]&#]G"(SV:I@7TPBC-T.L)ZD_A*>>Q
MO0BS1IF7O,GGRG0JSAT9['DT)KAB#F*T4TKM'A^,8=0119GAPZ]1P%"(66\_
M63B'.YQJ^ 0#9],Q\^AWX0@H,=>X_&*2OG3.+))8^D%OBN!(#2O*2-S+Y0\J
M3\Z4,9WZI=T^.GF#9Q?M;TZ-:H)%<_LN@B%(<A,Q1Z927P5ZP9/]</#7N_.#
MHV-8ZS3 &*(T9G)9KR0B>X+G3M$+A<[Y(C\#I'!IZ!/_II"7W%!$+A/DT0W0
MW-B.40'P!S<QQOM "T+C4,IN1D&:#,$2?W-XOO_J4:#!%N&!W5=U! 23Z8Q/
MHG(XPH07C'.A9L+UO;:9!:8=4U5R<_*1',P6G8S1YY H5/S<RX2LN*$2LUCM
MI^/C-[**],GU9LW+Z1*]:BS^S6_<ES<2,#@)2Q\U1#(S@'7;XN9*8;CL]Z32
MA(!9T1K/+1;F8'X!2("OFI:J6[J=?X@_Y7YZU(C]F";9WF0?5&SX&XF32S1W
M]TNMO;*:4:6?:P)%HS!/.-L[_/./_5>[C7.JB3AWM2F4@^EG4(X)!4P!X"X8
M0!*P 9GO"4Z0I$Q)8+EME\B_"R/MA48J=,M=8GCR69GQ#JC3%C5Y0A\3-?#-
MH2YC]GRO/FI;R)2C]SJ5BR4])SK^;^$YL6S\WR: #S!-Y#=/=7-G^NPU:[\6
M79(\$V36IXUZ]GY=T<:L$##MN&((8@"]YTVW<\V[B3^"<(:?="!#?7_& \;&
MO6FX-A<Y1Q^%Z-@8%7>)=,M&.%0"HY86Q! A&G;)$" M$.2<".'G@X,+O-_2
M*QS,3&W#IX_CO+9*TC.VRVDDSV-&!Y3/^"#F30,[]5,>(XMYWB![YV^*,0WI
M@OJ#/#GU TE_X%/^I&W2#VB,XICS0^8>X<&JE X3S$(:Y7E4D]S8QI^ZO-^%
MDDC&P"1^LMQ=8/"JQ2K921G:HNC'2L"42Z>7F$$X15<8MUQS8_$F3P-L#V+,
M#I+[^E$*L2 -,^^K<7@N(\N1ZC ]_U_F*_0Q;Z+ADV"3D_B&N79K+HJ&FT$B
M<88['2681I8GJT<\BP]T8Q@"<YPR'JX8(_-\KEK\B@,@3<RSR*0)^8E*5LKY
M7Y[&BY#@:8A4\O.$[^+46-X:'T[KFS/C8=;A*&"AS.I\67X53H.V$L[H8PHH
M&N?%+-6[QT5.Y5$-(H>UK)>]+\='AXRQPX#(UJ^X:<\[>Q;HA[Z5&%G[$&_5
M\L/AJ?C2",CD>^(!-*6#DOE@$FH=N$V;0XJY2[\T,T*6E8(CJ8:Q*E+ $CL=
M6'4'!2:Q)1AOKAW_CJN4.6_;(N:FY09FQ=WH"&-ZPSQB7MHK!Y\._SP^E[5*
MUXM:BDPC@MR,K WQRG0CJOQ(#G)[3E)U<X/T=O. !W. #<RS#U@DG-E^=;OO
M()L,AH_BX**?6W-LRQMUMYY:+66A<6XS>0OQ%-4%KMX_AN/<HM,LE/OBL'C6
MYR(W+OXU9[+2VX.+XR\'7SOLZH6\=L9#TV2^@V28_+JY1#NO=..R'"!_D,04
MU@-J3;S]/%E;#A>VAR.#;+6<&><MYCN,>%"YU*68\H9./%"HOB?PFH2I\%-,
M$>U*N&UE..2O5!D3>.A_1U<)Z%5C3.2NO7F5E*\5:<9</Z_'H1!EV??%'= D
MCR>QMP#1X'V&DZ/DBM_<J[(5 :/?,ATSE0X'H$K/QZFMY">JQG!H8T@$\\]1
MT 9)QMA)+6FLC.C^#QF.7S7LI[U/[&]'^](1X<D6H$Q/LZS3,0<XB.1=A?T8
M#RFGX2F8,/<RGJI:'))98V5&(XM=ILDXC>@$1[VHC1I))\"!_"E83'L7G]Z=
MW OPK;ZY%/1GTC20Z\DZ^[I=,0;8-@[P[/7%_:QY283=QQ#\!!E(/5R QGMN
M&A>"@1\"O4*G'UCS8*;B12$FG<J#ZW(V-A-CAV221C^!Z(&W ,+Q-%>48+:T
MAVF.LR['1M+=P@1(:>_=AS?[[.;%5DNC)363K;00@$?[R>@[( ;S)C!YP=/D
M>C5G2G&[C3DHRL!56S?9XZY(&7V1^UV:2DA^@<[#4]TN#OY7=EWW19XQ.">^
M]'LYA)@\F$>V,"6.YRS$F)SKQ5$VH*5W#B%\/+ID#KOWR33%Q<+L)[DHD_9.
MC]^?[/,TB])5RSQU4L*RLNO7!8'3H>L$TV_34;'UO]A&#I/1)1(/L%O#T5ZQ
MO ])GN^D?7(Y8YJR$SEC,UQF0^!"/,OO)Y]0.JG=SSZ>8L(WK.@@IQG$S(+$
MS@M3 G_AF+EW?'#^U_XV5@NX%0"%JHI7/9A1"Q0.D@33,8OTJ^)>WLP%=^Y"
MKLHUE(RN8$8L8POI?H1\ (:=#++:'6?N\"TN.DO7F'"'::FU"\ZPF@@6Z.?W
M[(LE]*6SXFX@=[>VLURQ9$&*C R]94#R-V6F#RAZ<83)LA-4ID#F7J9DF$EX
M?YAY9[-!DK)'\#[FL0^F &=,OT/'/;MF6%04\/%Z.#+P_"+9;,H>+7E\,4^_
MY29>;MU-3R+NHAQX@C'<K#MGL'9_DKGS%Z0N_DZF9'$=L[A.BK>625 FZLW)
M2(3M7M%:IAZ327%^KX*?>2^_IP+Z+R<_.AH0!IH\ZVH(@FV:YIEZ3*&&S]D=
M;<S^1/<WX$]QH "D/Y-KU*);R8(HJ2=E)0EV^9U-7UQ*NJQI;"4-L# ,VP*R
MAG;A$N:IKS"TI(P2RS!>3'DP)$^>;J>,%OG=.:-IGVVE/403'K,H0,FL3(8P
M9>I!;YD1&;BB_&)D?; \I;:77R\J#NPR23#21N()1Z?\3.:,3H?C.+FA^5FQ
MJ H=71:?XJG4ES;+:7:-MYY20,(DPYM7C*\]M[6^(A7!K2:'G&&,9?$'U/]Y
M>1YN18RJ40%4SS&[<=4QU;XTLS97Z5LSXW3S[&679MM]<\4AFRLK;_?*083:
M5Y"O%9;JK -^L^/CLI6^YBX]^I+K=:PUP'3><FUS>>A>\+H>*3,'4+Q5PR\-
M4#0%"BXV:HPV/RT>?L\+?N5)V*!<X@U9[O)"D3?"-9!NITK=EU)SBN32DB=G
M<]N"<^K:Q?^FE.0IO1F[23[A!7*2,,P "'@5M;V9*XKLKPPJMU=59HN.@GG7
M]' F5!O2J"K%0XLK5W_EWQ^48> ]=CDG9/5"/ #>]7[)*HNK?LM\M'NL\J*E
M V58Z0M$ QWE:?=Q].\T"HK(>ZT\6&ZAE><]'0.8<XR#A8+YG+!KK#?<-UQF
M,_#[E5QGF7=TM8I#6!=F<E,E-( F\;DL7L1+8\R1>C7'---O\AQ7?MT#Z\%<
MLIH5LWI@N=3GJFW6! ?Z@T;E/O.=]8#=UE^J:OX,V4WJ4;$#[E+@1;MNI/?O
MCPY94F)Y>:99Y($!FQ5TF@7E),&Z)J"J/+>5:N8[PX5=IEL$!;VUOQ8$X+R>
M X<S5P4!O]>7O]Q>9!T:#!C/=:6YBEG <"8[E\:Y'IB[/W"\^H SIWH[^;?&
M,Q8,UY?>1#6C ]/:;QEO9@@F<H!FJTD*<^BZ?ECP+>#Y%)V13$K>C]MNN2C6
M1N_S-AD;TK+N]HWR@)@\R[B\9#\@BEZ1N,!G4*'4.K8Q0T9FY4TJ+,8W5<NL
MZ8'H^$O0B&B]R%'8-M6^4W^743(Z!^F$B6#XTZQMWFMK)L]5QUA^*ZIF]>WZ
MRR")?E!>?B,KZZS!BZ954T07;5DSS-J;MVQ956J G+/G<SJ>L#O[C8V#TO0'
MN_ Z'2?=3**HD5ANO\9@@)J ??JYS9/;@Q@=PCJB#6;'*RPRRXO9E-FT+!I2
M"3\,;4[KAB57VUALB&3<7!V!2)<F(+BN"BUN27W@7BO0K%B?_K!PK!SX?C)E
M'26D#UA*H"S&EQ=27:[NUQ95K;E@ETK9$7N4HH-)XF4%RVI$]>)^I-K^N-A^
M%6>:([66J[YX]UI&UO;6,OJ4>UF G,\J&MD]% &RCF-^?Y1EK6?3(5H1O]"T
MGJ:E,PGK C19P:3Q+7H2$U8Q-V"MT(,5[I9VA31R?EV$25+0]&2F/X\S^K+X
MX14@*/"WFY?1B.V-??0J'SZ/K70$@-E\_'$5:N@K/-R0MX/-9\X?]]FC5K\2
M_LQ6^ZX^_S%(@[G/%@VK:GW%F?_IHF$7/S,4ZWX6JR\U[)(M=^=V)7:7Z<[+
ML>AA6B8YMW$+UC'I@KDZ3KBKX[CAZKA+1^(EFC:O#)YA% 0QW0QX4.U;HIGU
M*CVK.<O(F0"V$\I J@42;F51W^JMA(VZ5AQQ%S3VSBL@Y=!C''IIT"WLM-;-
M_M&E.$< /#"D\8K?'M-RDFF&96-Z17N"TAFZC#S;K@V1(:ITV7XK9KX$$LUB
MAN]3"IBQ,SW1/W&G:C:GV=A2&]SMAH++;7&[.PWJ6L]0M85MXY9%U37VI+QU
MRCG-*@72[032&6;/<=7-(=W*O#F7VCO#F\]*[U1^M7(/(X/[2\.Z8[^/C6JZ
MMKC=5+-G:SU7<7_K%.^;3;>F7)I-"X3;1H33U9YC.1M!N$>O/F.RR=V8LU!I
MMI%6@#DKAO5;IRAT:(%PRR.<YO9<S=@(PCUZ_7F&.<]F[,WUIFJKP:&3DK80
MW3!3<Y=5S\=_/MIF3 /&#%ZPR*"XMO7L=2V6L*77MFP1$181X<<?$3[%+',1
M$!8!81$0WMKXJ0@(/R*/E@@(/P:_@J:J/<NT1$188-T#[@VL@9ZB&"(D+$+"
M(D*W@M?'-7J6;>^R7TX@W$XAG&/T5%,7(6$1$A8ZS:W,6>F9IB9"PMMT*(\:
MX6R[9]@B)"Q"P@\5<G162'C9/M7S\9^/;6YA2'B+"]=T%@U:LMI3O:#"$@6<
M>.VE-())L'8)+R'.9TRIGUR.8.E!56CH[?G_]HI*)'AI?FX5D:ZVVTM>!G>W
M^3(X \VNW?YFE2G:B#2G*E>K?B8><HDGSW6M5I^#U<$P:E5">GB+'&M.L(J?
M?:E[WJ7*=C:GU52U5NJ#S:LJC8HQS8D_K4@S458KJL6R0BKZR:F@:.6'?VJ6
MJ\&_%GMLET/&M]OU;LJ2-HRHL&3.M*QOU%U )R_*D,%*8.MY#4R<ME$)YQ9D
MW$ ACCEMU5EY).R1L&-D=#9J%W31'$0@U6K57:DWE)A<)^UZ8'"&,VV!L[S9
MJ\_+0V6L/%39Q:[5/9A!L%X6ZYQCQN',/!VUW?#]O.'$63PFO/9W^;SH/]'+
MJU@U"F81Z3I)X^ Z"FBOH\<Q[+:L^E56#ADE0)*\BT UW5ZMRGU*0YKF\@HF
M.SAY*SFN(N7-D?_Z<+!?U+EE9;!@'C;8,&])P!O5=Q7%C^D5(\0X&A=5\/?(
M?E%<"DL3LP*"3'V =5P!^F(1P !KI@9T3!F^26F4_<BKJ>:%<08T33(_AG]Y
M1X4TB)(KDL%B2%D7O7XXP%G@NR5PH'$V;U@KFB5.-#\Q*6=U^>>LAOO)6W7^
MR5:G"AQLS"O>);<=<=&S&H?&4F+\+.H]2[' 5ZUO02>$VT#C+2P*F($.-V@4
MS<OKJ65P<DG,,"8;8_U@3!/#*:MNG*WZD$A,-,6J?M$O!L&YI>3JO5Z6+J*W
MZ?)QO67KQ_$7A^2F6'S>'Q%;4%3-39\;2FNDE X)@+;J7LDKR-5:8/$2O4B%
M\ZK6U4J!A].455ZFH*JSPV/$6E]0G%Q+03*%9V#+7F*KR.2&Q*R -!XTGPF[
MG_#NNEE-<G;PLCX(&1#T,5:,4]T2CT:L'W?0.-BB->5U,HT#5B[<PQJBB#P9
MBU5A99QQ6;&]L\5[FS8"9&?9U!\P' (FQ:H[>UB-O 1%!35L+<8V>U/50ZQV
M-TO.3[< WLZ7(@6Y%$])WJJVJ01@A43?3]* M95CPO[-P?D?H$F/(S^3',5A
M#%X%?M\4#2!XL>)7I4I8BB7)#47X$!::$K_H&7(X!<0#]MBB4U8K=>IE$S+*
MR]E6O2=9?QJ:(OVP]25>G'<2N842RZ*3'7@LO>%USDM2X.NO*)_X@XA>,8V:
MTT_-+N5<,L(B[I,HI:R?+= X)2DH W7ZUY2*_LO>;_.ZIF"IKV(3A;[0*HK9
M, !F>%^K>']?.IJ6C0]:_0N6MH2:DJ@&@^<*EP/*(D,$CZY+BVQ93D^6J1S,
MK5&9\VY>=EOBS7D8'16E'O$H4E8O.BN*ZQ5: LMDSP^G_"R.>,U\Q.WZMT71
MQZ!0B(NSG%,D$NB9I6>R0_Z#Q(PDSP>4=OI>'MJ-LJ)1F-<P1HH$YN*S;F4D
MSGOI[9Z=> ;V0E7VDQF)S@(CL;-R=TV;+Z S3_G?SZW'3T6U]%F[X8QK+XO'
M;\F4F5F:Y::QXGFA0'>?7[[;B&MM[Y,!8.PH[X>7_];1,;P%FL6V,*LW7710
M9+_PTLH?BO=G=E$W N8"ME<^6M$"[J+4]Z?O9=UU7-:.2_[SC[]+D[;7^?YD
M$*6!S*O;LY, @>Q/02)3;C(7M>X9E&H66*O'WTSG^7;?MYK9UNQ)Z@_ D(&A
M!A3_/@'=_0_I*DJGJ*"$U.>FU!_T)AD%G1LH>^!6 G46!KV.WI:\Y'/+O./Z
M!VRE.I1U&(/U577AA&@!5MXETUIYY%MWEVQSS'X.RZQ0%5&:Y-9N1F/*6@"A
M"CB"!7#/!ZIF8&AGDYPBJMKYW![-4;G"[:IC1>$3J_6P8*I*WJ2'==VAZ83P
M5AJ3-/+SUDVL[S&S='F'(#K3&Y3$<)9 O&R\.>Z(HHU&DXOCEG/;@+OD<J.!
MU1E.KFAZTV/6]+"@Q+R+7[F_>5T_>KF>CZTOIDQAQHX#A3SBP$MX+ZOD&AL!
M<GUMZ$6\ZU]#@#4X!+#U'[T<W%4EY5K%;!1%6 ,W[Q,=YXW=B/2Y?XZ&1K.M
M(B+743J]E ZP_9&?\YNT5L&\AR6V<P8(^%BA2[4$UB:M],RA7ZK3\0"SA_5W
MKUD/$^:Z0&=FQ\!L;VOAG[S9,)NWWJ1TO7ZV336KJ-FT"Q6+7JLU"*_+SD#4
MU=I"K\>M2%."=CCIGJM]2_*J?;7/I>5^RZHYB^C7 B4'!\BG45::9G:6REG(
MF9K$*+WLBU)?R!R>N9+#$-059B.5;@*$-G<+YFOE^QI&@3P!?,\ZUC&K=%?P
M8*0^Y[NYZY\Q\V\Q[DOJK'77XWC#JFQC!?^(@[ D: [OZZ2@*#Y/C7<S_0KT
M&NXYR'_1]U?8AO"OK=F_=I W !SAM<(JCMQ86I,!1@C3*(RP(Q<0&\A-T'_]
MR1SO&P:\+S&DDN/> H*O3Q)0UMN0A<U0X..S'Q3_SGK\HM*2%=I!WEVOWI\J
M5ROR5N:@VZ17D5]^4:REK3&4\H:W#61= ;E_D;V^E.70YIH+!H?EHG.Q6"Q
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MY,-+J(])DS0B,;#YZT$$V 2C36.V?VD 9T61FB<9#.S#;IK?]& 5/T&L36X
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M_!+_W5>+I.*Q=4W'"2>M*Q)/28'V&?LR&>/OG),"$0!']B<TR!].1VB\7::
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MR3?<=[]3G6__;(,2+MX5V%?P%W8)K\T]-K"G?,K^%L!?&G6%:75->Z%;PS=
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M\ 1_EXZ=UBL4XZ9<^EHS+F75D&P ;R75@0J_:(>I**VE:+NY[7GK%?452=E
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M3&Y-:4200!P9%/8 :UP&P%H"A* 2A6F25/K1JL(%D2;4K80R75D8^B@>J%A
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M.1]GN8M,E3@EA 6RHL#9<+HC$M;:G5HKS#Y39*(7/ECKAH,S4XX[0%WF<'V
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M5+%4@WIO,,RK"_O8["JD4607T+ G5(+>/T8U1CJ>?%$ $+Y1/ZU3]EH[W>.
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M9GM"GR?.] G^,_<7UE__'U!+ P04    "  ]@015T*+\^3D2  "BP@  $0
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M#81JWIO)[W5]MO5[U*M"NV.GXEB-*LP[7M($U74(9D6=[[1C/DTY#Z;AH#S
M*T&_(3_ KZ8:I;O3ZT6G8Y=>DZ6)6/1JR6XM02W5\4XK=#,8_.;[_@/O.L)[
M],3+*]B([![TLC_LM%+E)H4V0?G>LBLK[FL;A7V)/*;T_@:B#1BY>K6>V5CT
M3O21G:X1DGBB:9C$M.WRJ.E"ZW#I/>CC=GI;-$<VV^A 9PYLYD-P.<(-?77
M;![)1TU<).90E-S+FC8&D?\Z*;.?2)K>)I]T6JE"ESP5RG\#1,85$>%9MT4R
M)";40B()#A9^3NT69T>"(<=_!L# I\=:%CV%0&_,3^UT6=,"A17B^&N._Z\'
MRQ>OA]^7+F>75[-'/S6AI"-OA?Y#WO,'FHJ]1^QV^46 'XB+V=(QT/F1SCV(
M6+A@R!'O]T;(E[=,R^OFW^]50T(\^5Q>.BU8(&^JEC_8<3;#S*/N0-TE[08L
MRJ.%[X;A+;3P @\]>4,_R%1X(I!M/C,:S-[OA0T]@:=[5G@A=?AD2@E,._9R
M!6\D\L7-]:FAB*_NH6PFB<;N#9X.Y875"ZY#@D.F<YM7X:\4)_-?*#ESZ11Y
MI 0O6573>G9T$"9P=(>9BIQ!#WI#WQNK[NZQ+T=^0.?J]3 ;,4K$'7K1:FQ-
M;&NHK@.+Q.OI[FT@)=4;10'C@-YC@I]RV<]K7LQ?^+LCU?CPB,!CS$JPT4?@
MPT5BN/'@LX AB$:?YW)3 %6!J9]I;@9/=#"A@71\^&#B,8&5.8$V8$;O@ +]
M?"T-;L+D[?DS\($86BP#>N;RVYO S76XJE'VTB5N;S3R''R)'.D1ONC9*@%H
M G^K<RA<VB557=$'[1:]T=T$<0PJF#LG*^$P=(9^>IYA!VQ*;$IZ([49*NLZ
MKZ8S1A_#\. 6 S,#3("^Q..N[],G262^W=H8?E,]J@L\P@S6O7L,GK>,^W23
M(Z>Q"1,B86LO:<#">MXE8YMH$1OC@E9/\/BE1W!&,S .5\0-'$7%9[""HL!W
M,X<^$Z3UE4X(IY+*Z-,5A$&/JM.O7R_.%RX[/-"/:QU,)HS  #L30GTZ?HFN
MY4D4OQ9H4@E($SB49&'F>,B_I0++D/,W3TP\<NN!<7JY0"\%?):'-X/;*,;\
M@I'[9P"K)V;\BMPACEQ8%XI8+05L I])GS;'D)5WB@L0F, O$,;DBG^!P_^O
MB,RD*/.:N/$BQWLH!VQLQ'HELUS('\#RP8$YP'W'//D[F+GLYK0WEL/[*)T9
MN_A7Y :Y'B]:= K!3-!<:3\I4;N;=P$0BQ)7UA5;WB)($SA,7JC?+;C*7^T]
MY<:RU1%M@']7G$V@)7."(;Y*:3'0*7\9J(2<P:1((_J(?&E/H /.'PC8&]_[
M@5WYRT^:^*8<L*'!7Y3ZRXYCY<\RYS!="&>LO?J&@7"T\ #O$/NNG\LZ"!/F
M<'R9ICQ8=AD0^:/K):U4&4@3..S>]WZ_^-(/9C/_I21K6A 3>/H$6*<HD1>Y
MI&Q>CRYS)B 8_G^P1D)TFI];J82DO@UZW2G9%8,)#G=FRDI7 V&"<%?6A"_8
M=P<T.GL@LZ)9VU#=*65"+AGGE.LW(=?$;.A2M,S*@OIY:<0M)><!8[H-KTHX
M#!T'L%Q?^A?ES5Q68Q/FP#4&SP=GG_9YB>W518"E>;H$IP&4MSN"J#W^GBOD
M]1&;:@C/P;]@R*6])X+9]?5Y48R1W=H(X<=YM61Q!(0%-4*I6JA,& .5,[Z
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MI*D;95M[SE>C'ZP%;"GHAK'48N(?PE^+)\AZ:?3SD+;81#-=I-P,F$'%R=R
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MVKR10S="F)0S9S)%T+J64PA/Z+ P"#$JY-+Z5+K%_8?"P+.Q#?0@\'Y9F9:
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M1B20U@0A,/+8P]/AP=?UMS:MK=1VAVUMW;6OA\QG)U@.27F(E@50*5#0JJP
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M@6V<C_9L')L+OX=V?14C26 )ZL]A.%WL:R^'L_KN>S;% 8OH& H&QA@"ZE&
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MK%*8S.[^T46Q:9>Y].18M9S'?ARM)@:R3%6U;^WVX'6UGA/MQ=P!C9.A$NY
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M,D:A N$4B7?B_-FW CNE^;30WSH":YWF0Y*ZD;(BN0R<MG/&<LU9*IGV$F;
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ML2_H*!NS>*X_2$M6SRVGN,3R&0-';SW&X*S2CIP8#+(87CNZ>I;*8/WAMJT
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M^\@N\Y7&)&<GQK1YXB>628OOM81;PZLL9"O0E)F5[[,>0"GRGT"6RR>E!W!
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MLXC*UG)HLUT;L5+';BY7OU1WEMV9'S&?1"&#01#%$'G8@;$C7(@1DCY1P/T
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M"H>9 TE(!4P$1@2YG)#$-]F)UN]Z:KO5=]=/X/WEXR_@T\/];S=7UU?@W=_
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MIK;LJ>P DN:J&Q8 @GPM=_.CI322"J ,+:E@C\L6QJ.DN5H-C?W0ZTT%;JT
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M?,\7O@N%M,L@XHZ L1/%T!7(=R,G#GUD=!53L]^I,>.52(04C(-<?!&+I;@
M"U'=(VSD!:]U1CG3X#6]0= CP@&@'9CY5A*#KZFZ-=7(? '64E^ C=PV0]6,
M@+(6I*;7Z\CA:490[ >FF;W>I_S0=OZ)7\2</V4?2:G2[ZBCN$U6LDU.GH8V
M537#HIP%(69Q3#&,7>I E' 78A>'\I^^H,Q/X@!1G133=L0Q8K8Q4DNK/BZ
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M&1."%Q^D6%78D2H%HJK45*<KLS"( AIB'Q(/<U5,'D$:<0XQB=W YU[H,:.
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MA <;Z4$M?L^49/J#HL=+PT ]]!9IZWIG+3;LB[)YQAICP&REE-'O>-R<+\:
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M6 PS(E))&4L3YE3\MCM1A[9>K3T?D[$J:G2\23IOE<35S=0Z.,3>?<+^&SC
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MSEN!-4\H-U=;.W>0'DNO><)CNPZ;KX>^NS_H9KJ<CZ>+,2]J Y 8!9CQ6"^
MQ+3D40(RA 6,0R5CCE JW4YL.I-T:&OEY=>O\[S+#UC+>:+60,\SV[M3J/U\
M_9A^H0OKF7]/S]#A61F><VA'SA_5/W08[@Y=1$<&].PE>M+/*P.,@S@B,J42
M)MPT<5.$PHQP"@4)(Y(E2D;,:<6P&'-HW'\[FWXM3^6>ML[D3L<DMX;]3+=0
M.S"[W@*UQ]&?ZV<?F:X]/K41A^'HV8? VK]SX%9?!7LN.9^MM%G](+D<?\LS
M1B7!"4FE@!QE3'./DI#$*H0IEU(% G&<(+<&DC;#6GTQO79^K&0$\[60YU;H
M.8"V'>5X0_!=:_&L$7TXC:B'ZCO'(>JLY,Z!(=^YSLYQ$$X7UVFXU[U.QZ/D
MJ[G>R*.0/8V7^LWGF8S3,(A@&$>FH$Y(8!9("8,H)DPBPA+,;8MT[#Y\:,9,
M+I2);D#A3^QG4(EK7Z-C#[UFWC@7DX[YP14.I_H<Q_1N59QC[V&]5>8XID:]
M+,?1:UJ<^I@T?]/MFDY,KL9B1!!G48HXQ%EDG%8QUUN0.("*AVFJ2(18:-6'
M\]##A_9Y;L3+$XXL:^<<A,WB?.4,,#K^+CWBX'"$<08>/9U([.+BZUCAB.:-
MIP2[]_3G]#\B[98/_]@UK5TE>M,A%I^T((]T(C_39<YWIK#I;#*1O'#4J)OI
M-[DH2I2,3._/C*4(!IF)WA=(02HC#!E349K%/$M$X.@Z<95A:/16J0#,A((%
M+=;>\49@9T^*\ZQ8>U:ZQ+IC]MR&V<A_ 2H-BB+*:QT,_C<6^+?QP+1%T)]'
MQEF"OCTT;2$ZX+%I_2CW1C-7^EFSR5@8WT=>D&TL%WEO7H2T>2:2$%(J$,1,
M*$ADE$(:IU$:IXEDR&HGU33(T#BM+B>H!#W5Q=<>TF:^\@54Y^9<"XR<NM:<
M N&,!C9'']U;+YM3RM7;VIR\MF6WAPE=:/[(\^EOQU-YLY0OBU$0J(B$*(!9
M0BC$*(Q@AG@"I52$8H3".+3ZWAM'&=P';X0$]ZKL:_F'$13DDCH>!!W&U,Y
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M6!K3T=(4V+/CJ&,#.1'3>KCN/J+/=/ZG++Z,C;!Z3=:B%FXT-RXZBJ\= ?E
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M^!=*.)[.M9D NZ6[8U [7H9+Z8L V4I^\)=6 %0:&-=Y%2-1*6'2B?VMI&=
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M^:*[,Z7IEQ+]0+='FYX>VXY:?Y43\33[3)=Y;FBMT46UI1UE898D:1!#*L(
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M5K'U^_P*O9WL*E,E)'3A/$Q5;\?>XYS$3L4^.P_[H0L0V'V.W<JTVIYX?OV
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ML7U ."+#H]V,2EM]RNX23._G;<.WS[FZZ7J\6F;\Y__PUWD&(YA0FLCI#R.
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M_.=/[U[_\&*13D]POO[A^1+#&O,/OT_7GW[X1\;5;S^4Y>+DAW\LEK]-OP2
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M/?@B.&2>M2O*<&/=3=XK[2LB?J.6%:8_?UQ\^9$^^,<JC_K%1C ;H=Q9[DQ
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MOJL=Z=^4OZW.]LC$6"^*SHH.9A'JVV-=LU84$^CD R\^&M':B7Z0H#'$8TV
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M+U@3/A/&>'$9.6EW,_W#%0C:6[ F1)VEY?1/>S_])A'#0J:!8K>7C>\AY1'
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M6OY[&KRV-R+[5]P(KNCV*1X7!M%(&6J?0 050ST&JEA#<");*_GM[HRC[0[
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M$:JO?/'QZW(U69(P9*/ )F7)";(6?*+M)JF=#](KH5KWB7N:HG%CE0.D?R]
M:<?X[NL$-YNK]P4'&(G-OQ_"5#Q$VC &0]=9D,YH,%:07 T)-Q9D(%40,8>8
MO?$G9S#>34.\R%,--=EY]6/-SVLP.\9R2;F YC4;2ND( :4%[J1*GO% NG($
M*_(,F5V9EEUPLHUI:2FB$[$WC4N0G__H$);IV(7%=V HE!$"7:(0Q9.?:EF=
MCA4S2*>]X(H[Y5O??@]AKM;?_!F7:3']5AEX<75M0X[()87Q-L?Z9J[!9>N
M:582RSISWKJEQ!/D=&5^=I'[P^;G<)9W<*FV3>&AS*YP1O;2I\(IE#.BCD=,
M9*ZS1HS%&&Q=9MY]-7 S".Q1$[R+/'J&V(WZD4C.?I9<@G4AD3,@$,@+$.!<
M-LYX84QHG>;P(FJ"=X+"'C7!N\AE[ N\U_/%MUI>AG\G;^/?YV%1O_MV]GM8
MAHRS<%G%JH1#R0LP7E//A<O@"QT#*216?%2*^^TFG&VU7*<(VE?"\T'9/3:
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MI/=KYBT_S3_@#/^<(-.VU*>V4M8WJ(S<@E(;9J%1%HD(A=O-;WGX^SU>]C0
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M.]"=U,WW4<35.QQ_GBY3K8C\0('&[[A()(M)4=4OU.06.NEK]F8$;RF@$'3
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M@KLRD%62W!@FI-MJ?O$.[NTM L8]B_J(EO:72 =PVI]QU]N>Y;LZJXP*=3R
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M\&>,J^O_FF1MLI!T'B3E6'T\TM79X"!1"^N]09%T8Y.X+6V=^(*CX7!067:
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M+3(P,C(P-C,P+FAT;5!+ 0(4 Q0    ( #V!!%70HOSY.1(  *+"   1
M          "  =ZW 0!A<G=R+3(P,C(P-C,P+GAS9%!+ 0(4 Q0    ( #V!
M!%76P#:N!!L  '\) 0 5              "  4;* 0!A<G=R+3(P,C(P-C,P
M7V-A;"YX;6Q02P$"% ,4    "  ]@015:1= &]U3  !1LP, %0
M    @ %]Y0$ 87)W<BTR,#(R,#8S,%]D968N>&UL4$L! A0#%     @ /8$$
M5=W@)%LOS@  E(,( !4              ( !C3D" &%R=W(M,C R,C V,S!?
M;&%B+GAM;%!+ 0(4 Q0    ( #V!!%6*&W*"87\  .7F!0 5
M  "  >\' P!A<G=R+3(P,C(P-C,P7W!R92YX;6Q02P$"% ,4    "  ]@015
M3 4H2AP(  #R)0  &               @ &#AP, 87)W<BTR,#(R,#8S,'AE
M>'@S,3$N:'1M4$L! A0#%     @ /8$$5>C;#?H)"   \"4  !@
M     ( !U8\# &%R=W(M,C R,C V,S!X97AX,S$R+FAT;5!+ 0(4 Q0    (
M #V!!%60F_RBW00  *H0   8              "  128 P!A<G=R+3(P,C(P
M-C,P>&5X>#,R,2YH=&U02P$"% ,4    "  ]@015*7E1$:T$   4#P  &
M            @ $GG0, 87)W<BTR,#(R,#8S,'AE>'@S,C(N:'1M4$L%!@
0   *  H H@(   JB P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
